<!doctype html>
<html class="">
	<head>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no" />
		<meta name="description" content="We’re on a journey to advance and democratize artificial intelligence through open source and open science." />
		<meta property="fb:app_id" content="1321688464574422" />
		<meta name="twitter:card" content="summary_large_image" />
		<meta name="twitter:site" content="@huggingface" />
		<meta name="twitter:image" content="https://cdn-thumbnails.huggingface.co/social-thumbnails/datasets/ChuGyouk/medical-o1-train-kormedmcqa.png" />
		<meta property="og:title" content="ChuGyouk/medical-o1-train-kormedmcqa · Datasets at Hugging Face" />
		<meta property="og:type" content="website" />
		<meta property="og:url" content="https://huggingface.co/datasets/ChuGyouk/medical-o1-train-kormedmcqa" />
		<meta property="og:image" content="https://cdn-thumbnails.huggingface.co/social-thumbnails/datasets/ChuGyouk/medical-o1-train-kormedmcqa.png" />

		<link rel="stylesheet" href="/front/build/kube-68d7aa0/style.css" />

		<link rel="preconnect" href="https://fonts.gstatic.com" />
		<link
			href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:ital,wght@0,200;0,300;0,400;0,600;0,700;0,900;1,200;1,300;1,400;1,600;1,700;1,900&display=swap"
			rel="stylesheet"
		/>
		<link
			href="https://fonts.googleapis.com/css2?family=IBM+Plex+Mono:wght@400;600;700&display=swap"
			rel="stylesheet"
		/>

		<link
			rel="preload"
			href="https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.12.0/katex.min.css"
			as="style"
			onload="this.onload=null;this.rel='stylesheet'"
		/>
		<noscript>
			<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.12.0/katex.min.css" />
		</noscript>

		<script>const guestTheme = document.cookie.match(/theme=(\w+)/)?.[1]; document.documentElement.classList.toggle('dark', guestTheme === 'dark' || ( (!guestTheme || guestTheme === 'system') && window.matchMedia('(prefers-color-scheme: dark)').matches));</script>
<link rel="canonical" href="https://huggingface.co/datasets/ChuGyouk/medical-o1-train-kormedmcqa"> <script type="application/ld+json">{
  "@context": {
    "@language": "en",
    "@vocab": "https:\/\/schema.org\/",
    "arrayShape": "cr:arrayShape",
    "citeAs": "cr:citeAs",
    "column": "cr:column",
    "conformsTo": "dct:conformsTo",
    "cr": "http:\/\/mlcommons.org\/croissant\/",
    "data": {
      "@id": "cr:data",
      "@type": "@json"
    },
    "dataBiases": "cr:dataBiases",
    "dataCollection": "cr:dataCollection",
    "dataType": {
      "@id": "cr:dataType",
      "@type": "@vocab"
    },
    "dct": "http:\/\/purl.org\/dc\/terms\/",
    "extract": "cr:extract",
    "field": "cr:field",
    "fileProperty": "cr:fileProperty",
    "fileObject": "cr:fileObject",
    "fileSet": "cr:fileSet",
    "format": "cr:format",
    "includes": "cr:includes",
    "isArray": "cr:isArray",
    "isLiveDataset": "cr:isLiveDataset",
    "jsonPath": "cr:jsonPath",
    "key": "cr:key",
    "md5": "cr:md5",
    "parentField": "cr:parentField",
    "path": "cr:path",
    "personalSensitiveInformation": "cr:personalSensitiveInformation",
    "recordSet": "cr:recordSet",
    "references": "cr:references",
    "regex": "cr:regex",
    "repeated": "cr:repeated",
    "replace": "cr:replace",
    "sc": "https:\/\/schema.org\/",
    "separator": "cr:separator",
    "source": "cr:source",
    "subField": "cr:subField",
    "transform": "cr:transform"
  },
  "@type": "sc:Dataset",
  "distribution": [
    {
      "@type": "cr:FileObject",
      "@id": "repo",
      "name": "repo",
      "description": "The Hugging Face git repository.",
      "contentUrl": "https:\/\/huggingface.co\/datasets\/ChuGyouk\/medical-o1-train-kormedmcqa\/tree\/refs%2Fconvert%2Fparquet",
      "encodingFormat": "git+https",
      "sha256": "https:\/\/github.com\/mlcommons\/croissant\/issues\/80"
    },
    {
      "@type": "cr:FileSet",
      "@id": "parquet-files-for-config-default",
      "containedIn": {
        "@id": "repo"
      },
      "encodingFormat": "application\/x-parquet",
      "includes": "default\/*\/*.parquet"
    }
  ],
  "recordSet": [
    {
      "@type": "cr:RecordSet",
      "dataType": "cr:Split",
      "key": {
        "@id": "default_splits\/split_name"
      },
      "@id": "default_splits",
      "name": "default_splits",
      "description": "Splits for the default config.",
      "field": [
        {
          "@type": "cr:Field",
          "@id": "default_splits\/split_name",
          "dataType": "sc:Text"
        }
      ],
      "data": [
        {
          "default_splits\/split_name": "train"
        }
      ]
    },
    {
      "@type": "cr:RecordSet",
      "@id": "default",
      "description": "ChuGyouk\/medical-o1-train-kormedmcqa - 'default' subset",
      "field": [
        {
          "@type": "cr:Field",
          "@id": "default\/split",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "fileProperty": "fullpath"
            },
            "transform": {
              "regex": "default\/(?:partial-)?(train)\/.+parquet$"
            }
          },
          "references": {
            "field": {
              "@id": "default_splits\/split_name"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/subject",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "subject"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/year",
          "dataType": "cr:Int64",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "year"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/period",
          "dataType": "cr:Int64",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "period"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/q_number",
          "dataType": "cr:Int64",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "q_number"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/question",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "question"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/A",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "A"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/B",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "B"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/C",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "C"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/D",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "D"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/E",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "E"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/answer",
          "dataType": "cr:Int64",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "answer"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/thinking",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "thinking"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/response",
          "dataType": "sc:Text",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "response"
            }
          }
        },
        {
          "@type": "cr:Field",
          "@id": "default\/__index_level_0__",
          "dataType": "cr:Int64",
          "source": {
            "fileSet": {
              "@id": "parquet-files-for-config-default"
            },
            "extract": {
              "column": "__index_level_0__"
            }
          }
        }
      ]
    }
  ],
  "conformsTo": "http:\/\/mlcommons.org\/croissant\/1.1",
  "name": "medical-o1-train-kormedmcqa",
  "description": "\n\t\n\t\t\n\t\tInformation\n\t\n\nThis data includes the training data from KorMedMCQA, as well as a portion of the trainind data from the additional KorMedMCQA support set (private).\nThis dataset is based on the responses generated by gemini-flash-thinking-exp-01-21 model and has undergone MANUAL rejection sampling.\n",
  "alternateName": [
    "ChuGyouk\/medical-o1-train-kormedmcqa"
  ],
  "creator": {
    "@type": "Person",
    "name": "ChuGyouk",
    "url": "https:\/\/huggingface.co\/ChuGyouk"
  },
  "keywords": [
    "1K - 10K",
    "parquet",
    "Tabular",
    "Text",
    "Datasets",
    "pandas",
    "Croissant",
    "Polars",
    "🇺🇸 Region: US"
  ],
  "url": "https:\/\/huggingface.co\/datasets\/ChuGyouk\/medical-o1-train-kormedmcqa"
}</script> 

		<title>ChuGyouk/medical-o1-train-kormedmcqa · Datasets at Hugging Face</title>

		<script
			defer
			data-domain="huggingface.co"
			event-loggedIn="false"
			src="/js/script.pageview-props.js"
		></script>
		<script>
			window.plausible =
				window.plausible ||
				function () {
					(window.plausible.q = window.plausible.q || []).push(arguments);
				};
		</script>
		<script>
			window.hubConfig = {"features":{"signupDisabled":false},"sshGitUrl":"git@hf.co","moonHttpUrl":"https:\/\/huggingface.co","captchaApiKey":"bd5f2066-93dc-4bdd-a64b-a24646ca3859","captchaDisabledOnSignup":true,"datasetViewerPublicUrl":"https:\/\/datasets-server.huggingface.co","stripePublicKey":"pk_live_x2tdjFXBCvXo2FFmMybezpeM00J6gPCAAc","environment":"production","userAgent":"HuggingFace (production)","spacesIframeDomain":"hf.space","spacesApiUrl":"https:\/\/api.hf.space","docSearchKey":"ece5e02e57300e17d152c08056145326e90c4bff3dd07d7d1ae40cf1c8d39cb6","logoDev":{"apiUrl":"https:\/\/img.logo.dev\/","apiKey":"pk_UHS2HZOeRnaSOdDp7jbd5w"}};
		</script>
		<script type="text/javascript" src="https://de5282c3ca0c.edge.sdk.awswaf.com/de5282c3ca0c/526cf06acb0d/challenge.js" defer></script>
	</head>
	<body class="flex flex-col min-h-dvh bg-white dark:bg-gray-950 text-black DatasetPage">
		<div class="flex min-h-dvh flex-col"><div class="SVELTE_HYDRATER contents" data-target="SystemThemeMonitor" data-props="{&quot;isLoggedIn&quot;:false}"></div>

	<div class="SVELTE_HYDRATER contents" data-target="MainHeader" data-props="{&quot;classNames&quot;:&quot;&quot;,&quot;isWide&quot;:false,&quot;isZh&quot;:false,&quot;isPro&quot;:false}"><header class="border-b border-gray-100 "><div class="w-full px-4 container flex h-16 items-center"><div class="flex flex-1 items-center"><a class="mr-5 flex flex-none items-center lg:mr-6" href="/"><img alt="Hugging Face's logo" class="w-7 md:mr-2" src="/front/assets/huggingface_logo-noborder.svg">
				<span class="hidden whitespace-nowrap text-lg font-bold md:block">Hugging Face</span></a>
			<div class="relative flex-1 lg:max-w-sm mr-2 sm:mr-4 md:mr-3 xl:mr-6"><input autocomplete="off" class="w-full dark:bg-gray-950 pl-8 form-input-alt h-9 pr-3 focus:shadow-xl " name="" placeholder="Search models, datasets, users..."   spellcheck="false" type="text" value="">
	<svg class="absolute left-2.5 text-gray-400 top-1/2 transform -translate-y-1/2" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M30 28.59L22.45 21A11 11 0 1 0 21 22.45L28.59 30zM5 14a9 9 0 1 1 9 9a9 9 0 0 1-9-9z" fill="currentColor"></path></svg>
	</div>
			<div class="flex flex-none items-center justify-center p-0.5 place-self-stretch lg:hidden"><button class="relative z-40 flex h-6 w-8 items-center justify-center" type="button"><svg width="1em" height="1em" viewBox="0 0 10 10" class="text-xl" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" preserveAspectRatio="xMidYMid meet" fill="currentColor"><path fill-rule="evenodd" clip-rule="evenodd" d="M1.65039 2.9999C1.65039 2.8066 1.80709 2.6499 2.00039 2.6499H8.00039C8.19369 2.6499 8.35039 2.8066 8.35039 2.9999C8.35039 3.1932 8.19369 3.3499 8.00039 3.3499H2.00039C1.80709 3.3499 1.65039 3.1932 1.65039 2.9999ZM1.65039 4.9999C1.65039 4.8066 1.80709 4.6499 2.00039 4.6499H8.00039C8.19369 4.6499 8.35039 4.8066 8.35039 4.9999C8.35039 5.1932 8.19369 5.3499 8.00039 5.3499H2.00039C1.80709 5.3499 1.65039 5.1932 1.65039 4.9999ZM2.00039 6.6499C1.80709 6.6499 1.65039 6.8066 1.65039 6.9999C1.65039 7.1932 1.80709 7.3499 2.00039 7.3499H8.00039C8.19369 7.3499 8.35039 7.1932 8.35039 6.9999C8.35039 6.8066 8.19369 6.6499 8.00039 6.6499H2.00039Z"></path></svg>
		</button>

	</div></div>
		<nav aria-label="Main" class="ml-auto hidden lg:block"><ul class="flex items-center space-x-1.5 2xl:space-x-2"><li class="hover:text-indigo-700"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/models"><svg class="mr-1.5 text-gray-400 group-hover:text-indigo-500" style="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 24 24"><path class="uim-quaternary" d="M20.23 7.24L12 12L3.77 7.24a1.98 1.98 0 0 1 .7-.71L11 2.76c.62-.35 1.38-.35 2 0l6.53 3.77c.29.173.531.418.7.71z" opacity=".25" fill="currentColor"></path><path class="uim-tertiary" d="M12 12v9.5a2.09 2.09 0 0 1-.91-.21L4.5 17.48a2.003 2.003 0 0 1-1-1.73v-7.5a2.06 2.06 0 0 1 .27-1.01L12 12z" opacity=".5" fill="currentColor"></path><path class="uim-primary" d="M20.5 8.25v7.5a2.003 2.003 0 0 1-1 1.73l-6.62 3.82c-.275.13-.576.198-.88.2V12l8.23-4.76c.175.308.268.656.27 1.01z" fill="currentColor"></path></svg>
					Models</a>
			</li><li class="hover:text-red-700"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/datasets"><svg class="mr-1.5 text-gray-400 group-hover:text-red-500" style="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 25 25"><ellipse cx="12.5" cy="5" fill="currentColor" fill-opacity="0.25" rx="7.5" ry="2"></ellipse><path d="M12.5 15C16.6421 15 20 14.1046 20 13V20C20 21.1046 16.6421 22 12.5 22C8.35786 22 5 21.1046 5 20V13C5 14.1046 8.35786 15 12.5 15Z" fill="currentColor" opacity="0.5"></path><path d="M12.5 7C16.6421 7 20 6.10457 20 5V11.5C20 12.6046 16.6421 13.5 12.5 13.5C8.35786 13.5 5 12.6046 5 11.5V5C5 6.10457 8.35786 7 12.5 7Z" fill="currentColor" opacity="0.5"></path><path d="M5.23628 12C5.08204 12.1598 5 12.8273 5 13C5 14.1046 8.35786 15 12.5 15C16.6421 15 20 14.1046 20 13C20 12.8273 19.918 12.1598 19.7637 12C18.9311 12.8626 15.9947 13.5 12.5 13.5C9.0053 13.5 6.06886 12.8626 5.23628 12Z" fill="currentColor"></path></svg>
					Datasets</a>
			</li><li class="hover:text-blue-700"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/spaces"><svg class="mr-1.5 text-gray-400 group-hover:text-blue-500" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" viewBox="0 0 25 25"><path opacity=".5" d="M6.016 14.674v4.31h4.31v-4.31h-4.31ZM14.674 14.674v4.31h4.31v-4.31h-4.31ZM6.016 6.016v4.31h4.31v-4.31h-4.31Z" fill="currentColor"></path><path opacity=".75" fill-rule="evenodd" clip-rule="evenodd" d="M3 4.914C3 3.857 3.857 3 4.914 3h6.514c.884 0 1.628.6 1.848 1.414a5.171 5.171 0 0 1 7.31 7.31c.815.22 1.414.964 1.414 1.848v6.514A1.914 1.914 0 0 1 20.086 22H4.914A1.914 1.914 0 0 1 3 20.086V4.914Zm3.016 1.102v4.31h4.31v-4.31h-4.31Zm0 12.968v-4.31h4.31v4.31h-4.31Zm8.658 0v-4.31h4.31v4.31h-4.31Zm0-10.813a2.155 2.155 0 1 1 4.31 0 2.155 2.155 0 0 1-4.31 0Z" fill="currentColor"></path><path opacity=".25" d="M16.829 6.016a2.155 2.155 0 1 0 0 4.31 2.155 2.155 0 0 0 0-4.31Z" fill="currentColor"></path></svg>
					Spaces</a>
			</li><li class="hover:text-yellow-700 max-xl:hidden"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/posts"><svg class="mr-1.5 text-gray-400 group-hover:text-yellow-500 text-yellow-500!" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" viewBox="0 0 12 12" preserveAspectRatio="xMidYMid meet"><path fill="currentColor" fill-rule="evenodd" d="M3.73 2.4A4.25 4.25 0 1 1 6 10.26H2.17l-.13-.02a.43.43 0 0 1-.3-.43l.01-.06a.43.43 0 0 1 .12-.22l.84-.84A4.26 4.26 0 0 1 3.73 2.4Z" clip-rule="evenodd"></path></svg>
					Posts</a>
			</li><li class="hover:text-yellow-700"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/docs"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" class="mr-1.5 text-gray-400 group-hover:text-yellow-500" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 16 16"><path d="m2.28 3.7-.3.16a.67.67 0 0 0-.34.58v8.73l.01.04.02.07.01.04.03.06.02.04.02.03.04.06.05.05.04.04.06.04.06.04.08.04.08.02h.05l.07.02h.11l.04-.01.07-.02.03-.01.07-.03.22-.12a5.33 5.33 0 0 1 5.15.1.67.67 0 0 0 .66 0 5.33 5.33 0 0 1 5.33 0 .67.67 0 0 0 1-.58V4.36a.67.67 0 0 0-.34-.5l-.3-.17v7.78a.63.63 0 0 1-.87.59 4.9 4.9 0 0 0-4.35.35l-.65.39a.29.29 0 0 1-.15.04.29.29 0 0 1-.16-.04l-.65-.4a4.9 4.9 0 0 0-4.34-.34.63.63 0 0 1-.87-.59V3.7Z" fill="currentColor" class="dark:opacity-40"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M8 3.1a5.99 5.99 0 0 0-5.3-.43.66.66 0 0 0-.42.62v8.18c0 .45.46.76.87.59a4.9 4.9 0 0 1 4.34.35l.65.39c.05.03.1.04.16.04.05 0 .1-.01.15-.04l.65-.4a4.9 4.9 0 0 1 4.35-.34.63.63 0 0 0 .86-.59V3.3a.67.67 0 0 0-.41-.62 5.99 5.99 0 0 0-5.3.43l-.3.17L8 3.1Zm.73 1.87a.43.43 0 1 0-.86 0v5.48a.43.43 0 0 0 .86 0V4.97Z" fill="currentColor" class="opacity-40 dark:opacity-100"></path><path d="M8.73 4.97a.43.43 0 1 0-.86 0v5.48a.43.43 0 1 0 .86 0V4.96Z" fill="currentColor" class="dark:opacity-40"></path></svg>
					Docs</a>
			</li><li class="hover:text-black dark:hover:text-white"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/enterprise"><svg class="mr-1.5 text-gray-400 group-hover:text-black dark:group-hover:text-white" xmlns="http://www.w3.org/2000/svg" fill="none" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 33 27"><path fill="currentColor" fill-rule="evenodd" d="M13.5.7a8.7 8.7 0 0 0-7.7 5.7L1 20.6c-1 3.1.9 5.7 4.1 5.7h15c3.3 0 6.8-2.6 7.8-5.7l4.6-14.2c1-3.1-.8-5.7-4-5.7h-15Zm1.1 5.7L9.8 20.3h9.8l1-3.1h-5.8l.8-2.5h4.8l1.1-3h-4.8l.8-2.3H23l1-3h-9.5Z" clip-rule="evenodd"></path></svg>
					Enterprise</a>
			</li>

		<li><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/pricing">Pricing
			</a></li>

		<li><div class="relative group">
	<button class="px-2 py-0.5 hover:text-gray-500 dark:hover:text-gray-600 flex items-center " type="button">
		<svg class=" text-gray-500 w-5 group-hover:text-gray-400 dark:text-gray-300 dark:group-hover:text-gray-100" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" viewBox="0 0 32 18" preserveAspectRatio="xMidYMid meet"><path fill-rule="evenodd" clip-rule="evenodd" d="M14.4504 3.30221C14.4504 2.836 14.8284 2.45807 15.2946 2.45807H28.4933C28.9595 2.45807 29.3374 2.836 29.3374 3.30221C29.3374 3.76842 28.9595 4.14635 28.4933 4.14635H15.2946C14.8284 4.14635 14.4504 3.76842 14.4504 3.30221Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M14.4504 9.00002C14.4504 8.53382 14.8284 8.15588 15.2946 8.15588H28.4933C28.9595 8.15588 29.3374 8.53382 29.3374 9.00002C29.3374 9.46623 28.9595 9.84417 28.4933 9.84417H15.2946C14.8284 9.84417 14.4504 9.46623 14.4504 9.00002Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M14.4504 14.6978C14.4504 14.2316 14.8284 13.8537 15.2946 13.8537H28.4933C28.9595 13.8537 29.3374 14.2316 29.3374 14.6978C29.3374 15.164 28.9595 15.542 28.4933 15.542H15.2946C14.8284 15.542 14.4504 15.164 14.4504 14.6978Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M1.94549 6.87377C2.27514 6.54411 2.80962 6.54411 3.13928 6.87377L6.23458 9.96907L9.32988 6.87377C9.65954 6.54411 10.194 6.54411 10.5237 6.87377C10.8533 7.20343 10.8533 7.73791 10.5237 8.06756L6.23458 12.3567L1.94549 8.06756C1.61583 7.73791 1.61583 7.20343 1.94549 6.87377Z" fill="currentColor"></path></svg>
			
		</button>
	
	
	</div></li>
		<li><hr class="h-5 w-0.5 border-none bg-gray-100 dark:bg-gray-800"></li>
		<li><a class="block cursor-pointer whitespace-nowrap px-2 py-0.5 hover:text-gray-500 dark:text-gray-300 dark:hover:text-gray-100" href="/login">Log In
				</a></li>
			<li><a class="whitespace-nowrap rounded-full border border-transparent bg-gray-900 px-3 py-1 leading-none text-white hover:border-black hover:bg-white hover:text-black" href="/join">Sign Up
					</a></li></ul></nav></div></header></div>
	
	
	
	<div class="SVELTE_HYDRATER contents" data-target="SSOBanner" data-props="{}"></div>
	
	

	<main class="flex flex-1 flex-col">
	<div class="SVELTE_HYDRATER contents" data-target="DatasetHeader" data-props="{&quot;activeTab&quot;:&quot;datasetCard&quot;,&quot;author&quot;:{&quot;_id&quot;:&quot;64ad53921db46d71a5c576e5&quot;,&quot;avatarUrl&quot;:&quot;https://cdn-avatars.huggingface.co/v1/production/uploads/64ad53921db46d71a5c576e5/fH08R-GANVBhZdYCDQjeG.png&quot;,&quot;fullname&quot;:&quot;ChuGyouk&quot;,&quot;name&quot;:&quot;ChuGyouk&quot;,&quot;type&quot;:&quot;user&quot;,&quot;isPro&quot;:true,&quot;isHf&quot;:false,&quot;isHfAdmin&quot;:false,&quot;isMod&quot;:false,&quot;followerCount&quot;:21},&quot;canReadRepoSettings&quot;:false,&quot;dataset&quot;:{&quot;author&quot;:&quot;ChuGyouk&quot;,&quot;cardData&quot;:{&quot;dataset_info&quot;:{&quot;features&quot;:[{&quot;name&quot;:&quot;subject&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;year&quot;,&quot;dtype&quot;:&quot;int64&quot;},{&quot;name&quot;:&quot;period&quot;,&quot;dtype&quot;:&quot;int64&quot;},{&quot;name&quot;:&quot;q_number&quot;,&quot;dtype&quot;:&quot;int64&quot;},{&quot;name&quot;:&quot;question&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;A&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;B&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;C&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;D&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;E&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;answer&quot;,&quot;dtype&quot;:&quot;int64&quot;},{&quot;name&quot;:&quot;thinking&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;response&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;__index_level_0__&quot;,&quot;dtype&quot;:&quot;int64&quot;}],&quot;splits&quot;:[{&quot;name&quot;:&quot;train&quot;,&quot;num_bytes&quot;:76942094,&quot;num_examples&quot;:8751}],&quot;download_size&quot;:38580816,&quot;dataset_size&quot;:76942094},&quot;configs&quot;:[{&quot;config_name&quot;:&quot;default&quot;,&quot;data_files&quot;:[{&quot;split&quot;:&quot;train&quot;,&quot;path&quot;:&quot;data/train-*&quot;}]}]},&quot;cardExists&quot;:true,&quot;createdAt&quot;:&quot;2025-02-17T16:00:27.000Z&quot;,&quot;description&quot;:&quot;\n\t\n\t\t\n\t\tInformation\n\t\n\nThis data includes the training data from KorMedMCQA, as well as a portion of the trainind data from the additional KorMedMCQA support set (private).\nThis dataset is based on the responses generated by gemini-flash-thinking-exp-01-21 model and has undergone MANUAL rejection sampling.\n&quot;,&quot;downloads&quot;:22,&quot;downloadsAllTime&quot;:22,&quot;id&quot;:&quot;ChuGyouk/medical-o1-train-kormedmcqa&quot;,&quot;isLikedByUser&quot;:false,&quot;lastModified&quot;:&quot;2025-03-21T06:06:33.000Z&quot;,&quot;likes&quot;:5,&quot;datasetsServerInfo&quot;:{&quot;viewer&quot;:&quot;viewer&quot;,&quot;numRows&quot;:8751,&quot;libraries&quot;:[&quot;datasets&quot;,&quot;pandas&quot;,&quot;mlcroissant&quot;,&quot;polars&quot;],&quot;formats&quot;:[&quot;parquet&quot;],&quot;modalities&quot;:[&quot;tabular&quot;,&quot;text&quot;]},&quot;discussionsDisabled&quot;:false,&quot;repoType&quot;:&quot;dataset&quot;,&quot;private&quot;:false,&quot;gated&quot;:false,&quot;tags&quot;:[&quot;size_categories:1K<n<10K&quot;,&quot;format:parquet&quot;,&quot;modality:tabular&quot;,&quot;modality:text&quot;,&quot;library:datasets&quot;,&quot;library:pandas&quot;,&quot;library:mlcroissant&quot;,&quot;library:polars&quot;,&quot;region:us&quot;],&quot;tag_objs&quot;:[{&quot;id&quot;:&quot;size_categories:1K<n<10K&quot;,&quot;label&quot;:&quot;1K - 10K&quot;,&quot;type&quot;:&quot;size_categories&quot;},{&quot;id&quot;:&quot;format:parquet&quot;,&quot;label&quot;:&quot;parquet&quot;,&quot;type&quot;:&quot;format&quot;},{&quot;id&quot;:&quot;modality:tabular&quot;,&quot;label&quot;:&quot;Tabular&quot;,&quot;type&quot;:&quot;modality&quot;},{&quot;id&quot;:&quot;modality:text&quot;,&quot;label&quot;:&quot;Text&quot;,&quot;type&quot;:&quot;modality&quot;},{&quot;id&quot;:&quot;library:datasets&quot;,&quot;label&quot;:&quot;Datasets&quot;,&quot;type&quot;:&quot;library&quot;},{&quot;id&quot;:&quot;library:pandas&quot;,&quot;label&quot;:&quot;pandas&quot;,&quot;type&quot;:&quot;library&quot;},{&quot;id&quot;:&quot;library:mlcroissant&quot;,&quot;label&quot;:&quot;Croissant&quot;,&quot;type&quot;:&quot;library&quot;},{&quot;id&quot;:&quot;library:polars&quot;,&quot;label&quot;:&quot;Polars&quot;,&quot;type&quot;:&quot;library&quot;},{&quot;type&quot;:&quot;region&quot;,&quot;label&quot;:&quot;🇺🇸 Region: US&quot;,&quot;id&quot;:&quot;region:us&quot;}],&quot;hasBlockedOids&quot;:false,&quot;region&quot;:&quot;us&quot;,&quot;xetEnabled&quot;:false},&quot;discussionsStats&quot;:{&quot;closed&quot;:0,&quot;open&quot;:1,&quot;total&quot;:1}}"><header class="bg-linear-to-t border-b border-gray-100 pt-6 sm:pt-9 from-gray-50-to-white via-white dark:via-gray-950"><div class="container relative "><h1 class="flex flex-wrap items-center max-md:leading-tight mb-3 text-lg max-sm:gap-y-1.5 md:text-xl"><a href="/datasets" class="group flex items-center"><svg class="sm:mr-1.5 -mr-1 text-gray-400" style="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 25 25"><ellipse cx="12.5" cy="5" fill="currentColor" fill-opacity="0.25" rx="7.5" ry="2"></ellipse><path d="M12.5 15C16.6421 15 20 14.1046 20 13V20C20 21.1046 16.6421 22 12.5 22C8.35786 22 5 21.1046 5 20V13C5 14.1046 8.35786 15 12.5 15Z" fill="currentColor" opacity="0.5"></path><path d="M12.5 7C16.6421 7 20 6.10457 20 5V11.5C20 12.6046 16.6421 13.5 12.5 13.5C8.35786 13.5 5 12.6046 5 11.5V5C5 6.10457 8.35786 7 12.5 7Z" fill="currentColor" opacity="0.5"></path><path d="M5.23628 12C5.08204 12.1598 5 12.8273 5 13C5 14.1046 8.35786 15 12.5 15C16.6421 15 20 14.1046 20 13C20 12.8273 19.918 12.1598 19.7637 12C18.9311 12.8626 15.9947 13.5 12.5 13.5C9.0053 13.5 6.06886 12.8626 5.23628 12Z" fill="currentColor"></path></svg>
					<span class="mr-2.5 font-semibold text-gray-400 group-hover:text-gray-500 max-sm:hidden">Datasets:</span></a>
				<hr class="mx-1.5 h-2 translate-y-px rounded-sm border-r dark:border-gray-600 sm:hidden">
			<div class="group flex flex-none items-center"><div class="relative mr-1 flex items-center">

			

<span class="inline-block "><span class="contents"><a href="/ChuGyouk" class="text-gray-400 hover:text-blue-600"><img alt="" class="w-3.5 h-3.5 rounded-full  flex-none" src="https://cdn-avatars.huggingface.co/v1/production/uploads/64ad53921db46d71a5c576e5/fH08R-GANVBhZdYCDQjeG.png" crossorigin="anonymous"></a></span>
	</span></div>
		

<span class="inline-block "><span class="contents"><a href="/ChuGyouk" class="text-gray-400 hover:text-blue-600">ChuGyouk</a></span>
	</span>
		<div class="mx-0.5 text-gray-300">/</div></div>

<div class="max-w-full "><a class="break-words font-mono font-semibold hover:text-blue-600 " href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa">medical-o1-train-kormedmcqa</a>
	<button class="relative text-sm mr-4 focus:outline-hidden inline-flex cursor-pointer items-center text-sm  mx-0.5   text-gray-600 " title="Copy dataset name to clipboard" type="button"><svg class="" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" fill="currentColor" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M28,10V28H10V10H28m0-2H10a2,2,0,0,0-2,2V28a2,2,0,0,0,2,2H28a2,2,0,0,0,2-2V10a2,2,0,0,0-2-2Z" transform="translate(0)"></path><path d="M4,18H2V4A2,2,0,0,1,4,2H18V4H4Z" transform="translate(0)"></path><rect fill="none" width="32" height="32"></rect></svg>
	
	</button></div>
			<div class="inline-flex items-center overflow-hidden whitespace-nowrap rounded-md border bg-white text-sm leading-none text-gray-500  mr-2"><button class="relative flex items-center overflow-hidden from-red-50 to-transparent dark:from-red-900 px-1.5 py-1 hover:bg-linear-to-t focus:outline-hidden"  title="Like"><svg class="left-1.5 absolute" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32" fill="currentColor"><path d="M22.45,6a5.47,5.47,0,0,1,3.91,1.64,5.7,5.7,0,0,1,0,8L16,26.13,5.64,15.64a5.7,5.7,0,0,1,0-8,5.48,5.48,0,0,1,7.82,0L16,10.24l2.53-2.58A5.44,5.44,0,0,1,22.45,6m0-2a7.47,7.47,0,0,0-5.34,2.24L16,7.36,14.89,6.24a7.49,7.49,0,0,0-10.68,0,7.72,7.72,0,0,0,0,10.82L16,29,27.79,17.06a7.72,7.72,0,0,0,0-10.82A7.49,7.49,0,0,0,22.45,4Z"></path></svg>

		
		<span class="ml-4 pl-0.5 ">like</span></button>
	<button class="focus:outline-hidden flex items-center border-l px-1.5 py-1 text-gray-400 hover:bg-gray-50 focus:bg-gray-100 dark:hover:bg-gray-900 dark:focus:bg-gray-800" title="See users who liked this repository">5</button></div>




			
			
	</h1>
		<div class="mb-3 flex flex-wrap md:mb-4"><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">Modalities:
	</span>
	<a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?modality=modality%3Atabular"><div class="tag tag-white   ">
		<svg class="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path fill-rule="evenodd" clip-rule="evenodd" d="M4.619 4.619C2.667 6.572 2.667 9.715 2.667 16s0 9.43 1.952 11.38C6.572 29.333 9.715 29.333 16 29.333s9.43 0 11.38-1.953c1.953-1.952 1.953-5.095 1.953-11.38 0-6.285 0-9.427-1.953-11.381C25.428 2.667 22.285 2.667 16 2.667c-6.285 0-9.427 0-11.381 1.952ZM16.615 10a1 1 0 1 1 0 2h-1.23a1 1 0 1 1 0-2h1.23Zm0 5a1 1 0 1 1 0 2h-1.23a1 1 0 1 1 0-2h1.23Zm3.154 1a1 1 0 0 0 1 1H22a1 1 0 1 0 0-2h-1.23a1 1 0 0 0-1 1Zm-3.154 4a1 1 0 1 1 0 2h-1.23a1 1 0 1 1 0-2h1.23Zm3.154 1a1 1 0 0 0 1 1H22a1 1 0 1 0 0-2h-1.23a1 1 0 0 0-1 1Zm0-10a1 1 0 0 0 1 1H22a1 1 0 1 0 0-2h-1.23a1 1 0 0 0-1 1Zm-8.538-1H10a1 1 0 1 0 0 2h1.23a1 1 0 1 0 0-2Zm0 5H10a1 1 0 1 0 0 2h1.23a1 1 0 1 0 0-2Zm0 5H10a1 1 0 1 0 0 2h1.23a1 1 0 1 0 0-2Z" fill="currentColor"></path></svg>

	

	<span>Tabular</span>
	

	</div></a><a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?modality=modality%3Atext"><div class="tag tag-white   ">
		<svg class="text-red-700 dark:text-red-600" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path fill-rule="evenodd" clip-rule="evenodd" d="M4.619 4.619C2.667 6.573 2.667 9.715 2.667 16s0 9.428 1.952 11.38C6.573 29.333 9.715 29.333 16 29.333s9.428 0 11.38-1.953c1.953-1.95 1.953-5.095 1.953-11.38s0-9.428-1.953-11.381C25.43 2.667 22.285 2.667 16 2.667s-9.428 0-11.381 1.952m8.65 3.714c-.573 0-1.109 0-1.546.066-.495.073-1.003.248-1.41.7-.392.436-.53.956-.59 1.452-.056.464-.056 1.04-.056 1.689V13a1 1 0 1 0 2 0v-.704c0-.724.001-1.176.041-1.505q.015-.15.061-.294a.2.2 0 0 1 .031-.061q0-.003.016-.01a.8.8 0 0 1 .203-.05c.272-.04.654-.043 1.314-.043H15v11.334h-2.333a1 1 0 1 0 0 2H20a1 1 0 0 0 0-2h-3V10.333h1.667c.66 0 1.042.003 1.314.043.123.019.18.04.203.05l.015.009a.2.2 0 0 1 .032.061c.018.05.042.14.061.295.04.329.041.781.041 1.506V13a1 1 0 1 0 2 0v-.76c0-.65 0-1.225-.056-1.69-.06-.495-.198-1.015-.59-1.453-.407-.45-.915-.625-1.41-.698-.437-.067-.973-.067-1.546-.066z" fill="currentColor"></path></svg>

	

	<span>Text</span>
	

	</div></a>

	</div><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">Formats:
	</span>
	<a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?format=format%3Aparquet"><div class="tag tag-white   ">
		<svg class="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 34 34"><path fill-rule="evenodd" clip-rule="evenodd" d="m17.97 18.44-3.98-2.3-7.1 3.78 3.98 2.3 7.1-3.78Zm15.1-1.4-3.99-2.3-16.22 8.63 3.98 2.3 16.22-8.63Zm-5.98-3.45-3.97-2.3-7.1 3.78 3.98 2.3 7.1-3.78Zm-9.94-5.74 3.98 2.3-11.16 5.93L6 13.78l11.16-5.93Zm-13.19 7 3.98 2.3-3.04 1.62-3.98-2.3 3.04-1.61Z" fill="currentColor"></path></svg>

	

	<span>parquet</span>
	

	</div></a>

	</div><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">Size:
	</span>
	<a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?size_categories=size_categories%3A1K%3Cn%3C10K"><div class="tag tag-white   ">

	

	<span>1K - 10K</span>
	

	</div></a>

	</div><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">Libraries:
	</span>
	<a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?library=library%3Adatasets"><div class="tag tag-white   "><svg class="text-black inline-block text-sm" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" preserveAspectRatio="xMidYMid meet" width="1em" height="1em" viewBox="0 0 95 88"><path fill="#fff" d="M94.25 70.08a8.28 8.28 0 0 1-.43 6.46 10.57 10.57 0 0 1-3 3.6 25.18 25.18 0 0 1-5.7 3.2 65.74 65.74 0 0 1-7.56 2.65 46.67 46.67 0 0 1-11.42 1.68c-5.42.05-10.09-1.23-13.4-4.5a40.4 40.4 0 0 1-10.14.03c-3.34 3.25-7.99 4.52-13.39 4.47a46.82 46.82 0 0 1-11.43-1.68 66.37 66.37 0 0 1-7.55-2.65c-2.28-.98-4.17-2-5.68-3.2a10.5 10.5 0 0 1-3.02-3.6c-.99-2-1.18-4.3-.42-6.46a8.54 8.54 0 0 1-.33-5.63c.25-.95.66-1.83 1.18-2.61a8.67 8.67 0 0 1 2.1-8.47 8.23 8.23 0 0 1 2.82-2.07 41.75 41.75 0 1 1 81.3-.12 8.27 8.27 0 0 1 3.11 2.19 8.7 8.7 0 0 1 2.1 8.47c.52.78.93 1.66 1.18 2.61a8.61 8.61 0 0 1-.32 5.63Z"></path><path fill="#FFD21E" d="M47.21 76.5a34.75 34.75 0 1 0 0-69.5 34.75 34.75 0 0 0 0 69.5Z"></path><path fill="#FF9D0B" d="M81.96 41.75a34.75 34.75 0 1 0-69.5 0 34.75 34.75 0 0 0 69.5 0Zm-73.5 0a38.75 38.75 0 1 1 77.5 0 38.75 38.75 0 0 1-77.5 0Z"></path><path fill="#3A3B45" d="M58.5 32.3c1.28.44 1.78 3.06 3.07 2.38a5 5 0 1 0-6.76-2.07c.61 1.15 2.55-.72 3.7-.32ZM34.95 32.3c-1.28.44-1.79 3.06-3.07 2.38a5 5 0 1 1 6.76-2.07c-.61 1.15-2.56-.72-3.7-.32Z"></path><path fill="#FF323D" d="M46.96 56.29c9.83 0 13-8.76 13-13.26 0-2.34-1.57-1.6-4.09-.36-2.33 1.15-5.46 2.74-8.9 2.74-7.19 0-13-6.88-13-2.38s3.16 13.26 13 13.26Z"></path><path fill="#3A3B45" fill-rule="evenodd" d="M39.43 54a8.7 8.7 0 0 1 5.3-4.49c.4-.12.81.57 1.24 1.28.4.68.82 1.37 1.24 1.37.45 0 .9-.68 1.33-1.35.45-.7.89-1.38 1.32-1.25a8.61 8.61 0 0 1 5 4.17c3.73-2.94 5.1-7.74 5.1-10.7 0-2.34-1.57-1.6-4.09-.36l-.14.07c-2.31 1.15-5.39 2.67-8.77 2.67s-6.45-1.52-8.77-2.67c-2.6-1.29-4.23-2.1-4.23.29 0 3.05 1.46 8.06 5.47 10.97Z" clip-rule="evenodd"></path><path fill="#FF9D0B" d="M70.71 37a3.25 3.25 0 1 0 0-6.5 3.25 3.25 0 0 0 0 6.5ZM24.21 37a3.25 3.25 0 1 0 0-6.5 3.25 3.25 0 0 0 0 6.5ZM17.52 48c-1.62 0-3.06.66-4.07 1.87a5.97 5.97 0 0 0-1.33 3.76 7.1 7.1 0 0 0-1.94-.3c-1.55 0-2.95.59-3.94 1.66a5.8 5.8 0 0 0-.8 7 5.3 5.3 0 0 0-1.79 2.82c-.24.9-.48 2.8.8 4.74a5.22 5.22 0 0 0-.37 5.02c1.02 2.32 3.57 4.14 8.52 6.1 3.07 1.22 5.89 2 5.91 2.01a44.33 44.33 0 0 0 10.93 1.6c5.86 0 10.05-1.8 12.46-5.34 3.88-5.69 3.33-10.9-1.7-15.92-2.77-2.78-4.62-6.87-5-7.77-.78-2.66-2.84-5.62-6.25-5.62a5.7 5.7 0 0 0-4.6 2.46c-1-1.26-1.98-2.25-2.86-2.82A7.4 7.4 0 0 0 17.52 48Zm0 4c.51 0 1.14.22 1.82.65 2.14 1.36 6.25 8.43 7.76 11.18.5.92 1.37 1.31 2.14 1.31 1.55 0 2.75-1.53.15-3.48-3.92-2.93-2.55-7.72-.68-8.01.08-.02.17-.02.24-.02 1.7 0 2.45 2.93 2.45 2.93s2.2 5.52 5.98 9.3c3.77 3.77 3.97 6.8 1.22 10.83-1.88 2.75-5.47 3.58-9.16 3.58-3.81 0-7.73-.9-9.92-1.46-.11-.03-13.45-3.8-11.76-7 .28-.54.75-.76 1.34-.76 2.38 0 6.7 3.54 8.57 3.54.41 0 .7-.17.83-.6.79-2.85-12.06-4.05-10.98-8.17.2-.73.71-1.02 1.44-1.02 3.14 0 10.2 5.53 11.68 5.53.11 0 .2-.03.24-.1.74-1.2.33-2.04-4.9-5.2-5.21-3.16-8.88-5.06-6.8-7.33.24-.26.58-.38 1-.38 3.17 0 10.66 6.82 10.66 6.82s2.02 2.1 3.25 2.1c.28 0 .52-.1.68-.38.86-1.46-8.06-8.22-8.56-11.01-.34-1.9.24-2.85 1.31-2.85Z"></path><path fill="#FFD21E" d="M38.6 76.69c2.75-4.04 2.55-7.07-1.22-10.84-3.78-3.77-5.98-9.3-5.98-9.3s-.82-3.2-2.69-2.9c-1.87.3-3.24 5.08.68 8.01 3.91 2.93-.78 4.92-2.29 2.17-1.5-2.75-5.62-9.82-7.76-11.18-2.13-1.35-3.63-.6-3.13 2.2.5 2.79 9.43 9.55 8.56 11-.87 1.47-3.93-1.71-3.93-1.71s-9.57-8.71-11.66-6.44c-2.08 2.27 1.59 4.17 6.8 7.33 5.23 3.16 5.64 4 4.9 5.2-.75 1.2-12.28-8.53-13.36-4.4-1.08 4.11 11.77 5.3 10.98 8.15-.8 2.85-9.06-5.38-10.74-2.18-1.7 3.21 11.65 6.98 11.76 7.01 4.3 1.12 15.25 3.49 19.08-2.12Z"></path><path fill="#FF9D0B" d="M77.4 48c1.62 0 3.07.66 4.07 1.87a5.97 5.97 0 0 1 1.33 3.76 7.1 7.1 0 0 1 1.95-.3c1.55 0 2.95.59 3.94 1.66a5.8 5.8 0 0 1 .8 7 5.3 5.3 0 0 1 1.78 2.82c.24.9.48 2.8-.8 4.74a5.22 5.22 0 0 1 .37 5.02c-1.02 2.32-3.57 4.14-8.51 6.1-3.08 1.22-5.9 2-5.92 2.01a44.33 44.33 0 0 1-10.93 1.6c-5.86 0-10.05-1.8-12.46-5.34-3.88-5.69-3.33-10.9 1.7-15.92 2.78-2.78 4.63-6.87 5.01-7.77.78-2.66 2.83-5.62 6.24-5.62a5.7 5.7 0 0 1 4.6 2.46c1-1.26 1.98-2.25 2.87-2.82A7.4 7.4 0 0 1 77.4 48Zm0 4c-.51 0-1.13.22-1.82.65-2.13 1.36-6.25 8.43-7.76 11.18a2.43 2.43 0 0 1-2.14 1.31c-1.54 0-2.75-1.53-.14-3.48 3.91-2.93 2.54-7.72.67-8.01a1.54 1.54 0 0 0-.24-.02c-1.7 0-2.45 2.93-2.45 2.93s-2.2 5.52-5.97 9.3c-3.78 3.77-3.98 6.8-1.22 10.83 1.87 2.75 5.47 3.58 9.15 3.58 3.82 0 7.73-.9 9.93-1.46.1-.03 13.45-3.8 11.76-7-.29-.54-.75-.76-1.34-.76-2.38 0-6.71 3.54-8.57 3.54-.42 0-.71-.17-.83-.6-.8-2.85 12.05-4.05 10.97-8.17-.19-.73-.7-1.02-1.44-1.02-3.14 0-10.2 5.53-11.68 5.53-.1 0-.19-.03-.23-.1-.74-1.2-.34-2.04 4.88-5.2 5.23-3.16 8.9-5.06 6.8-7.33-.23-.26-.57-.38-.98-.38-3.18 0-10.67 6.82-10.67 6.82s-2.02 2.1-3.24 2.1a.74.74 0 0 1-.68-.38c-.87-1.46 8.05-8.22 8.55-11.01.34-1.9-.24-2.85-1.31-2.85Z"></path><path fill="#FFD21E" d="M56.33 76.69c-2.75-4.04-2.56-7.07 1.22-10.84 3.77-3.77 5.97-9.3 5.97-9.3s.82-3.2 2.7-2.9c1.86.3 3.23 5.08-.68 8.01-3.92 2.93.78 4.92 2.28 2.17 1.51-2.75 5.63-9.82 7.76-11.18 2.13-1.35 3.64-.6 3.13 2.2-.5 2.79-9.42 9.55-8.55 11 .86 1.47 3.92-1.71 3.92-1.71s9.58-8.71 11.66-6.44c2.08 2.27-1.58 4.17-6.8 7.33-5.23 3.16-5.63 4-4.9 5.2.75 1.2 12.28-8.53 13.36-4.4 1.08 4.11-11.76 5.3-10.97 8.15.8 2.85 9.05-5.38 10.74-2.18 1.69 3.21-11.65 6.98-11.76 7.01-4.31 1.12-15.26 3.49-19.08-2.12Z"></path></svg>

	

	<span>Datasets</span>
	

	</div></a><a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?library=library%3Apandas"><div class="tag tag-white   "><svg class="text-black inline-block text-sm text-[#130754] dark:text-gray-200" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" fill="currentColor" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid slice" viewBox="0 0 210.21 280.43"><rect fill="currentColor" x="74.51" y="43.03" width="24.09" height="50.02"></rect><rect fill="currentColor" x="74.51" y="145.78" width="24.09" height="50.02"></rect><rect fill="#ffca00" x="74.51" y="107.65" width="24.09" height="23.6"></rect><rect fill="currentColor" x="35.81" y="84.15" width="24.09" height="166.27"></rect><rect fill="currentColor" x="112.41" y="187.05" width="24.09" height="50.02"></rect><rect fill="currentColor" x="112.41" y="84.21" width="24.09" height="50.02"></rect><rect fill="#e70488" x="112.41" y="148.84" width="24.09" height="23.6"></rect><rect fill="currentColor" x="150.3" y="30" width="24.09" height="166.27"></rect></svg>

	

	<span>pandas</span>
	

	</div></a><div class="relative inline-block ">
	<button class="group mr-1 mb-1 md:mr-1.5 md:mb-1.5  rounded-lg rounded-br-none " type="button">
		<div class="tag tag-white   relative rounded-br-none pr-2.5"><svg class="text-black inline-block text-sm" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" fill="none" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M22.2812 12.2656L25.9532 15.7187C26.8932 16.6587 28.0913 17.3931 29.0313 16.4531C29.8594 15.7812 29.9332 14.1 29.9532 13.5C29.9532 11.5625 28.9219 8.375 27.25 6.71875C25.5604 5.04493 23.3782 3.91692 22.7032 3.78125L22.2812 12.2656Z" fill="#F5AB6A"></path><path d="M22.2812 12.2656L25.9532 15.7187C26.8932 16.6587 28.0913 17.3931 29.0313 16.4531C29.8594 15.7812 29.9332 14.1 29.9532 13.5C29.9532 11.5625 28.9219 8.375 27.25 6.71875C25.5604 5.04493 23.3782 3.91692 22.7032 3.78125L22.2812 12.2656Z" fill="url(#paint0_radial_18_31665)"></path><g filter="url(#filter0_f_18_31665)"><path d="M22.2849 12.1817L23.4375 13.2656L24.4375 4.70312C23.5121 4.1242 23.0198 3.96369 22.6563 3.89062L22.2849 12.1817Z" fill="url(#paint1_linear_18_31665)"></path></g><path d="M22.7969 3.05741L21.8437 2.65269C19.6421 1.96765 17.2344 1.81208 14.6719 2.23236C12.1094 2.65264 11.5156 3.2442 11.5156 3.2442C10.896 3.3674 10.8671 3.88898 11.1718 4.45363C13.0797 6.72576 15.176 13.4043 18.0469 14.2506C18.89 14.4662 21.3791 14.4776 22.2019 14.1593L22.3238 14.108C22.6692 13.9745 23.1672 13.2814 23.1875 12.9118L23.4219 4.03043C23.4523 3.59924 23.1484 3.25204 22.7969 3.05741Z" fill="url(#paint2_radial_18_31665)"></path><path d="M22.7969 3.05741L21.8437 2.65269C19.6421 1.96765 17.2344 1.81208 14.6719 2.23236C12.1094 2.65264 11.5156 3.2442 11.5156 3.2442C10.896 3.3674 10.8671 3.88898 11.1718 4.45363C13.0797 6.72576 15.176 13.4043 18.0469 14.2506C18.89 14.4662 21.3791 14.4776 22.2019 14.1593L22.3238 14.108C22.6692 13.9745 23.1672 13.2814 23.1875 12.9118L23.4219 4.03043C23.4523 3.59924 23.1484 3.25204 22.7969 3.05741Z" fill="url(#paint3_radial_18_31665)"></path><path d="M22.7969 3.05741L21.8437 2.65269C19.6421 1.96765 17.2344 1.81208 14.6719 2.23236C12.1094 2.65264 11.5156 3.2442 11.5156 3.2442C10.896 3.3674 10.8671 3.88898 11.1718 4.45363C13.0797 6.72576 15.176 13.4043 18.0469 14.2506C18.89 14.4662 21.3791 14.4776 22.2019 14.1593L22.3238 14.108C22.6692 13.9745 23.1672 13.2814 23.1875 12.9118L23.4219 4.03043C23.4523 3.59924 23.1484 3.25204 22.7969 3.05741Z" fill="url(#paint4_radial_18_31665)"></path><path d="M22.7969 3.05741L21.8437 2.65269C19.6421 1.96765 17.2344 1.81208 14.6719 2.23236C12.1094 2.65264 11.5156 3.2442 11.5156 3.2442C10.896 3.3674 10.8671 3.88898 11.1718 4.45363C13.0797 6.72576 15.176 13.4043 18.0469 14.2506C18.89 14.4662 21.3791 14.4776 22.2019 14.1593L22.3238 14.108C22.6692 13.9745 23.1672 13.2814 23.1875 12.9118L23.4219 4.03043C23.4523 3.59924 23.1484 3.25204 22.7969 3.05741Z" fill="url(#paint5_radial_18_31665)"></path><path d="M22.7969 3.05741L21.8437 2.65269C19.6421 1.96765 17.2344 1.81208 14.6719 2.23236C12.1094 2.65264 11.5156 3.2442 11.5156 3.2442C10.896 3.3674 10.8671 3.88898 11.1718 4.45363C13.0797 6.72576 15.176 13.4043 18.0469 14.2506C18.89 14.4662 21.3791 14.4776 22.2019 14.1593L22.3238 14.108C22.6692 13.9745 23.1672 13.2814 23.1875 12.9118L23.4219 4.03043C23.4523 3.59924 23.1484 3.25204 22.7969 3.05741Z" fill="url(#paint6_linear_18_31665)"></path><g filter="url(#filter1_f_18_31665)"><path d="M13.1016 2.72656C11.862 3.06924 11.5298 3.40016 11.5298 3.40016C10.9102 3.52335 10.936 4.11525 11.2408 4.6799C13.1487 6.95202 15.1361 13.2496 18.007 14.0958C18.2707 14.1633 18.6953 14.2107 19.1797 14.2344L13.1016 2.72656Z" fill="url(#paint7_linear_18_31665)"></path></g><path d="M12.2187 22.7187L15.7656 26.2031C16.7332 27.1171 17.3334 28.2487 16.4219 29.2188C15.7749 30.0687 14.2241 29.9933 13.625 30.0313C11.6883 30.0891 9.09014 29.5622 6.84373 27.5313C5.07737 25.9343 4.09321 23.688 3.93751 23.0156L12.2187 22.7187Z" fill="url(#paint8_radial_18_31665)"></path><path d="M12.2187 22.7187L15.7656 26.2031C16.7332 27.1171 17.3334 28.2487 16.4219 29.2188C15.7749 30.0687 14.2241 29.9933 13.625 30.0313C11.6883 30.0891 9.09014 29.5622 6.84373 27.5313C5.07737 25.9343 4.09321 23.688 3.93751 23.0156L12.2187 22.7187Z" fill="url(#paint9_radial_18_31665)"></path><g filter="url(#filter2_f_18_31665)"><path d="M12.0523 22.7916L13.2187 23.9375L4.81018 24.5721C4.4328 23.8671 4.20835 23.2768 4.14062 22.9844L12.0523 22.7916Z" fill="url(#paint10_linear_18_31665)"></path><path d="M12.0523 22.7916L13.2187 23.9375L4.81018 24.5721C4.4328 23.8671 4.20835 23.2768 4.14062 22.9844L12.0523 22.7916Z" fill="url(#paint11_radial_18_31665)"></path></g><path d="M2.99219 22.6484C2.07068 20.538 1.78913 17.4452 2.21096 15.0703C2.63279 12.6953 3.20759 11.951 3.20759 11.951C3.31231 11.3264 3.83281 11.2818 4.40626 11.5703C6.73409 13.4144 13.3119 15.2264 14.2432 18.0781C14.5947 19.3034 14.6279 21.3125 14.1641 22.5156C14.0409 22.8657 13.5 23.3516 13.0625 23.4141C12.625 23.4765 9.47656 23.3516 8.61719 23.3516C7.75781 23.3516 4.64844 23.6719 4.14062 23.6172C3.63281 23.5625 3.23437 23.2031 2.99219 22.6484Z" fill="#EC9F6A"></path><path d="M2.99219 22.6484C2.07068 20.538 1.78913 17.4452 2.21096 15.0703C2.63279 12.6953 3.20759 11.951 3.20759 11.951C3.31231 11.3264 3.83281 11.2818 4.40626 11.5703C6.73409 13.4144 13.3119 15.2264 14.2432 18.0781C14.5947 19.3034 14.6279 21.3125 14.1641 22.5156C14.0409 22.8657 13.5 23.3516 13.0625 23.4141C12.625 23.4765 9.47656 23.3516 8.61719 23.3516C7.75781 23.3516 4.64844 23.6719 4.14062 23.6172C3.63281 23.5625 3.23437 23.2031 2.99219 22.6484Z" fill="url(#paint12_radial_18_31665)"></path><path d="M2.99219 22.6484C2.07068 20.538 1.78913 17.4452 2.21096 15.0703C2.63279 12.6953 3.20759 11.951 3.20759 11.951C3.31231 11.3264 3.83281 11.2818 4.40626 11.5703C6.73409 13.4144 13.3119 15.2264 14.2432 18.0781C14.5947 19.3034 14.6279 21.3125 14.1641 22.5156C14.0409 22.8657 13.5 23.3516 13.0625 23.4141C12.625 23.4765 9.47656 23.3516 8.61719 23.3516C7.75781 23.3516 4.64844 23.6719 4.14062 23.6172C3.63281 23.5625 3.23437 23.2031 2.99219 22.6484Z" fill="url(#paint13_linear_18_31665)"></path><path d="M2.99219 22.6484C2.07068 20.538 1.78913 17.4452 2.21096 15.0703C2.63279 12.6953 3.20759 11.951 3.20759 11.951C3.31231 11.3264 3.83281 11.2818 4.40626 11.5703C6.73409 13.4144 13.3119 15.2264 14.2432 18.0781C14.5947 19.3034 14.6279 21.3125 14.1641 22.5156C14.0409 22.8657 13.5 23.3516 13.0625 23.4141C12.625 23.4765 9.47656 23.3516 8.61719 23.3516C7.75781 23.3516 4.64844 23.6719 4.14062 23.6172C3.63281 23.5625 3.23437 23.2031 2.99219 22.6484Z" fill="url(#paint14_radial_18_31665)"></path><path d="M2.99219 22.6484C2.07068 20.538 1.78913 17.4452 2.21096 15.0703C2.63279 12.6953 3.20759 11.951 3.20759 11.951C3.31231 11.3264 3.83281 11.2818 4.40626 11.5703C6.73409 13.4144 13.3119 15.2264 14.2432 18.0781C14.5947 19.3034 14.6279 21.3125 14.1641 22.5156C14.0409 22.8657 13.5 23.3516 13.0625 23.4141C12.625 23.4765 9.47656 23.3516 8.61719 23.3516C7.75781 23.3516 4.64844 23.6719 4.14062 23.6172C3.63281 23.5625 3.23437 23.2031 2.99219 22.6484Z" fill="url(#paint15_radial_18_31665)"></path><path d="M2.99219 22.6484C2.07068 20.538 1.78913 17.4452 2.21096 15.0703C2.63279 12.6953 3.20759 11.951 3.20759 11.951C3.31231 11.3264 3.83281 11.2818 4.40626 11.5703C6.73409 13.4144 13.3119 15.2264 14.2432 18.0781C14.5947 19.3034 14.6279 21.3125 14.1641 22.5156C14.0409 22.8657 13.5 23.3516 13.0625 23.4141C12.625 23.4765 9.47656 23.3516 8.61719 23.3516C7.75781 23.3516 4.64844 23.6719 4.14062 23.6172C3.63281 23.5625 3.23437 23.2031 2.99219 22.6484Z" fill="url(#paint16_radial_18_31665)"></path><g filter="url(#filter3_f_18_31665)"><path d="M2.70313 13.6719C3.04135 12.4711 3.36224 12.0555 3.36224 12.0555C3.46697 11.4309 3.98746 11.3864 4.56092 11.6749C6.88874 13.5189 13.0809 15.1104 14.0121 17.9622C14.1731 18.5231 14.2766 19.0394 14.3287 19.5128L2.70313 13.6719Z" fill="url(#paint17_linear_18_31665)"></path><path d="M2.70313 13.6719C3.04135 12.4711 3.36224 12.0555 3.36224 12.0555C3.46697 11.4309 3.98746 11.3864 4.56092 11.6749C6.88874 13.5189 13.0809 15.1104 14.0121 17.9622C14.1731 18.5231 14.2766 19.0394 14.3287 19.5128L2.70313 13.6719Z" fill="url(#paint18_linear_18_31665)"></path></g><path d="M9.83184 2.82184C6.62184 4.07184 4.07184 6.62184 2.82184 9.83184C2.48184 10.7118 2.82184 11.7018 3.62184 12.1918L14.0418 18.5418C14.6618 18.9218 15.4418 18.9218 16.0618 18.5418C17.0718 17.9218 17.9318 17.0718 18.5418 16.0618C18.9218 15.4418 18.9218 14.6618 18.5418 14.0418L12.1918 3.62184C11.7018 2.82184 10.7118 2.48184 9.83184 2.82184Z" fill="#D79453"></path><path d="M9.83184 2.82184C6.62184 4.07184 4.07184 6.62184 2.82184 9.83184C2.48184 10.7118 2.82184 11.7018 3.62184 12.1918L14.0418 18.5418C14.6618 18.9218 15.4418 18.9218 16.0618 18.5418C17.0718 17.9218 17.9318 17.0718 18.5418 16.0618C18.9218 15.4418 18.9218 14.6618 18.5418 14.0418L12.1918 3.62184C11.7018 2.82184 10.7118 2.48184 9.83184 2.82184Z" fill="url(#paint19_radial_18_31665)"></path><path d="M9.83184 2.82184C6.62184 4.07184 4.07184 6.62184 2.82184 9.83184C2.48184 10.7118 2.82184 11.7018 3.62184 12.1918L14.0418 18.5418C14.6618 18.9218 15.4418 18.9218 16.0618 18.5418C17.0718 17.9218 17.9318 17.0718 18.5418 16.0618C18.9218 15.4418 18.9218 14.6618 18.5418 14.0418L12.1918 3.62184C11.7018 2.82184 10.7118 2.48184 9.83184 2.82184Z" fill="url(#paint20_radial_18_31665)"></path><path d="M9.83184 2.82184C6.62184 4.07184 4.07184 6.62184 2.82184 9.83184C2.48184 10.7118 2.82184 11.7018 3.62184 12.1918L14.0418 18.5418C14.6618 18.9218 15.4418 18.9218 16.0618 18.5418C17.0718 17.9218 17.9318 17.0718 18.5418 16.0618C18.9218 15.4418 18.9218 14.6618 18.5418 14.0418L12.1918 3.62184C11.7018 2.82184 10.7118 2.48184 9.83184 2.82184Z" fill="url(#paint21_radial_18_31665)"></path><path d="M9.83184 2.82184C6.62184 4.07184 4.07184 6.62184 2.82184 9.83184C2.48184 10.7118 2.82184 11.7018 3.62184 12.1918L14.0418 18.5418C14.6618 18.9218 15.4418 18.9218 16.0618 18.5418C17.0718 17.9218 17.9318 17.0718 18.5418 16.0618C18.9218 15.4418 18.9218 14.6618 18.5418 14.0418L12.1918 3.62184C11.7018 2.82184 10.7118 2.48184 9.83184 2.82184Z" fill="url(#paint22_linear_18_31665)"></path><path d="M9.83184 2.82184C6.62184 4.07184 4.07184 6.62184 2.82184 9.83184C2.48184 10.7118 2.82184 11.7018 3.62184 12.1918L14.0418 18.5418C14.6618 18.9218 15.4418 18.9218 16.0618 18.5418C17.0718 17.9218 17.9318 17.0718 18.5418 16.0618C18.9218 15.4418 18.9218 14.6618 18.5418 14.0418L12.1918 3.62184C11.7018 2.82184 10.7118 2.48184 9.83184 2.82184Z" fill="url(#paint23_radial_18_31665)"></path><path d="M9.83184 2.82184C6.62184 4.07184 4.07184 6.62184 2.82184 9.83184C2.48184 10.7118 2.82184 11.7018 3.62184 12.1918L14.0418 18.5418C14.6618 18.9218 15.4418 18.9218 16.0618 18.5418C17.0718 17.9218 17.9318 17.0718 18.5418 16.0618C18.9218 15.4418 18.9218 14.6618 18.5418 14.0418L12.1918 3.62184C11.7018 2.82184 10.7118 2.48184 9.83184 2.82184Z" fill="url(#paint24_radial_18_31665)"></path><defs><filter id="filter0_f_18_31665" x="22.0349" y="3.64062" width="2.65265" height="9.875" filterUnits="userSpaceOnUse" color-interpolation-filters="sRGB"><feFlood flood-opacity="0" result="BackgroundImageFix"></feFlood><feBlend mode="normal" in="SourceGraphic" in2="BackgroundImageFix" result="shape"></feBlend><feGaussianBlur stdDeviation="0.125" result="effect1_foregroundBlur_18_31665"></feGaussianBlur></filter><filter id="filter1_f_18_31665" x="10.7815" y="2.47656" width="8.64819" height="12.0078" filterUnits="userSpaceOnUse" color-interpolation-filters="sRGB"><feFlood flood-opacity="0" result="BackgroundImageFix"></feFlood><feBlend mode="normal" in="SourceGraphic" in2="BackgroundImageFix" result="shape"></feBlend><feGaussianBlur stdDeviation="0.125" result="effect1_foregroundBlur_18_31665"></feGaussianBlur></filter><filter id="filter2_f_18_31665" x="3.89062" y="22.5416" width="9.57812" height="2.2804" filterUnits="userSpaceOnUse" color-interpolation-filters="sRGB"><feFlood flood-opacity="0" result="BackgroundImageFix"></feFlood><feBlend mode="normal" in="SourceGraphic" in2="BackgroundImageFix" result="shape"></feBlend><feGaussianBlur stdDeviation="0.125" result="effect1_foregroundBlur_18_31665"></feGaussianBlur></filter><filter id="filter3_f_18_31665" x="2.45312" y="11.2538" width="12.1255" height="8.50903" filterUnits="userSpaceOnUse" color-interpolation-filters="sRGB"><feFlood flood-opacity="0" result="BackgroundImageFix"></feFlood><feBlend mode="normal" in="SourceGraphic" in2="BackgroundImageFix" result="shape"></feBlend><feGaussianBlur stdDeviation="0.125" result="effect1_foregroundBlur_18_31665"></feGaussianBlur></filter><radialGradient id="paint0_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(22.8125 12.9375) rotate(42.7741) scale(12.5164 7.08839)"><stop offset="0.0937591" stop-color="#C05159"></stop><stop offset="0.553697" stop-color="#F6AC6A"></stop><stop offset="0.832916" stop-color="#FFD186"></stop><stop offset="0.916927" stop-color="#FFDC87"></stop></radialGradient><linearGradient id="paint1_linear_18_31665" x1="24.7344" y1="4.67187" x2="20.8594" y2="12.8906" gradientUnits="userSpaceOnUse"><stop stop-color="#EBD67C"></stop><stop offset="0.0655686" stop-color="#FFFFA6"></stop><stop offset="0.530552" stop-color="#F8C281"></stop><stop offset="0.937338" stop-color="#E99E6B"></stop></linearGradient><radialGradient id="paint2_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(22.9009 13.1847) rotate(-127.648) scale(14.3438 11.7966)"><stop stop-color="#FFBE66"></stop><stop offset="1" stop-color="#E2AE5B"></stop></radialGradient><radialGradient id="paint3_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(18 11.4375) rotate(53.9726) scale(11.9013 4.84018)"><stop stop-color="#D67C63"></stop><stop offset="1" stop-color="#D97D67" stop-opacity="0"></stop></radialGradient><radialGradient id="paint4_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(23 4.1875) rotate(45.7639) scale(3.31486 5.75622)"><stop stop-color="#FFE4A6"></stop><stop offset="0.711285" stop-color="#F8B76F"></stop><stop offset="1" stop-color="#F9B870" stop-opacity="0"></stop></radialGradient><radialGradient id="paint5_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(22.875 12.4375) rotate(88.9391) scale(3.37558 1.29066)"><stop stop-color="#FFBC67"></stop><stop offset="1" stop-color="#FFBC67" stop-opacity="0"></stop></radialGradient><linearGradient id="paint6_linear_18_31665" x1="20.375" y1="15.6875" x2="20.125" y2="12.7813" gradientUnits="userSpaceOnUse"><stop offset="0.461609" stop-color="#B45077"></stop><stop offset="0.855389" stop-color="#B75077" stop-opacity="0"></stop></linearGradient><linearGradient id="paint7_linear_18_31665" x1="12.9375" y1="2.57056" x2="18.5625" y2="14.3891" gradientUnits="userSpaceOnUse"><stop stop-color="#DDC173"></stop><stop offset="0.485173" stop-color="#D59F65"></stop><stop offset="1" stop-color="#E49966"></stop></linearGradient><radialGradient id="paint8_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(13.5625 23.5) rotate(109.113) scale(6.68078 10.2578)"><stop offset="0.165756" stop-color="#FFBF7E"></stop><stop offset="0.827674" stop-color="#DF8C6D"></stop><stop offset="1" stop-color="#B05A66"></stop></radialGradient><radialGradient id="paint9_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(15.1875 26) rotate(41.0652) scale(8.37243 2.03649)"><stop stop-color="#FFD483"></stop><stop offset="1" stop-color="#FFD688" stop-opacity="0"></stop></radialGradient><linearGradient id="paint10_linear_18_31665" x1="3.96063" y1="23.794" x2="13.3748" y2="23.5143" gradientUnits="userSpaceOnUse"><stop stop-color="#A8716F"></stop><stop offset="0.103615" stop-color="#B37173"></stop><stop offset="0.225484" stop-color="#DB9F84"></stop><stop offset="0.799889" stop-color="#F1BB8A"></stop><stop offset="1" stop-color="#FFD780"></stop></linearGradient><radialGradient id="paint11_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(11.4219 23.1719) rotate(-178.616) scale(3.23532 0.569081)"><stop offset="0.621498" stop-color="#AF5A3E"></stop><stop offset="1" stop-color="#B35445" stop-opacity="0"></stop></radialGradient><radialGradient id="paint12_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(13.625 19.125) rotate(-171.737) scale(15.2205 15.0767)"><stop offset="0.138435" stop-color="#FFB974"></stop><stop offset="0.403618" stop-color="#F2A56D"></stop><stop offset="0.925938" stop-color="#A16948"></stop></radialGradient><linearGradient id="paint13_linear_18_31665" x1="8.22184" y1="13.125" x2="6.81191" y2="15.4996" gradientUnits="userSpaceOnUse"><stop offset="0.610751" stop-color="#984847"></stop><stop offset="0.850075" stop-color="#9A4947" stop-opacity="0"></stop></linearGradient><radialGradient id="paint14_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(7.25 23.7461) scale(11.25 5.68361)"><stop stop-color="#C66364"></stop><stop offset="1" stop-color="#D4766B" stop-opacity="0"></stop></radialGradient><radialGradient id="paint15_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(7.875 23.5313) scale(10.0937 1.29657)"><stop stop-color="#B64B4B"></stop><stop offset="1" stop-color="#C56158" stop-opacity="0"></stop></radialGradient><radialGradient id="paint16_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(11.4375 19.875) rotate(-46.8882) scale(4.02385 7.51767)"><stop stop-color="#FFC083"></stop><stop offset="0.620218" stop-color="#FFBD7D" stop-opacity="0"></stop></radialGradient><linearGradient id="paint17_linear_18_31665" x1="2.8125" y1="13.0312" x2="14.5582" y2="18.9404" gradientUnits="userSpaceOnUse"><stop stop-color="#B89367"></stop><stop offset="1" stop-color="#C5835E"></stop></linearGradient><linearGradient id="paint18_linear_18_31665" x1="8.21875" y1="14.6406" x2="7.59349" y2="15.6717" gradientUnits="userSpaceOnUse"><stop offset="0.351552" stop-color="#A74746"></stop><stop offset="0.845198" stop-color="#A04346" stop-opacity="0"></stop></linearGradient><radialGradient id="paint19_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(15.5625 14.5625) rotate(140.244) scale(18.3733 13.7403)"><stop stop-color="#FDAE69"></stop><stop offset="0.729021" stop-color="#CE8C4F"></stop><stop offset="0.921546" stop-color="#AD7B45"></stop><stop offset="1" stop-color="#8B6B4A"></stop></radialGradient><radialGradient id="paint20_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(15.0625 7) rotate(65.3152) scale(11.0745 3.16547)"><stop offset="0.233237" stop-color="#FFD47C"></stop><stop offset="0.853648" stop-color="#FFD98B" stop-opacity="0"></stop></radialGradient><radialGradient id="paint21_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(15.3125 8.875) rotate(100.886) scale(6.6191 5.57808)"><stop offset="0.128419" stop-color="#FFD88C"></stop><stop offset="0.924134" stop-color="#FFBE7B" stop-opacity="0"></stop></radialGradient><linearGradient id="paint22_linear_18_31665" x1="7.25" y1="15.1875" x2="10.7588" y2="10.3142" gradientUnits="userSpaceOnUse"><stop offset="0.142353" stop-color="#C15F4D"></stop><stop offset="1" stop-color="#D58366" stop-opacity="0"></stop></linearGradient><radialGradient id="paint23_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(8.15625 15.7813) rotate(28.5422) scale(12.5574 1.96589)"><stop offset="0.149989" stop-color="#E4745D"></stop><stop offset="0.453292" stop-color="#C8604C"></stop><stop offset="0.632597" stop-color="#C0605F"></stop><stop offset="1" stop-color="#C0605F" stop-opacity="0"></stop></radialGradient><radialGradient id="paint24_radial_18_31665" cx="0" cy="0" r="1" gradientUnits="userSpaceOnUse" gradientTransform="translate(1.40625 2.69067) rotate(46.0943) scale(22.3963)"><stop offset="0.935802" stop-color="#C17C61" stop-opacity="0"></stop><stop offset="0.982109" stop-color="#C17C61"></stop></radialGradient></defs></svg>

	

	<span>Croissant</span>
	

	<div class="border-br-gray-200 absolute bottom-0.5 right-0.5 h-1 w-1 border-[3px] border-l-transparent border-t-transparent border-b-gray-200 border-r-gray-200 dark:border-b-gray-700 dark:border-r-gray-700"></div></div>
		
		</button>
	
	
	</div>

	<button class="tag tag-ghost px-1! -ml-0.5 mb-1 md:mb-1.5" type="button">+ 1</button></div></div>

		<div class="flex flex-col-reverse lg:flex-row lg:items-center lg:justify-between"><div class="-mb-px flex h-12 items-center overflow-x-auto overflow-y-hidden ">
	<a class="tab-alternate active" href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa"><svg class="mr-1.5 text-gray-400 flex-none" style="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 24 24"><path class="uim-quaternary" d="M20.23 7.24L12 12L3.77 7.24a1.98 1.98 0 0 1 .7-.71L11 2.76c.62-.35 1.38-.35 2 0l6.53 3.77c.29.173.531.418.7.71z" opacity=".25" fill="currentColor"></path><path class="uim-tertiary" d="M12 12v9.5a2.09 2.09 0 0 1-.91-.21L4.5 17.48a2.003 2.003 0 0 1-1-1.73v-7.5a2.06 2.06 0 0 1 .27-1.01L12 12z" opacity=".5" fill="currentColor"></path><path class="uim-primary" d="M20.5 8.25v7.5a2.003 2.003 0 0 1-1 1.73l-6.62 3.82c-.275.13-.576.198-.88.2V12l8.23-4.76c.175.308.268.656.27 1.01z" fill="currentColor"></path></svg>
	Dataset card
	

	
		</a><a class="tab-alternate" href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/viewer/"><svg class="mr-1.5 text-gray-400 flex-none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 12 12"><path fill="currentColor" d="M2.5 2h7a1 1 0 0 1 1 1v6a1 1 0 0 1-1 1h-7a1 1 0 0 1-1-1V3a1 1 0 0 1 1-1Zm0 2v2h3V4h-3Zm4 0v2h3V4h-3Zm-4 3v2h3V7h-3Zm4 0v2h3V7h-3Z"></path></svg>
	Data Studio
	

	
		</a><a class="tab-alternate" href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/tree/main"><svg class="mr-1.5 text-gray-400 flex-none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 24 24"><path class="uim-tertiary" d="M21 19h-8a1 1 0 0 1 0-2h8a1 1 0 0 1 0 2zm0-4h-8a1 1 0 0 1 0-2h8a1 1 0 0 1 0 2zm0-8h-8a1 1 0 0 1 0-2h8a1 1 0 0 1 0 2zm0 4h-8a1 1 0 0 1 0-2h8a1 1 0 0 1 0 2z" opacity=".5" fill="currentColor"></path><path class="uim-primary" d="M9 19a1 1 0 0 1-1-1V6a1 1 0 0 1 2 0v12a1 1 0 0 1-1 1zm-6-4.333a1 1 0 0 1-.64-1.769L3.438 12l-1.078-.898a1 1 0 0 1 1.28-1.538l2 1.667a1 1 0 0 1 0 1.538l-2 1.667a.999.999 0 0 1-.64.231z" fill="currentColor"></path></svg>
	<span class="xl:hidden">Files</span>
		<span class="hidden xl:inline">Files and versions</span>
	

	
		</a><a class="tab-alternate" href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/discussions"><svg class="mr-1.5 text-gray-400 flex-none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M20.6081 3C21.7684 3 22.8053 3.49196 23.5284 4.38415C23.9756 4.93678 24.4428 5.82749 24.4808 7.16133C24.9674 7.01707 25.4353 6.93643 25.8725 6.93643C26.9833 6.93643 27.9865 7.37587 28.696 8.17411C29.6075 9.19872 30.0124 10.4579 29.8361 11.7177C29.7523 12.3177 29.5581 12.8555 29.2678 13.3534C29.8798 13.8646 30.3306 14.5763 30.5485 15.4322C30.719 16.1032 30.8939 17.5006 29.9808 18.9403C30.0389 19.0342 30.0934 19.1319 30.1442 19.2318C30.6932 20.3074 30.7283 21.5229 30.2439 22.6548C29.5093 24.3704 27.6841 25.7219 24.1397 27.1727C21.9347 28.0753 19.9174 28.6523 19.8994 28.6575C16.9842 29.4379 14.3477 29.8345 12.0653 29.8345C7.87017 29.8345 4.8668 28.508 3.13831 25.8921C0.356375 21.6797 0.754104 17.8269 4.35369 14.1131C6.34591 12.058 7.67023 9.02782 7.94613 8.36275C8.50224 6.39343 9.97271 4.20438 12.4172 4.20438H12.4179C12.6236 4.20438 12.8314 4.2214 13.0364 4.25468C14.107 4.42854 15.0428 5.06476 15.7115 6.02205C16.4331 5.09583 17.134 4.359 17.7682 3.94323C18.7242 3.31737 19.6794 3 20.6081 3ZM20.6081 5.95917C20.2427 5.95917 19.7963 6.1197 19.3039 6.44225C17.7754 7.44319 14.8258 12.6772 13.7458 14.7131C13.3839 15.3952 12.7655 15.6837 12.2086 15.6837C11.1036 15.6837 10.2408 14.5497 12.1076 13.1085C14.9146 10.9402 13.9299 7.39584 12.5898 7.1776C12.5311 7.16799 12.4731 7.16355 12.4172 7.16355C11.1989 7.16355 10.6615 9.33114 10.6615 9.33114C10.6615 9.33114 9.0863 13.4148 6.38031 16.206C3.67434 18.998 3.5346 21.2388 5.50675 24.2246C6.85185 26.2606 9.42666 26.8753 12.0653 26.8753C14.8021 26.8753 17.6077 26.2139 19.1799 25.793C19.2574 25.7723 28.8193 22.984 27.6081 20.6107C27.4046 20.212 27.0693 20.0522 26.6471 20.0522C24.9416 20.0522 21.8393 22.6726 20.5057 22.6726C20.2076 22.6726 19.9976 22.5416 19.9116 22.222C19.3433 20.1173 28.552 19.2325 27.7758 16.1839C27.639 15.6445 27.2677 15.4256 26.746 15.4263C24.4923 15.4263 19.4358 19.5181 18.3759 19.5181C18.2949 19.5181 18.2368 19.4937 18.2053 19.4419C17.6743 18.557 17.9653 17.9394 21.7082 15.6009C25.4511 13.2617 28.0783 11.8545 26.5841 10.1752C26.4121 9.98141 26.1684 9.8956 25.8725 9.8956C23.6001 9.89634 18.2311 14.9403 18.2311 14.9403C18.2311 14.9403 16.7821 16.496 15.9057 16.496C15.7043 16.496 15.533 16.4139 15.4169 16.2112C14.7956 15.1296 21.1879 10.1286 21.5484 8.06535C21.7928 6.66715 21.3771 5.95917 20.6081 5.95917Z" fill="#FF9D00"></path><path d="M5.50686 24.2246C3.53472 21.2387 3.67446 18.9979 6.38043 16.206C9.08641 13.4147 10.6615 9.33111 10.6615 9.33111C10.6615 9.33111 11.2499 6.95933 12.59 7.17757C13.93 7.39581 14.9139 10.9401 12.1069 13.1084C9.29997 15.276 12.6659 16.7489 13.7459 14.713C14.8258 12.6772 17.7747 7.44316 19.304 6.44221C20.8326 5.44128 21.9089 6.00204 21.5484 8.06532C21.188 10.1286 14.795 15.1295 15.4171 16.2118C16.0391 17.2934 18.2312 14.9402 18.2312 14.9402C18.2312 14.9402 25.0907 8.49588 26.5842 10.1752C28.0776 11.8545 25.4512 13.2616 21.7082 15.6008C17.9646 17.9393 17.6744 18.557 18.2054 19.4418C18.7372 20.3266 26.9998 13.1351 27.7759 16.1838C28.5513 19.2324 19.3434 20.1173 19.9117 22.2219C20.48 24.3274 26.3979 18.2382 27.6082 20.6107C28.8193 22.9839 19.2574 25.7722 19.18 25.7929C16.0914 26.62 8.24723 28.3726 5.50686 24.2246Z" fill="#FFD21E"></path></svg>
	Community
	<div class="ml-1.5 flex h-4 min-w-[1rem] items-center justify-center rounded px-1 text-xs leading-none shadow-sm bg-black text-white dark:bg-gray-800 dark:text-gray-200">1</div>

	
		</a></div>
	
			</div></div></header>
</div>
	
<div class="container relative flex flex-col md:grid md:space-y-0 w-full md:grid-cols-12 md:flex-1 md:grid-rows-full space-y-4 md:gap-6 ">
		<section class="pt-6 border-gray-100 md:col-span-8 pb-24 relative break-words copiable-code-container">
				<div class="SVELTE_HYDRATER contents" data-target="UnsafeBanner" data-props="{&quot;classNames&quot;:&quot;mb-4&quot;,&quot;repoId&quot;:&quot;ChuGyouk/medical-o1-train-kormedmcqa&quot;,&quot;repoType&quot;:&quot;dataset&quot;,&quot;minLevel&quot;:&quot;unsafe&quot;}"></div>
					<div class="SVELTE_HYDRATER contents" data-target="DatasetViewer" data-props="{&quot;data&quot;:{&quot;kind&quot;:&quot;DatasetAndSampleData&quot;,&quot;datasetInfo&quot;:[{&quot;isValid&quot;:true,&quot;href&quot;:&quot;&quot;,&quot;label&quot;:&quot;Size of downloaded dataset files:&quot;,&quot;value&quot;:&quot;38.6 MB&quot;},{&quot;isValid&quot;:true,&quot;href&quot;:&quot;/datasets/ChuGyouk/medical-o1-train-kormedmcqa/tree/refs%2Fconvert%2Fparquet/&quot;,&quot;label&quot;:&quot;Size of the auto-converted Parquet files:&quot;,&quot;value&quot;:&quot;38.6 MB&quot;},{&quot;isValid&quot;:true,&quot;href&quot;:&quot;&quot;,&quot;label&quot;:&quot;Number of rows:&quot;,&quot;value&quot;:&quot;8,751&quot;}],&quot;partial&quot;:false,&quot;configsData&quot;:{&quot;configInfos&quot;:[{&quot;name&quot;:&quot;default&quot;,&quot;status&quot;:&quot;ok&quot;,&quot;numRows&quot;:8751}],&quot;selectedConfig&quot;:&quot;default&quot;,&quot;hasSelectedConfigParquet&quot;:true},&quot;splitsData&quot;:{&quot;splitInfos&quot;:[{&quot;name&quot;:&quot;train&quot;,&quot;numRows&quot;:8751}],&quot;selectedSplit&quot;:&quot;train&quot;},&quot;sampleData&quot;:{&quot;dataset&quot;:&quot;ChuGyouk/medical-o1-train-kormedmcqa&quot;,&quot;config&quot;:&quot;default&quot;,&quot;split&quot;:&quot;train&quot;,&quot;capabilities&quot;:{&quot;rows&quot;:true,&quot;search&quot;:true,&quot;filter&quot;:true,&quot;statistics&quot;:true},&quot;navigation&quot;:{&quot;p&quot;:0},&quot;jwt&quot;:&quot;eyJhbGciOiJFZERTQSJ9.eyJyZWFkIjp0cnVlLCJwZXJtaXNzaW9ucyI6eyJyZXBvLmNvbnRlbnQucmVhZCI6dHJ1ZX0sImlhdCI6MTc0MjkxODU5NSwic3ViIjoiL2RhdGFzZXRzL0NodUd5b3VrL21lZGljYWwtbzEtdHJhaW4ta29ybWVkbWNxYSIsImV4cCI6MTc0MjkyMjE5NSwiaXNzIjoiaHR0cHM6Ly9odWdnaW5nZmFjZS5jbyJ9.g808faITaKa-pthwVwEDvQiTnhFE-F3DXBvuwxgcS-G0noSf5EX_9TjNaEoxLe-Pnrn8vbE91HdDdvAeKzL-Dw&quot;,&quot;sampleData&quot;:{&quot;columns&quot;:[{&quot;name&quot;:&quot;subject&quot;,&quot;align&quot;:&quot;depends on text direction&quot;,&quot;type&quot;:&quot;string&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;subject&quot;,&quot;column_type&quot;:&quot;string_label&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;no_label_count&quot;:0,&quot;no_label_proportion&quot;:0,&quot;n_unique&quot;:10,&quot;frequencies&quot;:{&quot;physical_therapist&quot;:867,&quot;pharm&quot;:888,&quot;doctor&quot;:1875,&quot;paramedic_1&quot;:681,&quot;medical_laboratory_technologist&quot;:977,&quot;dentist&quot;:514,&quot;dental_hygienist&quot;:817,&quot;dental_technician&quot;:844,&quot;nurse&quot;:820,&quot;nurse_assistant&quot;:468}}}},{&quot;name&quot;:&quot;year&quot;,&quot;align&quot;:&quot;right&quot;,&quot;type&quot;:&quot;int64&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;year&quot;,&quot;column_type&quot;:&quot;int&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:2012,&quot;max&quot;:2024,&quot;mean&quot;:2019.80368,&quot;median&quot;:2020,&quot;std&quot;:2.75757,&quot;histogram&quot;:{&quot;hist&quot;:[522,436,343,1574,3640,2142,94],&quot;bin_edges&quot;:[2012,2014,2016,2018,2020,2022,2024,2024]}}}},{&quot;name&quot;:&quot;period&quot;,&quot;align&quot;:&quot;right&quot;,&quot;type&quot;:&quot;int64&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;period&quot;,&quot;column_type&quot;:&quot;int&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:1,&quot;max&quot;:7,&quot;mean&quot;:2.03051,&quot;median&quot;:2,&quot;std&quot;:1.25004,&quot;histogram&quot;:{&quot;hist&quot;:[3761,2853,1017,596,314,173,37],&quot;bin_edges&quot;:[1,2,3,4,5,6,7,7]}}}},{&quot;name&quot;:&quot;q_number&quot;,&quot;align&quot;:&quot;right&quot;,&quot;type&quot;:&quot;int64&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;q_number&quot;,&quot;column_type&quot;:&quot;int&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:1,&quot;max&quot;:120,&quot;mean&quot;:48.02765,&quot;median&quot;:47,&quot;std&quot;:28.51835,&quot;histogram&quot;:{&quot;hist&quot;:[1143,1090,1117,1151,1194,1107,866,654,350,79],&quot;bin_edges&quot;:[1,13,25,37,49,61,73,85,97,109,120]}}}},{&quot;name&quot;:&quot;question&quot;,&quot;align&quot;:&quot;depends on text direction&quot;,&quot;type&quot;:&quot;string&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;question&quot;,&quot;column_type&quot;:&quot;string_text&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:1,&quot;max&quot;:646,&quot;mean&quot;:90.32328,&quot;median&quot;:57,&quot;std&quot;:88.73939,&quot;histogram&quot;:{&quot;hist&quot;:[4949,2055,786,393,265,150,93,40,15,5],&quot;bin_edges&quot;:[1,66,131,196,261,326,391,456,521,586,646]}}}},{&quot;name&quot;:&quot;A&quot;,&quot;align&quot;:&quot;depends on text direction&quot;,&quot;type&quot;:&quot;string&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;A&quot;,&quot;column_type&quot;:&quot;string_text&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:1,&quot;max&quot;:57,&quot;mean&quot;:9.08468,&quot;median&quot;:6,&quot;std&quot;:7.15048,&quot;histogram&quot;:{&quot;hist&quot;:[4557,1780,1414,693,198,73,25,8,2,1],&quot;bin_edges&quot;:[1,7,13,19,25,31,37,43,49,55,57]}}}},{&quot;name&quot;:&quot;B&quot;,&quot;align&quot;:&quot;depends on text direction&quot;,&quot;type&quot;:&quot;string&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;B&quot;,&quot;column_type&quot;:&quot;string_text&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:1,&quot;max&quot;:71,&quot;mean&quot;:10.60336,&quot;median&quot;:7,&quot;std&quot;:8.06685,&quot;histogram&quot;:{&quot;hist&quot;:[4796,1914,1477,424,109,26,1,3,1],&quot;bin_edges&quot;:[1,9,17,25,33,41,49,57,65,71]}}}},{&quot;name&quot;:&quot;C&quot;,&quot;align&quot;:&quot;depends on text direction&quot;,&quot;type&quot;:&quot;string&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;C&quot;,&quot;column_type&quot;:&quot;string_text&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:1,&quot;max&quot;:72,&quot;mean&quot;:12.06194,&quot;median&quot;:8,&quot;std&quot;:9.04837,&quot;histogram&quot;:{&quot;hist&quot;:[4378,1841,1587,693,186,49,11,5,1],&quot;bin_edges&quot;:[1,9,17,25,33,41,49,57,65,72]}}}},{&quot;name&quot;:&quot;D&quot;,&quot;align&quot;:&quot;depends on text direction&quot;,&quot;type&quot;:&quot;string&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;D&quot;,&quot;column_type&quot;:&quot;string_text&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:1,&quot;max&quot;:77,&quot;mean&quot;:13.75431,&quot;median&quot;:10,&quot;std&quot;:10.19524,&quot;histogram&quot;:{&quot;hist&quot;:[3864,1914,1579,904,351,91,32,11,4,1],&quot;bin_edges&quot;:[1,9,17,25,33,41,49,57,65,73,77]}}}},{&quot;name&quot;:&quot;E&quot;,&quot;align&quot;:&quot;depends on text direction&quot;,&quot;type&quot;:&quot;string&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;E&quot;,&quot;column_type&quot;:&quot;string_text&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:1,&quot;max&quot;:101,&quot;mean&quot;:16.23746,&quot;median&quot;:12,&quot;std&quot;:12.01406,&quot;histogram&quot;:{&quot;hist&quot;:[4189,2136,1569,639,161,39,12,4,1,1],&quot;bin_edges&quot;:[1,12,23,34,45,56,67,78,89,100,101]}}}},{&quot;name&quot;:&quot;answer&quot;,&quot;align&quot;:&quot;right&quot;,&quot;type&quot;:&quot;int64&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;answer&quot;,&quot;column_type&quot;:&quot;int&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:1,&quot;max&quot;:5,&quot;mean&quot;:3.10627,&quot;median&quot;:3,&quot;std&quot;:1.40534,&quot;histogram&quot;:{&quot;hist&quot;:[1540,1684,1754,1852,1921],&quot;bin_edges&quot;:[1,2,3,4,5,5]}}}},{&quot;name&quot;:&quot;thinking&quot;,&quot;align&quot;:&quot;depends on text direction&quot;,&quot;type&quot;:&quot;string&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;thinking&quot;,&quot;column_type&quot;:&quot;string_text&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:646,&quot;max&quot;:27750,&quot;mean&quot;:5498.54657,&quot;median&quot;:5352,&quot;std&quot;:1773.52489,&quot;histogram&quot;:{&quot;hist&quot;:[655,5484,2280,240,67,14,4,2,3,2],&quot;bin_edges&quot;:[646,3357,6068,8779,11490,14201,16912,19623,22334,25045,27750]}}}},{&quot;name&quot;:&quot;response&quot;,&quot;align&quot;:&quot;depends on text direction&quot;,&quot;type&quot;:&quot;string&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;response&quot;,&quot;column_type&quot;:&quot;string_text&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:105,&quot;max&quot;:3328,&quot;mean&quot;:1227.67455,&quot;median&quot;:1174,&quot;std&quot;:370.18657,&quot;histogram&quot;:{&quot;hist&quot;:[50,472,2723,3196,1458,568,197,67,16,4],&quot;bin_edges&quot;:[105,428,751,1074,1397,1720,2043,2366,2689,3012,3328]}}}},{&quot;name&quot;:&quot;__index_level_0__&quot;,&quot;align&quot;:&quot;right&quot;,&quot;type&quot;:&quot;int64&quot;,&quot;statistics&quot;:{&quot;column_name&quot;:&quot;__index_level_0__&quot;,&quot;column_type&quot;:&quot;int&quot;,&quot;column_statistics&quot;:{&quot;nan_count&quot;:0,&quot;nan_proportion&quot;:0,&quot;min&quot;:0,&quot;max&quot;:8343,&quot;mean&quot;:3986.92915,&quot;median&quot;:3968,&quot;std&quot;:2496.3533,&quot;histogram&quot;:{&quot;hist&quot;:[1242,835,835,835,835,835,835,835,835,829],&quot;bin_edges&quot;:[0,835,1670,2505,3340,4175,5010,5845,6680,7515,8343]}}}}],&quot;rows&quot;:[{&quot;rowIdx&quot;:0,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;paramedic_1&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2023,&quot;string&quot;:&quot;2,023&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:90,&quot;string&quot;:&quot;90&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;과량투여 시 피부 및 점막의 건조, 동공확대, 고체온 등의 중독 증상이 나타나며 피소스티그민(피조스티그민)을 해독제로 사용할 수 있는 물질은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;다이아제팜&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;아트로핀&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;살충제&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;모르핀&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;에탄올&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;\nThe question is asking for a substance that, when overdosed, causes symptoms like dry skin and mucous membranes, dilated pupils, and hyperthermia, and for which physostigmine is used as an antidote.  Let's analyze each option and see which one fits the description.\n\n* **Symptoms described:** Dry skin and mucous membranes, dilated pupils, hyperthermia. These are classic signs of **anticholinergic toxicity**.  Anticholinergic drugs block the action of acetylcholine, a neurotransmitter responsible for various functions, including muscle contraction, gland secretions, and heart rate regulation. Blocking acetylcholine leads to these symptoms.\n\n* **Physostigmine as an antidote:** Physostigmine is a cholinesterase inhibitor. It increases the level of acetylcholine in the synapse by preventing its breakdown.  It's used as an antidote for anticholinergic poisoning because it counteracts the effects of anticholinergic drugs by increasing acetylcholine levels, thus overcoming the blockade.\n\nNow let's examine each option:\n\n* **A. 다이아제팜 (Diazepam):**  Diazepam is a benzodiazepine, primarily used as an anxiolytic, sedative, muscle relaxant, and anticonvulsant.  Overdose symptoms of diazepam include drowsiness, confusion, impaired coordination, and respiratory depression.  It's not typically associated with anticholinergic effects like dry skin, dilated pupils, and hyperthermia.  Flumazenil is the antidote for benzodiazepine overdose, not physostigmine.\n\n* **B. 아트로핀 (Atropine):** Atropine is a classic anticholinergic drug. It's a muscarinic antagonist, meaning it blocks the muscarinic acetylcholine receptors.  Overdose of atropine would directly cause the symptoms listed: dry skin (decreased sweating), dry mucous membranes (decreased saliva), dilated pupils (mydriasis), and hyperthermia (due to decreased sweating).  Physostigmine is indeed used as an antidote for atropine poisoning to reverse these anticholinergic effects.\n\n* **C. 살충제 (Insecticide):**  This is a broad category.  Some insecticides, like organophosphates and carbamates, are cholinesterase inhibitors.  They *increase* acetylcholine levels, leading to cholinergic toxicity (opposite of anticholinergic). Symptoms of organophosphate/carbamate poisoning include SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) and muscle weakness, miosis (constricted pupils), bradycardia.  Other insecticides, like pyrethroids, primarily affect the nervous system through sodium channel modulation, and don't typically cause anticholinergic symptoms.  However, some older insecticides might have anticholinergic properties, but generally, insecticides are not the primary cause of anticholinergic poisoning for which physostigmine is a first-line antidote.  Organophosphate poisoning, which is more common with insecticides, is treated with atropine (ironically, to block the *excess* acetylcholine effects) and pralidoxime (to reactivate cholinesterase), not physostigmine.  This option is less likely than atropine.\n\n* **D. 모르핀 (Morphine):** Morphine is an opioid analgesic.  Overdose symptoms of morphine include respiratory depression, pinpoint pupils (miosis), constipation, and decreased level of consciousness.  It does not cause anticholinergic symptoms like dilated pupils and hyperthermia.  Naloxone is the antidote for opioid overdose.\n\n* **E. 에탄올 (Ethanol):** Ethanol is alcohol.  Ethanol intoxication symptoms include impaired coordination, slurred speech, confusion, and respiratory depression in severe cases.  While it can cause vasodilation which might contribute to warmth, it doesn't typically cause hyperthermia in the same way anticholinergics do.  It also doesn't cause dilated pupils in the same way.  The primary concerns with ethanol overdose are CNS depression and respiratory depression.  There is no specific antidote in the same way as physostigmine for anticholinergics or naloxone for opioids. Treatment is supportive.\n\n**Conclusion:**\n\nBased on the symptoms and the antidote, **atropine (B)** is the most fitting answer.  Atropine is a known anticholinergic drug that causes the described symptoms upon overdose, and physostigmine is a well-established antidote for anticholinergic poisoning, including atropine poisoning.\n\nLet's double check the symptoms and antidote for atropine overdose:\n\n* **Symptoms of Atropine Overdose (Anticholinergic Toxidrome):**\n    * **Mad as a hatter:** Delirium, hallucinations, confusion\n    * **Blind as a bat:** Mydriasis (dilated pupils), blurred vision\n    * **Red as a beet:** Vasodilation, flushed skin\n    * **Hot as a hare:** Hyperthermia, anhidrosis (lack of sweating)\n    * **Dry as a bone:** Dry skin, dry mucous membranes\n    * **Other:** Tachycardia, urinary retention, decreased bowel sounds\n\nThe symptoms listed in the question (dry skin and mucous membranes, dilated pupils, hyperthermia) are all core components of anticholinergic toxidrome and are characteristic of atropine overdose.  And physostigmine is indeed used to treat anticholinergic poisoning, particularly in cases with severe delirium or other significant symptoms.\n\nTherefore, the most appropriate answer is **B. 아트로핀 (Atropine)**.\n\n\nLet's consider why other options are less likely:\n\n* **Diazepam:**  Wrong symptoms, wrong antidote.\n* **Insecticide:** Too broad, and while some might have anticholinergic properties, the more common insecticide poisonings (organophosphates, carbamates) cause cholinergic, not anticholinergic symptoms. Physostigmine might be contraindicated in organophosphate poisoning in some contexts (though it's complex and sometimes used with caution in specific situations), and atropine is the primary anticholinergic used as antidote for organophosphate poisoning.\n* **Morphine:** Wrong symptoms, wrong antidote.\n* **Ethanol:** Wrong symptoms, no specific antidote like physostigmine for this symptom profile.\n\n\nThus, Atropine is the clear best answer.\n&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **B. 아트로핀**입니다.\n\n**해설:**\n\n**제시된 증상:**\n\n* **피부 및 점막 건조:**  땀 분비 감소 및 침 분비 감소로 인해 나타나는 증상으로, 부교감 신경 억제(항콜린 작용)와 관련이 있습니다.\n* **동공 확대:**  동공 조절 근육의 마비로 인해 나타나는 증상으로, 부교감 신경 억제(항콜린 작용)의 대표적인 증상입니다.\n* **고체온:**  땀 분비 감소로 인한 체온 조절 장애로 발생할 수 있으며, 항콜린 작용과 관련이 있습니다.\n\n**해독제: 피소스티그민 (피조스티그민)**\n\n* 피소스티그민은 콜린에스터라제 억제제입니다. 콜린에스터라제는 아세틸콜린을 분해하는 효소이므로, 피소스티그민은 아세틸콜린의 분해를 억제하여 아세틸콜린의 농도를 증가시킵니다.\n* 이는 **항콜린 작용 물질의 중독을 해독하는 데 사용**됩니다. 항콜린 작용 물질은 아세틸콜린의 작용을 억제하므로, 피소스티그민은 아세틸콜린 농도를 높여 항콜린 작용을 상쇄시키는 효과를 나타냅니다.\n\n**각 선택지 분석:**\n\n* **A. 다이아제팜:**  벤조디아제핀 계열의 약물로, 주로 진정, 수면, 항불안 작용을 합니다. 과량 투여 시 졸음, 혼란, 운동실조, 호흡 억제 등의 증상이 나타나지만, 피부 건조, 동공 확대, 고체온과 같은 항콜린 증상은 나타나지 않습니다. 해독제는 플루마제닐입니다.\n\n* **B. 아트로핀:**  대표적인 **항콜린 작용제**입니다.  과량 투여 시 제시된 증상인 피부 및 점막 건조, 동공 확대, 고체온 등이 나타납니다. 또한, 피소스티그민은 아트로핀 중독의 해독제로 사용됩니다.\n\n* **C. 살충제:**  살충제의 종류는 매우 다양합니다. 유기인계 살충제나 카바메이트계 살충제는 콜린에스터라제 억제제로서, 오히려 콜린성 증상(근육 경련, 침 흘림, 동공 축소 등)을 유발하며, 해독제로는 아트로핀 (항콜린제)과 옥심 제제가 사용됩니다. 제시된 증상과는 반대되는 경우가 많습니다.\n\n* **D. 모르핀:**  마약성 진통제인 오피오이드 계열 약물입니다. 과량 투여 시 호흡 억제, 동공 축소, 변비 등의 증상이 나타나며, 해독제는 날록손입니다. 제시된 증상과는 거리가 멉니다.\n\n* **E. 에탄올:**  알코올입니다. 과량 섭취 시 중추신경 억제, 운동 실조, 판단력 저하 등의 증상이 나타나지만, 피부 건조, 동공 확대, 고체온과 같은 항콜린 증상은 나타나지 않습니다.\n\n**결론:**\n\n제시된 중독 증상과 해독제(피소스티그민)를 고려했을 때, 가장 적합한 물질은 **B. 아트로핀**입니다. 아트로핀은 항콜린 작용제로서 과량 투여 시 제시된 증상을 유발하며, 피소스티그민은 아트로핀 중독의 해독제로 사용됩니다.\n\n**따라서 정답은 B입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:7494,&quot;string&quot;:&quot;7,494&quot;}}},{&quot;rowIdx&quot;:1,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;paramedic_1&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2023,&quot;string&quot;:&quot;2,023&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:65,&quot;string&quot;:&quot;65&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;척추손상이 의심되는 환자를 이송하기 위한 척추보호조치 (척추움직임제한) 방법으로 옳은 것은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;몸통을 긴척추고정판에 완전히 고정한 후에 머리를 고정&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;머리기울이고턱들기 자세가 유지되도록 목 고정장치 적용&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;목 고정장치는 좌우로 45° 돌릴 수 있도록 느슨하게 고정&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;목뼈의 굽힘이나 압박이 발생하지 않도록 과신전 상태로 고정&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;몸통은 위아래로는 움직이고 왼쪽 · 오른쪽으로는 움직이지 않도록 고정&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;\nThe question is asking about the correct method of spinal motion restriction (spinal immobilization) for a patient suspected of having a spinal injury during transport.  Let's analyze each option in Korean and then translate to English for clarity.\n\n* **Understanding the Goal:** The primary goal of spinal motion restriction is to prevent further injury to the spinal cord by minimizing movement of the spine, especially in cases of suspected spinal injury. This is crucial during patient transport to avoid exacerbating potential damage.\n\n* **Analyzing each option:**\n\n    * **A. 몸통을 긴척추고정판에 완전히 고정한 후에 머리를 고정 (Fix the torso completely to a long spine board first, then fix the head.)**\n        * **Thinking:** This sounds like a logical sequence.  Stabilizing the torso first provides a stable base before immobilizing the head. If you fix the head first and then try to move the torso onto the board, you risk moving the neck and spine. So, torso first, then head sounds correct.\n\n    * **B. 머리기울이고턱들기 자세가 유지되도록 목 고정장치 적용 (Apply a cervical collar so that the head-tilt and chin-lift position is maintained.)**\n        * **Thinking:** The head-tilt chin-lift maneuver is used to open the airway in unresponsive patients, *not* for spinal immobilization.  In spinal injury, we want to maintain a *neutral* position if possible, not necessarily head-tilt chin-lift.  Also, maintaining head-tilt chin-lift with a cervical collar sounds contradictory and potentially harmful for spinal injury.  This option seems incorrect.\n\n    * **C. 목 고정장치는 좌우로 45° 돌릴 수 있도록 느슨하게 고정 (Fix the cervical collar loosely so that it can be turned 45° left and right.)**\n        * **Thinking:**  The purpose of a cervical collar (목 고정장치) in spinal immobilization is to *restrict* movement, not allow it. Allowing 45° rotation defeats the purpose.  This is definitely incorrect.  Spinal immobilization needs to be *rigid*, not loose.\n\n    * **D. 목뼈의 굽힘이나 압박이 발생하지 않도록 과신전 상태로 고정 (Fix in a hyperextended position to prevent flexion or compression of the cervical vertebrae.)**\n        * **Thinking:** Hyperextension (과신전) of the neck is generally *contraindicated* in suspected spinal injury.  It can worsen the injury, especially if there's already a fracture or dislocation.  Neutral alignment is preferred.  Forcing hyperextension can cause more harm.  This is likely incorrect and dangerous.\n\n    * **E. 몸통은 위아래로는 움직이고 왼쪽 · 오른쪽으로는 움직이지 않도록 고정 (Fix the torso so that it moves up and down but not left and right.)**\n        * **Thinking:**  This option is confusing and nonsensical for spinal immobilization.  Spinal immobilization aims to restrict *all* movement of the torso and spine in all directions – up/down, left/right, rotation, flexion, extension. Allowing up and down movement while restricting left/right is not a standard or recommended practice for spinal immobilization. This is incorrect and illogical.\n\n\n* **Re-evaluating and confirming the best answer:**\n\n    * Option A makes the most sense in terms of sequence and overall principle of immobilization.\n    * Options B, C, D, and E are all clearly wrong based on basic principles of spinal immobilization and first aid.\n\n* **Translating and confirming in English for clarity:**\n\n    * A. Fix the torso completely to a long spine board first, then fix the head. (Sounds correct)\n    * B. Apply a cervical collar so that the head-tilt and chin-lift position is maintained. (Incorrect - head-tilt chin-lift is for airway, not immobilization; and contraindicated for spinal injury in this context.)\n    * C. Fix the cervical collar loosely so that it can be turned 45° left and right. (Incorrect - collar must restrict, not allow movement.)\n    * D. Fix in a hyperextended position to prevent flexion or compression of the cervical vertebrae. (Incorrect and dangerous - hyperextension is generally contraindicated; neutral is preferred.)\n    * E. Fix the torso so that it moves up and down but not left and right. (Incorrect and illogical - immobilization needs to restrict all torso movement.)\n\n\n* **Conclusion:** Option A appears to be the only correct method for spinal motion restriction in the context of transporting a patient with suspected spinal injury.\n\n\nTherefore, the answer is A.\n\nLet's double-check typical spinal immobilization procedures:\n\n1. **Manual stabilization:**  Immediately stabilize the patient's head and neck manually, preventing any movement.\n2. **Cervical collar application:** Apply a properly sized cervical collar.\n3. **Log roll (if needed):** If the patient needs to be moved (e.g., onto a spine board), perform a log roll while maintaining manual stabilization of the head and neck.\n4. **Spine board application:** Center the patient onto a long spine board. Secure the torso to the board first (straps across chest, pelvis, thighs).\n5. **Head immobilization:**  Secure the head to the spine board using head blocks and tape or straps. Ensure the head is in a neutral, in-line position if possible (unless resistance is met or it causes pain).\n6. **Extremity immobilization (optional):**  Sometimes, straps are also used to secure the legs to the spine board.\n\nThis process aligns with option A:  torso to spine board first, then head.\n\n&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **A. 몸통을 긴척추고정판에 완전히 고정한 후에 머리를 고정**입니다.\n\n**해설:**\n\n척추 손상이 의심되는 환자의 척추 보호 조치 (척추 움직임 제한)의 핵심은 척추의 추가적인 움직임을 최소화하여 2차 손상을 예방하는 것입니다.  각 선택지를 분석해 보겠습니다.\n\n* **A. 몸통을 긴척추고정판에 완전히 고정한 후에 머리를 고정:**  **옳은 방법입니다.**  척추 고정판을 사용하여 몸통을 먼저 안정적으로 고정하는 것은 척추 전체를 안정화하는 데 중요합니다. 몸통이 고정된 후에 머리를 고정해야 척추의 축 방향 움직임을 최소화하고, 머리 고정 시 발생할 수 있는 몸통의 움직임을 방지할 수 있습니다.\n\n* **B. 머리기울이고턱들기 자세가 유지되도록 목 고정장치 적용:** **틀린 방법입니다.** 머리기울이고턱들기 (head-tilt chin-lift) 자세는 기도 확보를 위해 사용하는 방법으로, 척추 손상 환자에게는 금기입니다. 척추 손상 환자에게는 척추를 중립 자세로 유지하고 움직임을 최소화하는 것이 중요하며, 머리기울이고턱들기 자세는 척추에 불필요한 움직임을 유발할 수 있습니다.\n\n* **C. 목 고정장치는 좌우로 45° 돌릴 수 있도록 느슨하게 고정:** **틀린 방법입니다.** 목 고정장치 (cervical collar)는 목뼈의 움직임을 최대한 제한하기 위해 사용하는 것입니다. 느슨하게 고정하면 목뼈를 제대로 고정할 수 없고, 오히려 움직임이 발생하여 척추 손상을 악화시킬 수 있습니다. 목 고정장치는 적절한 크기로 환자의 목에 딱 맞게, 움직임이 거의 없도록 단단히 고정해야 합니다.\n\n* **D. 목뼈의 굽힘이나 압박이 발생하지 않도록 과신전 상태로 고정:** **틀린 방법입니다.** 척추를 과신전 (hyperextension) 상태로 고정하는 것은 오히려 척추 손상을 악화시킬 수 있습니다. 특히 척추 골절이나 탈구가 있는 경우 과신전은 신경 손상을 유발하거나 악화시킬 위험이 있습니다. 척추는 가능한 한 중립 자세 (neutral position)로 유지하는 것이 원칙입니다.\n\n* **E. 몸통은 위아래로는 움직이고 왼쪽 · 오른쪽으로는 움직이지 않도록 고정:** **틀린 방법입니다.** 척추 보호 조치는 척추의 모든 방향으로의 움직임을 제한하는 것을 목표로 합니다. 몸통을 위아래로 움직이게 허용하는 것은 척추의 움직임을 완전히 제한하는 것이 아니며, 척추 손상 환자에게는 위험한 처치입니다. 몸통은 모든 방향으로 움직이지 않도록 고정해야 합니다.\n\n\n**따라서, 척추손상 의심 환자 이송 시 척추 보호 조치로 가장 적절한 방법은 A입니다.**\n\n**정답: A**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:7472,&quot;string&quot;:&quot;7,472&quot;}}},{&quot;rowIdx&quot;:2,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;paramedic_1&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2021,&quot;string&quot;:&quot;2,021&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:82,&quot;string&quot;:&quot;82&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;65세 남자가 20분 전에 갑자기 1,000cc 정도 두차례 피를 토한 후 내원하였다. 환자는 5년 전부터 알코올성 간경화로 치료받고 있으며, 응급실 내원 후에도 계속적인 선홍색 토혈을 하였다. 의식은 혼수상태이며, 혈압 60/40mmHg, 맥박 115회/분, 호흡 28회/분이고, 피부는 차고 축축하다. 우선 해야 할 처치는?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;아이겔 삽입&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;기관내 삽관&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;비위관튜브 삽입&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;후두튜브기도기 삽입&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;후두튜브마스크 삽입&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down this medical case step-by-step, simulating a thought process to arrive at the correct answer.\n\n**1. Deconstructing the Patient Information:**\n\n* **Age and Gender:** 65-year-old male.  Age is relevant as older patients might have comorbidities or less physiological reserve.\n* **Chief Complaint:** Sudden onset of massive hematemesis (vomiting blood) - 1000cc twice in 20 minutes. This is a *huge* amount of blood loss in a short time.\n* **Medical History:** Alcoholic liver cirrhosis (5 years).  This is *critical*.  Cirrhosis is a major risk factor for esophageal varices, a common cause of upper GI bleeding and hematemesis in these patients.\n* **Current Status on Arrival:**\n    * **Ongoing hematemesis:** Still vomiting bright red blood. This indicates active, ongoing bleeding and emphasizes the urgency of the situation.\n    * **Consciousness:** Comatose.  This is extremely concerning and suggests significant blood loss and likely hypoperfusion of the brain. Airway compromise is a major concern.\n    * **Vitals:**\n        * **BP 60/40 mmHg:**  Severe hypotension.  This is shock.\n        * **HR 115 bpm:** Tachycardia.  Compensatory mechanism for hypovolemia.\n        * **RR 28 bpm:** Tachypnea.  Likely compensatory for metabolic acidosis and hypoxemia due to blood loss.\n        * **Skin:** Cold and clammy.  Signs of peripheral vasoconstriction and poor perfusion, further indicating shock.\n\n**2. Synthesizing the Information and Identifying the Problem:**\n\n* **Massive Hemorrhage:** The patient is experiencing a massive upper GI bleed, most likely due to esophageal varices secondary to liver cirrhosis.\n* **Hypovolemic Shock:**  The vital signs (hypotension, tachycardia, tachypnea, cold/clammy skin) and altered mental status (coma) definitively indicate hypovolemic shock due to blood loss.\n* **Airway Compromise:** Comatose state and ongoing hematemesis put the patient at extremely high risk for airway obstruction due to aspiration of blood.  The patient may also have reduced respiratory drive due to shock.\n\n**3. Prioritizing Immediate Actions - The ABCs:**\n\nIn any emergency, especially with a comatose and bleeding patient, the ABCs (Airway, Breathing, Circulation) are paramount.\n\n* **Airway (A):**  This is *the most critical* priority in this scenario. The patient is comatose and vomiting blood.  The immediate risk is airway obstruction from aspiration. We *must* secure the airway.\n* **Breathing (B):**  Tachypnea is present, but the quality of breathing is unknown and potentially compromised due to coma and shock.  Securing the airway will likely necessitate assisted ventilation.\n* **Circulation (C):**  The patient is in severe shock.  While addressing circulation is crucial (IV access, fluids, blood products), it is secondary to securing the airway in this *immediate* moment because without a patent airway and adequate oxygenation, circulatory interventions will be less effective, and the patient will quickly deteriorate further.\n\n**4. Evaluating the Answer Choices in Light of Priorities:**\n\n* **A. 아이겔 삽입 (i-gel insertion):**  An i-gel is a supraglottic airway device (SGAD).  It can provide a decent airway, is relatively easy to insert, and can protect against aspiration to some extent.  It's better than nothing, but not ideal in this situation.\n* **B. 기관내 삽관 (Endotracheal intubation):**  Endotracheal intubation (ETI) is the *gold standard* for airway management. It provides a definitive airway, protects against aspiration, allows for positive pressure ventilation and high FiO2 delivery.  It's more complex than SGADs, but in a comatose patient with massive hematemesis, it's the most secure and protective option.\n* **C. 비위관튜브 삽입 (Nasogastric tube insertion):** An NG tube is used to decompress the stomach and can help remove blood and gastric contents.  While helpful *later* for managing the bleeding and assessing ongoing loss, it does *not* address the immediate airway crisis.  It could even *increase* the risk of aspiration during insertion in a comatose patient.\n* **D. 후두튜브기도기 삽입 (Laryngeal tube insertion):** A laryngeal tube (like the King LT) is another type of SGAD.  Similar to the i-gel, it can provide an airway, but less secure than ETI, and may not be optimal for aspiration risk.\n* **E. 후두튜브마스크 삽입 (Laryngeal mask airway (LMA) insertion):** An LMA is also an SGAD.  Similar pros and cons to i-gel and laryngeal tube.  Less secure than ETI, especially in a patient with high aspiration risk and ongoing bleeding.\n\n**5. Choosing the Best Answer:**\n\nConsidering the patient's comatose state, massive hematemesis, and high risk of aspiration, the *most important* and *first* intervention is to secure the airway definitively.  Endotracheal intubation (B) is the best option because it provides the most secure airway, protects against aspiration, and allows for controlled ventilation and oxygenation, which are crucial in this critical situation.\n\nWhile SGADs (A, D, E) might be considered in less critical airway situations or if intubation is immediately impossible, in this scenario, the patient is clearly unstable and requires the most definitive airway management. NG tube (C) is not the *priority* initial intervention and doesn't address the airway.\n\n**Final Answer Selection and Justification:**\n\nThe best answer is **B. 기관내 삽관 (Endotracheal intubation)**.\n\n**Reasoning Summary:**\n\n* **Life-threatening situation:** Massive hematemesis, coma, and shock.\n* **Primary concern:** Airway protection and securing breathing due to coma and aspiration risk from vomiting blood.\n* **Endotracheal intubation (ETI):** Gold standard for airway management, provides definitive airway, aspiration protection, and ventilation control.\n* **Other options (SGADs):** Less secure airway, higher aspiration risk, less ideal in this critical patient.\n* **NG tube:** Not the priority for initial airway management and doesn't address immediate airway threats.\n\nTherefore, securing the airway with endotracheal intubation is the most appropriate first action in this emergency situation.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;## 정답 해설\n\n정답은 **B. 기관내 삽관** 입니다.\n\n**해설:**\n\n환자는 다음과 같은 심각한 상태입니다.\n\n* **대량 토혈:** 1,000cc 두 차례 토혈은 매우 많은 양이며, 활력 징후를 불안정하게 만들 수 있습니다.\n* **지속적인 토혈:** 응급실 내원 후에도 계속 토혈을 한다는 것은 출혈이 멈추지 않고 있다는 것을 의미하며, 더욱 위험한 상황입니다.\n* **혼수상태:** 의식 저하는 뇌 혈류 감소 또는 심각한 전신 상태 악화를 의미하며, 기도 유지 및 호흡 관리가 매우 중요합니다.\n* **쇼크 상태:** 혈압 60/40mmHg는 심각한 저혈압으로 쇼크 상태를 의미하며, 즉각적인 혈액량 보충 및 원인 치료가 필요합니다.\n* **빈맥 및 빈호흡:** 심박수 115회/분, 호흡수 28회/분은 쇼크에 대한 보상 기전으로 나타나는 반응입니다.\n* **차가운 피부:** 말초 혈관 수축으로 인한 쇼크의 징후입니다.\n* **알코올성 간경화:** 기저 질환으로 식도 정맥류 출혈의 가능성이 매우 높습니다. 식도 정맥류 출혈은 간경변 환자에서 흔하게 발생하는 대량 토혈의 원인입니다.\n\n**우선적으로 해야 할 처치:**\n\n가장 급하고 중요한 처치는 **기도 확보 및 유지** 입니다. 환자는 혼수상태이고 지속적인 토혈을 하고 있어 기도 흡인의 위험이 매우 높습니다. 또한 쇼크 상태로 자발 호흡이 충분하지 않을 가능성이 높습니다.\n\n따라서, **기관내 삽관**을 통해 기도를 확보하고 인공호흡을 시작하여 산소 공급 및 기도 흡인을 예방하는 것이 최우선적으로 해야 할 처치입니다.\n\n**각 선택지별 설명:**\n\n* **A. 아이겔 삽입:** 아이겔은 후두마스크기도기(LMA)의 일종으로, 기관내 삽관보다는 간단하게 기도 확보가 가능하지만, 대량 토혈 환자나 혼수상태 환자에서는 기도 흡인의 위험이 높고, 기관내 삽관만큼 확실한 기도 보호가 어렵습니다. 우선적인 처치로는 적절하지 않습니다.\n* **B. 기관내 삽관:** 위에서 설명한 것처럼, 혼수상태 및 대량 토혈 환자에게 가장 확실하고 안전한 기도 확보 방법입니다. 인공호흡기를 연결하여 적절한 환기를 제공하고, 기도 흡인을 예방하며, 향후 처치를 위한 안정적인 환경을 제공합니다. **정답**입니다.\n* **C. 비위관튜브 삽입:** 비위관 튜브 삽입은 위장관 내 출혈량을 확인하고 위 내용물을 제거하여 흡인을 예방하는 데 도움이 될 수 있습니다. 하지만 기도 확보가 우선이며, 비위관 삽입은 기관내 삽관 후 고려할 수 있습니다. 우선적인 처치는 아닙니다.\n* **D. 후두튜브기도기 삽입:** 후두튜브기도기는 LMA와 마찬가지로 기관내 삽관보다는 간단하게 기도 확보가 가능하지만, 대량 토혈 환자나 혼수상태 환자에서는 기도 흡인의 위험이 높고, 기관내 삽관만큼 확실한 기도 보호가 어렵습니다. 우선적인 처치로는 적절하지 않습니다.\n* **E. 후두튜브마스크 삽입:** 후두튜브마스크 (LMA)는 아이겔과 마찬가지로 기관내 삽관보다는 간단하게 기도 확보가 가능하지만, 대량 토혈 환자나 혼수상태 환자에서는 기도 흡인의 위험이 높고, 기관내 삽관만큼 확실한 기도 보호가 어렵습니다. 우선적인 처치로는 적절하지 않습니다.\n\n**결론적으로,**  혼수상태 및 대량 토혈, 쇼크 상태인 환자에게 가장 우선적으로 해야 할 처치는 **기관내 삽관을 통한 기도 확보 및 유지** 입니다. 이후 수액 및 혈액 제제 투여를 통한 혈압 안정화, 출혈 원인 파악 및 지혈 등의 추가적인 처치를 진행해야 합니다.&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:7146,&quot;string&quot;:&quot;7,146&quot;}}},{&quot;rowIdx&quot;:3,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;doctor&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2014,&quot;string&quot;:&quot;2,014&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:3,&quot;string&quot;:&quot;3&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:14,&quot;string&quot;:&quot;14&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;요양병원을 개설 운영하고 있는 의사 '갑'은 의료기관 인증평가를 받은 후 의료기관 인증서를 교부받았다. 의사 '갑'이 요양병원 진료내용과 인증 결과를 시내버스 차량의 외부 옆면에 광고하기 위해 미리 심의를 받으려 할 때 의료광고 심의신청서를 제출해야 하는 기관은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;대한의사협회&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;국민건강보험공단&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;한국보건의료연구원&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;의료기관인증평가원&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;한국의료분쟁조정중재원&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down this Korean medical law question step-by-step to arrive at the correct answer.\n\n**1. Understanding the Question (Analyze the Korean Text)**\n\n* **요양병원 (yoyangbyeongwon):**  Nursing hospital or long-term care hospital. This is the type of medical institution we are dealing with.\n* **개설 운영하고 있는 의사 '갑' (gaeseol unyeonghago inneun uisa 'gap'):** Doctor 'Gap' who establishes and operates. This tells us the subject is a doctor who runs a nursing hospital.\n* **의료기관 인증평가를 받은 후 의료기관 인증서를 교부받았다 (uiryogigwan 인증pyeonggareul badeun hu uiryogigwan 인증seoreul gyobubadeatda):**  Received medical institution certification after undergoing medical institution accreditation assessment and receiving a medical institution certification certificate. This is important – the hospital is certified.\n* **요양병원 진료내용과 인증 결과를 시내버스 차량의 외부 옆면에 광고하기 위해 (yoyangbyeongwon jinryonaeyonggwa 인증 gyeolgwaleul sinaebeoseu charyang-ui oebu yeopmyeone gwang-gohagi wihae):** In order to advertise the nursing hospital's treatment details and certification results on the external side of a city bus. This is the core action: advertising.\n* **미리 심의를 받으려 할 때 의료광고 심의신청서를 제출해야 하는 기관은? (miri simuireul badeuryeo hal ttae uiryogwanggo simuisincheongseoreul jechulhaeya haneun gigwan-eun?):**  Which institution should the medical advertisement review application be submitted to when intending to receive prior review? This is the question itself - where to apply for pre-approval for the advertisement.\n\n**In simpler English:**  A doctor operating a certified nursing hospital wants to advertise their hospital's services and certification on the side of a city bus.  Where should they submit their application for pre-approval of this medical advertisement?\n\n**2. Identifying the Key Issue: Medical Advertisement Review**\n\nThe core of the question is *의료광고 심의 (uiryogwanggo simui)* - medical advertisement review or pre-approval.  This is the central concept to focus on. We need to know which organization is responsible for reviewing medical advertisements in Korea.\n\n**3. Recalling Knowledge of Korean Medical Law/Regulations (or Quick Research if Unfamiliar)**\n\n* **Medical Advertising Regulations in Korea:**  Korean medical law is quite strict about advertising medical institutions and services.  Pre-approval is generally required for many types of medical advertisements to protect patients and prevent misleading information.\n* **Who Reviews Medical Ads?**  This is the crucial piece of information. In Korea, the **의료광고심의위원회 (uiryogwanggo simui wiwonhoe)** – Medical Advertisement Review Committee – is responsible for this. This committee is usually associated with or delegated to specific medical professional associations.\n\n**4. Evaluating the Answer Choices (Analyze each option in Korean and English):**\n\n* **A. 대한의사협회 (Daehan Uisa Hyeophoe): Korean Medical Association (KMA)** -  The KMA is the main professional organization for doctors in Korea.  They *do* play a role in medical advertisement review.  In fact, the Medical Advertisement Review Committee is often under the KMA's umbrella or delegated to them. This is a strong candidate.\n\n* **B. 국민건강보험공단 (Gungmin Geongang Boheom Gongdan): National Health Insurance Service (NHIS)** - The NHIS is responsible for managing the national health insurance system. Their primary focus is on insurance, payments, and healthcare policy *financing*.  They are *not* primarily involved in advertisement review.  Less likely.\n\n* **C. 한국보건의료연구원 (Hanguk Bogeon Uiryo Yeonguwon): Korea Institute for Health and Social Affairs (KIHASA)** - KIHASA is a research institute focused on health and social welfare policy. They conduct research and advise the government. They are not involved in *advertisement review*. Unlikely.\n\n* **D. 의료기관인증평가원 (Uryogigwan Injeungpyeonggawon): Korea Institute for Healthcare Accreditation (KOIHA)** - KOIHA is the organization that conducts medical institution accreditation assessments (as mentioned in the question itself).  They *certify* hospitals. While related to hospital quality, their main role isn't *advertisement review*. Less likely.\n\n* **E. 한국의료분쟁조정중재원 (Hanguk Uiryo Bunjaeng Jojeong Jungjaewon): Korea Medical Dispute Mediation and Arbitration Agency (KMDMA)** - KMDMA handles medical disputes and mediation.  They are about *resolving* issues after they occur, not *preventing* misleading advertising.  Unlikely.\n\n**5. Selecting the Most Likely Answer:**\n\nBased on the analysis, the **Korean Medical Association (대한의사협회)** is the most likely organization to handle medical advertisement review applications.  They are the central professional body for doctors and are often delegated this responsibility by the Ministry of Health and Welfare.\n\n**6. Confirmation (If Possible):**\n\nA quick search for \&quot;의료광고 심의 대한의사협회\&quot; (medical advertisement review Korean Medical Association) in Korean would likely confirm that the KMA is indeed the relevant body for medical advertisement pre-approval in many cases, particularly for doctors and clinics.\n\n**Conclusion:**\n\nTherefore, the answer is **A. 대한의사협회 (Korean Medical Association)**.  The reasoning is based on understanding the core issue of medical advertisement review and knowing or deducing the relevant organization responsible for this in Korea.  The other options are related to healthcare but have different primary functions and are not the correct body for advertisement pre-approval.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **A. 대한의사협회**입니다.\n\n**해설:**\n\n* **의료법** 제56조 및 동법 시행령 제23조에 따르면, 의료기관의 기능, 진료과목, 진료 내용 등에 대한 광고는 **사전심의**를 받아야 합니다.\n* 의료광고 심의 업무는 의료법에 따라 **각 의료인 단체(의사협회, 치과의사협회, 한의사협회 등)**에 위탁되어 있습니다.\n* 따라서 의사 '갑'은 의사이기 때문에, **대한의사협회**에 의료광고 심의신청서를 제출해야 합니다.\n\n**오답 이유:**\n\n* **B. 국민건강보험공단:** 국민건강보험공단은 건강보험 및 장기요양보험 운영을 담당하는 기관으로 의료광고 심의와는 관련이 없습니다.\n* **C. 한국보건의료연구원:** 한국보건의료연구원은 보건의료 기술 평가 및 연구를 수행하는 기관으로 의료광고 심의와는 직접적인 관련이 없습니다.\n* **D. 의료기관인증평가원:** 의료기관인증평가원은 의료기관 인증평가를 담당하는 기관으로, 인증 자체는 광고에 활용될 수 있지만 광고 심의를 담당하지는 않습니다.\n* **E. 한국의료분쟁조정중재원:** 한국의료분쟁조정중재원은 의료분쟁 조정 및 중재를 담당하는 기관으로 의료광고 심의와는 관련이 없습니다.\n\n**핵심 요약:**\n\n의료광고 사전심의는 **해당 의료인의 직역별 중앙회 (의사협회, 치과의사협회 등)**에서 담당합니다. 따라서 의사인 '갑'은 **대한의사협회**에 심의신청을 해야 합니다.&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:61,&quot;string&quot;:&quot;61&quot;}}},{&quot;rowIdx&quot;:4,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;nurse_assistant&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2023,&quot;string&quot;:&quot;2,023&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;간호조무사가 직업윤리를 실천하는 목적은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;법적인 책임 면제&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;업무 수행 시간 단축&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;환자의 비밀을 친구와 공유&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;직면한 윤리적 딜레마 회피&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;인간의 존엄성과 인격 존중&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;\nThe question is asking about the purpose of a nursing assistant practicing professional ethics. I need to analyze each option and choose the one that best represents the core reason for ethical practice in nursing assistance.\n\n* **Analyze each option:**\n    * **A. 법적인 책임 면제 (Exemption from legal responsibility):** While ethical practice *can* help prevent legal issues, it's not the primary *purpose*. Ethics goes beyond just avoiding legal trouble. Legal compliance is a consequence, not the main goal.\n    * **B. 업무 수행 시간 단축 (Shortening work performance time):** Ethical practice might *sometimes* involve efficiency, but it's definitely not about shortening work time as the main purpose.  Ethical considerations can sometimes *increase* the time spent on a task (e.g., ensuring informed consent, providing emotional support).\n    * **C. 환자의 비밀을 친구와 공유 (Sharing patient's secrets with friends):** This is the *opposite* of ethical practice.  Patient confidentiality is a core ethical principle. This option is clearly wrong.\n    * **D. 직면한 윤리적 딜레마 회피 (Avoiding ethical dilemmas faced):** Ethical practice isn't about avoiding dilemmas, but about *resolving* them in a principled way.  Dilemmas are inherent in healthcare, and ethics provides a framework for navigating them. This option is also incorrect.\n    * **E. 인간의 존엄성과 인격 존중 (Respect for human dignity and personality):** This aligns perfectly with the core principles of healthcare ethics.  Ethical practice in nursing, and nursing assistance, is fundamentally about respecting patients as individuals with inherent dignity and worth.\n\n* **Identify the best answer:** Option E directly addresses the fundamental purpose of healthcare ethics – respecting patients' dignity and personhood.  The other options are either irrelevant, incorrect, or represent side effects rather than the primary purpose.\n\n* **Confirm the answer:**  Thinking about the core values of nursing and healthcare, patient-centered care, respect, dignity, and autonomy are central. Ethical practice is the means to uphold these values. Option E encapsulates this perfectly.\n\nTherefore, the answer should be E.\n&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **E. 인간의 존엄성과 인격 존중**입니다.\n\n**해설:**\n\n간호조무사가 직업윤리를 실천하는 가장 중요한 목적은 환자를 인간으로서 존중하고, 그들의 존엄성과 인격을 보호하는 데 있습니다.  다른 선택지들은 윤리 실천의 목적과는 거리가 멉니다.\n\n* **A. 법적인 책임 면제:** 윤리적 실천은 법적 문제를 예방하는 데 도움이 될 수 있지만, 법적 책임을 회피하는 것이 윤리 실천의 주된 목적은 아닙니다. 윤리는 법률보다 더 높은 도덕적 기준을 포함합니다.\n* **B. 업무 수행 시간 단축:** 윤리적 실천은 때로는 업무 시간을 늘릴 수도 있습니다. 환자의 권리를 존중하고 윤리적 문제를 해결하는 데 충분한 시간을 할애해야 하기 때문입니다.\n* **C. 환자의 비밀을 친구와 공유:** 이는 명백히 윤리 위반입니다. 환자의 비밀 유지는 간호 직업 윤리의 핵심입니다.\n* **D. 직면한 윤리적 딜레마 회피:** 윤리적 딜레마를 회피하는 것이 아니라, 윤리적 원칙에 따라 딜레마를 해결하고 최선의 결정을 내리는 것이 윤리 실천의 목표입니다.\n* **E. 인간의 존엄성과 인격 존중:**  환자를 단순히 치료의 대상으로 보는 것이 아니라, 존엄한 인간으로서 존중하고 그들의 가치와 권리를 보호하는 것이 윤리적 실천의 핵심입니다. 이는 간호 및 의료 윤리의 가장 기본적인 원칙입니다.\n\n**따라서 정답은 E입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:6586,&quot;string&quot;:&quot;6,586&quot;}}},{&quot;rowIdx&quot;:5,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;pharm&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2019,&quot;string&quot;:&quot;2,019&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:86,&quot;string&quot;:&quot;86&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정맥류가 지속될 때 발생하는 합병증인 갈색경화성 정체피부염(stasis dermatitis) 의 발생 기전은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;알부민의 혈관 외 침착&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정맥류 부위의 세균 감염&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;혈관 외로 유출된 적혈구의 용해&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;혈관 외로 유출된 대식세포의 식작용&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;혈관 외로 유출된 림프구의 면역반응&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:3,&quot;string&quot;:&quot;3&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to arrive at the correct answer and explanation for the question about stasis dermatitis and its mechanism.\n\n**1. Deconstructing the Question:**\n\n* **Keywords:** 정맥류 (varicose veins), 지속될 때 (persistent), 합병증 (complication), 갈색경화성 정체피부염 (stasis dermatitis), 발생 기전 (pathogenesis/mechanism).\n* **Core Question:** What is the underlying process that leads to stasis dermatitis when varicose veins persist?\n* **Target Condition:** Stasis dermatitis (also known as venous stasis dermatitis or gravitational dermatitis).  This immediately signals a connection to venous insufficiency or poor venous return.\n* **Answer Choices:**  The choices focus on different cellular/molecular events: albumin deposition, bacterial infection, red blood cell lysis, macrophage phagocytosis, lymphocyte immune response.  These are all plausible elements in various inflammatory or tissue damage scenarios, so we need to connect them specifically to venous insufficiency and stasis dermatitis.\n\n**2.  Recalling Knowledge about Stasis Dermatitis:**\n\n* **Etiology (Cause):** Primarily caused by chronic venous insufficiency. Varicose veins are a common manifestation of this.  The key is impaired venous return from the legs.\n* **Pathophysiology (Mechanism):**  Venous hypertension (high pressure in veins) is the central issue. This leads to:\n    * **Fluid leakage:** Increased pressure pushes fluid out of capillaries and venules into the surrounding tissues.\n    * **Red blood cell extravasation:**  RBCs also leak out, along with other blood components.\n    * **Inflammation:** The presence of leaked fluid and blood components triggers an inflammatory response.\n    * **Skin changes:**  Chronic inflammation leads to the characteristic skin changes: edema, hyperpigmentation (brown discoloration), induration (hardening), and potentially ulceration.\n\n**3.  Analyzing Each Answer Choice in Light of Stasis Dermatitis Pathophysiology:**\n\n* **A. 알부민의 혈관 외 침착 (Albumin extravascular deposition):** Albumin is a major plasma protein.  Increased vascular permeability *does* lead to albumin leakage. Albumin in the interstitial space can contribute to edema and inflammation.  This sounds *plausible*.\n\n* **B. 정맥류 부위의 세균 감염 (Bacterial infection in varicose vein area):** While secondary bacterial infections can occur in stasis dermatitis (especially if ulcers develop), infection is *not* the primary mechanism of *developing* stasis dermatitis.  It's a complication *of* stasis dermatitis or ulcers, not the cause of the initial skin changes. This is *less likely* to be the primary mechanism.\n\n* **C. 혈관 외로 유출된 적혈구의 용해 (Lysis of extravasated red blood cells):** This is a *key* point in stasis dermatitis.  Extravasated RBCs release hemoglobin.  Hemoglobin breaks down into hemosiderin, an iron-containing pigment. Hemosiderin deposition in the skin is responsible for the characteristic *brown* discoloration (hyperpigmentation) of stasis dermatitis. This sounds *very likely*.\n\n* **D. 혈관 외로 유출된 대식세포의 식작용 (Phagocytosis by extravasated macrophages):** Macrophages are involved in inflammation and tissue repair. They *will* be present in the area and *will* phagocytose debris, including RBCs and hemosiderin. However, their phagocytosis is a *response* to the underlying issue (RBC extravasation and lysis), not the primary *mechanism causing* the dermatitis. This is *less likely* to be the *primary* mechanism, although macrophages are involved in the overall process.\n\n* **E. 혈관 외로 유출된 림프구의 면역반응 (Immune response by extravasated lymphocytes):** Lymphocytes are also involved in inflammation and immune responses. In chronic inflammation like stasis dermatitis, lymphocytes are present.  However, the *primary driver* of the skin changes isn't primarily a lymphocyte-mediated immune reaction like in allergic contact dermatitis.  While lymphocytes contribute to the inflammatory milieu, they aren't the *initiating mechanism* responsible for the characteristic skin changes. This is *less likely* to be the primary mechanism.\n\n**4.  Comparing and Contrasting, Focusing on \&quot;Mechanism\&quot;:**\n\nWe need to identify the *most direct and primary* mechanism for the *characteristic features* of stasis dermatitis, especially the brown discoloration.\n\n* **Choice C (RBC lysis and hemosiderin deposition)** directly explains the brown discoloration, a hallmark of stasis dermatitis.  It's a direct consequence of venous hypertension and RBC extravasation.\n* **Choice A (Albumin leakage)** contributes to edema but doesn't directly explain the *brown* discoloration.\n* **Choices B, D, and E** are either secondary events (infection) or components of the inflammatory response but don't directly explain the *brown* pigmentation characteristic of stasis dermatitis.\n\n**5.  Conclusion and Explanation:**\n\nChoice C (혈관 외로 유출된 적혈구의 용해 - Lysis of extravasated red blood cells) is the most accurate and direct answer.\n\n* **Explanation in Korean (similar to the provided example):** 정맥류가 지속되면 정맥압 상승으로 인해 혈관에서 적혈구가 혈관 밖으로 유출됩니다. 유출된 적혈구는 용해되어 헤모글로빈을 방출하고, 헤모글로빈은 헤모시데린으로 전환됩니다. 헤모시데린은 갈색 색소이므로, 피부에 침착되어 갈색의 색소 침착을 유발합니다. 또한, 적혈구 용해 과정에서 방출되는 물질들은 염증 반응을 유발하여 피부염을 악화시킵니다. 따라서 갈색경화성 정체피부염의 발생 기전은 혈관 외로 유출된 적혈구의 용해입니다.\n\n* **Explanation in English (for further clarity):**  Persistent varicose veins lead to venous hypertension, causing red blood cells to leak out of blood vessels into the surrounding tissues. These extravasated red blood cells are then lysed (broken down), releasing hemoglobin. Hemoglobin is further degraded into hemosiderin, an iron-containing pigment that is brown in color.  Hemosiderin deposition in the skin causes the characteristic brown pigmentation of stasis dermatitis.  Furthermore, the breakdown products of red blood cells contribute to inflammation, exacerbating the dermatitis. Therefore, the mechanism of stasis dermatitis is primarily the lysis of extravasated red blood cells.\n\nThis detailed thought process systematically eliminates incorrect options and reinforces why choice C is the correct answer, linking it directly to the key pathological feature of stasis dermatitis – the brown discoloration and the underlying venous insufficiency mechanism.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **C. 혈관 외로 유출된 적혈구의 용해** 입니다.\n\n**해설:**\n\n갈색경화성 정체피부염(stasis dermatitis)은 만성 정맥 기능 부전으로 인해 발생하는 피부 질환입니다.  정맥류가 지속되면 다음과 같은 기전으로 갈색경화성 정체피부염이 발생합니다.\n\n1. **정맥압 상승:** 정맥류는 정맥의 판막 기능 부전으로 인해 발생하며, 이는 다리 정맥의 혈액 순환 장애를 일으키고 정맥압을 상승시킵니다.\n2. **혈관 투과성 증가:** 지속적인 정맥압 상승은 모세혈관과 소정맥의 투과성을 증가시킵니다.\n3. **적혈구 및 혈장 성분 유출:** 증가된 혈관 투과성으로 인해 적혈구, 알부민, 섬유소원 등 혈장 성분들이 혈관 밖 조직으로 유출됩니다.\n4. **적혈구 용해 및 헤모시데린 침착:** 혈관 밖으로 유출된 적혈구는 파괴(용해)되고, 적혈구 내의 헤모글로빈은 헤모시데린이라는 갈색 색소로 변환됩니다. 이 헤모시데린이 피부에 침착되어 갈색의 색소 침착을 유발합니다. 이것이 갈색경화성 정체피부염의 특징적인 갈색 변색의 원인입니다.\n5. **염증 반응 및 섬유화:** 유출된 혈장 성분과 적혈구 용해 산물은 피부에 염증 반응을 유발하고, 만성적인 염증은 피부의 섬유화를 촉진하여 피부를 두껍고 단단하게 만들며 (경화), 가려움증, 통증, 궤양 등을 유발할 수 있습니다.\n\n**오답 선택지 해설:**\n\n* **A. 알부민의 혈관 외 침착:** 알부민은 혈관 밖으로 유출될 수 있지만, 갈색경화성 정체피부염의 주된 발생 기전이라기보다는 부종과 관련이 깊습니다. 알부민 자체는 갈색 색소 침착을 유발하지 않습니다.\n* **B. 정맥류 부위의 세균 감염:** 세균 감염은 갈색경화성 정체피부염의 합병증으로 발생할 수 있지만, 일차적인 발생 기전은 아닙니다. 감염은 피부염을 악화시킬 수 있지만, 피부염 자체의 시작 원인은 아닙니다.\n* **D. 혈관 외로 유출된 대식세포의 식작용:** 대식세포는 혈관 밖으로 유출되어 식작용을 할 수 있지만, 갈색경화성 정체피부염의 갈색 색소 침착의 직접적인 원인은 아닙니다. 대식세포는 염증 반응에 관여하지만, 주된 기전은 적혈구 용해와 헤모시데린 침착입니다.\n* **E. 혈관 외로 유출된 림프구의 면역반응:** 림프구는 면역 반응에 관여하며, 갈색경화성 정체피부염에도 염증 반응의 일부로 림프구가 관여할 수 있습니다. 하지만 주된 발생 기전은 림프구의 면역 반응보다는 적혈구 용해와 헤모시데린 침착입니다.\n\n**결론적으로, 갈색경화성 정체피부염의 핵심 발생 기전은 정맥압 상승으로 인한 적혈구의 혈관 외 유출 및 용해, 그리고 그 결과로 발생하는 헤모시데린 침착입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:3145,&quot;string&quot;:&quot;3,145&quot;}}},{&quot;rowIdx&quot;:6,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;nurse&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2019,&quot;string&quot;:&quot;2,019&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:45,&quot;string&quot;:&quot;45&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;지역사회간호사가 영아를 둔 다문화 여성을 대상으로 고형식에 대해 교육하려고 할 때 문화적 차이점을 확인하기 위해 사정해야 할 사항은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;유치의 개수&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;아기의 월령&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;고형식 수행 여부&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;아기의 키와 몸무게&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;출신국과 한국의 음식 문화&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;\nThe question is asking about what a community health nurse should assess to understand cultural differences when educating a multicultural woman with an infant about solid foods.  Let's break down each option and think about its relevance to cultural differences and solid food education.\n\n* **A. 유치의 개수 (Number of baby teeth):**  While the number of teeth *can* be an indicator of readiness for certain textures of food (and sometimes related to developmental stage), it's not directly tied to cultural differences in solid food introduction.  Different cultures might introduce solids at different stages regardless of teeth, and the types of solids offered could vary culturally.  Teeth are more of a biological factor than a cultural one in this context.\n\n* **B. 아기의 월령 (Infant's age in months):**  Age is a crucial factor in determining when to start solids in general.  However, cultural practices can significantly influence *when* and *how* solids are introduced.  For example, some cultures might start earlier or later than the generally recommended age, and the types of first foods might differ based on cultural norms.  Age provides a baseline, but cultural context is essential for tailoring education.\n\n* **C. 고형식 수행 여부 (Whether solid foods are being given):**  Knowing if the mother is *already* introducing solids is important.  If she is, the nurse needs to understand *what* she's giving and *why*.  This can reveal cultural practices and potential misunderstandings or needs for guidance.  If she isn't, the nurse needs to understand her knowledge and beliefs about when to start, which can also be culturally influenced.  This option seems quite relevant to understanding current practices and potential cultural influences.\n\n* **D. 아기의 키와 몸무게 (Infant's height and weight):**  Growth parameters are important for assessing the infant's overall health and nutritional status.  While nutrition is related to solid food introduction, height and weight themselves don't directly reveal cultural differences in *approaches* to solid foods.  They are more about the *outcome* of feeding practices, not the cultural practices themselves.  Growth monitoring is important in general, but not the primary factor for assessing cultural differences in solid food education.\n\n* **E. 출신국과 한국의 음식 문화 (Country of origin and Korean food culture):**  This option directly addresses cultural differences.  Understanding the mother's country of origin and its food culture is crucial to understand her background beliefs and practices regarding infant feeding.  Comparing her culture's food practices with Korean food culture (the context of the nurse's practice and potentially the dominant culture the mother is navigating) is essential for culturally sensitive education.  This option appears highly relevant to assessing cultural differences.\n\n**Comparing C and E:** Both C and E are strong contenders.\n\n* **C (고형식 수행 여부):**  Focuses on current practice.  It's important to know what's happening *now*.  However, it doesn't directly address the *cultural background* driving those practices.\n\n* **E (출신국과 한국의 음식 문화):** Directly addresses the cultural background.  Knowing her origin and comparing it to the local culture provides the context for understanding *why* certain practices might be in place or preferred.\n\n**The question is specifically about identifying cultural differences.**  While knowing if solids are being given (C) is useful information, understanding the cultural *context* (E) is more directly relevant to identifying and addressing cultural differences in solid food education.  Knowing the cultural background helps the nurse understand the *reasons* behind current practices and tailor education accordingly.\n\n**Consider a scenario:** A nurse is educating a woman from a Southeast Asian country about solid foods.\n\n* Knowing the number of teeth (A) or height/weight (D) is generally useful but not culturally specific.\n* Knowing the infant's age (B) is important for general guidance but doesn't capture cultural nuances.\n* Knowing if she's giving solids (C) is helpful to know current practice, but not *why* she's doing it that way.\n* Knowing her country of origin and understanding its food culture (E) is *crucial*.  For example, in some cultures, rice porridge might be a very early and culturally preferred first food, while in others, pureed fruits or vegetables might be more common.  Understanding these cultural norms is essential for respectful and effective education.  Comparing it to Korean food culture can also highlight potential differences or areas where she might need support navigating the new cultural context.\n\n\n**Conclusion:** Option E, \&quot;출신국과 한국의 음식 문화 (Country of origin and Korean food culture),\&quot; is the most direct and relevant factor to assess to understand cultural differences when educating a multicultural woman about solid foods.  It provides the cultural context needed to tailor education effectively.  While C is also relevant, E is more fundamental for understanding cultural differences.\n\n\nTherefore, the answer is likely **E**.\n\nLet's re-examine the options in Korean to double-check the nuances:\n\n* A. 유치의 개수: Number of deciduous teeth (baby teeth)\n* B. 아기의 월령: Baby's age in months\n* C. 고형식 수행 여부: Whether solid food is being implemented/given\n* D. 아기의 키와 몸무게: Baby's height and weight\n* E. 출신국과 한국의 음식 문화: Country of origin and Korean food culture\n\nThe question specifically asks about assessing \&quot;문화적 차이점 (cultural differences).\&quot;  Option E directly addresses this.  The other options are less directly related to cultural differences in solid food education specifically.\n\n**Final Answer: E.**\n\nLet's confirm the logic again.  To provide culturally competent education on solid foods, a community health nurse needs to understand the mother's cultural background and how it might differ from the dominant culture (Korean in this case).  This understanding is best achieved by assessing her country of origin and the food culture of both her origin and the host country. This allows for tailoring the education to respect her cultural practices while ensuring the infant's nutritional needs are met within a safe and healthy framework.\n&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;**정답은 E. 출신국과 한국의 음식 문화**입니다.\n\n**해설:**\n\n지역사회간호사가 다문화 여성에게 영아 고형식 교육을 할 때 문화적 차이를 확인하기 위해 가장 먼저 사정해야 할 것은 **출신국과 한국의 음식 문화**입니다. 그 이유는 다음과 같습니다.\n\n* **문화적 배경의 중요성:**  고형식 시작 시기, 종류, 방법 등은 문화적 배경에 따라 크게 다를 수 있습니다.  각 문화권마다 전통적으로 영아에게 먹이는 음식, 선호하는 질감, 식재료 등이 다르며, 이러한 문화적 차이를 이해하는 것이 중요합니다.\n* **효과적인 교육:**  다문화 여성의 출신국 음식 문화를 이해하면, 한국 문화와의 차이점을 파악하고, 그녀의 문화적 배경을 존중하면서 한국 문화에 적응할 수 있도록 맞춤형 교육을 제공할 수 있습니다. 예를 들어, 특정 문화권에서는 쌀미음을 먼저 시작하는 반면, 다른 문화권에서는 과일이나 채소를 먼저 시작할 수 있습니다. 이러한 차이를 알고 교육해야 교육의 효과를 높일 수 있습니다.\n* **신뢰 관계 형성:**  간호사가 대상자의 문화적 배경에 관심을 가지고 이해하려는 노력을 보이면, 대상자와의 신뢰 관계를 형성하는 데 도움이 됩니다. 신뢰 관계는 효과적인 간호 중재의 기본입니다.\n\n**다른 선택지 오답 이유:**\n\n* **A. 유치의 개수:** 유치의 개수는 고형식 시작 시기를 결정하는 일반적인 지표가 될 수 있지만, 문화적 차이를 파악하는 데 직접적인 정보는 아닙니다. 유치 발달은 개인차가 크고 문화적 배경과 직접적인 관련은 적습니다.\n* **B. 아기의 월령:** 아기의 월령은 고형식 시작 시기를 결정하는 중요한 요소이지만, 문화적 차이를 설명해주지는 않습니다. 월령은 일반적인 가이드라인일 뿐, 문화에 따라 고형식 시작 시기에 대한 관점이 다를 수 있습니다.\n* **C. 고형식 수행 여부:** 고형식 수행 여부를 확인하는 것은 현재 상황을 파악하는 데 도움이 되지만, 문화적 차이의 근본적인 원인을 알 수는 없습니다. 이미 고형식을 하고 있다면 어떤 종류의 음식을 주고 있는지, 그 이유는 무엇인지 문화적 배경과 함께 파악해야 합니다.\n* **D. 아기의 키와 몸무게:** 아기의 키와 몸무게는 성장 발달 상태를 평가하는 중요한 지표이지만, 문화적 차이를 직접적으로 반영하지 않습니다. 영양 상태 평가에 필요하지만, 문화적 차이 사정의 우선순위는 아닙니다.\n\n**결론적으로, 다문화 여성에게 효과적인 고형식 교육을 제공하기 위해서는 그녀의 문화적 배경을 이해하는 것이 가장 중요하며, 이를 위해 출신국과 한국의 음식 문화에 대한 사정이 필수적입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2411,&quot;string&quot;:&quot;2,411&quot;}}},{&quot;rowIdx&quot;:7,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;dental_technician&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2019,&quot;string&quot;:&quot;2,019&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;안궁(face bow)에 관한 설명으로 옳은 것은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;교합관계를 재현하기 위한 기구이다.&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;전방운동의 가이드(guide) 역할을 하는 기구이다.&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;측방운동의 가이드(guide) 역할을 하는 기구이다.&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;두개골에서 상악의 위치 관계를 옮기는 기구이다.&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;보철물을 제작하는 데에 가이드(guide) 역할을 하는 기구 이다.&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:4,&quot;string&quot;:&quot;4&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to arrive at the correct answer (D) for the question about face bows.\n\n**1. Understanding the Question:**\n\nThe question is asking for the *correct* description of a face bow.  This immediately tells me I need to know what a face bow is and what it does.  The Korean term \&quot;안궁\&quot; is given, and it's translated as \&quot;face bow\&quot; in English.  The answer choices are all in Korean and relate to different aspects of dental procedures.  I need to translate and understand each choice in the context of a face bow.\n\n**2.  Initial Brainstorm and Recall about Face Bows:**\n\nMy immediate thoughts about face bows are:\n\n* **Dentistry:** It's a dental instrument.\n* **Relating jaws to skull:**  It's used to transfer the relationship of the upper jaw (maxilla) to the skull.  This is the key function I recall.\n* **Articulator:** It's used in conjunction with an articulator (교합기 in Korean), a device that simulates jaw movements for dental lab work.\n* **Mounting maxillary cast:** The face bow helps mount the maxillary cast (upper jaw model) onto the articulator in a way that mimics the patient's actual jaw position relative to their skull.\n* **Not about guides for movements:** It's *not* primarily about guiding jaw movements like protrusion (forward) or lateral (sideways).  Those are related to condylar guidance and incisal guidance, which are *set on the articulator* *after* mounting the casts, often *using* face bow information, but the face bow itself isn't the guide.\n* **Not directly for prosthesis fabrication guide:** While the face bow information *is* crucial for accurate prosthesis fabrication, it's not *directly* a \&quot;guide\&quot; in the sense of shaping the prosthesis itself. It sets up the *articulation* which *then* guides prosthesis fabrication.\n\n**3. Analyzing Each Answer Choice (and Translating):**\n\nLet's translate and analyze each option:\n\n* **A. 교합관계를 재현하기 위한 기구이다. (It is an instrument to reproduce occlusal relationships.)**\n    * *Analysis:*  While face bows contribute to reproducing occlusal relationships on the articulator, this is a *very* broad statement and could apply to many dental instruments.  It's not *specific* to the primary function of a face bow. It's *partially* true but not the best answer.\n\n* **B. 전방운동의 가이드(guide) 역할을 하는 기구이다. (It is an instrument that acts as a guide for protrusive movement.)**\n    * *Analysis:* Face bows do *not* directly guide protrusive movement.  Protrusive movement is guided by the condylar guidance on the articulator, set *after* face bow transfer.  This is *incorrect*.\n\n* **C. 측방운동의 가이드(guide) 역할을 하는 기구이다. (It is an instrument that acts as a guide for lateral movement.)**\n    * *Analysis:* Similar to B, face bows do *not* directly guide lateral movement. Lateral movement is also guided by condylar guidance on the articulator. This is *incorrect*.\n\n* **D. 두개골에서 상악의 위치 관계를 옮기는 기구이다. (It is an instrument that transfers the positional relationship of the maxilla from the skull.)**\n    * *Analysis:* This is the *most accurate and specific* description of a face bow's primary function.  \&quot;두개골\&quot; (skull), \&quot;상악\&quot; (maxilla), \&quot;위치 관계\&quot; (positional relationship), and \&quot;옮기는 기구\&quot; (instrument to transfer) perfectly describe what a face bow does. This looks like the correct answer.\n\n* **E. 보철물을 제작하는 데에 가이드(guide) 역할을 하는 기구 이다. (It is an instrument that acts as a guide in fabricating prostheses.)**\n    * *Analysis:* Again, while face bow information is *essential* for accurate prosthesis fabrication, the face bow itself isn't a *direct guide* in the *fabrication process*. It provides the *foundation* (accurate articulation) upon which a prosthesis can be fabricated correctly.  It's too broad and not the *primary* function.  It's *indirectly* related, but not the best answer.\n\n**4.  Confirming the Best Answer:**\n\nComparing the analyses, option D stands out as the most precise and accurate description of the core function of a face bow. Options A and E are too general, while B and C are factually incorrect.\n\n**5. Final Answer Selection:**\n\nTherefore, the best and most correct answer is **D**.\n\n**Self-Correction/Refinement during the Process:**\n\n* Initially, I might have considered A as *partially* correct because face bows *do* contribute to occlusal relationships.  However, realizing it's too broad and doesn't capture the *specific* function helped me refine my thinking.\n* I double-checked my understanding of \&quot;guide\&quot; in the context of B, C, and E. I clarified that \&quot;guide\&quot; in these options is meant in the sense of *directly controlling movement* or *shaping the prosthesis*, which is not what a face bow does directly. It's more about establishing the *correct starting point* for articulation.\n* I focused on the keyword \&quot;두개골에서 상악의 위치 관계를 옮기는\&quot; (transferring the positional relationship of the maxilla from the skull) in option D and recognized this as the defining purpose of a face bow.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **D. 두개골에서 상악의 위치 관계를 옮기는 기구이다.** 입니다.\n\n**해설:**\n\n* **안궁 (Face Bow) 의 주요 기능:** 안궁은 환자의 **두개골**을 기준으로 **상악** 치아궁의 **3차원적인 위치 관계**를 채득하여 교합기라는 기계로 옮기는 기구입니다.  쉽게 말해, 환자의 얼굴에서 윗턱의 위치를 정확하게 본떠서 교합기에 재현하는 역할을 합니다.\n\n* **각 선택지별 오답 이유:**\n\n    * **A. 교합관계를 재현하기 위한 기구이다.**  (X) : 교합관계 재현에 *일정 부분* 기여하지만, 안궁의 *주요 기능*은 교합관계 자체를 재현하는 것이 아니라 **상악의 위치 관계**를 옮기는 것입니다. 교합관계는 교합기 상에서 하악 모형과 함께 재현됩니다.  따라서 너무 포괄적인 설명입니다.\n\n    * **B. 전방운동의 가이드(guide) 역할을 하는 기구이다.** (X) : 전방운동의 가이드 (protrusive guide) 는 주로 교합기 상에서 **과로 (condylar path)** 설정을 통해 재현됩니다. 안궁은 전방운동 가이드와 직접적인 관련이 없습니다.\n\n    * **C. 측방운동의 가이드(guide) 역할을 하는 기구이다.** (X) : 측방운동의 가이드 (lateral guide) 역시 주로 교합기 상에서 **과로 (condylar path)** 및 **Bennet angle** 설정을 통해 재현됩니다. 안궁은 측방운동 가이드와 직접적인 관련이 없습니다.\n\n    * **E. 보철물을 제작하는 데에 가이드(guide) 역할을 하는 기구 이다.** (X) : 안궁은 보철물 제작 과정에서 **정확한 교합**을 구현하는 데 *필수적인 정보*를 제공하지만, 직접적으로 보철물 제작을 *가이드* 하는 기구는 아닙니다. 보철물 제작 가이드는 주로 인상재, 왁스업, 레진 등 다른 재료와 기구를 통해 이루어집니다.  안궁은 그 **기초적인 위치 정보**를 제공하는 역할입니다.\n\n**결론적으로, 안궁의 가장 핵심적인 기능은 두개골을 기준으로 한 상악의 위치 관계를 정확하게 옮겨 교합기에서 재현하여, 환자의 실제 구강 내 상황과 유사한 환경에서 보철물을 제작할 수 있도록 돕는 것입니다. 따라서 D가 가장 정확한 설명입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:4750,&quot;string&quot;:&quot;4,750&quot;}}},{&quot;rowIdx&quot;:8,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;pharm&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2020,&quot;string&quot;:&quot;2,020&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:3,&quot;string&quot;:&quot;3&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:64,&quot;string&quot;:&quot;64&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;현재 유방암 치료 중인 52세 환자에게 폐경기 혈관운동증상(vasomotor symptom) 과 우울증상이 나타나 치료를 시작하려고 한다. 적절한 약물은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;라록시펜(raloxifene)&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;벤라팍신(venlafaxine)&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;메드록시프로게스테론(medroxyprogesterone)&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;바제독시펜/에스트로겐(bazedoxifene/conjugated equine estrogen)&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;에스트라디올/메드록시프로게스테론(estradiol/medroxyprogesterone)&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to arrive at the correct answer for this clinical scenario.\n\n**1. Deconstructing the Question:**\n\n* **Patient Profile:** 52-year-old woman, currently undergoing breast cancer treatment.  This is *critical*. Breast cancer treatment immediately raises red flags regarding hormone-sensitive therapies.\n* **Symptoms:** Vasomotor symptoms (hot flashes, night sweats) and depressive symptoms. These are common menopausal symptoms, but also could be side effects of breast cancer treatment itself (like chemotherapy or endocrine therapy).\n* **Goal:**  Treat vasomotor and depressive symptoms *in the context of ongoing breast cancer treatment*. This means we need to prioritize safety and avoid exacerbating the cancer or interfering with its treatment.\n* **Question Type:**  \&quot;Appropriate medication.\&quot; This is a medication selection question, requiring knowledge of drug classes and their contraindications/indications, particularly in the context of breast cancer.\n\n**2. Analyzing Each Answer Option:**\n\n* **A. Raloxifene (라록시펜):**\n    * Class: Selective Estrogen Receptor Modulator (SERM).\n    * Mechanism: Estrogen agonist in bone, antagonist in breast and uterus.\n    * Breast Cancer: Used for breast cancer risk reduction and treatment of osteoporosis in postmenopausal women.  However, it's *not* for vasomotor symptoms and *could* potentially have complex interactions in a patient currently *undergoing* breast cancer treatment.  While it's not directly contraindicated, it's not a primary choice for vasomotor symptoms, and we need to be cautious in a patient actively being treated.  *Initial thought: Maybe, but unlikely best option for symptoms.*\n\n* **B. Venlafaxine (벤라팍신):**\n    * Class: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI).\n    * Mechanism: Antidepressant, also effective for vasomotor symptoms in menopausal women, especially those who cannot or should not take hormone therapy.\n    * Breast Cancer: Generally considered safe in breast cancer patients.  Non-hormonal approach.  Addresses both depression and vasomotor symptoms. *Initial thought: Strong candidate.*\n\n* **C. Medroxyprogesterone (메드록시프로게스테론):**\n    * Class: Progestin (synthetic progesterone).\n    * Mechanism: Can sometimes help with vasomotor symptoms, but less effective than estrogen. Historically used, but not preferred.\n    * Breast Cancer:  Progestins *can* stimulate breast cancer growth in some cases.  Generally contraindicated or used with extreme caution in breast cancer patients.  Definitely not a first-line choice. *Initial thought:  Likely contraindicated, very risky.*\n\n* **D. Bazedoxifene/Conjugated Equine Estrogen (바제독시펜/에스트로겐):**\n    * Class:  Estrogen with a SERM (bazedoxifene).  \&quot;Tissue-selective estrogen complex (TSEC)\&quot;.\n    * Mechanism:  Estrogen component for vasomotor symptoms; bazedoxifene to protect the uterus from estrogen's proliferative effects.\n    * Breast Cancer: *Estrogen is generally contraindicated in breast cancer patients*, especially those currently being treated.  Adding bazedoxifene doesn't negate the estrogen risk in breast tissue.  This combination is for menopausal symptoms, but absolutely contraindicated due to the estrogen component. *Initial thought:  Strong contraindication, definitely wrong.*\n\n* **E. Estradiol/Medroxyprogesterone (에스트라디올/메드록시프로게스테론):**\n    * Class:  Estrogen and Progestin (Hormone Therapy - HT).\n    * Mechanism: Estrogen for vasomotor symptoms; progestin to protect the uterus from estrogen.\n    * Breast Cancer: *Absolutely contraindicated* in breast cancer patients, especially during active treatment.  Estrogen and progestin can fuel breast cancer growth.  This is the classic hormone therapy regimen and is the *opposite* of what's safe in this context. *Initial thought:  Strongest contraindication, definitively wrong.*\n\n**3. Prioritization and Selection:**\n\n* **Rule out contraindicated options:** D and E are estrogen-containing therapies, absolutely contraindicated in breast cancer. C (medroxyprogesterone alone) is also risky and less effective, not a good choice.\n* **Compare remaining options:** A (raloxifene) and B (venlafaxine).\n    * Raloxifene is a SERM, and while not directly contraindicated, it's not the best choice for vasomotor symptoms, and its complex estrogen agonist/antagonist profile raises concerns during active breast cancer treatment. It's more for osteoporosis prevention and breast cancer risk reduction in *high-risk* women, not symptom management in *active* breast cancer.\n    * Venlafaxine is a non-hormonal SNRI, effective for both vasomotor symptoms and depression. It's considered safe and often used in breast cancer patients experiencing menopausal symptoms.\n\n**4. Final Answer and Justification:**\n\nVenlafaxine (벤라팍신) is the most appropriate choice because:\n\n* It effectively treats both vasomotor symptoms and depressive symptoms.\n* It is a non-hormonal option, avoiding the risks associated with estrogen or progestin in a breast cancer patient.\n* It is generally considered safe and well-tolerated in breast cancer patients.\n\nTherefore, the answer is **B**.\n\n**Self-Correction/Refinement during the process:**\n\nInitially, I might have briefly considered raloxifene because it has some \&quot;breast-related\&quot; actions. However, upon closer examination, realizing it's not primarily for symptom relief and the context of *active* breast cancer treatment, venlafaxine emerges as the clearly superior and safer choice.  The key is always to prioritize patient safety and contraindications, especially in complex cases like this.  Thinking about *why* each option is right or wrong, and explicitly considering the patient's specific situation, leads to the correct answer.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **B. 벤라팍신(venlafaxine)** 입니다.\n\n**해설:**\n\n**환자 상태:**\n\n* 52세 여성\n* 현재 유방암 치료 중\n* 폐경기 혈관운동증상 (vasomotor symptom, 안면홍조, 야간 발한 등)\n* 우울 증상\n\n**각 선택지 분석:**\n\n* **A. 라록시펜(raloxifene):**  선택적 에스트로겐 수용체 조절제(SERM)로, 폐경 후 여성의 골다공증 치료 및 유방암 예방에 사용됩니다.  하지만 혈관운동증상 완화 효과는 제한적이며, 유방암 환자에게는 주된 치료 옵션이 아닙니다. 오히려 유방암 치료 중인 환자에게는 신중하게 사용해야 합니다.\n\n* **B. 벤라팍신(venlafaxine):**  세로토닌-노르에피네프린 재흡수 억제제(SNRI) 계열의 항우울제로, 혈관운동증상 완화 효과가 입증되었습니다.  특히 유방암 환자나 호르몬 치료가 금기인 여성에게 혈관운동증상 치료의 1차 선택 약물로 권장됩니다. 우울 증상 개선에도 효과적이므로 이 환자에게 적절한 선택입니다.\n\n* **C. 메드록시프로게스테론(medroxyprogesterone):**  프로게스틴 제제로, 과거 혈관운동증상 치료에 사용되기도 했지만, 에스트로겐에 비해 효과가 떨어지고 부작용 위험이 있습니다. 특히 유방암 환자에게는 프로게스테론이 유방암 세포 성장을 촉진할 수 있다는 우려 때문에 일반적으로 권장되지 않습니다.\n\n* **D. 바제독시펜/에스트로겐(bazedoxifene/conjugated equine estrogen):**  에스트로겐과 선택적 에스트로겐 수용체 조절제(SERM) 복합제입니다. 에스트로겐은 혈관운동증상 완화에 효과적이지만, 유방암 병력이 있거나 현재 치료 중인 환자에게는 금기입니다. 에스트로겐은 유방암 재발 위험을 높일 수 있습니다.\n\n* **E. 에스트라디올/메드록시프로게스테론(estradiol/medroxyprogesterone):**  에스트로겐과 프로게스테론 복합 호르몬 치료제입니다.  D와 마찬가지로 에스트로겐 성분 때문에 유방암 환자에게는 금기입니다.\n\n**결론:**\n\n유방암 치료 중인 환자에게 혈관운동증상과 우울 증상 치료를 위해 가장 적절한 약물은 **B. 벤라팍신(venlafaxine)** 입니다. 벤라팍신은 비호르몬 제제로 유방암에 대한 위험 없이 혈관운동증상과 우울 증상을 동시에 효과적으로 관리할 수 있습니다.\n\n**참고:**\n\n* 유방암 환자의 폐경기 증상 관리는 호르몬 치료보다는 비호르몬 치료를 우선적으로 고려합니다.\n* 벤라팍신 외에도 선택적 세로토닌 재흡수 억제제(SSRI) 계열의 항우울제 (예: 파록세틴, 시탈로프람, 에스시탈로프람) 또한 혈관운동증상 완화에 효과적이며 유방암 환자에게 사용 가능합니다.\n* 환자의 상태와 선호도, 약물 부작용 등을 고려하여 개별적으로 치료 계획을 수립해야 합니다.&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:3579,&quot;string&quot;:&quot;3,579&quot;}}},{&quot;rowIdx&quot;:9,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;dentist&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2020,&quot;string&quot;:&quot;2,020&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:28,&quot;string&quot;:&quot;28&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;총의치 악간관계 기록과정에서 다음 술식으로 채득하는 것은?\n· 술자의 왼손으로 환자의 구강내 상하악 기록상을 치조제에 정확하게 위치시킨다. · 술자의 오른손 엄지를 환자의 이부에 위치시키고 턱을 가볍게 잡는다. · 환자의 하악을 후상방으로 가볍게 밀면서 접번운동을 확인 후 폐구시킨다.&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;중심위&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;전방활주로&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;최대개구위&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;최전방접촉위&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;후방한계개구로&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to arrive at the correct answer for the given question about interocclusal record taking in complete dentures.\n\n**1. Deconstructing the Question:**\n\nThe question is asking about a specific technique for obtaining an interocclusal record in complete denture prosthodontics.  It provides a step-by-step procedure and asks what position this procedure is intended to record.  The key is to carefully analyze the described steps.\n\n**2. Analyzing the Provided Steps:**\n\nLet's go through each step and interpret its significance:\n\n* **\&quot;술자의 왼손으로 환자의 구강내 상하악 기록상을 치조제에 정확하게 위치시킨다.\&quot;** (The operator's left hand accurately positions the maxillary and mandibular record bases onto the alveolar ridges within the patient's mouth.)\n    * *Interpretation:* This step sets the stage for recording a jaw relationship. Record bases are used in complete denture fabrication to simulate denture bases and provide a stable platform for recording jaw positions.  \&quot;치조제\&quot; (alveolar ridge) is crucial – it indicates we're dealing with edentulous patients.\n\n* **\&quot;술자의 오른손 엄지를 환자의 이부에 위치시키고 턱을 가볍게 잡는다.\&quot;** (The operator's right thumb is positioned on the patient's chin and gently holds the jaw.)\n    * *Interpretation:* This step describes how the operator is manipulating the patient's mandible.  Placing the thumb on the chin and gently holding the jaw implies controlled mandibular manipulation.\n\n* **\&quot;환자의 하악을 후상방으로 가볍게 밀면서 접번운동을 확인 후 폐구시킨다.\&quot;** (Gently push the patient's mandible posteriorly and superiorly, check for hinge movement, and then close the mouth.)\n    * *Interpretation:* This is the *most* critical step. \&quot;후상방으로 가볍게 밀면서\&quot; (gently push posteriorly and superiorly) is the key maneuver. \&quot;접번운동\&quot; (hinge movement) is also extremely important. This procedure is designed to guide the mandible into a specific, repeatable position.  Pushing posteriorly and superiorly, along with checking for hinge movement, strongly suggests an attempt to locate the **centric relation**.\n\n**3. Connecting Steps to Dental Concepts:**\n\nNow, let's link these interpreted steps to known dental concepts, especially related to interocclusal records:\n\n* **Centric Relation (CR):**  CR is a maxillomandibular relationship where the condyles are in their most superior-anterior position in the glenoid fossae, resting against the posterior slopes of the articular eminences, with the discs interposed.  It's a hinge position, and it's considered a reproducible and physiologically acceptable starting point for denture construction.  The described technique of pushing posteriorly and superiorly *strongly* aligns with attempts to achieve CR.\n\n* **Protrusive Record (전방활주로):** This record captures the mandible in a protruded position, used for setting condylar guidance on articulators. The described technique doesn't involve protrusion; it's about posterior and superior movement.\n\n* **Maximum Intercuspation (MI) or Maximum Opening (최대개구위):** MI is the position of maximum tooth contact. Maximum opening is the widest mouth opening.  The described technique isn't about either of these.  It's about a specific jaw *relationship*, not maximum opening or tooth intercuspation (which isn't relevant in edentulous patients with record bases).\n\n* **Retruded Contact Position (RCP) or Centric Occlusion (CO) (최전방접촉위):** RCP/CO refers to the first tooth contact in centric relation.  While related to CR, the description emphasizes achieving the condylar position (hinge movement) rather than just the first contact.  The focus is on the *position* of the condyles, which is the definition of CR.  \&quot;최전방접촉위\&quot; (most anterior contact position) could be misinterpreted as CO, but in the context of the procedure described (posterior-superior guidance), it's not the best fit.  Also, \&quot;최전방접촉위\&quot; is a less common term, and while it might sometimes be used synonymously with CO, it doesn't capture the essence of the CR-seeking maneuver.\n\n* **Maximum Retrusion (후방한계개구로):** This refers to the most retruded position the mandible can achieve.  While the technique involves posterior movement, the description doesn't aim for the *extreme* retrusion.  It's about a controlled, reproducible hinge position, not just pushing the mandible as far back as possible.  Also, \&quot;후방한계개구로\&quot; is a less direct translation and might be confusing in this context. \&quot;후방한계개구로\&quot; might refer to the posterior limit of opening movement, which is not what the procedure is describing.\n\n**4. Selecting the Best Answer:**\n\nBased on the analysis, the procedure described is clearly aimed at recording **Centric Relation (중심위)**. The key phrases \&quot;후상방으로 가볍게 밀면서\&quot; (gently push posteriorly and superiorly) and \&quot;접번운동\&quot; (hinge movement) are strong indicators of a centric relation recording technique.\n\n**5. Confirming and Refining (Self-Correction):**\n\nLet's re-read the question and the steps to ensure no misinterpretations. The steps are consistent with a common technique for guiding the mandible into centric relation in edentulous patients. The options are:\n\n* A. 중심위 (Centric Relation) - **Strong candidate**\n* B. 전방활주로 (Protrusive Record) - Incorrect, procedure is posterior, not anterior.\n* C. 최대개구위 (Maximum Opening Position) - Incorrect, procedure is about jaw relation, not opening.\n* D. 최전방접촉위 (Most Anterior Contact Position) - Less precise, and the technique is focused on condylar position, not first contact.  Also, \&quot;최전방접촉위\&quot; is a slightly unusual term; \&quot;중심교합위\&quot; (Centric Occlusion) would be more common and still not the best fit.\n* E. 후방한계개구로 (Maximum Retrusion Opening) -  Incorrect, procedure is not about maximum retrusion or opening limit.\n\n**Conclusion:**  The most accurate answer is **A. 중심위 (Centric Relation)**. The described technique is a classic method for guiding the mandible into centric relation for recording in complete denture prosthodontics.  The other options are not supported by the described steps.  The Korean terms also reinforce this conclusion, with \&quot;중심위\&quot; being the standard term for Centric Relation in Korean dentistry.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **A. 중심위**입니다.\n\n**해설:**\n\n제시된 술식은 하악을 후상방으로 유도하여 접번운동을 확인하는 과정으로, 이는 **중심위(Centric Relation)**를 채득하기 위한 대표적인 방법입니다.\n\n각 선택지별 설명은 다음과 같습니다.\n\n* **A. 중심위 (Centric Relation):**  하악 과두가 관절와의 가장 상방-후방 위치에 놓이는 악위 관계입니다. 총의치 제작 시 기준 악위로 사용되며, 재현성이 높은 위치입니다. 제시된 술식은 하악을 후상방으로 유도하여 중심위를 채득하는 전형적인 방법과 일치합니다.\n\n* **B. 전방활주로 (Protrusive Record):** 하악을 전방으로 내밀었을 때의 악위 관계를 기록하는 것입니다.  주로 교합기 상에서 전방유도각을 설정하기 위해 사용됩니다. 제시된 술식은 하악을 전방으로 내미는 것이 아니라 후상방으로 유도하므로 전방활주로와는 거리가 멉니다.\n\n* **C. 최대개구위 (Maximum Opening Position):** 입을 최대한 크게 벌렸을 때의 위치입니다. 악관절 질환 평가 등에 사용될 수 있지만, 악간관계 기록과는 관련이 적습니다. 제시된 술식은 입을 벌리는 동작과는 관련이 없고, 하악의 특정 위치를 유도하는 것에 초점을 맞추고 있습니다.\n\n* **D. 최전방접촉위 (Most Anterior Contact Position):** 하악을 최대한 전방으로 내밀어 치아가 처음 닿는 위치를 의미할 수 있습니다. 하지만 일반적으로 \&quot;최전방접촉위\&quot;라는 용어는 중심위나 중심교합위와 같은 특정 악위 관계를 지칭하는 표준적인 용어는 아닙니다.  제시된 술식은 하악을 후상방으로 유도하므로 최전방접촉위와는 반대 방향입니다.\n\n* **E. 후방한계개구로 (Maximum Retrusion Opening):** 하악을 최대한 후방으로 밀면서 입을 벌릴 때의 경로를 의미합니다.  악관절 평가 등에 사용될 수 있지만, 악간관계 기록과는 직접적인 관련이 적습니다.  제시된 술식은 하악을 후방으로 유도하지만, 개구 운동보다는 폐구 상태에서 중심위를 기록하는 것을 목표로 합니다.\n\n**결론적으로, 제시된 술식은 하악을 후상방으로 유도하여 접번운동을 확인하는 중심위 채득 방법과 정확히 일치하므로, 정답은 A. 중심위입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:16,&quot;string&quot;:&quot;16&quot;}}},{&quot;rowIdx&quot;:10,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;doctor&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2013,&quot;string&quot;:&quot;2,013&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:26,&quot;string&quot;:&quot;26&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;6개월 남아가 출생 후부터 하지의 움직임이 없어 병원에 왔다. 개구리 다리 모양을 하고 누워 있었다.혀에 근섬유다발수축(fasciculation) 이 보였다. 다리에 자극을 주어도 움직임이 없었고, 깊은힘줄반사는없었다. 혈액검사 결과는 다음과 같았다. 진단은?아스파르테이트아미노전달효소 30 U/L, 알라닌아미노전달효소 20 U/L,크레아틴키나아제 100 U/L (참고치, 5～130), 젖산탈수소효소 170 U/L (참고치, 170～580) &quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;뇌성마비&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;중증근무력증&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;길랭- 바레증후군&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;진행근디스트로피&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;척수근위축증&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down this medical case step-by-step to arrive at the most likely diagnosis.\n\n**1. Understanding the Patient Presentation:**\n\n* **Age:** 6 months old infant. This is crucial, as certain conditions are more common or present differently at this age.\n* **Chief Complaint:** Lack of leg movement since birth. This is a significant neurological symptom.\n* **Posture:** \&quot;Frog-leg position.\&quot;  This posture in infants often suggests hypotonia (low muscle tone) and weakness, particularly in the hips and legs.\n* **Physical Exam Findings:**\n    * **Tongue fasciculations:** Involuntary muscle twitches of the tongue. This is a key finding indicating *lower motor neuron* involvement.\n    * **No leg movement to stimulation:**  Strongly suggests paralysis or severe weakness in the legs.\n    * **Absent deep tendon reflexes:**  This is another crucial finding pointing towards *lower motor neuron* pathology.\n\n**2. Interpreting the Lab Results:**\n\n* **Aspartate aminotransferase (AST) 30 U/L, Alanine aminotransferase (ALT) 20 U/L:** These are liver enzymes.  The values are within normal limits.  This is not particularly helpful for differentiating the given diagnoses.  It rules out significant liver damage, which is not directly relevant to the neurological symptoms.\n* **Creatine kinase (CK) 100 U/L (Reference: 5-130 U/L):** CK is an enzyme released from muscle tissue when it's damaged. The value is *within the normal range*.  While some muscle diseases elevate CK, a normal CK level doesn't exclude all muscle disorders.  It makes rapidly progressing muscle degeneration *less likely*, but doesn't rule out slower or congenital myopathies entirely.  However, in the context of other findings, it weakens the possibility of something like Duchenne muscular dystrophy (which usually has *very* high CK levels).\n* **Lactate dehydrogenase (LDH) 170 U/L (Reference: 170-580 U/L):** LDH is another enzyme found in many tissues, including muscle.  The value is at the *lower end of the normal range*. This is also not particularly helpful in differentiating the diagnoses and does not point strongly to muscle damage.\n\n**3.  Analyzing the Differential Diagnoses and Matching with Findings:**\n\nLet's evaluate each option based on the clinical picture:\n\n* **A. Cerebral Palsy (뇌성마비):**\n    * **Pros:** Can present with limb weakness and abnormal posture.\n    * **Cons:**  *Usually* presents with *upper motor neuron* signs (increased reflexes, spasticity).  Tongue fasciculations and absent deep tendon reflexes are *not* typical of cerebral palsy.  Cerebral palsy is caused by brain damage, not primarily lower motor neuron issues.  While hypotonia can occur in some forms of CP, the combination of hypotonia, absent reflexes, and fasciculations makes CP less likely as the *primary* diagnosis.\n\n* **B. Myasthenia Gravis (중증근무력증):**\n    * **Pros:** Can cause muscle weakness, and in infants, it can present with generalized weakness (\&quot;floppy baby\&quot;).\n    * **Cons:**  *No fasciculations*.  Myasthenia gravis is a *neuromuscular junction* disorder, not a motor neuron disease. Deep tendon reflexes are typically *normal* or only mildly reduced.  Tongue fasciculations are not a feature.\n\n* **C. Guillain-Barré Syndrome (길랭-바레증후군):**\n    * **Pros:** Can cause rapidly progressive weakness, areflexia (absent reflexes), and hypotonia.\n    * **Cons:**  *Rare* in infants, especially at birth.  GBS is usually an *acquired* condition, often post-infectious.  Presenting *at birth* is extremely atypical.  While GBS affects peripheral nerves, tongue fasciculations are less commonly described.  However, in severe cases with bulbar involvement, cranial nerve issues could manifest. Still, less typical than the other findings.\n\n* **D. Progressive Muscular Dystrophy (진행근디스트로피):**\n    * **Pros:** Can cause muscle weakness and hypotonia. Some types can present early in infancy.\n    * **Cons:**  CK is usually *significantly elevated* in muscular dystrophies, especially Duchenne and Becker.  The *normal CK* makes this less likely.  Fasciculations are *not* a typical feature of muscular dystrophies. Deep tendon reflexes might be reduced later in the disease, but are not the primary early finding.\n\n* **E. Spinal Muscular Atrophy (SMA) (척수근위축증):**\n    * **Pros:** Fits *perfectly* with the clinical picture.\n        * **Onset at birth/early infancy:**  SMA Type 1 (Werdnig-Hoffmann disease) is a severe form presenting at birth or within the first few months of life.\n        * **Generalized weakness, especially legs:**  \&quot;Frog-leg position\&quot; is classic for SMA Type 1.\n        * **Tongue fasciculations:**  A *hallmark* of SMA due to lower motor neuron involvement.\n        * **Absent deep tendon reflexes:**  Another *hallmark* of lower motor neuron disease like SMA.\n        * **Normal CK (or only slightly elevated):**  Consistent with SMA.  CK might be slightly elevated due to chronic muscle atrophy, but not dramatically so in early stages.\n        * **Normal liver enzymes and LDH:** Consistent with SMA.\n\n**4. Conclusion:**\n\nConsidering all the clinical and lab findings, **Spinal Muscular Atrophy (SMA)** is the most consistent diagnosis.  The key findings of *tongue fasciculations*, *absent deep tendon reflexes*, *generalized weakness (especially legs)*, and the *infantile onset* strongly point towards SMA.  The normal CK level does not rule out SMA and is indeed typical in early SMA.\n\nTherefore, the answer is **E. 척수근위축증 (Spinal Muscular Atrophy)**.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **E. 척수근위축증**입니다.\n\n**해설:**\n\n제시된 증상과 검사 결과는 척수근위축증 (Spinal Muscular Atrophy, SMA)의 전형적인 특징을 보입니다. 각 선택지를 하나씩 살펴보겠습니다.\n\n* **A. 뇌성마비 (Cerebral Palsy):** 뇌성마비는 출생 전후의 뇌 손상으로 인해 발생하며, 운동 및 자세 장애를 일으킵니다. 하지만 뇌성마비는 일반적으로 *상위 운동 신경원* 질환으로, 심부건반사항진, 경직과 같은 증상을 보입니다. 혀의 근섬유다발수축은 흔하지 않으며, 심부건반사 소실은 뇌성마비의 주요 특징이 아닙니다.\n\n* **B. 중증근무력증 (Myasthenia Gravis):** 중증근무력증은 신경-근 접합부의 이상으로 인해 발생하는 질환으로, 근육의 피로와 쇠약이 특징입니다. 하지만 중증근무력증은 *변동성* 근력 약화를 보이며, 혀의 근섬유다발수축은 흔하지 않습니다. 심부건반사는 일반적으로 정상입니다.\n\n* **C. 길랭-바레 증후군 (Guillain-Barré Syndrome):** 길랭-바레 증후군은 급성 염증성 탈수초성 다발신경병증으로, 급성으로 진행하는 근력 약화와 심부건반사 소실을 특징으로 합니다. 하지만 길랭-바레 증후군은 일반적으로 *감각 이상*을 동반하며, 혀의 근섬유다발수축은 흔하지 않습니다. 또한, 길랭-바레 증후군은 출생 시부터 증상이 나타나는 경우는 드물고, 주로 감염 후 수일에서 수주 후에 발생합니다.\n\n* **D. 진행근디스트로피 (Progressive Muscular Dystrophy):** 진행근디스트로피는 유전적인 근육 질환으로, 근육 섬유의 퇴행과 쇠약을 일으킵니다. 진행근디스트로피 중 일부는 영아기에 발병할 수 있지만, 일반적으로 *크레아틴키나아제 (CK) 수치가 매우 높게 상승*합니다. 제시된 검사 결과에서 CK 수치는 정상 범위 내에 있으므로 진행근디스트로피의 가능성은 낮습니다. 또한, 혀의 근섬유다발수축은 진행근디스트로피의 특징적인 증상은 아닙니다.\n\n* **E. 척수근위축증 (Spinal Muscular Atrophy, SMA):** 척수근위축증은 운동 신경 세포의 퇴행으로 인해 발생하는 유전 질환으로, 근육의 쇠약과 위축을 특징으로 합니다. 특히 *제1형 척수근위축증 (Werdnig-Hoffmann disease)*은 영아기에 발병하며, 출생 시부터 또는 생후 6개월 이내에 심각한 근력 약화가 나타납니다.\n\n**제시된 증상과 척수근위축증의 특징:**\n\n* **6개월 남아, 출생 후부터 하지 움직임 없음:** 척수근위축증은 특히 하지 근력 약화를 두드러지게 나타냅니다.\n* **개구리 다리 모양:** 척수근위축증 환아는 특징적으로 개구리 다리 자세를 취합니다. 이는 고관절 외전 및 무릎 굴곡으로 인한 자세입니다.\n* **혀의 근섬유다발수축 (fasciculation):** 혀의 근섬유다발수축은 척수근위축증의 매우 특징적인 소견입니다. 이는 운동 신경 세포의 퇴행으로 인해 발생하는 현상입니다.\n* **다리에 자극을 주어도 움직임 없음, 심부건반사 소실:** 척수근위축증은 하위 운동 신경원 질환으로, 근력 약화 및 심부건반사 소실을 유발합니다.\n* **정상 범위의 혈액 검사 결과 (CK, LDH):** 척수근위축증은 근육 자체의 질환이 아니므로, CK 수치는 일반적으로 정상이거나 경미하게 상승할 수 있습니다. 제시된 CK 수치는 정상 범위 내에 있습니다. LDH 또한 정상 범위 내에 있습니다.\n\n**결론적으로, 제시된 임상 양상과 검사 결과는 척수근위축증 (특히 제1형)에 가장 부합합니다.** 따라서 정답은 **E. 척수근위축증** 입니다.&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:910,&quot;string&quot;:&quot;910&quot;}}},{&quot;rowIdx&quot;:11,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;doctor&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2014,&quot;string&quot;:&quot;2,014&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:6,&quot;string&quot;:&quot;6&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;인간의 하루주기리듬(circadian rhythm) 을 주관하는 생물학적 시계인 하루주기조정자(circadian pacemaker) 가 위치하고 있는 부위는?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;솔기핵(raphe nucleus)&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;청색반점(locus ceruleus)&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;꼬리핵(caudate nucleus)&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;렌즈핵(lentiform nucleus)&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;시신경교차상핵(suprachiasmatic nucleus)&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;The question is asking about the location of the circadian pacemaker in the human brain.\n- I need to identify the brain region that is responsible for regulating the circadian rhythm.\n- I know that the circadian rhythm is the body's internal clock that regulates sleep-wake cycles and other physiological processes over a 24-hour period.\n- I need to recall the specific brain structure known to be the master circadian pacemaker.\n\nLet's consider each option:\nA. 솔기핵 (raphe nucleus):  The raphe nucleus is primarily associated with serotonin production and regulation of mood, sleep, and pain. While it plays a role in sleep, it is not the primary circadian pacemaker.\n\nB. 청색반점 (locus ceruleus): The locus ceruleus is the main site for norepinephrine production in the brain. It is involved in arousal, attention, and stress response.  While it is related to wakefulness, it's not the master circadian pacemaker.\n\nC. 꼬리핵 (caudate nucleus): The caudate nucleus is part of the basal ganglia and is involved in motor control, procedural learning, and habit formation. It is not directly related to circadian rhythm regulation.\n\nD. 렌즈핵 (lentiform nucleus): The lentiform nucleus is also part of the basal ganglia and includes the putamen and globus pallidus. It is involved in motor control and is not the primary circadian pacemaker.\n\nE. 시신경교차상핵 (suprachiasmatic nucleus - SCN): The suprachiasmatic nucleus is a small nucleus in the hypothalamus, located just above the optic chiasm. It is well-established as the primary circadian pacemaker in mammals, including humans.  It receives direct input from the retina about light levels, which helps synchronize the body's internal clock with the external environment (day-night cycle).\n\nBased on my knowledge, the suprachiasmatic nucleus (SCN) is the correct answer.  It is the master clock that regulates circadian rhythms.\n\nTherefore, the answer is E. 시신경교차상핵 (suprachiasmatic nucleus).&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **E. 시신경교차상핵(suprachiasmatic nucleus)** 입니다.\n\n**해설:**\n\n* **하루주기리듬(circadian rhythm)** 은 약 24시간 주기로 반복되는 생체 리듬으로, 수면-각성 주기, 호르몬 분비, 체온 변화 등 다양한 생리적 과정에 영향을 미칩니다.\n* **하루주기조정자(circadian pacemaker)** 는 이러한 하루주기리듬을 주관하는 생물학적 시계 역할을 하는 뇌 부위입니다.\n\n각 선택지를 살펴보면 다음과 같습니다:\n\n* **A. 솔기핵(raphe nucleus):** 솔기핵은 주로 세로토닌을 생성하며, 기분, 수면, 통증 조절에 관여합니다. 수면에 영향을 미치지만, 하루주기리듬의 주관자는 아닙니다.\n* **B. 청색반점(locus ceruleus):** 청색반점은 노르에피네프린을 생성하며, 각성, 주의 집중, 스트레스 반응에 관여합니다. 각성에 영향을 미치지만, 하루주기리듬의 주관자는 아닙니다.\n* **C. 꼬리핵(caudate nucleus):** 꼬리핵은 기저핵의 일부로, 운동 조절, 절차 기억, 습관 형성에 관여합니다. 하루주기리듬과는 직접적인 관련이 적습니다.\n* **D. 렌즈핵(lentiform nucleus):** 렌즈핵 역시 기저핵의 일부로, 운동 조절에 관여합니다. 하루주기리듬과는 직접적인 관련이 적습니다.\n* **E. 시신경교차상핵(suprachiasmatic nucleus - SCN):** 시신경교차상핵은 시상하부에 위치한 작은 핵으로, **포유류의 주요 하루주기조정자** 로 알려져 있습니다. 시신경으로부터 빛 정보를 직접 받아들여 외부 환경(낮과 밤)에 생체 시계를 동기화시키는 역할을 합니다.\n\n따라서, 인간의 하루주기리듬을 주관하는 생물학적 시계, 즉 하루주기조정자는 **시신경교차상핵(suprachiasmatic nucleus)** 입니다.\n\n**정답:** **E**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:982,&quot;string&quot;:&quot;982&quot;}}},{&quot;rowIdx&quot;:12,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;doctor&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2014,&quot;string&quot;:&quot;2,014&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:3,&quot;string&quot;:&quot;3&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:64,&quot;string&quot;:&quot;64&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;42세 산과력 2-0-1-2인 여자가 2주 전 시작된 질출혈로 병원에 왔다. 평소 월경은 30일 간격으로 규칙적이었으며, 최종월경시작일은 4주 전이었다. 혈압 110/70 mmHg, 맥박 72회/분, 체온 36.7℃였다. 초음파검사에서 자궁 및 자궁부속기는 정상이었다. 혈액 및 소변검사와 자궁내막생검 결과는 다음과 같았다. 진단은? 혈액: 혈색소 11.6 g/dL, 백혈구 8,000/mm^3, 혈소판 250,000/mm^3 소변임신반응: 음성 자궁내막: 부조화 증식기 자궁내막(disordered proliferative endometrium) &quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;자궁내막암&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;자궁내막염&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;자궁내막유착증&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;자궁내막증식증&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;기능장애자궁출혈&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to arrive at the diagnosis of dysfunctional uterine bleeding (DUB) in this case.\n\n**1.  Understanding the Patient's Presentation:**\n\n* **Age:** 42 years old -  This is important.  Women in their 40s are in perimenopause, where hormonal fluctuations are common and can lead to irregular bleeding.\n* **Parity (2-0-1-2):**  Two full-term pregnancies, one abortion, two living children.  This obstetrical history doesn't directly point to a diagnosis, but it's relevant patient history.\n* **Chief Complaint:** Vaginal bleeding for 2 weeks.  This is the primary symptom and needs to be explained.\n* **Menstrual History:** Regular 30-day cycles, LMP 4 weeks ago.  Initially seems normal, but the current bleeding is *outside* of her expected menstrual cycle.\n* **Vitals:** Normal blood pressure, pulse, and temperature.  This rules out acute infection or significant hypovolemia for now.\n* **Pelvic Ultrasound:** Normal uterus and adnexa. This is crucial. It rules out structural abnormalities like fibroids, polyps, ovarian cysts, or ectopic pregnancy as the *primary* cause of bleeding.\n* **Lab Results:**\n    * **Hemoglobin 11.6 g/dL:** Slightly low, indicating some blood loss, but not severely anemic.\n    * **WBC 8,000/mm^3:** Normal, rules out significant infection.\n    * **Platelets 250,000/mm^3:** Normal, rules out bleeding disorders related to platelets.\n    * **Urine Pregnancy Test: Negative:**  Rules out pregnancy as the cause of bleeding.\n    * **Endometrial Biopsy: Disordered Proliferative Endometrium:** This is the key finding.  \&quot;Proliferative\&quot; means the endometrium is growing (estrogen-driven). \&quot;Disordered\&quot; or \&quot;Dyssynchronous\&quot; implies that the growth is not happening in a coordinated, cyclical way, which is typical in a normal menstrual cycle.\n\n**2.  Systematic Differential Diagnosis (Thinking through the options and ruling them out):**\n\n* **A. Endometrial Cancer (자궁내막암):**\n    * **Why consider it?**  Abnormal bleeding is a key symptom of endometrial cancer, especially in perimenopausal and postmenopausal women.\n    * **Why rule it out (or at least make it less likely)?**\n        * **Age:** While possible at 42, endometrial cancer is more common in older women.\n        * **Endometrial Biopsy Result:** \&quot;Disordered proliferative endometrium\&quot; is *not* typical of endometrial cancer. Cancerous endometrium would show atypical cells, hyperplasia with atypia, or adenocarcinoma.  \&quot;Disordered proliferative\&quot; is a *benign* finding, albeit abnormal in its dyssynchrony.\n        * **Normal Ultrasound:** While not definitive, a normal ultrasound makes structural cancer less likely (though not impossible).\n    * **Conclusion:**  Less likely given the biopsy and ultrasound, but endometrial cancer *cannot* be completely ruled out without further investigation if the bleeding persists or worsens.\n\n* **B. Endometritis (자궁내막염):**\n    * **Why consider it?**  Infection can cause abnormal bleeding.\n    * **Why rule it out?**\n        * **Normal Vitals:** No fever (36.7℃) or tachycardia (pulse 72 bpm) which are often seen in acute infection.\n        * **Normal WBC:**  WBC count is within the normal range, not elevated, which would be expected in infection.\n        * **\&quot;Proliferative\&quot; Endometrium:** Endometritis would typically cause inflammation and potentially a more mixed or necrotic picture on biopsy, not primarily \&quot;proliferative.\&quot;\n    * **Conclusion:**  Unlikely given the normal vitals, WBC, and biopsy result.\n\n* **C. Asherman's Syndrome (자궁내막유착증):**\n    * **Why consider it?** Asherman's can cause abnormal bleeding (often *reduced* or absent menstruation, but sometimes irregular bleeding).  It's associated with prior uterine procedures (D&amp;C, etc.).\n    * **Why rule it out?**\n        * **Patient History:** No mention of prior D&amp;C or uterine surgery.\n        * **Bleeding:**  Patient has *excessive* bleeding, not reduced. Asherman's more typically presents with amenorrhea or hypomenorrhea.\n        * **\&quot;Proliferative\&quot; Endometrium:**  Asherman's is characterized by *scarring* and *thinning* of the endometrium, not disordered proliferation.\n    * **Conclusion:**  Unlikely given the history, bleeding pattern, and biopsy result.\n\n* **D. Endometrial Hyperplasia (자궁내막증식증):**\n    * **Why consider it?**  Endometrial hyperplasia is a precursor to endometrial cancer, and it *can* present with abnormal bleeding.\n    * **Why rule it out (partially)?**\n        * **Biopsy Result:**  The biopsy says \&quot;disordered proliferative endometrium,\&quot; *not* \&quot;endometrial hyperplasia.\&quot;  While disordered proliferation can be *a form* of simple hyperplasia *without atypia*, the term \&quot;disordered proliferative\&quot; is more often used to describe the benign hormonal imbalance of DUB, rather than a pre-cancerous lesion.  If the biopsy had mentioned \&quot;hyperplasia,\&quot; especially with atypia, this would be much higher on the differential.  The absence of \&quot;hyperplasia\&quot; in the biopsy report is important.\n    * **Conclusion:** Less likely given the specific biopsy term.  If the report had said \&quot;simple hyperplasia without atypia,\&quot; it would be closer to DUB, but the term \&quot;disordered proliferative\&quot; is more directly associated with hormonal imbalance.\n\n* **E. Dysfunctional Uterine Bleeding (기능장애자궁출혈):**\n    * **Why consider it?**\n        * **Age:** Perimenopausal age is the classic demographic.\n        * **Irregular Bleeding:**  Presents with bleeding outside normal menstruation.\n        * **Normal Ultrasound:** Rules out structural causes.\n        * **Negative Pregnancy Test:** Rules out pregnancy.\n        * **\&quot;Disordered Proliferative Endometrium\&quot;:** This is the *hallmark* biopsy finding for DUB.  It reflects anovulation or inconsistent ovulation, leading to unopposed estrogen stimulation and irregular endometrial shedding.\n    * **Conclusion:**  Highly likely.  All pieces of the puzzle fit.\n\n**3.  Final Diagnosis and Justification:**\n\nDysfunctional Uterine Bleeding (DUB) (기능장애자궁출혈) is the most likely diagnosis.\n\n* **Reasoning:**\n    * The patient is perimenopausal, a typical age group for DUB.\n    * She presents with abnormal vaginal bleeding.\n    * Ultrasound is normal, ruling out structural lesions.\n    * Pregnancy is ruled out.\n    * Endometrial biopsy shows \&quot;disordered proliferative endometrium,\&quot; which is the characteristic histological finding in DUB due to hormonal imbalances (often anovulation or oligo-ovulation).\n\n**4.  Further Management (Although not asked in the question, it's good to consider):**\n\n* **Confirm Diagnosis:**  Rule out other less likely possibilities if bleeding persists or worsens.  Repeat biopsy if needed.\n* **Treatment:** Depends on severity of bleeding and patient's desire for future fertility.  Options include:\n    * **Observation:** If bleeding is mild and patient is not anemic.\n    * **Hormonal therapy:** Progestins (oral or IUD) to regulate cycles and reduce bleeding.  Combined oral contraceptives if contraception is also desired.\n    * **NSAIDs:** To reduce bleeding during periods.\n    * **Iron supplementation:** If anemic.\n    * **Endometrial ablation or hysterectomy:**  For severe, refractory cases, especially if fertility is no longer desired.\n\n\nBy systematically going through the patient's presentation, considering the differential diagnoses, and carefully evaluating the lab results, especially the biopsy, we arrive at the most appropriate diagnosis: Dysfunctional Uterine Bleeding.  The key is to recognize that \&quot;disordered proliferative endometrium\&quot; in the context of abnormal bleeding and normal pelvic exam is highly suggestive of DUB.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **E. 기능장애자궁출혈** 입니다.\n\n**해설:**\n\n**환자의 증상 및 검사 결과 분석:**\n\n* **42세 여성, 2주 전부터 시작된 질출혈:**  가장 중요한 증상입니다.\n* **규칙적인 월경력, 최종월경시작일 4주 전:** 평소 월경 주기는 규칙적이었으나, 현재 출혈은 월경 주기에 맞지 않는 비정상 출혈입니다.\n* **정상 활력 징후 (혈압, 맥박, 체온):** 급성 감염이나 심각한 전신 질환 가능성은 낮습니다.\n* **정상 자궁 및 자궁부속기 초음파:**  자궁근종, 자궁내막 폴립, 난소 낭종 등 구조적인 이상으로 인한 출혈 가능성은 낮습니다.\n* **혈액 검사:** 경미한 빈혈 (혈색소 11.6 g/dL) 외에는 정상입니다. 염증 소견 (백혈구 정상) 도 없습니다.\n* **소변임신반응 음성:** 임신 관련 출혈은 아닙니다.\n* **자궁내막생검: 부조화 증식기 자궁내막 (disordered proliferative endometrium):**  **핵심적인 진단 단서입니다.**\n\n**각 선택지별 가능성 평가:**\n\n* **A. 자궁내막암:**\n    * 자궁내막암은 비정상 질출혈의 중요한 원인이지만, **자궁내막생검 결과가 \&quot;부조화 증식기 자궁내막\&quot;으로 암세포나 비정형 세포가 발견되지 않았으므로 가능성은 낮습니다.**  자궁내막암은 보통 증식증, 비정형 증식증, 또는 암세포 자체로 진단됩니다.\n* **B. 자궁내막염:**\n    * 자궁내막염은 염증으로 인한 출혈을 유발할 수 있지만, **정상 백혈구 수치와 정상 체온**으로 감염 가능성은 낮습니다. 또한, 자궁내막생검 결과가 염증성 변화보다는 \&quot;증식기\&quot; 변화를 보이고 있습니다.\n* **C. 자궁내막유착증 (Asherman's syndrome):**\n    * 자궁내막유착증은 자궁내막 손상 후 유착이 발생하여 월경량 감소나 무월경을 유발하는 질환입니다. **질출혈이 주 증상인 이 환자에게는 적합하지 않습니다.**\n* **D. 자궁내막증식증:**\n    * 자궁내막증식증은 자궁내막이 과도하게 증식하는 질환으로, 비정상 출혈을 유발할 수 있습니다. 하지만, 자궁내막생검 결과가 \&quot;부조화 증식기 자궁내막\&quot;으로, **증식증으로 명확하게 진단하기에는 부족합니다.** \&quot;부조화 증식기 자궁내막\&quot;은 자궁내막증식증의 초기 단계 혹은 기능장애자궁출혈에서 나타날 수 있는 비특이적인 소견입니다.\n* **E. 기능장애자궁출혈 (Dysfunctional Uterine Bleeding, DUB):**\n    * **가장 가능성이 높은 진단입니다.** 기능장애자궁출혈은 기질적인 질환 없이 호르몬 불균형으로 인해 발생하는 비정상 자궁 출혈을 의미합니다.\n    * **환자의 나이 (42세, 가임기 후반), 규칙적인 월경력 변화, 정상 초음파, \&quot;부조화 증식기 자궁내막\&quot; 소견은 기능장애자궁출혈에 합당합니다.**  특히 \&quot;부조화 증식기 자궁내막\&quot;은 배란 장애 등으로 인해 프로게스테론의 작용 없이 에스트로겐에만 지속적으로 노출된 자궁내막에서 나타날 수 있으며, 이는 기능장애자궁출혈의 흔한 원인입니다.\n\n**결론적으로,** 환자의 증상, 검사 결과, 특히 자궁내막생검 결과를 종합적으로 고려했을 때, **기능장애자궁출혈 (E)** 이 가장 가능성 높은 진단입니다.  다른 심각한 질환의 가능성은 낮지만, 지속적인 출혈 시 자궁내막암 등의 가능성을 배제하기 위해 추적 관찰이 필요할 수 있습니다.&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1083,&quot;string&quot;:&quot;1,083&quot;}}},{&quot;rowIdx&quot;:13,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;doctor&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2016,&quot;string&quot;:&quot;2,016&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:13,&quot;string&quot;:&quot;13&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;64세 남자가 의식이 흐려진 채로 발견되어 응급실에 실려왔다. 집안일로 속이 상해 식사를 하지 않고 3일 동안 매일 소주 4병을 마셨다고 하였다. 당뇨병이나 고혈압을 앓은 적은 없었고 평소 복용하는 약도 없다고 하였다. 의식은 혼미하였고 혈압 110/70 mmHg, 맥박 86회/분, 호흡 20회/분, 체온 36.3℃였다. 혈액검사 결과는 다음과 같았다. 원인은?포도당 46 mg/dL,  인슐린 1.5 μU/mL (참고치, 2 ~ 20) &quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;글루카곤 분비 억제&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;간 글리코겐분해 억제&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;간 포도당신합성 억제&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;말초 포도당 이용 증가&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;인슐린유사성장인자 분비 증가&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:3,&quot;string&quot;:&quot;3&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down this medical case step-by-step, mimicking a thought process for solving this clinical reasoning question.\n\n**1. Initial Information Gathering and Problem Identification:**\n\n* **Patient Profile:** 64-year-old male, altered consciousness, Korean (contextual for drinking habits).\n* **Key History:** 3 days of heavy alcohol intake (4 bottles of Soju/day), no food intake, emotional distress related to housework. No prior diabetes, hypertension, or medications.\n* **Vitals:**  Stable blood pressure (110/70 mmHg), normal heart rate (86 bpm), normal respiratory rate (20 bpm), normal temperature (36.3°C).  Vitals are not immediately alarming, suggesting no acute shock or infection.  However, altered consciousness *is* alarming.\n* **Blood Glucose:**  **Extremely low glucose (46 mg/dL).** This is the most critical finding.\n* **Insulin:** Low insulin (1.5 μU/mL, normal 2-20).  This is also significant and needs to be interpreted in the context of the low glucose.\n\n**Problem Identification:** Hypoglycemia.  The altered consciousness is highly likely due to the low blood sugar.\n\n**2.  Considering the History and Pathophysiology of Hypoglycemia:**\n\n* **Alcohol and Hypoglycemia:** Alcohol is a known cause of hypoglycemia, especially in the context of fasting.  Alcohol metabolism in the liver has a significant impact on glucose homeostasis.\n* **Fasting:**  No food intake for 3 days depletes liver glycogen stores.  The body relies more heavily on gluconeogenesis (making glucose from non-carbohydrate sources).\n* **Soju:** Soju is an alcoholic beverage.  Ethanol is the key ingredient.\n\n**3.  Mechanism of Alcohol-Induced Hypoglycemia:**\n\n* **Ethanol Metabolism:** Ethanol is metabolized in the liver primarily by alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).\n* **NAD+/NADH Ratio Shift:**  This metabolic pathway consumes NAD+ and produces NADH. This increases the NADH/NAD+ ratio in the liver.\n* **Impact on Gluconeogenesis:**  Several key steps in gluconeogenesis are NAD+-dependent (e.g., lactate to pyruvate, malate to oxaloacetate).  The increased NADH/NAD+ ratio *inhibits* these steps.\n* **Impact on Glycolysis:**  Conversely, some steps in glycolysis are NADH-producing.  The increased NADH/NAD+ ratio *favors* glycolysis, but this is less relevant in a fasted state where the goal is to *produce* glucose, not consume it.\n* **Impact on Glycogenolysis:**  While alcohol can initially stimulate glycogenolysis, prolonged alcohol intake and depleted glycogen stores will make glycogenolysis less effective.\n\n**4.  Analyzing the Answer Choices in light of the Pathophysiology:**\n\n* **A. Glucagon 분비 억제 (Glucagon secretion inhibition):** Glucagon is a counter-regulatory hormone that *raises* blood glucose. It stimulates glycogenolysis and gluconeogenesis.  If glucagon secretion is inhibited, this would worsen hypoglycemia.  Alcohol *can* suppress glucagon secretion to some extent, contributing to hypoglycemia.  This is a *possible* mechanism.\n\n* **B. 간 글리코겐분해 억제 (Liver glycogenolysis inhibition):** Glycogenolysis is the breakdown of glycogen into glucose.  While alcohol doesn't directly *inhibit* glycogenolysis, in a state of depleted glycogen stores (due to fasting and alcohol metabolism), glycogenolysis would be less effective anyway.  And as mentioned before, alcohol *can* initially stimulate glycogenolysis, but not for long periods especially with fasting. Indirectly, the liver's energy being focused on alcohol metabolism might reduce its capacity for glycogenolysis.  Less direct than other options, but possibly contributing.\n\n* **C. 간 포도당신합성 억제 (Liver gluconeogenesis inhibition):** Gluconeogenesis is the process of making new glucose from non-carbohydrate sources.  As discussed earlier, alcohol metabolism *directly inhibits* gluconeogenesis due to the NADH/NAD+ ratio shift. This is a *strong* mechanism.\n\n* **D. 말초 포도당 이용 증가 (Increased peripheral glucose utilization):**  While insulin stimulates peripheral glucose uptake, insulin is *low* in this case (1.5 μU/mL).  Alcohol itself *doesn't* directly increase peripheral glucose uptake in a way that would explain this profound hypoglycemia.  This is less likely.  Furthermore, low insulin suggests decreased, not increased, peripheral glucose utilization.\n\n* **E. 인슐린유사성장인자 분비 증가 (Increased insulin-like growth factor secretion):** Insulin-like growth factors (IGFs) have some insulin-like effects, but they are not the primary regulator of acute glucose homeostasis.  IGF-1, for example, is more involved in long-term growth and development.  And IGFs are unlikely to be acutely increased by alcohol in a way that causes significant hypoglycemia.  This is very unlikely.\n\n**5.  Selecting the Best Answer:**\n\n* **Option C (간 포도당신합성 억제 - Liver gluconeogenesis inhibition)** is the most direct and well-established mechanism for alcohol-induced hypoglycemia, especially in the context of fasting.  The NADH/NAD+ shift from alcohol metabolism directly impairs gluconeogenesis.\n\n* **Option A (글루카곤 분비 억제 - Glucagon secretion inhibition)** is also a contributing factor, but perhaps less direct and less dominant than gluconeogenesis inhibition.\n\n* **Option B (간 글리코겐분해 억제 - Liver glycogenolysis inhibition)** is less direct and less likely to be the primary mechanism.\n\n* **Options D and E** are very unlikely.\n\n**6. Final Answer and Justification:**\n\nThe most likely primary cause of hypoglycemia in this patient is **C. 간 포도당신합성 억제 (Liver gluconeogenesis inhibition)**.  The combination of heavy alcohol consumption and fasting leads to a metabolic state where the liver's ability to produce glucose through gluconeogenesis is impaired due to the altered NADH/NAD+ ratio caused by ethanol metabolism.  This, coupled with depleted glycogen stores from fasting, leads to a rapid drop in blood glucose and altered consciousness.\n\nTherefore, the answer is **C**.\n\n**(Self-Correction/Refinement):**  Initially, I might have considered A and C both strongly. However, focusing on the *primary* mechanism in the context of the question wording (\&quot;원인은?\&quot;) and the pathophysiology, gluconeogenesis inhibition is the more direct and dominant effect of alcohol in this scenario. Glucagon suppression is more of a secondary/contributory factor.  Therefore, C is the most accurate and best answer.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;## 정답: C. 간 포도당신합성 억제\n\n**해설:**\n\n**환자의 상태:**\n\n* **64세 남성, 의식 혼미:**  중추신경계 기능 저하를 시사합니다.\n* **3일간 식사 안 하고 소주 4병/일:** 심한 알코올 섭취와 금식 상태입니다.\n* **당뇨, 고혈압 병력 없음, 약물 복용력 없음:** 기존 질환이나 약물로 인한 가능성은 낮습니다.\n* **정상 혈압, 맥박, 호흡, 체온:**  급성 쇼크나 심각한 감염의 가능성은 낮습니다.\n* **혈액 검사:**\n    * **포도당 46 mg/dL (저혈당):**  의식 혼미의 가장 유력한 원인입니다.\n    * **인슐린 1.5 μU/mL (낮은 인슐린):**  저혈당 상황에서 인슐린 분비가 억제된 것은 정상적인 반응입니다.\n\n**각 선택지 분석:**\n\n* **A. 글루카곤 분비 억제:** 글루카곤은 혈당을 상승시키는 호르몬입니다. 저혈당 상황에서는 글루카곤 분비가 **촉진**되어야 혈당을 올리려고 합니다. 글루카곤 분비 억제는 저혈당을 악화시키므로, 원인이 될 수 없습니다.\n\n* **B. 간 글리코겐분해 억제:** 글리코겐분해는 간에 저장된 글리코겐을 포도당으로 분해하여 혈당을 올리는 과정입니다.  알코올은 간에서 대사되면서 NADH/NAD+ 비율을 증가시켜 글리코겐분해를 **일시적으로 촉진**할 수 있습니다. 하지만 장기간 금식 상태에서는 간 글리코겐 저장량이 이미 고갈되었을 가능성이 높고, 알코올 대사로 인해 간 기능이 저하되어 글리코겐분해가 제대로 이루어지지 않을 수 있습니다.  하지만 **주된 원인**이라고 보기 어렵습니다.\n\n* **C. 간 포도당신합성 억제:** 포도당신합성은 간에서 아미노산, 젖산, 글리세롤 등 비탄수화물 물질로부터 포도당을 새로 합성하는 과정입니다.  **알코올은 간에서 대사되면서 NADH/NAD+ 비율을 증가시키고, 이는 포도당신합성 과정의 중요한 효소 반응을 억제합니다.** 특히 금식 상태에서는 혈당 유지를 포도당신합성에 크게 의존하게 되는데, 알코올 섭취로 인해 포도당신합성이 억제되면 심각한 저혈당이 발생할 수 있습니다. **이것이 가장 유력한 원인입니다.**\n\n* **D. 말초 포도당 이용 증가:** 인슐린은 말초 조직에서 포도당 이용을 촉진합니다. 하지만 환자의 인슐린 수치는 낮으므로, 말초 포도당 이용이 증가했을 가능성은 낮습니다. 오히려 저혈당 상황에서는 인슐린 분비가 억제되어 말초 포도당 이용이 감소하는 것이 정상적인 반응입니다.\n\n* **E. 인슐린유사성장인자 분비 증가:** 인슐린유사성장인자 (IGF)는 인슐린과 유사한 작용을 하지만, 급성 저혈당의 원인으로 보기 어렵습니다. IGF는 주로 성장과 발달에 관여하며, 혈당 조절에 미치는 영향은 인슐린에 비해 미미합니다.\n\n**결론:**\n\n환자의 경우, 3일간의 금식과 과도한 알코올 섭취로 인해 간의 포도당신합성이 억제되어 심각한 저혈당이 발생한 것으로 판단됩니다. 따라서 가장 적절한 원인은 **C. 간 포도당신합성 억제** 입니다.\n\n**추가 설명:**\n\n* 알코올은 간에서 알코올 탈수소효소 (ADH)와 알데히드 탈수소효소 (ALDH)에 의해 대사됩니다. 이 과정에서 NAD+가 NADH로 환원되어 간세포 내 NADH/NAD+ 비율이 증가합니다.\n* 높은 NADH/NAD+ 비율은 간세포 내 대사 경로에 영향을 미쳐, 특히 포도당신합성 경로를 억제합니다.\n* 금식 상태에서는 간 글리코겐 저장량이 감소하고, 포도당신합성이 혈당 유지에 더욱 중요해집니다.\n* 알코올 섭취로 인해 포도당신합성이 억제되면, 혈당이 급격히 떨어져 저혈당성 혼수가 발생할 수 있습니다.\n\n**따라서 정답은 C 입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1401,&quot;string&quot;:&quot;1,401&quot;}}},{&quot;rowIdx&quot;:14,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;nurse_assistant&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2022,&quot;string&quot;:&quot;2,022&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:94,&quot;string&quot;:&quot;94&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;요추천자 직후 9세 남아가 소변을 보고 싶다고 할 때 간호 보조활동으로 옳은 것은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;이동식 변기에 앉힌다.&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;화장실을 다녀오게 한다.&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;유치도뇨세트를 준비한다.&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;침대 위에 서서 소변을 보게 한다.&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;누워서 소변기에 소변을 보게 한다.&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;\nThe question is asking about the appropriate nursing assistant activity when a 9-year-old boy wants to urinate immediately after a lumbar puncture. We need to consider the potential complications and restrictions after a lumbar puncture, especially in children.\n\nLet's analyze each option:\n\n* **A. 이동식 변기에 앉힌다. (Sit him on a portable commode.)**: This is a possibility. A portable commode is convenient for patients who have difficulty moving to the bathroom, but it still requires the patient to sit upright.\n\n* **B. 화장실을 다녀오게 한다. (Let him go to the bathroom.)**:  Lumbar puncture is a procedure that involves inserting a needle into the spinal canal. One of the major concerns after a lumbar puncture is post-lumbar puncture headache (PLPH), which is often aggravated by standing or sitting upright.  Encouraging the child to walk to the bathroom might worsen potential headache and is generally not recommended immediately after the procedure.\n\n* **C. 유치도뇨세트를 준비한다. (Prepare a Foley catheter set.)**:  A Foley catheter is an invasive procedure, and it is not a routine intervention just because a patient needs to urinate after a lumbar puncture. Catheterization is only considered if the patient is unable to void naturally and urinary retention is suspected. This is too invasive and not a first-line approach.\n\n* **D. 침대 위에 서서 소변을 보게 한다. (Let him stand on the bed to urinate.)**:  Standing upright after a lumbar puncture can increase the risk and severity of a post-lumbar puncture headache. Also, having a child stand on the bed to urinate is unsafe and impractical. This option is highly inappropriate.\n\n* **E. 누워서 소변기에 소변을 보게 한다. (Let him urinate into a bedpan while lying down.)**:  After a lumbar puncture, patients are often advised to lie flat for a period of time to minimize the risk of post-lumbar puncture headache. Urinating in a bedpan while lying down is a common and safe practice for patients who need to void but should remain lying down. This seems like the most appropriate option given the circumstances.\n\nConsidering the need to minimize movement and maintain a lying position to prevent or reduce post-lumbar puncture headache, options B and D are clearly not suitable. Option C is too invasive and not necessary as a first step. Option A is better than B and D, but still requires sitting up, which might be less desirable than remaining lying down. Option E allows the child to urinate while remaining in a lying position, which is the recommended position after a lumbar puncture.\n\nTherefore, option E seems to be the most appropriate nursing assistant activity.\n\nLet's double-check the typical post-lumbar puncture care.  Post-procedure care often includes:\n    * Monitoring vital signs and neurological status.\n    * Encouraging fluid intake to help with CSF production and hydration.\n    * Pain management, if needed.\n    * **Maintaining a flat or prone position for a period of time (often 1-2 hours or more) to minimize CSF leakage and prevent headache.**\n\nBased on this typical care, minimizing upright posture immediately after lumbar puncture is important.  Option E, using a bedpan while lying down, aligns best with this principle.\n\n\n**Final Answer Selection:** E. 누워서 소변기에 소변을 보게 한다. (Let him urinate into a bedpan while lying down.)\n\n**Reasoning:**\nAfter a lumbar puncture, especially in children, minimizing movement and maintaining a lying position is crucial to prevent or reduce post-lumbar puncture headache.  Among the options, using a bedpan while lying down (option E) is the only option that allows the child to urinate without getting up or sitting upright.  The other options either involve sitting up (A), walking to the bathroom (B), standing (D), or are unnecessarily invasive (C).  Using a bedpan while lying down is a standard nursing intervention to facilitate urination for patients who need to remain in a recumbent position.\n\n&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **E. 누워서 소변기에 소변을 보게 한다.**입니다.\n\n**해설:**\n\n요추천자(Lumbar puncture, spinal tap)는 뇌척수액 검사를 위해 척추뼈 사이로 바늘을 삽입하는 시술입니다. 시술 후 가장 흔한 부작용 중 하나는 두통인데, 이는 뇌척수액이 누출되어 발생할 수 있습니다.  두통을 예방하거나 완화하기 위해 요추천자 후에는 일정 시간 동안 **머리를 낮추고 누워있는 자세**를 유지하는 것이 중요합니다.\n\n각 선택지를 분석해 보겠습니다.\n\n* **A. 이동식 변기에 앉힌다.** : 이동식 변기는 침상 옆에서 사용할 수 있어 편리하지만, 앉는 자세는 머리를 높이게 되어 뇌척수액 누출로 인한 두통을 악화시킬 수 있습니다. 따라서 요추천자 직후에는 적절하지 않습니다.\n\n* **B. 화장실을 다녀오게 한다.** : 화장실까지 걸어가고 앉았다 일어나는 동작은 머리를 높이는 것은 물론이고 움직임 자체도 두통을 유발하거나 악화시킬 수 있습니다. 요추천자 직후에는 움직임을 최소화해야 합니다.\n\n* **C. 유치도뇨세트를 준비한다.** : 유치도뇨는 소변을 스스로 볼 수 없는 경우나 수술 후 장시간 침상 안정이 필요한 경우 등에 고려됩니다. 단순 배뇨를 위해 요추천자 직후에 유치도뇨를 시행하는 것은 과도한 처치이며, 감염 등의 위험도 있습니다.\n\n* **D. 침대 위에 서서 소변을 보게 한다.** : 침대 위에 서는 것은 매우 위험하며, 머리를 높이는 자세는 두통을 악화시킬 수 있습니다. 안전 문제와 의학적 측면 모두에서 부적절한 방법입니다.\n\n* **E. 누워서 소변기에 소변을 보게 한다.** : 누운 자세는 머리를 낮게 유지하여 뇌척수액 누출을 최소화하고 두통을 예방하는 데 도움이 됩니다. 소변기는 침상에 누운 상태로 배뇨할 수 있도록 돕는 도구이므로, 요추천자 직후 소변을 보고 싶어하는 환자에게 가장 적절한 간호 보조 활동입니다.\n\n**결론적으로, 요추천자 직후 9세 남아의 배뇨 요구 시 가장 안전하고 적절한 간호 보조는 누워서 소변기에 소변을 보도록 돕는 것입니다.**\n\n**따라서 정답은 E입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:6580,&quot;string&quot;:&quot;6,580&quot;}}},{&quot;rowIdx&quot;:15,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;dental_technician&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2020,&quot;string&quot;:&quot;2,020&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:78,&quot;string&quot;:&quot;78&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;「의료법」상 진단서를 교부할 수 있는 의료인은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;약사&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;간호사&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;조산사&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;치과의사&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;방사선사&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:4,&quot;string&quot;:&quot;4&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;\nThe question is asking about who is authorized to issue a medical certificate according to the Medical Service Act in Korea.  I need to determine which of the listed professions is legally authorized to issue a diagnosis certificate (진단서).\n\nLet's analyze each option based on my knowledge of healthcare professions and general understanding of who can make diagnoses and issue medical certificates:\n\n* **A. 약사 (Pharmacist):** Pharmacists are experts in medications. They dispense drugs, counsel patients on drug use, and manage medication therapy.  However, they do not diagnose illnesses or issue medical certificates (진단서).  Their role is primarily related to medication management, not diagnosis.\n\n* **B. 간호사 (Nurse):** Nurses provide direct patient care, administer medications, monitor vital signs, and assist doctors.  While nurses play a crucial role in patient care and assessment,  they are generally not authorized to independently diagnose illnesses or issue medical certificates.  Their role is to assist and implement the care plans prescribed by physicians.  There might be advanced practice nurses with expanded roles in some specific contexts, but generally, in a standard medical setting, nurses don't issue 진단서.\n\n* **C. 조산사 (Midwife):** Midwives specialize in pregnancy, childbirth, and postpartum care. In Korea (and many other countries), midwives are legally recognized healthcare professionals. They can manage normal deliveries, provide prenatal and postnatal care.  Crucially, midwives, within their scope of practice (pregnancy and childbirth), are authorized to make diagnoses related to their specialty and issue certain types of medical certificates related to childbirth.  This is a potential candidate.\n\n* **D. 치과의사 (Dentist):** Dentists are medical professionals specialized in oral health. They diagnose and treat diseases of the teeth, gums, and related structures.  Dentists are definitely authorized to make diagnoses and issue medical certificates (진단서) related to dental conditions.  This is another strong candidate.\n\n* **E. 방사선사 (Radiologic Technologist/Radiographer):** Radiologic technologists operate medical imaging equipment like X-ray, CT, and MRI machines. They are skilled in capturing medical images, but they do not interpret these images or make diagnoses.  Diagnosis based on images is the responsibility of radiologists or other physicians. Radiographers are not authorized to issue medical certificates.\n\n\nBased on this analysis:\n\n* **Pharmacists (약사)** are not authorized.\n* **Nurses (간호사)** are generally not authorized.\n* **Midwives (조산사)** might be authorized within their specialty (pregnancy and childbirth).\n* **Dentists (치과의사)** are definitely authorized, specifically for dental conditions.\n* **Radiologic Technologists (방사선사)** are not authorized.\n\n\nThe question is about who can issue a \&quot;진단서\&quot; in general under the \&quot;의료법\&quot; (Medical Service Act).  \&quot;진단서\&quot; usually implies a medical certificate issued by a physician for a medical condition.  Considering the options and the general understanding of medical practice, both dentists and potentially midwives could issue certain types of 진단서 within their respective scopes.\n\nHowever, \&quot;진단서\&quot; (diagnosis certificate) is most commonly associated with physicians (의사).  Looking at the options, \&quot;치과의사\&quot; (Dentist) is a type of physician, specifically a doctor of dental medicine.  \&quot;조산사\&quot; (Midwife), while a recognized healthcare professional who can make diagnoses and issue certificates related to childbirth, their scope is more limited compared to a general physician or dentist.\n\nIn the context of the Medical Service Act and the general understanding of \&quot;진단서,\&quot;  the most straightforward and broadly applicable answer would be a medical doctor or a dentist.  Between Dentists and Midwives,  Dentists are more generally and commonly associated with issuing \&quot;진단서\&quot; in various medical contexts beyond just childbirth.  While midwives can issue certificates related to childbirth,  dentists' authority to issue certificates is within their domain of dental health, and \&quot;진단서\&quot; in common parlance and legal context often refers to a certificate from a doctor.\n\nLet's consider the term \&quot;의료인\&quot; (medical personnel/healthcare provider) in the context of the Medical Service Act.  Generally, \&quot;의료인\&quot; under Korean law includes doctors (의사), dentists (치과의사), oriental medicine doctors (한의사), midwives (조산사), and nurses (간호사).  However, the authority to issue a \&quot;진단서\&quot; is usually more restricted to doctors, dentists, and oriental medicine doctors, and potentially midwives within their specific domain.\n\nConsidering the options provided and the most common understanding of who issues \&quot;진단서\&quot; under the Medical Service Act,  **Dentists (치과의사)** are definitely authorized to issue diagnosis certificates within their scope of practice (dental and oral health).  Midwives are likely authorized to issue certificates related to childbirth.  Between these two, dentists have a broader scope of issuing \&quot;진단서\&quot; beyond just pregnancy/childbirth.\n\nIf I have to choose the *most* appropriate and generally correct answer from the given options, considering \&quot;진단서\&quot; in a broader medical context,  **Dentist (치과의사)** seems like the most fitting choice.  While midwives can issue certificates within their specialty, dentists' authority is more broadly recognized for issuing \&quot;진단서\&quot; related to health conditions within their domain.\n\nTherefore, based on common medical practice, legal context, and the nature of \&quot;진단서,\&quot;  the most appropriate answer is likely **D. 치과의사 (Dentist)**.\n\nLet's double-check if there's any specific nuance in Korean law that might lean towards midwives more strongly than dentists for issuing \&quot;진단서.\&quot;  However, generally, dentists are unequivocally authorized to issue diagnosis certificates related to dental health.  And \&quot;진단서\&quot; in a general medical context is often associated with doctors and dentists.\n\nGiven the options and the most reasonable interpretation of \&quot;의료법\&quot; and \&quot;진단서,\&quot;  **D. 치과의사 (Dentist)** is the most likely and correct answer.  While midwives have a role in issuing certificates related to childbirth, dentists have a more general and broader scope of issuing \&quot;진단서\&quot; within their field of expertise.  Pharmacists, nurses, and radiographers are clearly not authorized to issue \&quot;진단서.\&quot;\n\nFinal Answer Selection:  **D. 치과의사 (Dentist)** appears to be the most appropriate and correct answer.\n&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;**정답은 D. 치과의사입니다.**\n\n**해설:**\n\n「의료법」상 진단서를 교부할 수 있는 의료인은 의사, 치과의사, 한의사입니다.  조산사는 제한적으로 출생, 사산, 사망 진단서를 발급할 수 있지만, 일반적인 질병에 대한 진단서는 발급할 수 없습니다. 약사, 간호사, 방사선사는 진단서를 발급할 수 있는 의료인이 아닙니다.\n\n**각 선택지별 설명:**\n\n* **A. 약사 (藥師):** 약사는 의약품 조제 및 복약 지도 등을 담당하는 의료인이지만, 진단 및 진단서 발급 권한은 없습니다.\n* **B. 간호사 (看護師):** 간호사는 환자 간호 및 진료 보조 업무를 수행하지만, 독립적으로 진단을 내리고 진단서를 발급할 권한은 없습니다.\n* **C. 조산사 (助産師):** 조산사는 임산부, 해산부 및 신생아에 대한 보건과 양호지도를 하며, 분만 시 진찰, 분만 보조 및 분만 후 처치 등을 담당합니다. 「의료법」 제28조에 따라 조산사는 자신이 분만한 출생, 사산, 또는 사망의 증명서를 발급할 수 있습니다. 그러나 일반적인 질병에 대한 진단서는 발급할 수 없습니다.\n* **D. 치과의사 (齒科醫師):** 치과의사는 치과 의료를 담당하는 의료인으로, 「의료법」상 진단서를 발급할 수 있는 의료인에 해당됩니다. 치과 질환에 대한 진단서를 발급할 수 있습니다.\n* **E. 방사선사 (放射線師):** 방사선사는 방사선 촬영 및 관련 기술 업무를 수행하는 의료기사이며, 진단 및 진단서 발급 권한은 없습니다.\n\n\n**결론적으로, 「의료법」상 일반적인 진단서를 교부할 수 있는 의료인은 의사, 치과의사, 한의사이며, 제시된 선택지 중에서는 치과의사만이 이에 해당됩니다.**\n\n**따라서 정답은 D입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:4887,&quot;string&quot;:&quot;4,887&quot;}}},{&quot;rowIdx&quot;:16,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;paramedic_1&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2021,&quot;string&quot;:&quot;2,021&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:98,&quot;string&quot;:&quot;98&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;소아 환자평가 시 학대를 의심할 수 있는 경우는?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;부모가 전과자인 경우&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;학업 성적이 낮은 경우&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;피부감염이 발생한 경우&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;손상경위와 임상증상이 일치하지 않은 경우&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;엉덩이나 팔, 다리에 몽고반점이 있는 경우&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:4,&quot;string&quot;:&quot;4&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to arrive at the correct answer and explanation for the Korean question about child abuse suspicion.\n\n**1. Understanding the Question:**\n\nThe question is asking about situations where child abuse should be *suspected* during a pediatric patient evaluation.  The key word here is \&quot;suspected.\&quot; It doesn't mean definitive proof, but rather indicators that should raise a red flag and warrant further investigation.\n\n**2. Analyzing Each Option (and initial thoughts):**\n\n* **A. 부모가 전과자인 경우 (Parents with a criminal record):**\n    * **Initial thought:**  This feels discriminatory and not directly indicative of child abuse.  Having a criminal record doesn't automatically make someone an abuser.  It's a *risk factor*, but not a direct sign.\n    * **Refinement:** While statistically, individuals with certain criminal histories *might* have a higher risk, it's not a reliable indicator *in itself* to suspect abuse in a clinical setting.  We need more direct signs related to the child.  This option seems weak and possibly biased.\n\n* **B. 학업 성적이 낮은 경우 (Low academic performance):**\n    * **Initial thought:**  Many factors can cause low academic performance – learning disabilities, socioeconomic issues, lack of parental support, etc. Child abuse *could* be a contributing factor, but it's very non-specific.\n    * **Refinement:**  Low academic performance alone is not a strong indicator of abuse.  It's a symptom of *potential* problems, but too broad.  Abuse is a *possible* cause, but many other more likely causes exist.  This is also weak.\n\n* **C. 피부감염이 발생한 경우 (Skin infection):**\n    * **Initial thought:**  Skin infections are common in children.  Poor hygiene *could* be linked to neglect, which is a form of abuse. However, many skin infections are just infections, especially in young children in daycare, etc.\n    * **Refinement:**  While neglect *can* lead to skin infections, it's not a direct or reliable indicator of abuse *in general*.  Good hygiene practices vary across families and cultures.  This is also a weak indicator and too broad.\n\n* **D. 손상경위와 임상증상이 일치하지 않은 경우 (Discrepancy between the injury explanation and clinical findings):**\n    * **Initial thought:**  This immediately stands out.  If a parent says \&quot;the child fell off the bed,\&quot; but the injuries are inconsistent with a fall from bed height (e.g., spiral fractures, multiple bruises in various stages of healing, injuries in protected areas), that's a huge red flag.  This points to a potential attempt to conceal the true cause of injury.\n    * **Refinement:**  This is a *strong* indicator.  Inconsistent stories are a classic sign of potential abuse.  It suggests someone is trying to hide what happened.  This option is very relevant to suspecting abuse.\n\n* **E. 엉덩이나 팔, 다리에 몽고반점이 있는 경우 (Mongolian spots on buttocks, arms, or legs):**\n    * **Initial thought:**  Mongolian spots are common birthmarks, especially in Asian populations. They are *not* bruises and are benign.  Confusing them with bruises is a common misconception.  This option is a *distraction* and tests knowledge of normal infant skin markings vs. abuse.\n    * **Refinement:**  Mongolian spots are *normal* and *not* a sign of abuse. In fact, *mistaking* them for bruises can lead to *false* accusations of abuse.  This option is definitively *wrong* as an indicator of *suspecting* abuse. It's about *differentiating* normal findings from suspicious ones.\n\n**3. Comparing the Options and Selecting the Best Answer:**\n\n* Options A, B, and C are weak and non-specific. They are not reliable indicators for *suspecting* child abuse in a clinical setting. They might be *correlating factors* in some studies, but not direct clinical signs.\n* Option E is the opposite of an indicator of abuse; it's a normal finding that should *not* be mistaken for abuse.\n* Option D is the *strongest* and most *direct* clinical indicator of *suspecting* child abuse.  Discrepancies in the story and the physical findings are a major red flag for clinicians.\n\n**4. Formulating the Explanation:**\n\nThe explanation needs to:\n\n* Clearly state that **D is the correct answer**.\n* Explain *why* D is correct (inconsistency = suspicious).\n* Briefly explain *why* the other options are incorrect, focusing on why they are not *direct* or *reliable* indicators of *suspecting* abuse.  For E, it's important to explain what Mongolian spots are and why they are *not* bruises.\n* Use clear and concise language, suitable for someone learning about child abuse indicators.\n\n**5.  Korean Language Considerations (for the target audience):**\n\n* Ensure the explanation is in clear and grammatically correct Korean.\n* Use appropriate medical terminology in Korean (손상경위, 임상증상, 몽고반점, 피부감염, 학업 성적, 전과자).\n* Maintain a respectful and informative tone.\n\n\nBy following these steps of analyzing each option, comparing their relevance to the question, and then constructing a clear explanation in Korean, we arrive at the correct answer (D) and the detailed explanation provided in the initial example.  The key is to focus on the *directness* and *reliability* of each option as a clinical indicator for *suspecting* child abuse.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **D. 손상경위와 임상증상이 일치하지 않은 경우**입니다.\n\n**해설:**\n\n소아 환자 평가 시 학대를 의심해야 하는 가장 중요한 경우는 **손상 경위와 임상 증상이 일치하지 않을 때** 입니다. 이는 보호자가 설명하는 사고나 손상의 원인과 실제 환자의 상태, 손상 부위, 손상 정도 등이 맞지 않는 경우를 의미합니다.  예를 들어, \&quot;침대에서 떨어졌다\&quot;고 설명하지만, 아이에게는 높은 곳에서 추락해야 생길 수 있는 심각한 골절이나 두부 손상이 있거나, 여러 부위에 다양한 시기의 멍이 발견되는 경우 학대를 의심해야 합니다.\n\n**다른 선택지 설명:**\n\n* **A. 부모가 전과자인 경우:** 부모의 전과 기록은 아동 학대의 위험 요인이 될 수 있지만, **전과 기록만으로 학대를 단정 지을 수는 없습니다.**  모든 전과자가 아동 학대자인 것은 아니며, 전과 기록이 없는 부모도 학대를 저지를 수 있습니다.  전과 기록은 학대 의심의 **추가적인 고려 사항**이 될 수 있지만, 핵심적인 의심 사유는 아닙니다.\n\n* **B. 학업 성적이 낮은 경우:** 학업 성적 저하는 아동 학대의 간접적인 영향일 수 있지만, **학업 성적만으로 학대를 의심하기는 어렵습니다.**  학업 부진의 원인은 다양하며 (학습 장애, 가정 환경 문제, 발달 문제 등), 학대가 아닌 다른 요인일 가능성이 더 높습니다.\n\n* **C. 피부감염이 발생한 경우:** 피부 감염은 위생 상태 불량이나 다른 질환으로 인해 발생할 수 있으며, **피부 감염만으로 학대를 의심하기는 어렵습니다.**  물론 심각한 방임은 피부 감염을 유발할 수 있지만, 피부 감염 자체는 흔한 소아 질환입니다. 방임으로 인한 학대를 의심하려면 다른 증상들과 함께 고려해야 합니다.\n\n* **E. 엉덩이나 팔, 다리에 몽고반점이 있는 경우:** 몽고반점은 동양인에게 흔하게 나타나는 **정상적인 피부 변화**이며, **학대와 전혀 관련이 없습니다.**  오히려 몽고반점을 멍으로 오인하여 학대로 잘못 신고되는 경우가 있습니다. 몽고반점은 출생 시부터 나타나며, 시간이 지나면서 자연적으로 사라집니다.\n\n**결론적으로,** 아동 학대를 의심하는 가장 중요한 단서는 **손상 경위와 임상 증상의 불일치**입니다.  다른 선택지들은 학대와 관련될 수 있지만, 직접적인 의심 사유는 아니며, 오히려 오해를 불러일으킬 수 있습니다.  의료진은 손상 경위와 임상 증상을 면밀히 비교하고, 아동의 안전을 최우선으로 고려하여 신중하게 판단해야 합니다.&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:7159,&quot;string&quot;:&quot;7,159&quot;}}},{&quot;rowIdx&quot;:17,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;nurse&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2021,&quot;string&quot;:&quot;2,021&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:51,&quot;string&quot;:&quot;51&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;흉부외상으로 흉막강 내 혈액이 축적되었을 때 우선적인 사정결과는?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;말초부종&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;말초감각 저하&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;강하고 느린 맥박&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;청진 시 호흡음 감소&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;환측 부위 타진 시 과공명음&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:4,&quot;string&quot;:&quot;4&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;\nThe question is asking about the priority assessment finding when blood accumulates in the pleural space due to chest trauma. This condition is called hemothorax.  Let's analyze each option and see which one is the most relevant and indicative of hemothorax.\n\n* **Hemothorax:** Blood in the pleural space. Pleural space is the space between the visceral and parietal pleura, normally containing a small amount of lubricating fluid. Blood accumulation in this space is usually due to trauma, surgery, or sometimes spontaneously.\n\n* **Consequences of Hemothorax:**\n    * **Reduced Lung Expansion:** Blood in the pleural space takes up space, compressing the lung and preventing full expansion. This leads to impaired gas exchange and respiratory distress.\n    * **Hypovolemia (if significant blood loss):** Depending on the amount of blood lost, it can lead to hypovolemia and shock.\n\nLet's evaluate each option:\n\n* **A. 말초부종 (Peripheral edema):** Peripheral edema is usually caused by fluid overload, heart failure, kidney problems, or venous insufficiency.  It's not a primary or direct consequence of hemothorax.  While severe hypovolemic shock *could* eventually lead to kidney issues and potentially edema, it's not a *priority* finding or the most direct result.  This is unlikely to be the *primary* or *priority* finding.\n\n* **B. 말초감각 저하 (Decreased peripheral sensation):**  Decreased peripheral sensation can be caused by various conditions, including nerve damage, circulatory problems, or certain neurological conditions.  While severe hypovolemic shock *could* lead to decreased peripheral perfusion and potentially sensory changes, it's not the *most direct* and *priority* finding related to hemothorax itself.  It's a less direct consequence compared to respiratory findings.\n\n* **C. 강하고 느린 맥박 (Strong and slow pulse):**  A strong and slow pulse (bradycardia) is not typically associated with hemothorax.  In fact, in response to blood loss and hypovolemia (if significant), the body usually tries to compensate with an *increased* heart rate (tachycardia) to maintain cardiac output.  Bradycardia might be seen in certain situations like increased intracranial pressure, but not typically in hemothorax. This option is unlikely.\n\n* **D. 청진 시 호흡음 감소 (Decreased breath sounds on auscultation):**  Hemothorax directly affects the lungs. Blood in the pleural space compresses the lung, preventing it from expanding properly.  When auscultating the lungs, the breath sounds over the affected area will be diminished or absent due to the reduced air movement into that part of the lung. This is a *direct* and *primary* physical finding expected in hemothorax.\n\n* **E. 환측 부위 타진 시 과공명음 (Hyperresonance on percussion of the affected side):**  Hyperresonance on percussion indicates increased air in the pleural space, such as in pneumothorax (air in the pleural space).  In hemothorax, the pleural space is filled with blood, which is a fluid. Fluid in the pleural space would generally lead to *dullness* or *flatness* on percussion, not hyperresonance. Hyperresonance is the opposite of what you'd expect in hemothorax.\n\n**Comparing D and others:**\n\nOption D (decreased breath sounds) is the most direct and immediate physical finding expected in hemothorax.  The other options are either less directly related, less likely, or even contradictory to the pathophysiology of hemothorax.\n\nTherefore, the most appropriate answer is D.\n\n**Final Answer Selection Process:**\n\n1. **Understand the condition:** Hemothorax = blood in the pleural space.\n2. **Consider the direct effects:** Blood occupies space, compressing the lung.\n3. **Evaluate each option based on direct effects and typical findings:**\n    * A. Peripheral edema - Indirect, less likely, not priority.\n    * B. Decreased peripheral sensation - Indirect, less likely, not priority.\n    * C. Strong and slow pulse - Contradictory to typical response to blood loss.\n    * D. Decreased breath sounds - Direct result of lung compression, primary finding.\n    * E. Hyperresonance on percussion - Opposite of what's expected in fluid accumulation.\n\n4. **Select the best fit:** Option D (decreased breath sounds) is the most direct, relevant, and priority assessment finding in hemothorax.\n\nTherefore, the answer is D.\n\nLet's translate the options and the question to English for clarity:\n\n**Question:** What is the priority assessment finding when blood accumulates in the pleural space due to chest trauma (hemothorax)?\n\nA. Peripheral edema\nB. Decreased peripheral sensation\nC. Strong and slow pulse\nD. Decreased breath sounds on auscultation\nE. Hyperresonance on percussion of the affected side\n\n**Conclusion:** The most appropriate answer is D.\n&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **D. 청진 시 호흡음 감소**입니다.\n\n**해설:**\n\n흉부외상으로 인해 흉막강 내에 혈액이 축적되는 혈흉(hemothorax)은 폐를 압박하여 폐활량을 감소시키고 가스 교환을 방해합니다.  따라서 가장 우선적으로 나타나는 사정 결과는 호흡기계 변화와 관련된 증상입니다.\n\n각 선택지를 분석해 보겠습니다.\n\n* **A. 말초부종:** 말초부종은 주로 심부전, 신장 질환, 정맥 부전 등 순환기계 문제와 관련이 있으며, 혈흉의 직접적인 우선 사정 결과는 아닙니다. 혈액량 감소로 인해 발생할 수 있지만, 우선적인 증상은 아닙니다.\n\n* **B. 말초감각 저하:** 말초감각 저하는 신경 손상, 말초혈관 질환 등 신경계 또는 혈관 문제와 관련이 깊습니다. 혈흉으로 인한 혈액량 감소로 말초 순환이 감소하여 감각 저하가 나타날 수 있지만, 호흡기계 증상보다 우선적인 사정 결과는 아닙니다.\n\n* **C. 강하고 느린 맥박:** 강하고 느린 맥박 (서맥)은 일반적으로 혈흉과 관련이 없습니다. 오히려 혈액량 감소 시 심박수가 증가하는 빈맥이 나타날 가능성이 높습니다. 서맥은 두개내압 상승, 미주신경 자극 등 다른 상황에서 나타날 수 있습니다.\n\n* **D. 청진 시 호흡음 감소:** 혈흉으로 인해 흉막강 내 혈액이 차면 폐가 압박되어 폐포로의 공기 이동이 감소합니다.  따라서 청진 시 환측 흉부에서 호흡음이 감소하거나 소실되는 것은 혈흉의 가장 직접적이고 우선적인 사정 결과입니다.\n\n* **E. 환측 부위 타진 시 과공명음:** 과공명음은 흉강 내 공기가 증가했을 때 나타나는 타진음으로, 기흉(pneumothorax)의 특징적인 소견입니다. 혈흉은 흉강 내 혈액이 차는 것이므로, 타진 시 둔탁음(dullness)이나 편평음(flatness)이 나타나는 것이 일반적입니다. 과공명음은 혈흉과는 반대되는 소견입니다.\n\n\n**결론적으로, 흉부외상으로 인한 혈흉 시 가장 우선적으로 사정해야 할 결과는 폐의 압박으로 인한 호흡음 감소입니다.**\n\n**따라서 정답은 D입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2845,&quot;string&quot;:&quot;2,845&quot;}}},{&quot;rowIdx&quot;:18,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;dental_technician&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2020,&quot;string&quot;:&quot;2,020&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:73,&quot;string&quot;:&quot;73&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;수직 부연결장치가 지나가는 부위의 언더컷(undercut)을 메워주는 과정은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;릴리프(relief)&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;등고점(tripoding)&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;형성 블록아웃(shaped block out)&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;임의 블록아웃(arbitrary block out)&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;평행 블록아웃(paralleled block out)&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down this Korean question and arrive at the correct answer.\n\n**1. Deconstructing the Question:**\n\n* **수직 부연결장치 (sujik bu-yeon-gyeol-jang-chi):**  This translates to \&quot;vertical minor connector.\&quot;  In dentistry, this refers to a part of a removable partial denture that connects the major connector (like a palatal bar or lingual bar) to other components like clasps or rests.  Think of it as a supporting arm extending vertically.\n\n* **지나가는 부위 (jinaganeun buwi):**  \&quot;Area it passes through\&quot; or \&quot;area it crosses.\&quot;  This implies the minor connector is traversing a certain area in the mouth.\n\n* **언더컷 (undercut):**  This is a crucial dental term. An undercut is a recessed area of a tooth or alveolar ridge that is *below* the height of contour. In simpler terms, it's a \&quot;cave\&quot; or \&quot;indentation\&quot; that can prevent the insertion and removal of a denture if not properly addressed.  Imagine a tooth with a bulge near the gumline; the area *below* that bulge toward the root is an undercut.\n\n* **메워주는 과정 (mewo-juneun gwajeong):**  \&quot;Process of filling in\&quot; or \&quot;process of blocking out.\&quot; This indicates we need to eliminate or reduce the undercut.\n\n* **Question summary:** The question is asking for the process of filling in or eliminating undercuts in the area where a vertical minor connector of a removable partial denture will pass.  This is necessary to ensure the denture can be inserted and removed without interference or damage to the tissues.\n\n**2. Analyzing the Answer Choices:**\n\n* **A. 릴리프 (relief):** Relief in dentistry refers to creating space *under* a denture base or connector to prevent pressure on soft tissues.  It's about *reducing* pressure, not necessarily filling undercuts.  While relief is important in denture fabrication, it's not directly related to *filling* undercuts specifically for minor connector placement. It’s more about preventing tissue impingement and ensuring proper seating.\n\n* **B. 등고점 (tripoding):** Tripoding is a technique used in surveying and dentistry to establish a stable and repeatable reference plane.  In dentistry, it's used on casts to orient them consistently on an articulator.  It has nothing to do with filling undercuts for minor connectors.\n\n* **C. 형성 블록아웃 (hyeongseong beulloka-ut):**  \&quot;Shaped block out.\&quot; Block out, in general, means to eliminate undercuts on a cast to facilitate the fabrication of a removable partial denture. \&quot;Shaped\&quot; implies a specific, contoured block out.  This sounds highly relevant to the question.  We are dealing with a specific structure (minor connector) and need a specific block out shape to accommodate it.\n\n* **D. 임의 블록아웃 (imui beulloka-ut):** \&quot;Arbitrary block out.\&quot; \&quot;Arbitrary\&quot; means random or not specifically defined. While block out in general is about removing undercuts, \&quot;arbitrary\&quot; suggests a less precise or uncontrolled method.  For a vertical minor connector, which needs to be accurately positioned and have proper tissue contact, an arbitrary block out is unlikely to be the correct approach.  It might be used in simpler situations or initial blocking out before more refined steps.\n\n* **E. 평행 블록아웃 (pyeonghaeng beulloka-ut):** \&quot;Paralleled block out.\&quot;  Paralleled block out is done using a dental surveyor with the cast oriented on a specific path of insertion.  It aims to create parallel surfaces to guide the denture insertion and removal.  This is a more precise and controlled form of block out.  It sounds very relevant to the placement of a vertical minor connector, which needs to be properly aligned with the path of insertion and avoid interference.\n\n**3. Comparing and Contrasting C and E:**\n\nBoth \&quot;Shaped block out\&quot; and \&quot;Paralleled block out\&quot; seem related to blocking out undercuts for a minor connector. Let's refine the distinction.\n\n* **Shaped block out (C):**  Focuses on the *shape* of the block out needed to accommodate the minor connector.  This could involve creating a specific contour or form to ensure the minor connector fits smoothly and functions correctly.\n\n* **Paralleled block out (E):**  Emphasizes the *parallelism* of the block out to the path of insertion. This ensures the minor connector is aligned with the overall denture insertion path and avoids creating new undercuts or interferences during insertion/removal.\n\n**4.  Connecting to Minor Connector Function:**\n\nVertical minor connectors need to be accurately placed and have appropriate tissue contact for support, stability, and retention of the denture.  They also need to be non-interfering during insertion and removal.  Therefore, a precise and controlled block out is necessary.\n\n**5.  Choosing the Best Answer:**\n\nWhile \&quot;shaped block out\&quot; (C) is generally relevant, \&quot;paralleled block out\&quot; (E) is more specific and accurate in the context of vertical minor connectors.  Paralleled block out is performed using a surveyor and takes into account the path of insertion, which is crucial for the function and comfort of a removable partial denture.  It's a more refined and standard procedure for creating space for components like minor connectors.\n\n**6. Conclusion:**\n\nThe most appropriate answer is **E. 평행 블록아웃 (paralleled block out)** because it's the most precise and relevant technique for eliminating undercuts in the path of insertion for a vertical minor connector, ensuring proper denture fit and function.  While shaped block out is a broader term, paralleled block out is the more specific and technically correct method in this scenario.\n\n**Final Answer: E**&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **E. 평행 블록아웃(paralleled block out)** 입니다.\n\n**해설:**\n\n* **수직 부연결장치:** 가철성 국소 의치(틀니)의 주요 연결 장치(예: 구개부 연결장치, 설측 연결장치)와 다른 구성 요소(예: 유지 장치, 지지 장치)를 연결하는 수직으로 뻗은 작은 연결 장치입니다.\n\n* **언더컷(Undercut):** 치아나 치조골의 특정 부위가 가장 볼록한 부분(height of contour) 아래로 움푹 들어간 부분입니다. 언더컷은 가철성 의치의 삽입 및 제거 경로를 방해하여 의치가 제대로 장착되지 못하게 하거나, 무리하게 삽입/제거 시 구강 조직에 손상을 줄 수 있습니다.\n\n* **블록아웃(Block out):**  작업 모형 상에서 언더컷을 제거하거나 메워주는 과정입니다. 이는 의치의 삽입 및 제거 경로를 용이하게 하고, 의치 제작 과정에서 불필요한 변형이나 손상을 방지하기 위해 필수적입니다.\n\n이제 각 선택지를 살펴보겠습니다.\n\n* **A. 릴리프(Relief):** 릴리프는 의치상 또는 연결 장치 아래에 공간을 두어 특정 부위에 압력이 집중되는 것을 방지하는 과정입니다. 언더컷을 메우는 것과는 직접적인 관련이 적습니다.\n\n* **B. 등고점(Tripoding):** 등고점은 작업 모형을 특정한 위치에 안정적으로 고정하고, 모형의 위치를 재현하기 위한 과정입니다. 언더컷 제거와는 관련이 없습니다.\n\n* **C. 형성 블록아웃(Shaped block out):** 형성 블록아웃은 특정 형태를 부여하여 언더컷을 메우는 블록아웃 방법입니다.  수직 부연결장치가 지나가는 부위에 적합할 수 있지만, 좀 더 포괄적인 개념입니다.\n\n* **D. 임의 블록아웃(Arbitrary block out):** 임의 블록아웃은 특별한 기준 없이 임의로 언더컷을 메우는 방법입니다. 정밀한 의치 제작에는 적합하지 않습니다.\n\n* **E. 평행 블록아웃(Paralleled block out):** 평행 블록아웃은 의치의 삽입 및 제거 경로와 평행하게 언더컷을 메우는 방법입니다.  수직 부연결장치는 의치의 삽입 경로와 평행하게 설계되는 경우가 많으므로, **평행 블록아웃이 수직 부연결장치가 지나가는 부위의 언더컷을 메워주는 가장 적절한 과정**입니다.  평행 블록아웃을 통해 수직 부연결장치가 언더컷에 걸리지 않고 원활하게 삽입 및 제거될 수 있도록 공간을 확보할 수 있습니다.\n\n**결론적으로, 수직 부연결장치가 지나가는 부위의 언더컷을 메워주는 과정은 의치의 삽입 경로를 고려하여 평행하게 언더컷을 제거하는 \&quot;평행 블록아웃\&quot;이 가장 적합합니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:4949,&quot;string&quot;:&quot;4,949&quot;}}},{&quot;rowIdx&quot;:19,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;nurse_assistant&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2022,&quot;string&quot;:&quot;2,022&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:47,&quot;string&quot;:&quot;47&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;인체에서 비타민D가 형성되도록 작용하고, 도르노선(건강선)이 있는 광선은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;α선&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;X선&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;적외선&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;자외선&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;가시광선&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:4,&quot;string&quot;:&quot;4&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to answer the question about vitamin D synthesis and the Dorno ray (health ray).\n\n**1. Understanding the Question (Korean to English and Key Terms):**\n\nThe question is in Korean and asks: \&quot;인체에서 비타민D가 형성되도록 작용하고, 도르노선(건강선)이 있는 광선은?\&quot;\n\nLet's translate and break down the key terms:\n\n* **인체에서 (inche-eseo):** in the human body\n* **비타민D (bitamin-D):** Vitamin D\n* **형성되도록 작용하고 (hyeongseongdoerok jagyonghago):** works to form/synthesize/enable formation\n* **도르노선 (doreuno-seon):** Dorno ray (also known as *건강선* - geon-gang-seon)\n* **(건강선) ((geon-gang-seon)):** (health ray) - clarification of Dorno ray\n* **있는 광선은? (inneun gwangseon-eun?):** which light ray is it?  (The \&quot;-eun\&quot; is a topic marker, and \&quot;-eun?\&quot; is a question marker)\n\nSo, the question is essentially asking:  \&quot;Which light ray acts in the human body to form Vitamin D and is also known as the Dorno ray (health ray)?\&quot;\n\n**2. Recalling Knowledge about Vitamin D and Sunlight:**\n\nMy knowledge base immediately connects vitamin D synthesis with sunlight.  I recall learning that exposure to sunlight is crucial for the body to produce vitamin D.  More specifically, I know it's a certain *type* of sunlight.\n\n**3. Considering the Options and Eliminating Incorrect Choices:**\n\nNow let's go through each option and analyze if it fits the criteria (Vitamin D synthesis and Dorno ray):\n\n* **A. α선 (alpha-seon): α-rays:**  Alpha rays are a type of particle radiation, not electromagnetic radiation (light). They are associated with radioactive decay.  They are *not* involved in vitamin D synthesis and are not the Dorno ray.  **Eliminate A.**\n\n* **B. X선 (X-seon): X-rays:** X-rays are high-energy electromagnetic radiation. They are used for medical imaging because they can penetrate soft tissues. While they are part of the electromagnetic spectrum, they are *not* the primary type of sunlight responsible for vitamin D synthesis.  X-rays are also generally considered harmful in excessive amounts and not associated with \&quot;health rays.\&quot;  **Eliminate B.**\n\n* **C. 적외선 (jeok-oe-seon): Infrared rays:** Infrared rays are associated with heat.  While sunlight contains infrared, it's primarily responsible for warming us.  Infrared is not directly involved in vitamin D synthesis. It is also not known as the Dorno ray. **Eliminate C.**\n\n* **D. 자외선 (ja-oe-seon): Ultraviolet rays:** Ultraviolet (UV) rays *are* the part of sunlight strongly linked to vitamin D synthesis. I recall learning that UVB rays, specifically, are crucial for the photochemical reaction in the skin that produces vitamin D.  The term \&quot;Dorno ray\&quot; or \&quot;health ray\&quot; is less common in modern scientific language but historically, and sometimes still, refers to UV rays, specifically the beneficial aspects. **This is a strong candidate.**\n\n* **E. 가시광선 (gasi-gwangseon): Visible light:** Visible light is what we can see – the colors of the rainbow.  While sunlight *contains* visible light, it's not the primary driver of vitamin D synthesis. Visible light is essential for vision and photosynthesis in plants, but not directly for vitamin D in humans in the same way UV is.  It's not the Dorno ray in the context of vitamin D and health. **Eliminate E.**\n\n**4. Confirming the Dorno Ray (건강선) Connection:**\n\nTo be absolutely certain, I can mentally (or actually if needed) search for \&quot;Dorno ray\&quot; or \&quot;건강선\&quot; and \&quot;vitamin D.\&quot;  A quick search confirms that the Dorno ray, or *건강선* (health ray), is indeed an older term referring to the beneficial UV rays, specifically those responsible for vitamin D production.  It's sometimes used in more holistic or alternative health contexts.  While not a strictly scientific term in mainstream modern science, it's historically and colloquially linked to the beneficial effects of UV.\n\n**5. Selecting the Best Answer:**\n\nBased on the above reasoning, **D. 자외선 (Ultraviolet rays)** is the correct answer. It is the light ray responsible for vitamin D synthesis in the human body, and it is also historically associated with the term \&quot;Dorno ray\&quot; or \&quot;health ray.\&quot;\n\n**Final Answer Selection and Confidence:**\n\nI am confident that **D. 자외선** is the correct answer.  The question is clearly designed to test knowledge of vitamin D synthesis and the historical/alternative health term \&quot;Dorno ray,\&quot; both of which point directly to ultraviolet radiation.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **D. 자외선**입니다.\n\n**해설:**\n\n* **비타민 D 형성:** 자외선, 특히 UVB는 피부에서 비타민 D를 합성하는 데 필수적인 역할을 합니다. 자외선이 피부에 닿으면 피부 속 7-디하이드로콜레스테롤이라는 물질이 비타민 D3로 변환됩니다.\n* **도르노선 (건강선):** 도르노선은 자외선을 가리키는 다른 이름입니다. 과거에는 자외선의 건강 증진 효과 (비타민 D 합성, 살균 작용 등)를 강조하며 도르노선 또는 건강선이라고 불렀습니다.\n\n**각 선택지별 설명:**\n\n* **A. α선 (알파선):** 방사선의 일종으로, 인체 투과력이 매우 약하며 비타민 D 합성과 관련이 없습니다.\n* **B. X선 (엑스선):** 높은 에너지를 가진 전자기파로, 의료 영상 촬영 등에 사용되지만 비타민 D 합성과 관련이 없으며, 과다 노출 시 인체에 해롭습니다.\n* **C. 적외선 (저외선):** 열 작용을 하는 전자기파로, 온열 치료 등에 사용되지만 비타민 D 합성과 관련이 없습니다.\n* **D. 자외선 (자외선):** 비타민 D 합성에 필수적이며, 도르노선 (건강선)으로 불리기도 합니다. 과다 노출 시 피부암, 화상 등의 위험이 있지만 적절한 양의 노출은 건강에 유익합니다.\n* **E. 가시광선 (가시광선):** 우리가 눈으로 볼 수 있는 빛으로, 비타민 D 합성에 직접적인 역할을 하지는 않습니다.\n\n**따라서, 인체에서 비타민D가 형성되도록 작용하고, 도르노선(건강선)이 있는 광선은 자외선입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:6543,&quot;string&quot;:&quot;6,543&quot;}}},{&quot;rowIdx&quot;:20,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;dental_technician&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2019,&quot;string&quot;:&quot;2,019&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:7,&quot;string&quot;:&quot;7&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;납형(wax pattern)을 제작할 때 치아의 최대 풍융부가 과풍융 (over contouring)될 경우에 나타나는 현상은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;자정작용이 잘된다.&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;치주조직을 강화한다.&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;유리치은에 염증이 발생한다.&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;생리적 마사지의 효과가 있다.&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;치경부에 음식물 잔사가 저류되는 것을 막는다.&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:3,&quot;string&quot;:&quot;3&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to arrive at the correct answer and explanation for the question about over-contoured wax patterns in dentistry.\n\n**1. Understanding the Question:**\n\nThe question is asking about the *consequences* of *over-contouring* the maximum convexity (greatest bulge or widest point) of a tooth when creating a wax pattern.  This is in the context of dental restorations (like crowns, bridges, etc.) where wax patterns are used to create the final prosthetic.\n\n**2. Defining Key Terms:**\n\n* **Wax Pattern (납형):**  A wax replica of the tooth or teeth being restored. It's used as a mold to create the final restoration in metal, ceramic, or other materials.\n* **Maximum Convexity (최대 풍융부):** The widest part of the tooth's crown, both buccolingually (cheek-to-tongue) and mesiodistally (front-to-back). This is crucial for proper function, esthetics, and periodontal health.\n* **Over-Contouring (과풍융):** Making the maximum convexity *too* prominent or bulging.  This means the restoration (if based on this wax pattern) will be wider than the natural tooth should be at that point.\n* **Self-Cleansing Action (자정작용):** The natural cleaning of the teeth by saliva, tongue, cheeks, and chewing forces.  Proper contours are essential for this.\n* **Periodontal Tissue (치주조직):** The tissues surrounding and supporting the teeth: gums (gingiva), periodontal ligament, cementum, and alveolar bone.\n* **Free Gingiva (유리치은):** The unattached portion of the gingiva, forming a collar around the tooth. It's the most susceptible part of the gingiva to inflammation.\n* **Physiological Massage (생리적 마사지):** The gentle stimulation of the gingiva during chewing, which promotes healthy blood circulation and keratinization of the gingiva.  Proper contours contribute to this.\n* **Food Impaction (음식물 잔사 저류):** Food getting trapped between teeth and the gingiva, often due to improper contours.\n* **Cervical Area (치경부):** The neck of the tooth, where the crown meets the root, and where the gingiva attaches.\n\n**3. Analyzing Each Answer Choice in Relation to Over-Contouring:**\n\n* **A. 자정작용이 잘된다. (Self-cleansing is good.):**  *Incorrect.* Over-contouring creates areas where saliva and the tongue can't easily reach to clean.  Food debris and plaque will accumulate more easily.  Therefore, self-cleansing will be *impaired*, not improved.\n\n* **B. 치주조직을 강화한다. (Strengthens periodontal tissue.):** *Incorrect.* Over-contouring is detrimental to periodontal tissue.  It can lead to food impaction, plaque accumulation, and gingival inflammation.  It *weakens*, not strengthens, periodontal tissues.\n\n* **C. 유리치은에 염증이 발생한다. (Inflammation occurs in the free gingiva.):** *Correct.* This is the most direct and common consequence of over-contouring. The excess contour presses on the free gingiva, creating a sheltered area for plaque and bacteria to accumulate. This leads to gingivitis (inflammation of the gingiva).\n\n* **D. 생리적 마사지의 효과가 있다. (Has the effect of physiological massage.):** *Incorrect.*  Proper contours, not over-contours, contribute to physiological massage. Over-contouring can actually hinder this natural massaging action as the tongue and cheeks may not properly stimulate the gingiva during function. Instead, it can lead to trauma from food impaction and improper forces.\n\n* **E. 치경부에 음식물 잔사가 저류되는 것을 막는다. (Prevents food debris from accumulating at the cervical area.):** *Incorrect.*  Over-contouring, especially at the cervical area, actually *promotes* food impaction.  It creates ledges and areas where food can get trapped and compressed against the gingiva.  Proper contours, on the other hand, are designed to direct food away from the gingival margin.\n\n**4.  Connecting Over-Contouring to Periodontal Health (The Core Concept):**\n\nThe central theme here is the relationship between tooth contours and periodontal health.  Proper tooth contours are crucial for:\n\n* **Gingival Health:**  Allowing for proper gingival adaptation and preventing irritation.\n* **Self-Cleansing:** Facilitating natural cleaning by saliva, tongue, and cheeks.\n* **Food Deflection:** Directing food away from the gingival sulcus (the space between the tooth and gingiva).\n* **Occlusal Harmony:**  Ensuring proper bite forces and distribution.\n\nOver-contouring disrupts all of these. It leads to:\n\n* **Gingival Irritation/Inflammation:**  Direct pressure and plaque accumulation.\n* **Impaired Self-Cleansing:**  Areas difficult to clean.\n* **Food Impaction:**  Trapping food against the gingiva.\n* **Potential Occlusal Problems:**  Interference with proper bite.\n\n**5.  Formulating the Explanation:**\n\nBased on the above analysis, the correct answer is C.  The explanation should clearly articulate *why* over-contouring leads to gingival inflammation.  This involves:\n\n* **Direct Pressure:** The over-contoured area pushes against the free gingiva.\n* **Plaque Accumulation:**  The over-contour creates a protected area where plaque and bacteria thrive because self-cleansing is reduced.\n* **Gingivitis:** This plaque accumulation and irritation cause inflammation of the gingiva (gingivitis).\n\n**6.  Review and Refine:**\n\nReread the question, answer choices, and explanation to ensure everything is clear, concise, and accurate.  Confirm that the explanation directly addresses why C is correct and why the other options are incorrect.  Make sure the terminology is appropriate for a dental context.\n\nThis systematic approach, starting from understanding the question and key terms, analyzing each option, and focusing on the core concept of periodontal health and tooth contours, leads to the correct answer and a comprehensive explanation.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **C. 유리치은에 염증이 발생한다.** 입니다.\n\n**해설:**\n\n납형 제작 시 치아의 최대 풍융부를 과풍융(over contouring)하게 되면 다음과 같은 현상이 나타납니다.\n\n* **유리치은 염증 발생:** 과도하게 볼록하게 형성된 최대 풍융부는 잇몸(유리치은)에 압박을 가하게 됩니다. 이는 치태와 음식물 잔사가 쉽게 축적되는 환경을 조성하고, 잇몸을 자극하여 염증을 유발합니다. 특히 유리치은은 치아와 직접 맞닿아 있어 더욱 민감하게 반응합니다.\n\n**오답 해설:**\n\n* **A. 자정작용이 잘된다:** 과풍융은 오히려 자정작용을 방해합니다.  정상적인 치아 형태는 혀와 볼, 입술의 움직임, 그리고 타액의 흐름을 통해 자연스럽게 치아가 세척되는 자정작용을 돕습니다. 하지만 과풍융은 이러한 자연적인 세척 작용을 어렵게 만들어 치태와 음식물 잔사가 쉽게 축적됩니다.\n\n* **B. 치주조직을 강화한다:** 과풍융은 치주조직에 오히려 해로운 영향을 미칩니다. 지속적인 압박과 염증은 치주조직을 약화시키고, 치주 질환을 유발할 수 있습니다.\n\n* **D. 생리적 마사지의 효과가 있다:**  정상적인 치아 형태는 저작 운동 시 잇몸에 적절한 생리적 마사지 효과를 제공하여 혈액 순환을 촉진하고 잇몸 건강을 유지하는 데 도움을 줍니다. 하지만 과풍융은 오히려 잇몸에 과도한 압박을 가하거나, 정상적인 자극을 방해하여 생리적 마사지 효과를 저해합니다.\n\n* **E. 치경부에 음식물 잔사가 저류되는 것을 막는다:** 과풍융은 오히려 치경부(치아와 잇몸 경계 부위)에 음식물 잔사가 더 쉽게 저류되도록 만듭니다. 과도하게 돌출된 부위는 음식물이 걸리기 쉽고, 칫솔질로도 깨끗하게 제거하기 어려워 충치나 치주 질환의 위험을 높입니다.\n\n**결론적으로, 납형 제작 시 최대 풍융부의 과풍융은 치주 건강에 부정적인 영향을 미치며, 특히 유리치은에 염증을 유발하는 주요 원인이 됩니다.** 따라서 납형 제작 시에는 적절한 치아 형태와 풍융도를 재현하는 것이 매우 중요합니다.&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:4752,&quot;string&quot;:&quot;4,752&quot;}}},{&quot;rowIdx&quot;:21,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;dental_technician&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2021,&quot;string&quot;:&quot;2,021&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:45,&quot;string&quot;:&quot;45&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;치과용 석고제품 중 압축강도가 가장 낮은 것은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;경석고&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;보통석고&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;인상용석고&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;저팽창용 초경석고&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;고팽창용 초경석고&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:3,&quot;string&quot;:&quot;3&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to arrive at the correct answer to the question \&quot;치과용 석고제품 중 압축강도가 가장 낮은 것은?\&quot; (Among dental gypsum products, which has the lowest compressive strength?).\n\n1. **Understanding the Question:** The question is asking about the compressive strength of different types of dental gypsum.  \&quot;가장 낮은\&quot; (lowest) is the key phrase.  We need to identify the gypsum product with the *weakest* compressive strength.\n\n2. **Translating and Identifying Key Terms:**  Let's translate and understand the options:\n    * 치과용 석고제품 (chigwa-yong seokgo-jepum): Dental gypsum products\n    * 압축강도 (apchuk-gangdo): Compressive strength\n    * 가장 낮은 (gajang najeun): Lowest, weakest\n    * A. 경석고 (gyeong-seokgo):  Dental Stone (Type III) - often translated as \&quot;hard stone\&quot; or \&quot;dental stone, hard\&quot; in English.\n    * B. 보통석고 (botong-seokgo): Plaster (Type II) - often translated as \&quot;model plaster\&quot; or \&quot;dental plaster\&quot;.\n    * C. 인상용석고 (insang-yong seokgo): Impression Plaster (Type I) - specifically for dental impressions.\n    * D. 저팽창용 초경석고 (jeo-paengchang-yong cho-gyeong-seokgo): Low-expansion die stone (Type IV).  \&quot;초경석고\&quot; (cho-gyeong-seokgo) means \&quot;super hard stone\&quot; or \&quot;die stone.\&quot; \&quot;저팽창용\&quot; (jeo-paengchang-yong) means \&quot;low expansion.\&quot;\n    * E. 고팽창용 초경석고 (go-paengchang-yong cho-gyeong-seokgo): High-expansion die stone (Type V). \&quot;고팽창용\&quot; (go-paengchang-yong) means \&quot;high expansion.\&quot;\n\n3. **Recalling Knowledge about Dental Gypsum Types:**  My knowledge base about dental materials immediately brings to mind the classification of dental gypsum products based on ADA (American Dental Association) specifications (or similar international standards).  These are categorized by type, roughly related to their strength and application:\n\n    * **Type I: Impression Plaster:**  Weakest.  Designed for taking impressions, where detail reproduction is more important than high strength.  Easy to separate from the impression.\n    * **Type II: Model Plaster:**  Slightly stronger than impression plaster. Used for study models, mounting casts on articulators, etc. Still relatively weak.\n    * **Type III: Dental Stone (or Hard Stone):** Stronger than plaster. Used for working casts, diagnostic casts, and denture bases.  More durable and resistant to abrasion than plaster.\n    * **Type IV: Die Stone (Low Expansion):**  Significantly stronger than dental stone.  High compressive strength and abrasion resistance. Low setting expansion for accurate dies used in crown and bridge fabrication.\n    * **Type V: Die Stone (High Expansion):**  Similar to Type IV in strength but with controlled, higher setting expansion to compensate for the shrinkage of certain casting alloys.\n\n4. **Relating Knowledge to the Options:** Now, let's match the options to the types and their relative strengths:\n\n    * A. 경석고 (Dental Stone) - Type III -  Moderate strength.\n    * B. 보통석고 (Plaster) - Type II -  Weaker strength than stone.\n    * C. 인상용석고 (Impression Plaster) - Type I -  Weakest strength.\n    * D. 저팽창용 초경석고 (Low-expansion die stone) - Type IV -  Highest strength (among these options).\n    * E. 고팽창용 초경석고 (High-expansion die stone) - Type V -  Highest strength (similar to Type IV, among these options).\n\n5. **Determining the Weakest:**  Based on the classification and understanding of the properties, Impression Plaster (Type I) is clearly the weakest among the given options.\n\n6. **Selecting the Answer:**  Therefore, the answer is **C. 인상용석고 (Impression Plaster)**.\n\n7. **Verification (Self-Correction/Confirmation):**  To double-check, I quickly review the characteristics of each gypsum type again.  Impression plaster is indeed formulated to be weak and easily broken, facilitating removal from the mouth and model separation.  Plaster is stronger, stone stronger still, and die stones are the strongest.  The question specifically asks for the *lowest* compressive strength, so Impression Plaster fits perfectly.  The other options are all stronger gypsum products.\n\nThis systematic process of translation, recall, comparison, and verification leads confidently to the correct answer, C.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **C. 인상용 석고**입니다.\n\n**해설:**\n\n치과용 석고 제품은 용도에 따라 다양한 종류가 있으며, 압축강도는 각 제품의 주요 특성 중 하나입니다. 압축강도는 석고가 압력에 얼마나 잘 견디는지를 나타내는 지표로, 높을수록 단단하고 강한 석고를 의미합니다.\n\n각 석고 제품별 압축강도를 비교하면 다음과 같습니다.\n\n* **인상용 석고 (Impression Plaster):**  **가장 낮은 압축강도**를 가집니다.  인상 채득 시 구강 내에서 쉽게 제거될 수 있도록 약하게 만들어졌으며, 정밀한 재현성보다는 용이한 제거에 초점을 맞춥니다.\n\n* **보통 석고 (Model Plaster):** 인상용 석고보다는 강하지만, 경석고나 초경석고보다는 **압축강도가 낮습니다**. 주로 진단 모형 제작이나 교정 모형 제작 등 비교적 강도가 덜 요구되는 용도에 사용됩니다.\n\n* **경석고 (Dental Stone):** 보통 석고보다 **압축강도가 높습니다**. 작업 모형, 왁스업, 의치상 제작 등 어느 정도 강도가 필요한 용도에 사용됩니다.\n\n* **초경석고 (Die Stone):**  **압축강도가 가장 높습니다**.  정밀한 보철물 제작을 위한 다이 모형 제작에 사용되며, 높은 강도와 내마모성이 요구됩니다. 저팽창용 초경석고와 고팽창용 초경석고 모두 경석고보다 훨씬 높은 압축강도를 가집니다.\n\n**따라서, 치과용 석고 제품 중 압축강도가 가장 낮은 것은 인상용 석고입니다.**\n\n**추가 설명:**\n\n* **압축강도 순서 (낮은 순 -> 높은 순):**  인상용 석고 < 보통 석고 < 경석고 < 초경석고 (저팽창용, 고팽창용)\n\n이러한 압축강도의 차이는 석고 제조 과정에서 사용되는 석고 입자의 형태, 크기, 물-석고 비율 등에 의해 결정됩니다.\n\n**결론적으로 정답은 C 입니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5013,&quot;string&quot;:&quot;5,013&quot;}}},{&quot;rowIdx&quot;:22,&quot;cells&quot;:{&quot;subject&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;dental_technician&quot;},&quot;year&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2022,&quot;string&quot;:&quot;2,022&quot;},&quot;period&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:1,&quot;string&quot;:&quot;1&quot;},&quot;q_number&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5,&quot;string&quot;:&quot;5&quot;},&quot;question&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;절치공을 통과하여 경구개의 전방 부위를 지배하는 신경은?&quot;},&quot;A&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;대구개신경&quot;},&quot;B&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;비구개신경&quot;},&quot;C&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;소구개신경&quot;},&quot;D&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;전상치조신경&quot;},&quot;E&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;중상치조신경&quot;},&quot;answer&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:2,&quot;string&quot;:&quot;2&quot;},&quot;thinking&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;Let's break down the thought process to arrive at the correct answer for the Korean question about nerves innervating the anterior hard palate via the incisive canal.\n\n**1. Deconstructing the Question (Korean to English Translation and Key Terms)**\n\n* **절치공 (jeolchi-gong):**  This translates to \&quot;incisive foramen\&quot; or \&quot;incisive canal.\&quot;  This is a crucial anatomical landmark.\n* **통과하여 (tong-gwaha-yeo):**  \&quot;Passing through\&quot; or \&quot;going through.\&quot; This indicates the nerve passes through the incisive canal.\n* **경구개 (gyeong-gu-gae):** \&quot;Hard palate.\&quot;  This is the area of innervation.\n* **전방 부위 (jeon-bang bu-wi):** \&quot;Anterior portion\&quot; or \&quot;front part.\&quot; This specifies the region of the hard palate.\n* **지배하는 신경 (ji-bae-ha-neun sin-gyeong):** \&quot;Nerve that innervates\&quot; or \&quot;nerve controlling.\&quot; This is asking for the nerve's name.\n* **신경 (sin-gyeong):** \&quot;Nerve.\&quot;\n\n**Putting it together in English:**  \&quot;Which nerve passes through the incisive canal to innervate the anterior portion of the hard palate?\&quot;\n\n**Key Anatomical Concepts:**\n\n* **Incisive Canal/Foramen:**  A passageway in the anterior midline of the hard palate, located just behind the central incisors.  It connects the nasal cavity and the oral cavity.\n* **Hard Palate Innervation:** The hard palate is primarily innervated by branches of the maxillary nerve (V2), a branch of the trigeminal nerve (V).\n\n**2. Analyzing the Answer Choices and Eliminating Incorrect Options**\n\nLet's go through each option and consider its anatomical relevance:\n\n* **A. 대구개신경 (dae-gu-gae sin-gyeong): Greater palatine nerve**\n    * \&quot;대\&quot; (dae) means \&quot;large\&quot; or \&quot;greater.\&quot;\n    * \&quot;구개\&quot; (gu-gae) means \&quot;palate.\&quot;\n    * The greater palatine nerve emerges from the greater palatine foramen, located in the posterior hard palate (near the molars).  It innervates the *posterior* hard palate and gingiva.  Therefore, this is *unlikely* to be the answer as the question specifies the *anterior* hard palate.\n\n* **B. 비구개신경 (bi-gu-gae sin-gyeong): Nasopalatine nerve**\n    * \&quot;비\&quot; (bi) relates to \&quot;nose\&quot; or \&quot;nasal.\&quot;\n    * \&quot;구개\&quot; (gu-gae) means \&quot;palate.\&quot;\n    * The nasopalatine nerve is known to pass through the incisive canal/foramen. It originates from the sphenopalatine ganglion and travels along the nasal septum before entering the incisive canal to reach the anterior hard palate. This is a *strong candidate*.\n\n* **C. 소구개신경 (so-gu-gae sin-gyeong): Lesser palatine nerve**\n    * \&quot;소\&quot; (so) means \&quot;small\&quot; or \&quot;lesser.\&quot;\n    * \&quot;구개\&quot; (gu-gae) means \&quot;palate.\&quot;\n    * The lesser palatine nerve emerges from the lesser palatine foramen, located *posterior* to the greater palatine foramen. It primarily innervates the *soft palate* and tonsillar area.  It does *not* innervate the anterior hard palate and does not pass through the incisive canal.  This is *unlikely*.\n\n* **D. 전상치조신경 (jeon-sang-chi-jo sin-gyeong): Anterior superior alveolar nerve (ASA)**\n    * \&quot;전상\&quot; (jeon-sang) means \&quot;anterior superior.\&quot;\n    * \&quot;치조\&quot; (chi-jo) refers to the \&quot;alveolar process\&quot; (the bone supporting the teeth).\n    * The ASA nerve innervates the anterior maxillary teeth (incisors, canines) and the *buccal* gingiva (cheek side) in the anterior maxilla. It runs within the maxillary bone and emerges onto the face. It does *not* pass through the incisive canal and primarily innervates teeth and buccal gingiva, not the palatal mucosa directly.  This is *unlikely*.\n\n* **E. 중상치조신경 (jung-sang-chi-jo sin-gyeong): Middle superior alveolar nerve (MSA)**\n    * \&quot;중상\&quot; (jung-sang) means \&quot;middle superior.\&quot;\n    * \&quot;치조\&quot; (chi-jo) refers to the \&quot;alveolar process.\&quot;\n    * The MSA nerve innervates the premolars, and sometimes the mesiobuccal root of the maxillary first molar, along with the buccal gingiva in the premolar region.  Like the ASA, it runs within the maxillary bone and doesn't pass through the incisive canal to innervate the hard palate.  This is *unlikely*.\n\n**3. Confirmation and Conclusion**\n\nBased on the anatomical knowledge and elimination process:\n\n* **Nasopalatine nerve (비구개신경)** is the only nerve that correctly matches the description of passing through the incisive canal and innervating the anterior hard palate.\n\nTherefore, the answer is **B. 비구개신경**.\n\n**Final Answer Justification (in Korean, as requested):**\n\n절치공은 경구개의 전방 중앙부에 위치하며, 비구개신경이 이 구멍을 통과하여 경구개의 전방 부위, 특히 앞니 부위의 점막과 골막을 지배합니다.  대구개신경은 후방 경구개를, 소구개신경은 연구개를 지배하며, 상치조신경들은 치아와 치조골, 그리고 뺨쪽 잇몸을 지배합니다. 따라서 절치공을 통과하여 경구개의 전방 부위를 지배하는 신경은 비구개신경이 가장 적절합니다.&quot;},&quot;response&quot;:{&quot;kind&quot;:&quot;string&quot;,&quot;value&quot;:&quot;정답은 **B. 비구개신경**입니다.\n\n**해설:**\n\n* **절치공 (Incisive foramen):**  경구개의 정중선, 앞니 바로 뒤에 위치한 구멍입니다.\n* **비구개신경 (Nasopalatine nerve):**  접형구개신경절에서 기원하여 비강을 통해 내려와 절치공을 통과하여 경구개의 전방 부위, 특히 앞니 부위의 점막과 골막을 지배하는 감각 신경입니다.\n\n**다른 선택지 설명:**\n\n* **A. 대구개신경 (Greater palatine nerve):**  대구개공을 통해 경구개로 나와 구치 부위의 경구개 점막과 잇몸을 지배합니다. 절치공을 통과하지 않으며 경구개의 전방 부위를 지배하지 않습니다.\n* **C. 소구개신경 (Lesser palatine nerve):**  소구개공을 통해 나와 연구개와 편도 부위를 지배합니다. 경구개를 지배하지 않습니다.\n* **D. 전상치조신경 (Anterior superior alveolar nerve):**  상악동 전벽 내에서 주행하며 상악 전치와 견치, 그리고 해당 부위의 뺨쪽 잇몸과 상악동 전방 부위를 지배합니다. 경구개를 직접 지배하지 않으며 절치공을 통과하지 않습니다.\n* **E. 중상치조신경 (Middle superior alveolar nerve):**  상악동 외벽 내에서 주행하며 상악 소구치와 제1대구치의 근심협측치근, 그리고 해당 부위의 뺨쪽 잇몸과 상악동 측벽 부위를 지배합니다. 경구개를 직접 지배하지 않으며 절치공을 통과하지 않습니다.\n\n**따라서 절치공을 통과하여 경구개의 전방 부위를 지배하는 신경은 비구개신경이 가장 정확합니다.**&quot;},&quot;__index_level_0__&quot;:{&quot;kind&quot;:&quot;number&quot;,&quot;value&quot;:5135,&quot;string&quot;:&quot;5,135&quot;}}}],&quot;truncated&quot;:true},&quot;paginationData&quot;:{&quot;pageIndex&quot;:0,&quot;numItemsPerPage&quot;:100,&quot;numTotalItems&quot;:8751,&quot;offset&quot;:0,&quot;length&quot;:100}},&quot;jwt&quot;:&quot;eyJhbGciOiJFZERTQSJ9.eyJyZWFkIjp0cnVlLCJwZXJtaXNzaW9ucyI6eyJyZXBvLmNvbnRlbnQucmVhZCI6dHJ1ZX0sImlhdCI6MTc0MjkxODU5NSwic3ViIjoiL2RhdGFzZXRzL0NodUd5b3VrL21lZGljYWwtbzEtdHJhaW4ta29ybWVkbWNxYSIsImV4cCI6MTc0MjkyMjE5NSwiaXNzIjoiaHR0cHM6Ly9odWdnaW5nZmFjZS5jbyJ9.g808faITaKa-pthwVwEDvQiTnhFE-F3DXBvuwxgcS-G0noSf5EX_9TjNaEoxLe-Pnrn8vbE91HdDdvAeKzL-Dw&quot;,&quot;displayUrls&quot;:true},&quot;dataset&quot;:&quot;ChuGyouk/medical-o1-train-kormedmcqa&quot;,&quot;isGated&quot;:false,&quot;isPrivate&quot;:false,&quot;hasParquetFormat&quot;:true,&quot;author&quot;:{&quot;_id&quot;:&quot;64ad53921db46d71a5c576e5&quot;,&quot;avatarUrl&quot;:&quot;https://cdn-avatars.huggingface.co/v1/production/uploads/64ad53921db46d71a5c576e5/fH08R-GANVBhZdYCDQjeG.png&quot;,&quot;fullname&quot;:&quot;ChuGyouk&quot;,&quot;name&quot;:&quot;ChuGyouk&quot;,&quot;type&quot;:&quot;user&quot;,&quot;isPro&quot;:true,&quot;isHf&quot;:false,&quot;isHfAdmin&quot;:false,&quot;isMod&quot;:false,&quot;followerCount&quot;:21},&quot;compact&quot;:true}"><div class="flex flex-col overflow-hidden shadow-xs mx-auto mb-10 rounded-lg border pt-2  px-2.5"><div class="mb-2 flex flex-wrap items-center gap-2"><div class="mr-auto flex items-center"><svg class="mr-1 flex-none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 12 12"><path fill="currentColor" d="M2.5 2h7a1 1 0 0 1 1 1v6a1 1 0 0 1-1 1h-7a1 1 0 0 1-1-1V3a1 1 0 0 1 1-1Zm0 2v2h3V4h-3Zm4 0v2h3V4h-3Zm-4 3v2h3V7h-3Zm4 0v2h3V7h-3Z"></path></svg>
	<div class="whitespace-nowrap font-semibold">Dataset Viewer</div>
	</div>
				<a href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/tree/refs%2Fconvert%2Fparquet/default" class="group mr-1 text-xs text-gray-400 max-sm:hidden"><svg class="text-[.6rem] mr-1 inline -translate-y-px" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path fill="currentColor" d="M12 10H6.78A11 11 0 0 1 27 16h2A13 13 0 0 0 6 7.68V4H4v8h8zm8 12h5.22A11 11 0 0 1 5 16H3a13 13 0 0 0 23 8.32V28h2v-8h-8z"></path></svg>
						<span class="underline decoration-gray-300 group-hover:decoration-gray-400 dark:decoration-gray-500 dark:group-hover:decoration-gray-300">Auto-converted</span> to Parquet
					</a>
				<button class="btn shadow-xs flex cursor-pointer items-center rounded-sm border px-1 py-0.5 text-xs font-normal text-gray-700 hover:text-gray-800 hover:shadow-inner dark:hover:text-gray-200"><svg class="mr-1.5" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32" style="transform: rotate(360deg);"><path d="M31 16l-7 7l-1.41-1.41L28.17 16l-5.58-5.59L24 9l7 7z" fill="currentColor"></path><path d="M1 16l7-7l1.41 1.41L3.83 16l5.58 5.59L8 23l-7-7z" fill="currentColor"></path><path d="M12.419 25.484L17.639 6l1.932.518L14.35 26z" fill="currentColor"></path></svg>API</button>
					<button class="btn shadow-xs flex cursor-pointer items-center rounded-sm border px-1 py-0.5 text-xs font-normal text-gray-700 hover:text-gray-800 hover:shadow-inner dark:hover:text-gray-200"><svg class="mr-1.5" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" fill="currentColor" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 12 12"><path d="M9.80603 2.86737H3.56107C3.37704 2.86737 3.20055 2.94048 3.07042 3.0706C2.94029 3.20073 2.86719 3.37723 2.86719 3.56126V9.80622C2.86719 9.99025 2.94029 10.1667 3.07042 10.2969C3.20055 10.427 3.37704 10.5001 3.56107 10.5001H9.80603C9.99006 10.5001 10.1666 10.427 10.2967 10.2969C10.4268 10.1667 10.4999 9.99025 10.4999 9.80622V3.56126C10.4999 3.37723 10.4268 3.20073 10.2967 3.0706C10.1666 2.94048 9.99006 2.86737 9.80603 2.86737Z" fill="currentColor" fill-opacity="0.3"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M2.40942 1.66191C2.05175 1.66191 1.7618 1.95186 1.7618 2.30953V6.76191H1.43799V2.30953C1.43799 1.77303 1.87291 1.3381 2.40942 1.3381H6.45704V1.66191H2.40942Z" fill="currentColor"></path></svg>Embed</button>

					<button class="bg-linear-to-b shadow-xs flex items-center gap-1.5 rounded-full border from-white to-red-100/90 px-2 py-0.5 text-xs font-medium text-[#2D3648] transition-shadow hover:shadow-inner dark:from-gray-900 dark:to-red-800/30 dark:text-gray-100 dark:hover:shadow-inner dark:hover:shadow-red-800/30" ><svg class="h-3.5 w-3.5 text-red-500" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 12 12"><path fill="currentColor" d="M2.5 2h7a1 1 0 0 1 1 1v6a1 1 0 0 1-1 1h-7a1 1 0 0 1-1-1V3a1 1 0 0 1 1-1Zm0 2v2h3V4h-3Zm4 0v2h3V4h-3Zm-4 3v2h3V7h-3Zm4 0v2h3V7h-3Z"></path></svg>
						<span>Data Studio</span></button></div>
		<div class="flex flex-1 flex-col overflow-hidden -mx-2.5"><div class="flex flex-1 flex-col overflow-hidden"><div class="flex min-h-0 flex-1"><div class="flex flex-1 flex-col overflow-hidden"><div class="md:-mx-2.5 flex min-w-0 flex-wrap border-t"><div class="flex min-w-0 flex-1 flex-wrap"><div class="grid flex-1 grid-cols-1 overflow-hidden text-sm md:grid-cols-2 md:place-content-center sm:mx-2.5"><label class="relative block flex-1 px-3 py-2 hover:bg-gray-50 dark:border-gray-850 dark:hover:bg-gray-950 md:border-r md:border-r-0 hidden" title="default"><span class="text-gray-500">Subset (1)</span>
			<div class="flex items-center whitespace-nowrap"><span class="truncate">default</span>
				<span class="mx-2 text-gray-500">·</span>
					<span class="text-gray-500">8.75k rows</span>
				<svg class="ml-auto min-w-6 pl-2" width="1em" height="1em" viewBox="0 0 12 7" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M1 1L6 6L11 1" stroke="currentColor"></path></svg></div>
			<select class="absolute inset-0 z-10 w-full cursor-pointer border-0 bg-white text-base opacity-0"><optgroup label="Subset (1)"><option value="default" selected>default (8.75k rows)</option></optgroup></select></label>
		<label class="relative block flex-1 px-3 py-2 hover:bg-gray-50 dark:border-gray-850 dark:hover:bg-gray-900 md:border-r md:border-r" title="train"><div class="text-gray-500">Split (1)</div>
				<div class="flex items-center overflow-hidden whitespace-nowrap"><span class="truncate">train</span>
					<span class="mx-2 text-gray-500">·</span>
						<span class="text-gray-500">8.75k rows</span>
					<svg class="ml-auto min-w-6 pl-2" width="1em" height="1em" viewBox="0 0 12 7" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M1 1L6 6L11 1" stroke="currentColor"></path></svg></div>
				<select class="absolute inset-0 z-10 w-full cursor-pointer border-0 bg-white text-base opacity-0"><optgroup label="Split (1)"><option value="train" selected>train (8.75k rows)</option></optgroup></select></label></div></div>
								</div>

							<div class="flex min-h-0 flex-1 flex-col ">
	<div class="bg-linear-to-r text-smd relative flex items-center dark:border-gray-900 dark:bg-gray-950 false border-t [&amp;:has(:focus)]:from-gray-50 [&amp;:has(:focus)]:to-transparent [&amp;:has(:focus)]:to-20% dark:[&amp;:has(:focus)]:from-gray-900"><form class="flex-1"><svg class="absolute left-3 top-1/2 transform -translate-y-1/2 pointer-events-none text-gray-400" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M30 28.59L22.45 21A11 11 0 1 0 21 22.45L28.59 30zM5 14a9 9 0 1 1 9 9a9 9 0 0 1-9-9z" fill="currentColor"></path></svg>
				<input disabled class="outline-hidden h-9 w-full border-none bg-transparent px-1 pl-9 pr-3 placeholder:text-gray-400 " placeholder="Search this dataset" dir="auto"></form>
			<div class="flex items-center gap-2 px-2 py-1"><button type="button" class="hover:bg-yellow-200/70 flex items-center gap-1 rounded-md border border-yellow-200 bg-yellow-100 pl-0.5 pr-1 text-[.8rem] leading-normal text-gray-700 dark:border-orange-500/25 dark:bg-orange-500/20 dark:text-gray-300 dark:hover:brightness-110 hidden"><div class="rounded-sm bg-yellow-300 px-1 font-mono text-[.7rem] font-bold text-black dark:bg-yellow-700 dark:text-gray-200">SQL
	</div>
	Console
</button></div></div>


<div class="flex flex-1 flex-col overflow-hidden min-h-64 border-t">
		

<div class="max-h-96 relative overflow-auto"><table class="w-full table-auto rounded-lg font-mono text-xs text-gray-900"><thead class="shadow-xs sticky left-0 right-0 top-0 z-1 bg-white align-top"><tr class="space-y-54 h-full min-w-fit divide-x border-b text-left"><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">subject
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>string</span><span class="italic text-gray-400 before:mx-1 before:content-['·']">classes</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><defs><clipPath id="rounded-bar"><rect x="0" y="0" width="130" height="8" rx="4"></rect></clipPath><pattern id="hatching" patternUnits="userSpaceOnUse" patternTransform="rotate(-45)" height="1" width="5"><line y1="0" class="stroke-gray-400 dark:stroke-gray-500/80" stroke-width="3" y2="1" x1="2" x2="2"></line></pattern><pattern id="hatching-faded" patternUnits="userSpaceOnUse" patternTransform="rotate(-45)" height="1" width="5"><line y1="0" class="stroke-gray-100 dark:stroke-gray-500/20" stroke-width="3" y2="1" x1="2" x2="2"></line></pattern></defs><g height="8" style="transform: translateY(20px)" clip-path="url(#rounded-bar)"><g style="transform: scaleX(1.0153846153846153) translateX(-1px)"><g><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="1" y="0" width="25.853959547480287" height="8" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="28.853959547480287" y="0" width="12.513769854873729" height="8" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="43.367729402354016" y="0" width="11.191635241686663" height="8" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="56.55936464404068" y="0" width="10.879670894754886" height="8" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="69.43903553879557" y="0" width="10.537995657639128" height="8" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="81.9770311964347" y="0" width="10.18146497543138" height="8" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="94.15849617186608" y="0" width="10.136898640155412" height="8" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="106.29539481202148" y="0" width="8.11655810764484" height="8" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="116.41195291966632" y="0" width="5.635698777282597" height="8" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" x="124.04765169694892" y="0" width="4.95234830305108" height="8" fill-opacity="1"></rect></g></g></g><g style="transform: scaleX(1.0153846153846153) translateX(-1px)"><g><rect class="fill-white cursor-pointer" x="0" y="0" width="27.853959547480287" height="28" fill-opacity="0"></rect><rect class="fill-white cursor-pointer" x="27.853959547480287" y="0" width="14.513769854873729" height="28" fill-opacity="0"></rect><rect class="fill-white cursor-pointer" x="42.367729402354016" y="0" width="13.191635241686663" height="28" fill-opacity="0"></rect><rect class="fill-white cursor-pointer" x="55.55936464404068" y="0" width="12.879670894754886" height="28" fill-opacity="0"></rect><rect class="fill-white cursor-pointer" x="68.43903553879557" y="0" width="12.537995657639128" height="28" fill-opacity="0"></rect><rect class="fill-white cursor-pointer" x="80.9770311964347" y="0" width="12.18146497543138" height="28" fill-opacity="0"></rect><rect class="fill-white cursor-pointer" x="93.15849617186608" y="0" width="12.136898640155412" height="28" fill-opacity="0"></rect><rect class="fill-white cursor-pointer" x="105.29539481202148" y="0" width="10.11655810764484" height="28" fill-opacity="0"></rect><rect class="fill-white cursor-pointer" x="115.41195291966632" y="0" width="7.635698777282597" height="28" fill-opacity="0"></rect><rect class="fill-white cursor-pointer" x="123.04765169694892" y="0" width="6.95234830305108" height="28" fill-opacity="0"></rect></g></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 max-w-full overflow-hidden text-ellipsis whitespace-nowrap">10
				values</div></div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">year
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>int64</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="0" y="22.271428571428572" width="16.857142857142858" height="7.728571428571429" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="18.857142857142858" y="22.885714285714286" width="16.857142857142858" height="7.114285714285714" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="37.714285714285715" y="23.55" width="16.857142857142858" height="6.45" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="56.57142857142857" y="14.757142857142858" width="16.857142857142858" height="15.242857142857142" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="75.42857142857143" y="0" width="16.857142857142858" height="30" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="94.28571428571429" y="10.7" width="16.857142857142858" height="19.3" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="113.14285714285714" y="25" width="16.857142857142858" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="17.857142857142858" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="36.714285714285715" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="55.57142857142857" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="74.42857142857143" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="93.28571428571429" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="112.14285714285714" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">2.01k</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">2.02k</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">period
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>int64</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="0" y="0" width="16.857142857142858" height="30" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="18.857142857142858" y="6.277053975006648" width="16.857142857142858" height="23.72294602499335" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="37.714285714285715" y="18.969423025791013" width="16.857142857142858" height="11.030576974208987" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="56.57142857142857" y="21.87981919702207" width="16.857142857142858" height="8.12018080297793" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="75.42857142857143" y="23.829300717894178" width="16.857142857142858" height="6.170699282105823" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="94.28571428571429" y="24.80404147833023" width="16.857142857142858" height="5.195958521669769" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="113.14285714285714" y="25" width="16.857142857142858" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="17.857142857142858" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="36.714285714285715" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="55.57142857142857" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="74.42857142857143" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="93.28571428571429" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="112.14285714285714" y="0" width="18.857142857142858" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">1</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">7</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">q_number
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>int64</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="0" y="1.110552763819097" width="11.2" height="28.889447236180903" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="13.2" y="2.2646566164154116" width="11.2" height="27.73534338358459" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="26.4" y="1.676716917922949" width="11.2" height="28.32328308207705" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="39.599999999999994" y="0.9363484087102165" width="11.2" height="29.063651591289783" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="52.8" y="0" width="11.2" height="30" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="66" y="1.8944723618090435" width="11.2" height="28.105527638190956" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="79.19999999999999" y="7.142378559463985" width="11.2" height="22.857621440536015" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="92.39999999999999" y="11.758793969849247" width="11.2" height="18.241206030150753" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="105.6" y="18.378559463986598" width="11.2" height="11.6214405360134" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="118.8" y="24.279731993299833" width="11.2" height="5.720268006700167" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="12.2" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="25.4" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="38.599999999999994" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="51.8" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="65" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="78.19999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="91.39999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="104.6" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="117.8" y="0" width="13.2" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">1</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">120</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">question
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>string</span><span class="italic text-gray-400 before:mx-1 before:content-['·']">lengths</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="0" y="0" width="11.2" height="30" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="13.2" y="15.203879571630633" width="11.2" height="14.796120428369367" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="26.4" y="21.870680945645585" width="11.2" height="8.129319054354415" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="39.599999999999994" y="23.935340472822794" width="11.2" height="6.0646595271772075" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="52.8" y="24.60779955546575" width="11.2" height="5.392200444534249" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="66" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="79.19999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="92.39999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="105.6" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="118.8" y="25" width="11.2" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="12.2" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="25.4" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="38.599999999999994" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="51.8" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="65" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="78.19999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="91.39999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="104.6" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="117.8" y="0" width="13.2" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">1</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">646</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">A
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>string</span><span class="italic text-gray-400 before:mx-1 before:content-['·']">lengths</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="0" y="0" width="11.2" height="30" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="13.2" y="15.844195742813254" width="11.2" height="14.155804257186746" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="26.4" y="17.932411674347158" width="11.2" height="12.067588325652842" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="39.599999999999994" y="22.046082949308754" width="11.2" height="7.953917050691244" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="52.8" y="24.870309414088215" width="11.2" height="5.129690585911784" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="66" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="79.19999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="92.39999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="105.6" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="118.8" y="25" width="11.2" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="12.2" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="25.4" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="38.599999999999994" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="51.8" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="65" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="78.19999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="91.39999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="104.6" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="117.8" y="0" width="13.2" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">1</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">57</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">B
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>string</span><span class="italic text-gray-400 before:mx-1 before:content-['·']">lengths</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="0" y="0" width="12.666666666666666" height="30" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="14.666666666666666" y="15.623853211009175" width="12.666666666666666" height="14.376146788990825" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="29.333333333333332" y="17.992910758965806" width="12.666666666666666" height="12.007089241034196" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="44" y="23.701417848206837" width="12.666666666666666" height="6.298582151793161" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="58.666666666666664" y="25" width="12.666666666666666" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="73.33333333333333" y="25" width="12.666666666666666" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="88" y="25" width="12.666666666666666" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="102.66666666666666" y="25" width="12.666666666666666" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="117.33333333333333" y="25" width="12.666666666666666" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="13.666666666666666" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="28.333333333333332" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="43" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="57.666666666666664" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="72.33333333333333" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="87" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="101.66666666666666" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="116.33333333333333" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">1</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">71</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">C
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>string</span><span class="italic text-gray-400 before:mx-1 before:content-['·']">lengths</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="0" y="0" width="12.666666666666666" height="30" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="14.666666666666666" y="15.066697121973505" width="12.666666666666666" height="14.933302878026495" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="29.333333333333332" y="16.57514846962083" width="12.666666666666666" height="13.424851530379168" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="44" y="21.884422110552762" width="12.666666666666666" height="8.115577889447236" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="58.666666666666664" y="24.89538602101416" width="12.666666666666666" height="5.104613978985839" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="73.33333333333333" y="25" width="12.666666666666666" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="88" y="25" width="12.666666666666666" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="102.66666666666666" y="25" width="12.666666666666666" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="117.33333333333333" y="25" width="12.666666666666666" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="13.666666666666666" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="28.333333333333332" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="43" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="57.666666666666664" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="72.33333333333333" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="87" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="101.66666666666666" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="116.33333333333333" y="0" width="14.666666666666666" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">1</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">72</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">D
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>string</span><span class="italic text-gray-400 before:mx-1 before:content-['·']">lengths</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="0" y="0" width="11.2" height="30" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="13.2" y="13.121118012422361" width="11.2" height="16.87888198757764" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="26.4" y="15.375258799171842" width="11.2" height="14.624741200828158" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="39.599999999999994" y="19.917184265010352" width="11.2" height="10.082815734989648" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="52.8" y="23.638198757763973" width="11.2" height="6.361801242236025" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="66" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="79.19999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="92.39999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="105.6" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="118.8" y="25" width="11.2" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="12.2" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="25.4" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="38.599999999999994" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="51.8" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="65" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="78.19999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="91.39999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="104.6" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="117.8" y="0" width="13.2" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">1</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">77</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">E
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>string</span><span class="italic text-gray-400 before:mx-1 before:content-['·']">lengths</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="0" y="0" width="11.2" height="30" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="13.2" y="12.7424206254476" width="11.2" height="17.2575793745524" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="26.4" y="16.261637622344235" width="11.2" height="13.738362377655765" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="39.599999999999994" y="22.033898305084747" width="11.2" height="7.966101694915254" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="52.8" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="66" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="79.19999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="92.39999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="105.6" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="118.8" y="25" width="11.2" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="12.2" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="25.4" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="38.599999999999994" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="51.8" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="65" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="78.19999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="91.39999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="104.6" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="117.8" y="0" width="13.2" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">1</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">101</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">answer
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>int64</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="0" y="5.15668922436231" width="24.4" height="24.84331077563769" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="26.4" y="3.20770432066632" width="24.4" height="26.79229567933368" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="52.8" y="2.260281103591879" width="24.4" height="27.73971889640812" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="79.19999999999999" y="0.9338885996876627" width="24.4" height="29.066111400312337" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="105.6" y="0" width="24.4" height="30" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="26.4" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="25.4" y="0" width="26.4" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="51.8" y="0" width="26.4" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="78.19999999999999" y="0" width="26.4" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="104.6" y="0" width="26.4" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">1</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">5</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">thinking
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>string</span><span class="italic text-gray-400 before:mx-1 before:content-['·']">lengths</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="0" y="22.894602479941646" width="11.2" height="7.105397520058352" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="13.2" y="0" width="11.2" height="30" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="26.4" y="15.190371991247265" width="11.2" height="14.809628008752735" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="39.599999999999994" y="24.86214442013129" width="11.2" height="5.137855579868709" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="52.8" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="66" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="79.19999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="92.39999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="105.6" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="118.8" y="25" width="11.2" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="12.2" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="25.4" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="38.599999999999994" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="51.8" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="65" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="78.19999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="91.39999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="104.6" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="117.8" y="0" width="13.2" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">646</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">27.8k</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">response
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>string</span><span class="italic text-gray-400 before:mx-1 before:content-['·']">lengths</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="0" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="13.2" y="22.16020025031289" width="11.2" height="7.839799749687109" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="26.4" y="3.84793491864831" width="11.2" height="26.15206508135169" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="39.599999999999994" y="0" width="11.2" height="30" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="52.8" y="14.13892365456821" width="11.2" height="15.86107634543179" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="66" y="21.37922403003755" width="11.2" height="8.620775969962452" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="79.19999999999999" y="24.397371714643306" width="11.2" height="5.602628285356696" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="92.39999999999999" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="105.6" y="25" width="11.2" height="5" fill-opacity="1"></rect><rect class="fill-gray-400 dark:fill-gray-500/80" rx="2" x="118.8" y="25" width="11.2" height="5" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="12.2" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="25.4" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="38.599999999999994" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="51.8" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="65" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="78.19999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="91.39999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="104.6" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="117.8" y="0" width="13.2" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">105</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">3.33k</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th><th class="h-full max-w-sm p-2 text-left  relative w-auto"><div class="flex h-full flex-col flex-nowrap justify-between"><div><div class="flex items-center justify-between">__index_level_0__
				<form class="flex flex-col"><button id="asc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="-rotate-180 transform text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button>
						<button id="desc" class="-mr-1 ml-2 h-[0.4rem] w-[0.8rem] transition ease-in-out"><svg class="text-gray-300 hover:text-gray-500" xmlns="http://www.w3.org/2000/svg" viewBox="0 64 256 128" fill="currentColor" aria-hidden="true"><path d="M213.65674,101.657l-80,79.99976a7.99945,7.99945,0,0,1-11.31348,0l-80-79.99976A8,8,0,0,1,48,88H208a8,8,0,0,1,5.65674,13.657Z"></path></svg></button></form></div>

			<div class="mb-2 whitespace-nowrap text-xs font-normal text-gray-500"><span>int64</span></div></div>

		<div><div class="" style="height: 40px; padding-top: 2px"><svg width="130" height="28"><g><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="0" y="0" width="11.2" height="30" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="13.2" y="8.52012882447665" width="11.2" height="21.47987117552335" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="26.4" y="8.52012882447665" width="11.2" height="21.47987117552335" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="39.599999999999994" y="8.52012882447665" width="11.2" height="21.47987117552335" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="52.8" y="8.52012882447665" width="11.2" height="21.47987117552335" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="66" y="8.52012882447665" width="11.2" height="21.47987117552335" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="79.19999999999999" y="8.52012882447665" width="11.2" height="21.47987117552335" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="92.39999999999999" y="8.52012882447665" width="11.2" height="21.47987117552335" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="105.6" y="8.52012882447665" width="11.2" height="21.47987117552335" fill-opacity="1"></rect><rect class="fill-indigo-500 dark:fill-indigo-600/80" rx="2" x="118.8" y="8.645732689210949" width="11.2" height="21.35426731078905" fill-opacity="1"></rect></g><rect class="fill-white dark:fill-gray-900" x="0" y="26" width="130" height="2" stroke-opacity="1"></rect><line class="stroke-gray-100 dark:stroke-gray-500/20" x1="0" y1="27.5" x2="130" y2="27.5" stroke-opacity="1"></line><g><rect class="fill-indigo-500 cursor-pointer" x="-1" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="12.2" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="25.4" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="38.599999999999994" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="51.8" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="65" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="78.19999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="91.39999999999999" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="104.6" y="0" width="13.2" height="30" fill-opacity="0"></rect><rect class="fill-indigo-500 cursor-pointer" x="117.8" y="0" width="13.2" height="30" fill-opacity="0"></rect></g></svg>
	<div class="relative font-light text-gray-400" style="height: 10px; width: 130px;"><div class="absolute left-0 overflow-hidden text-ellipsis whitespace-nowrap" style="max-width: 60px">0</div>
			<div class="absolute overflow-hidden text-ellipsis whitespace-nowrap" style="right: 0px; max-width: 60px">8.34k</div>
			</div></div></div></div>
	<div class="absolute right-0 top-0 z-10 h-full w-1 cursor-col-resize hover:bg-indigo-100 active:bg-indigo-500 dark:hover:bg-indigo-800 dark:active:bg-indigo-600/80"><div class="absolute right-0 top-0 h-full w-1"></div>
								</div>
						</th></tr></thead>
			<tbody class="h-16 overflow-scroll"><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="0"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">paramedic_1</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,023</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">90</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">과량투여 시 피부 및 점막의 건조, 동공확대, 고체온 등의 중독 증상이 나타나며 피소스티그민(피조스티그민)을 해독제로 사용할 수 있는 물질은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">다이아제팜</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">아트로핀</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">살충제</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">모르핀</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">에탄올</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">
The question is asking for a substance that, when overdosed, causes symptoms like dry skin and mucous membranes, dilated pupils, and hyperthermia, and for which physostigmine is used as an antidote.  Let's analyze each option and see which one fits the description.

* **Symptoms described:** Dry skin and mucous membranes, dilated pupils, hyperthermia. These are classic signs of **anticholinergic toxicity**.  Anticholinergic drugs block the action of acetylcholine, a neurotransmitter responsible for various functions, including muscle contraction, gland secretions, and heart rate regulation. Blocking acetylcholine leads to these symptoms.

* **Physostigmine as an antidote:** Physostigmine is a cholinesterase inhibitor. It increases the level of acetylcholine in the synapse by preventing its breakdown.  It's used as an antidote for anticholinergic poisoning because it counteracts the effects of anticholinergic drugs by increasing acetylcholine levels, thus overcoming the blockade.

Now let's examine each option:

* **A. 다이아제팜 (Diazepam):**  Diazepam is a benzodiazepine, primarily used as an anxiolytic, sedative, muscle relaxant, and anticonvulsant.  Overdose symptoms of diazepam include drowsiness, confusion, impaired coordination, and respiratory depression.  It's not typically associated with anticholinergic effects like dry skin, dilated pupils, and hyperthermia.  Flumazenil is the antidote for benzodiazepine overdose, not physostigmine.

* **B. 아트로핀 (Atropine):** Atropine is a classic anticholinergic drug. It's a muscarinic antagonist, meaning it blocks the muscarinic acetylcholine receptors.  Overdose of atropine would directly cause the symptoms listed: dry skin (decreased sweating), dry mucous membranes (decreased saliva), dilated pupils (mydriasis), and hyperthermia (due to decreased sweating).  Physostigmine is indeed used as an antidote for atropine poisoning to reverse these anticholinergic effects.

* **C. 살충제 (Insecticide):**  This is a broad category.  Some insecticides, like organophosphates and carbamates, are cholinesterase inhibitors.  They *increase* acetylcholine levels, leading to cholinergic toxicity (opposite of anticholinergic). Symptoms of organophosphate/carbamate poisoning include SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) and muscle weakness, miosis (constricted pupils), bradycardia.  Other insecticides, like pyrethroids, primarily affect the nervous system through sodium channel modulation, and don't typically cause anticholinergic symptoms.  However, some older insecticides might have anticholinergic properties, but generally, insecticides are not the primary cause of anticholinergic poisoning for which physostigmine is a first-line antidote.  Organophosphate poisoning, which is more common with insecticides, is treated with atropine (ironically, to block the *excess* acetylcholine effects) and pralidoxime (to reactivate cholinesterase), not physostigmine.  This option is less likely than atropine.

* **D. 모르핀 (Morphine):** Morphine is an opioid analgesic.  Overdose symptoms of morphine include respiratory depression, pinpoint pupils (miosis), constipation, and decreased level of consciousness.  It does not cause anticholinergic symptoms like dilated pupils and hyperthermia.  Naloxone is the antidote for opioid overdose.

* **E. 에탄올 (Ethanol):** Ethanol is alcohol.  Ethanol intoxication symptoms include impaired coordination, slurred speech, confusion, and respiratory depression in severe cases.  While it can cause vasodilation which might contribute to warmth, it doesn't typically cause hyperthermia in the same way anticholinergics do.  It also doesn't cause dilated pupils in the same way.  The primary concerns with ethanol overdose are CNS depression and respiratory depression.  There is no specific antidote in the same way as physostigmine for anticholinergics or naloxone for opioids. Treatment is supportive.

**Conclusion:**

Based on the symptoms and the antidote, **atropine (B)** is the most fitting answer.  Atropine is a known anticholinergic drug that causes the described symptoms upon overdose, and physostigmine is a well-established antidote for anticholinergic poisoning, including atropine poisoning.

Let's double check the symptoms and antidote for atropine overdose:

* **Symptoms of Atropine Overdose (Anticholinergic Toxidrome):**
    * **Mad as a hatter:** Delirium, hallucinations, confusion
    * **Blind as a bat:** Mydriasis (dilated pupils), blurred vision
    * **Red as a beet:** Vasodilation, flushed skin
    * **Hot as a hare:** Hyperthermia, anhidrosis (lack of sweating)
    * **Dry as a bone:** Dry skin, dry mucous membranes
    * **Other:** Tachycardia, urinary retention, decreased bowel sounds

The symptoms listed in the question (dry skin and mucous membranes, dilated pupils, hyperthermia) are all core components of anticholinergic toxidrome and are characteristic of atropine overdose.  And physostigmine is indeed used to treat anticholinergic poisoning, particularly in cases with severe delirium or other significant symptoms.

Therefore, the most appropriate answer is **B. 아트로핀 (Atropine)**.


Let's consider why other options are less likely:

* **Diazepam:**  Wrong symptoms, wrong antidote.
* **Insecticide:** Too broad, and while some might have anticholinergic properties, the more common insecticide poisonings (organophosphates, carbamates) cause cholinergic, not anticholinergic symptoms. Physostigmine might be contraindicated in organophosphate poisoning in some contexts (though it's complex and sometimes used with caution in specific situations), and atropine is the primary anticholinergic used as antidote for organophosphate poisoning.
* **Morphine:** Wrong symptoms, wrong antidote.
* **Ethanol:** Wrong symptoms, no specific antidote like physostigmine for this symptom profile.


Thus, Atropine is the clear best answer.
</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **B. 아트로핀**입니다.

**해설:**

**제시된 증상:**

* **피부 및 점막 건조:**  땀 분비 감소 및 침 분비 감소로 인해 나타나는 증상으로, 부교감 신경 억제(항콜린 작용)와 관련이 있습니다.
* **동공 확대:**  동공 조절 근육의 마비로 인해 나타나는 증상으로, 부교감 신경 억제(항콜린 작용)의 대표적인 증상입니다.
* **고체온:**  땀 분비 감소로 인한 체온 조절 장애로 발생할 수 있으며, 항콜린 작용과 관련이 있습니다.

**해독제: 피소스티그민 (피조스티그민)**

* 피소스티그민은 콜린에스터라제 억제제입니다. 콜린에스터라제는 아세틸콜린을 분해하는 효소이므로, 피소스티그민은 아세틸콜린의 분해를 억제하여 아세틸콜린의 농도를 증가시킵니다.
* 이는 **항콜린 작용 물질의 중독을 해독하는 데 사용**됩니다. 항콜린 작용 물질은 아세틸콜린의 작용을 억제하므로, 피소스티그민은 아세틸콜린 농도를 높여 항콜린 작용을 상쇄시키는 효과를 나타냅니다.

**각 선택지 분석:**

* **A. 다이아제팜:**  벤조디아제핀 계열의 약물로, 주로 진정, 수면, 항불안 작용을 합니다. 과량 투여 시 졸음, 혼란, 운동실조, 호흡 억제 등의 증상이 나타나지만, 피부 건조, 동공 확대, 고체온과 같은 항콜린 증상은 나타나지 않습니다. 해독제는 플루마제닐입니다.

* **B. 아트로핀:**  대표적인 **항콜린 작용제**입니다.  과량 투여 시 제시된 증상인 피부 및 점막 건조, 동공 확대, 고체온 등이 나타납니다. 또한, 피소스티그민은 아트로핀 중독의 해독제로 사용됩니다.

* **C. 살충제:**  살충제의 종류는 매우 다양합니다. 유기인계 살충제나 카바메이트계 살충제는 콜린에스터라제 억제제로서, 오히려 콜린성 증상(근육 경련, 침 흘림, 동공 축소 등)을 유발하며, 해독제로는 아트로핀 (항콜린제)과 옥심 제제가 사용됩니다. 제시된 증상과는 반대되는 경우가 많습니다.

* **D. 모르핀:**  마약성 진통제인 오피오이드 계열 약물입니다. 과량 투여 시 호흡 억제, 동공 축소, 변비 등의 증상이 나타나며, 해독제는 날록손입니다. 제시된 증상과는 거리가 멉니다.

* **E. 에탄올:**  알코올입니다. 과량 섭취 시 중추신경 억제, 운동 실조, 판단력 저하 등의 증상이 나타나지만, 피부 건조, 동공 확대, 고체온과 같은 항콜린 증상은 나타나지 않습니다.

**결론:**

제시된 중독 증상과 해독제(피소스티그민)를 고려했을 때, 가장 적합한 물질은 **B. 아트로핀**입니다. 아트로핀은 항콜린 작용제로서 과량 투여 시 제시된 증상을 유발하며, 피소스티그민은 아트로핀 중독의 해독제로 사용됩니다.

**따라서 정답은 B입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">7,494</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="1"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">paramedic_1</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,023</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">65</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">척추손상이 의심되는 환자를 이송하기 위한 척추보호조치 (척추움직임제한) 방법으로 옳은 것은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">몸통을 긴척추고정판에 완전히 고정한 후에 머리를 고정</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">머리기울이고턱들기 자세가 유지되도록 목 고정장치 적용</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">목 고정장치는 좌우로 45° 돌릴 수 있도록 느슨하게 고정</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">목뼈의 굽힘이나 압박이 발생하지 않도록 과신전 상태로 고정</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">몸통은 위아래로는 움직이고 왼쪽 · 오른쪽으로는 움직이지 않도록 고정</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">
The question is asking about the correct method of spinal motion restriction (spinal immobilization) for a patient suspected of having a spinal injury during transport.  Let's analyze each option in Korean and then translate to English for clarity.

* **Understanding the Goal:** The primary goal of spinal motion restriction is to prevent further injury to the spinal cord by minimizing movement of the spine, especially in cases of suspected spinal injury. This is crucial during patient transport to avoid exacerbating potential damage.

* **Analyzing each option:**

    * **A. 몸통을 긴척추고정판에 완전히 고정한 후에 머리를 고정 (Fix the torso completely to a long spine board first, then fix the head.)**
        * **Thinking:** This sounds like a logical sequence.  Stabilizing the torso first provides a stable base before immobilizing the head. If you fix the head first and then try to move the torso onto the board, you risk moving the neck and spine. So, torso first, then head sounds correct.

    * **B. 머리기울이고턱들기 자세가 유지되도록 목 고정장치 적용 (Apply a cervical collar so that the head-tilt and chin-lift position is maintained.)**
        * **Thinking:** The head-tilt chin-lift maneuver is used to open the airway in unresponsive patients, *not* for spinal immobilization.  In spinal injury, we want to maintain a *neutral* position if possible, not necessarily head-tilt chin-lift.  Also, maintaining head-tilt chin-lift with a cervical collar sounds contradictory and potentially harmful for spinal injury.  This option seems incorrect.

    * **C. 목 고정장치는 좌우로 45° 돌릴 수 있도록 느슨하게 고정 (Fix the cervical collar loosely so that it can be turned 45° left and right.)**
        * **Thinking:**  The purpose of a cervical collar (목 고정장치) in spinal immobilization is to *restrict* movement, not allow it. Allowing 45° rotation defeats the purpose.  This is definitely incorrect.  Spinal immobilization needs to be *rigid*, not loose.

    * **D. 목뼈의 굽힘이나 압박이 발생하지 않도록 과신전 상태로 고정 (Fix in a hyperextended position to prevent flexion or compression of the cervical vertebrae.)**
        * **Thinking:** Hyperextension (과신전) of the neck is generally *contraindicated* in suspected spinal injury.  It can worsen the injury, especially if there's already a fracture or dislocation.  Neutral alignment is preferred.  Forcing hyperextension can cause more harm.  This is likely incorrect and dangerous.

    * **E. 몸통은 위아래로는 움직이고 왼쪽 · 오른쪽으로는 움직이지 않도록 고정 (Fix the torso so that it moves up and down but not left and right.)**
        * **Thinking:**  This option is confusing and nonsensical for spinal immobilization.  Spinal immobilization aims to restrict *all* movement of the torso and spine in all directions – up/down, left/right, rotation, flexion, extension. Allowing up and down movement while restricting left/right is not a standard or recommended practice for spinal immobilization. This is incorrect and illogical.


* **Re-evaluating and confirming the best answer:**

    * Option A makes the most sense in terms of sequence and overall principle of immobilization.
    * Options B, C, D, and E are all clearly wrong based on basic principles of spinal immobilization and first aid.

* **Translating and confirming in English for clarity:**

    * A. Fix the torso completely to a long spine board first, then fix the head. (Sounds correct)
    * B. Apply a cervical collar so that the head-tilt and chin-lift position is maintained. (Incorrect - head-tilt chin-lift is for airway, not immobilization; and contraindicated for spinal injury in this context.)
    * C. Fix the cervical collar loosely so that it can be turned 45° left and right. (Incorrect - collar must restrict, not allow movement.)
    * D. Fix in a hyperextended position to prevent flexion or compression of the cervical vertebrae. (Incorrect and dangerous - hyperextension is generally contraindicated; neutral is preferred.)
    * E. Fix the torso so that it moves up and down but not left and right. (Incorrect and illogical - immobilization needs to restrict all torso movement.)


* **Conclusion:** Option A appears to be the only correct method for spinal motion restriction in the context of transporting a patient with suspected spinal injury.


Therefore, the answer is A.

Let's double-check typical spinal immobilization procedures:

1. **Manual stabilization:**  Immediately stabilize the patient's head and neck manually, preventing any movement.
2. **Cervical collar application:** Apply a properly sized cervical collar.
3. **Log roll (if needed):** If the patient needs to be moved (e.g., onto a spine board), perform a log roll while maintaining manual stabilization of the head and neck.
4. **Spine board application:** Center the patient onto a long spine board. Secure the torso to the board first (straps across chest, pelvis, thighs).
5. **Head immobilization:**  Secure the head to the spine board using head blocks and tape or straps. Ensure the head is in a neutral, in-line position if possible (unless resistance is met or it causes pain).
6. **Extremity immobilization (optional):**  Sometimes, straps are also used to secure the legs to the spine board.

This process aligns with option A:  torso to spine board first, then head.

</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **A. 몸통을 긴척추고정판에 완전히 고정한 후에 머리를 고정**입니다.

**해설:**

척추 손상이 의심되는 환자의 척추 보호 조치 (척추 움직임 제한)의 핵심은 척추의 추가적인 움직임을 최소화하여 2차 손상을 예방하는 것입니다.  각 선택지를 분석해 보겠습니다.

* **A. 몸통을 긴척추고정판에 완전히 고정한 후에 머리를 고정:**  **옳은 방법입니다.**  척추 고정판을 사용하여 몸통을 먼저 안정적으로 고정하는 것은 척추 전체를 안정화하는 데 중요합니다. 몸통이 고정된 후에 머리를 고정해야 척추의 축 방향 움직임을 최소화하고, 머리 고정 시 발생할 수 있는 몸통의 움직임을 방지할 수 있습니다.

* **B. 머리기울이고턱들기 자세가 유지되도록 목 고정장치 적용:** **틀린 방법입니다.** 머리기울이고턱들기 (head-tilt chin-lift) 자세는 기도 확보를 위해 사용하는 방법으로, 척추 손상 환자에게는 금기입니다. 척추 손상 환자에게는 척추를 중립 자세로 유지하고 움직임을 최소화하는 것이 중요하며, 머리기울이고턱들기 자세는 척추에 불필요한 움직임을 유발할 수 있습니다.

* **C. 목 고정장치는 좌우로 45° 돌릴 수 있도록 느슨하게 고정:** **틀린 방법입니다.** 목 고정장치 (cervical collar)는 목뼈의 움직임을 최대한 제한하기 위해 사용하는 것입니다. 느슨하게 고정하면 목뼈를 제대로 고정할 수 없고, 오히려 움직임이 발생하여 척추 손상을 악화시킬 수 있습니다. 목 고정장치는 적절한 크기로 환자의 목에 딱 맞게, 움직임이 거의 없도록 단단히 고정해야 합니다.

* **D. 목뼈의 굽힘이나 압박이 발생하지 않도록 과신전 상태로 고정:** **틀린 방법입니다.** 척추를 과신전 (hyperextension) 상태로 고정하는 것은 오히려 척추 손상을 악화시킬 수 있습니다. 특히 척추 골절이나 탈구가 있는 경우 과신전은 신경 손상을 유발하거나 악화시킬 위험이 있습니다. 척추는 가능한 한 중립 자세 (neutral position)로 유지하는 것이 원칙입니다.

* **E. 몸통은 위아래로는 움직이고 왼쪽 · 오른쪽으로는 움직이지 않도록 고정:** **틀린 방법입니다.** 척추 보호 조치는 척추의 모든 방향으로의 움직임을 제한하는 것을 목표로 합니다. 몸통을 위아래로 움직이게 허용하는 것은 척추의 움직임을 완전히 제한하는 것이 아니며, 척추 손상 환자에게는 위험한 처치입니다. 몸통은 모든 방향으로 움직이지 않도록 고정해야 합니다.


**따라서, 척추손상 의심 환자 이송 시 척추 보호 조치로 가장 적절한 방법은 A입니다.**

**정답: A**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">7,472</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="2"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">paramedic_1</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,021</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">82</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">65세 남자가 20분 전에 갑자기 1,000cc 정도 두차례 피를 토한 후 내원하였다. 환자는 5년 전부터 알코올성 간경화로 치료받고 있으며, 응급실 내원 후에도 계속적인 선홍색 토혈을 하였다. 의식은 혼수상태이며, 혈압 60/40mmHg, 맥박 115회/분, 호흡 28회/분이고, 피부는 차고 축축하다. 우선 해야 할 처치는?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">아이겔 삽입</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">기관내 삽관</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">비위관튜브 삽입</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">후두튜브기도기 삽입</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">후두튜브마스크 삽입</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down this medical case step-by-step, simulating a thought process to arrive at the correct answer.

**1. Deconstructing the Patient Information:**

* **Age and Gender:** 65-year-old male.  Age is relevant as older patients might have comorbidities or less physiological reserve.
* **Chief Complaint:** Sudden onset of massive hematemesis (vomiting blood) - 1000cc twice in 20 minutes. This is a *huge* amount of blood loss in a short time.
* **Medical History:** Alcoholic liver cirrhosis (5 years).  This is *critical*.  Cirrhosis is a major risk factor for esophageal varices, a common cause of upper GI bleeding and hematemesis in these patients.
* **Current Status on Arrival:**
    * **Ongoing hematemesis:** Still vomiting bright red blood. This indicates active, ongoing bleeding and emphasizes the urgency of the situation.
    * **Consciousness:** Comatose.  This is extremely concerning and suggests significant blood loss and likely hypoperfusion of the brain. Airway compromise is a major concern.
    * **Vitals:**
        * **BP 60/40 mmHg:**  Severe hypotension.  This is shock.
        * **HR 115 bpm:** Tachycardia.  Compensatory mechanism for hypovolemia.
        * **RR 28 bpm:** Tachypnea.  Likely compensatory for metabolic acidosis and hypoxemia due to blood loss.
        * **Skin:** Cold and clammy.  Signs of peripheral vasoconstriction and poor perfusion, further indicating shock.

**2. Synthesizing the Information and Identifying the Problem:**

* **Massive Hemorrhage:** The patient is experiencing a massive upper GI bleed, most likely due to esophageal varices secondary to liver cirrhosis.
* **Hypovolemic Shock:**  The vital signs (hypotension, tachycardia, tachypnea, cold/clammy skin) and altered mental status (coma) definitively indicate hypovolemic shock due to blood loss.
* **Airway Compromise:** Comatose state and ongoing hematemesis put the patient at extremely high risk for airway obstruction due to aspiration of blood.  The patient may also have reduced respiratory drive due to shock.

**3. Prioritizing Immediate Actions - The ABCs:**

In any emergency, especially with a comatose and bleeding patient, the ABCs (Airway, Breathing, Circulation) are paramount.

* **Airway (A):**  This is *the most critical* priority in this scenario. The patient is comatose and vomiting blood.  The immediate risk is airway obstruction from aspiration. We *must* secure the airway.
* **Breathing (B):**  Tachypnea is present, but the quality of breathing is unknown and potentially compromised due to coma and shock.  Securing the airway will likely necessitate assisted ventilation.
* **Circulation (C):**  The patient is in severe shock.  While addressing circulation is crucial (IV access, fluids, blood products), it is secondary to securing the airway in this *immediate* moment because without a patent airway and adequate oxygenation, circulatory interventions will be less effective, and the patient will quickly deteriorate further.

**4. Evaluating the Answer Choices in Light of Priorities:**

* **A. 아이겔 삽입 (i-gel insertion):**  An i-gel is a supraglottic airway device (SGAD).  It can provide a decent airway, is relatively easy to insert, and can protect against aspiration to some extent.  It's better than nothing, but not ideal in this situation.
* **B. 기관내 삽관 (Endotracheal intubation):**  Endotracheal intubation (ETI) is the *gold standard* for airway management. It provides a definitive airway, protects against aspiration, allows for positive pressure ventilation and high FiO2 delivery.  It's more complex than SGADs, but in a comatose patient with massive hematemesis, it's the most secure and protective option.
* **C. 비위관튜브 삽입 (Nasogastric tube insertion):** An NG tube is used to decompress the stomach and can help remove blood and gastric contents.  While helpful *later* for managing the bleeding and assessing ongoing loss, it does *not* address the immediate airway crisis.  It could even *increase* the risk of aspiration during insertion in a comatose patient.
* **D. 후두튜브기도기 삽입 (Laryngeal tube insertion):** A laryngeal tube (like the King LT) is another type of SGAD.  Similar to the i-gel, it can provide an airway, but less secure than ETI, and may not be optimal for aspiration risk.
* **E. 후두튜브마스크 삽입 (Laryngeal mask airway (LMA) insertion):** An LMA is also an SGAD.  Similar pros and cons to i-gel and laryngeal tube.  Less secure than ETI, especially in a patient with high aspiration risk and ongoing bleeding.

**5. Choosing the Best Answer:**

Considering the patient's comatose state, massive hematemesis, and high risk of aspiration, the *most important* and *first* intervention is to secure the airway definitively.  Endotracheal intubation (B) is the best option because it provides the most secure airway, protects against aspiration, and allows for controlled ventilation and oxygenation, which are crucial in this critical situation.

While SGADs (A, D, E) might be considered in less critical airway situations or if intubation is immediately impossible, in this scenario, the patient is clearly unstable and requires the most definitive airway management. NG tube (C) is not the *priority* initial intervention and doesn't address the airway.

**Final Answer Selection and Justification:**

The best answer is **B. 기관내 삽관 (Endotracheal intubation)**.

**Reasoning Summary:**

* **Life-threatening situation:** Massive hematemesis, coma, and shock.
* **Primary concern:** Airway protection and securing breathing due to coma and aspiration risk from vomiting blood.
* **Endotracheal intubation (ETI):** Gold standard for airway management, provides definitive airway, aspiration protection, and ventilation control.
* **Other options (SGADs):** Less secure airway, higher aspiration risk, less ideal in this critical patient.
* **NG tube:** Not the priority for initial airway management and doesn't address immediate airway threats.

Therefore, securing the airway with endotracheal intubation is the most appropriate first action in this emergency situation.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">## 정답 해설

정답은 **B. 기관내 삽관** 입니다.

**해설:**

환자는 다음과 같은 심각한 상태입니다.

* **대량 토혈:** 1,000cc 두 차례 토혈은 매우 많은 양이며, 활력 징후를 불안정하게 만들 수 있습니다.
* **지속적인 토혈:** 응급실 내원 후에도 계속 토혈을 한다는 것은 출혈이 멈추지 않고 있다는 것을 의미하며, 더욱 위험한 상황입니다.
* **혼수상태:** 의식 저하는 뇌 혈류 감소 또는 심각한 전신 상태 악화를 의미하며, 기도 유지 및 호흡 관리가 매우 중요합니다.
* **쇼크 상태:** 혈압 60/40mmHg는 심각한 저혈압으로 쇼크 상태를 의미하며, 즉각적인 혈액량 보충 및 원인 치료가 필요합니다.
* **빈맥 및 빈호흡:** 심박수 115회/분, 호흡수 28회/분은 쇼크에 대한 보상 기전으로 나타나는 반응입니다.
* **차가운 피부:** 말초 혈관 수축으로 인한 쇼크의 징후입니다.
* **알코올성 간경화:** 기저 질환으로 식도 정맥류 출혈의 가능성이 매우 높습니다. 식도 정맥류 출혈은 간경변 환자에서 흔하게 발생하는 대량 토혈의 원인입니다.

**우선적으로 해야 할 처치:**

가장 급하고 중요한 처치는 **기도 확보 및 유지** 입니다. 환자는 혼수상태이고 지속적인 토혈을 하고 있어 기도 흡인의 위험이 매우 높습니다. 또한 쇼크 상태로 자발 호흡이 충분하지 않을 가능성이 높습니다.

따라서, **기관내 삽관**을 통해 기도를 확보하고 인공호흡을 시작하여 산소 공급 및 기도 흡인을 예방하는 것이 최우선적으로 해야 할 처치입니다.

**각 선택지별 설명:**

* **A. 아이겔 삽입:** 아이겔은 후두마스크기도기(LMA)의 일종으로, 기관내 삽관보다는 간단하게 기도 확보가 가능하지만, 대량 토혈 환자나 혼수상태 환자에서는 기도 흡인의 위험이 높고, 기관내 삽관만큼 확실한 기도 보호가 어렵습니다. 우선적인 처치로는 적절하지 않습니다.
* **B. 기관내 삽관:** 위에서 설명한 것처럼, 혼수상태 및 대량 토혈 환자에게 가장 확실하고 안전한 기도 확보 방법입니다. 인공호흡기를 연결하여 적절한 환기를 제공하고, 기도 흡인을 예방하며, 향후 처치를 위한 안정적인 환경을 제공합니다. **정답**입니다.
* **C. 비위관튜브 삽입:** 비위관 튜브 삽입은 위장관 내 출혈량을 확인하고 위 내용물을 제거하여 흡인을 예방하는 데 도움이 될 수 있습니다. 하지만 기도 확보가 우선이며, 비위관 삽입은 기관내 삽관 후 고려할 수 있습니다. 우선적인 처치는 아닙니다.
* **D. 후두튜브기도기 삽입:** 후두튜브기도기는 LMA와 마찬가지로 기관내 삽관보다는 간단하게 기도 확보가 가능하지만, 대량 토혈 환자나 혼수상태 환자에서는 기도 흡인의 위험이 높고, 기관내 삽관만큼 확실한 기도 보호가 어렵습니다. 우선적인 처치로는 적절하지 않습니다.
* **E. 후두튜브마스크 삽입:** 후두튜브마스크 (LMA)는 아이겔과 마찬가지로 기관내 삽관보다는 간단하게 기도 확보가 가능하지만, 대량 토혈 환자나 혼수상태 환자에서는 기도 흡인의 위험이 높고, 기관내 삽관만큼 확실한 기도 보호가 어렵습니다. 우선적인 처치로는 적절하지 않습니다.

**결론적으로,**  혼수상태 및 대량 토혈, 쇼크 상태인 환자에게 가장 우선적으로 해야 할 처치는 **기관내 삽관을 통한 기도 확보 및 유지** 입니다. 이후 수액 및 혈액 제제 투여를 통한 혈압 안정화, 출혈 원인 파악 및 지혈 등의 추가적인 처치를 진행해야 합니다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">7,146</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="3"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">doctor</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,014</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">3</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">14</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">요양병원을 개설 운영하고 있는 의사 '갑'은 의료기관 인증평가를 받은 후 의료기관 인증서를 교부받았다. 의사 '갑'이 요양병원 진료내용과 인증 결과를 시내버스 차량의 외부 옆면에 광고하기 위해 미리 심의를 받으려 할 때 의료광고 심의신청서를 제출해야 하는 기관은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">대한의사협회</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">국민건강보험공단</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">한국보건의료연구원</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">의료기관인증평가원</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">한국의료분쟁조정중재원</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down this Korean medical law question step-by-step to arrive at the correct answer.

**1. Understanding the Question (Analyze the Korean Text)**

* **요양병원 (yoyangbyeongwon):**  Nursing hospital or long-term care hospital. This is the type of medical institution we are dealing with.
* **개설 운영하고 있는 의사 '갑' (gaeseol unyeonghago inneun uisa 'gap'):** Doctor 'Gap' who establishes and operates. This tells us the subject is a doctor who runs a nursing hospital.
* **의료기관 인증평가를 받은 후 의료기관 인증서를 교부받았다 (uiryogigwan 인증pyeonggareul badeun hu uiryogigwan 인증seoreul gyobubadeatda):**  Received medical institution certification after undergoing medical institution accreditation assessment and receiving a medical institution certification certificate. This is important – the hospital is certified.
* **요양병원 진료내용과 인증 결과를 시내버스 차량의 외부 옆면에 광고하기 위해 (yoyangbyeongwon jinryonaeyonggwa 인증 gyeolgwaleul sinaebeoseu charyang-ui oebu yeopmyeone gwang-gohagi wihae):** In order to advertise the nursing hospital's treatment details and certification results on the external side of a city bus. This is the core action: advertising.
* **미리 심의를 받으려 할 때 의료광고 심의신청서를 제출해야 하는 기관은? (miri simuireul badeuryeo hal ttae uiryogwanggo simuisincheongseoreul jechulhaeya haneun gigwan-eun?):**  Which institution should the medical advertisement review application be submitted to when intending to receive prior review? This is the question itself - where to apply for pre-approval for the advertisement.

**In simpler English:**  A doctor operating a certified nursing hospital wants to advertise their hospital's services and certification on the side of a city bus.  Where should they submit their application for pre-approval of this medical advertisement?

**2. Identifying the Key Issue: Medical Advertisement Review**

The core of the question is *의료광고 심의 (uiryogwanggo simui)* - medical advertisement review or pre-approval.  This is the central concept to focus on. We need to know which organization is responsible for reviewing medical advertisements in Korea.

**3. Recalling Knowledge of Korean Medical Law/Regulations (or Quick Research if Unfamiliar)**

* **Medical Advertising Regulations in Korea:**  Korean medical law is quite strict about advertising medical institutions and services.  Pre-approval is generally required for many types of medical advertisements to protect patients and prevent misleading information.
* **Who Reviews Medical Ads?**  This is the crucial piece of information. In Korea, the **의료광고심의위원회 (uiryogwanggo simui wiwonhoe)** – Medical Advertisement Review Committee – is responsible for this. This committee is usually associated with or delegated to specific medical professional associations.

**4. Evaluating the Answer Choices (Analyze each option in Korean and English):**

* **A. 대한의사협회 (Daehan Uisa Hyeophoe): Korean Medical Association (KMA)** -  The KMA is the main professional organization for doctors in Korea.  They *do* play a role in medical advertisement review.  In fact, the Medical Advertisement Review Committee is often under the KMA's umbrella or delegated to them. This is a strong candidate.

* **B. 국민건강보험공단 (Gungmin Geongang Boheom Gongdan): National Health Insurance Service (NHIS)** - The NHIS is responsible for managing the national health insurance system. Their primary focus is on insurance, payments, and healthcare policy *financing*.  They are *not* primarily involved in advertisement review.  Less likely.

* **C. 한국보건의료연구원 (Hanguk Bogeon Uiryo Yeonguwon): Korea Institute for Health and Social Affairs (KIHASA)** - KIHASA is a research institute focused on health and social welfare policy. They conduct research and advise the government. They are not involved in *advertisement review*. Unlikely.

* **D. 의료기관인증평가원 (Uryogigwan Injeungpyeonggawon): Korea Institute for Healthcare Accreditation (KOIHA)** - KOIHA is the organization that conducts medical institution accreditation assessments (as mentioned in the question itself).  They *certify* hospitals. While related to hospital quality, their main role isn't *advertisement review*. Less likely.

* **E. 한국의료분쟁조정중재원 (Hanguk Uiryo Bunjaeng Jojeong Jungjaewon): Korea Medical Dispute Mediation and Arbitration Agency (KMDMA)** - KMDMA handles medical disputes and mediation.  They are about *resolving* issues after they occur, not *preventing* misleading advertising.  Unlikely.

**5. Selecting the Most Likely Answer:**

Based on the analysis, the **Korean Medical Association (대한의사협회)** is the most likely organization to handle medical advertisement review applications.  They are the central professional body for doctors and are often delegated this responsibility by the Ministry of Health and Welfare.

**6. Confirmation (If Possible):**

A quick search for "의료광고 심의 대한의사협회" (medical advertisement review Korean Medical Association) in Korean would likely confirm that the KMA is indeed the relevant body for medical advertisement pre-approval in many cases, particularly for doctors and clinics.

**Conclusion:**

Therefore, the answer is **A. 대한의사협회 (Korean Medical Association)**.  The reasoning is based on understanding the core issue of medical advertisement review and knowing or deducing the relevant organization responsible for this in Korea.  The other options are related to healthcare but have different primary functions and are not the correct body for advertisement pre-approval.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **A. 대한의사협회**입니다.

**해설:**

* **의료법** 제56조 및 동법 시행령 제23조에 따르면, 의료기관의 기능, 진료과목, 진료 내용 등에 대한 광고는 **사전심의**를 받아야 합니다.
* 의료광고 심의 업무는 의료법에 따라 **각 의료인 단체(의사협회, 치과의사협회, 한의사협회 등)**에 위탁되어 있습니다.
* 따라서 의사 '갑'은 의사이기 때문에, **대한의사협회**에 의료광고 심의신청서를 제출해야 합니다.

**오답 이유:**

* **B. 국민건강보험공단:** 국민건강보험공단은 건강보험 및 장기요양보험 운영을 담당하는 기관으로 의료광고 심의와는 관련이 없습니다.
* **C. 한국보건의료연구원:** 한국보건의료연구원은 보건의료 기술 평가 및 연구를 수행하는 기관으로 의료광고 심의와는 직접적인 관련이 없습니다.
* **D. 의료기관인증평가원:** 의료기관인증평가원은 의료기관 인증평가를 담당하는 기관으로, 인증 자체는 광고에 활용될 수 있지만 광고 심의를 담당하지는 않습니다.
* **E. 한국의료분쟁조정중재원:** 한국의료분쟁조정중재원은 의료분쟁 조정 및 중재를 담당하는 기관으로 의료광고 심의와는 관련이 없습니다.

**핵심 요약:**

의료광고 사전심의는 **해당 의료인의 직역별 중앙회 (의사협회, 치과의사협회 등)**에서 담당합니다. 따라서 의사인 '갑'은 **대한의사협회**에 심의신청을 해야 합니다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">61</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="4"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">nurse_assistant</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,023</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">간호조무사가 직업윤리를 실천하는 목적은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">법적인 책임 면제</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">업무 수행 시간 단축</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">환자의 비밀을 친구와 공유</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">직면한 윤리적 딜레마 회피</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">인간의 존엄성과 인격 존중</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">
The question is asking about the purpose of a nursing assistant practicing professional ethics. I need to analyze each option and choose the one that best represents the core reason for ethical practice in nursing assistance.

* **Analyze each option:**
    * **A. 법적인 책임 면제 (Exemption from legal responsibility):** While ethical practice *can* help prevent legal issues, it's not the primary *purpose*. Ethics goes beyond just avoiding legal trouble. Legal compliance is a consequence, not the main goal.
    * **B. 업무 수행 시간 단축 (Shortening work performance time):** Ethical practice might *sometimes* involve efficiency, but it's definitely not about shortening work time as the main purpose.  Ethical considerations can sometimes *increase* the time spent on a task (e.g., ensuring informed consent, providing emotional support).
    * **C. 환자의 비밀을 친구와 공유 (Sharing patient's secrets with friends):** This is the *opposite* of ethical practice.  Patient confidentiality is a core ethical principle. This option is clearly wrong.
    * **D. 직면한 윤리적 딜레마 회피 (Avoiding ethical dilemmas faced):** Ethical practice isn't about avoiding dilemmas, but about *resolving* them in a principled way.  Dilemmas are inherent in healthcare, and ethics provides a framework for navigating them. This option is also incorrect.
    * **E. 인간의 존엄성과 인격 존중 (Respect for human dignity and personality):** This aligns perfectly with the core principles of healthcare ethics.  Ethical practice in nursing, and nursing assistance, is fundamentally about respecting patients as individuals with inherent dignity and worth.

* **Identify the best answer:** Option E directly addresses the fundamental purpose of healthcare ethics – respecting patients' dignity and personhood.  The other options are either irrelevant, incorrect, or represent side effects rather than the primary purpose.

* **Confirm the answer:**  Thinking about the core values of nursing and healthcare, patient-centered care, respect, dignity, and autonomy are central. Ethical practice is the means to uphold these values. Option E encapsulates this perfectly.

Therefore, the answer should be E.
</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **E. 인간의 존엄성과 인격 존중**입니다.

**해설:**

간호조무사가 직업윤리를 실천하는 가장 중요한 목적은 환자를 인간으로서 존중하고, 그들의 존엄성과 인격을 보호하는 데 있습니다.  다른 선택지들은 윤리 실천의 목적과는 거리가 멉니다.

* **A. 법적인 책임 면제:** 윤리적 실천은 법적 문제를 예방하는 데 도움이 될 수 있지만, 법적 책임을 회피하는 것이 윤리 실천의 주된 목적은 아닙니다. 윤리는 법률보다 더 높은 도덕적 기준을 포함합니다.
* **B. 업무 수행 시간 단축:** 윤리적 실천은 때로는 업무 시간을 늘릴 수도 있습니다. 환자의 권리를 존중하고 윤리적 문제를 해결하는 데 충분한 시간을 할애해야 하기 때문입니다.
* **C. 환자의 비밀을 친구와 공유:** 이는 명백히 윤리 위반입니다. 환자의 비밀 유지는 간호 직업 윤리의 핵심입니다.
* **D. 직면한 윤리적 딜레마 회피:** 윤리적 딜레마를 회피하는 것이 아니라, 윤리적 원칙에 따라 딜레마를 해결하고 최선의 결정을 내리는 것이 윤리 실천의 목표입니다.
* **E. 인간의 존엄성과 인격 존중:**  환자를 단순히 치료의 대상으로 보는 것이 아니라, 존엄한 인간으로서 존중하고 그들의 가치와 권리를 보호하는 것이 윤리적 실천의 핵심입니다. 이는 간호 및 의료 윤리의 가장 기본적인 원칙입니다.

**따라서 정답은 E입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">6,586</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="5"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">pharm</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,019</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">86</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정맥류가 지속될 때 발생하는 합병증인 갈색경화성 정체피부염(stasis dermatitis) 의 발생 기전은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">알부민의 혈관 외 침착</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정맥류 부위의 세균 감염</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">혈관 외로 유출된 적혈구의 용해</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">혈관 외로 유출된 대식세포의 식작용</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">혈관 외로 유출된 림프구의 면역반응</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">3</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to arrive at the correct answer and explanation for the question about stasis dermatitis and its mechanism.

**1. Deconstructing the Question:**

* **Keywords:** 정맥류 (varicose veins), 지속될 때 (persistent), 합병증 (complication), 갈색경화성 정체피부염 (stasis dermatitis), 발생 기전 (pathogenesis/mechanism).
* **Core Question:** What is the underlying process that leads to stasis dermatitis when varicose veins persist?
* **Target Condition:** Stasis dermatitis (also known as venous stasis dermatitis or gravitational dermatitis).  This immediately signals a connection to venous insufficiency or poor venous return.
* **Answer Choices:**  The choices focus on different cellular/molecular events: albumin deposition, bacterial infection, red blood cell lysis, macrophage phagocytosis, lymphocyte immune response.  These are all plausible elements in various inflammatory or tissue damage scenarios, so we need to connect them specifically to venous insufficiency and stasis dermatitis.

**2.  Recalling Knowledge about Stasis Dermatitis:**

* **Etiology (Cause):** Primarily caused by chronic venous insufficiency. Varicose veins are a common manifestation of this.  The key is impaired venous return from the legs.
* **Pathophysiology (Mechanism):**  Venous hypertension (high pressure in veins) is the central issue. This leads to:
    * **Fluid leakage:** Increased pressure pushes fluid out of capillaries and venules into the surrounding tissues.
    * **Red blood cell extravasation:**  RBCs also leak out, along with other blood components.
    * **Inflammation:** The presence of leaked fluid and blood components triggers an inflammatory response.
    * **Skin changes:**  Chronic inflammation leads to the characteristic skin changes: edema, hyperpigmentation (brown discoloration), induration (hardening), and potentially ulceration.

**3.  Analyzing Each Answer Choice in Light of Stasis Dermatitis Pathophysiology:**

* **A. 알부민의 혈관 외 침착 (Albumin extravascular deposition):** Albumin is a major plasma protein.  Increased vascular permeability *does* lead to albumin leakage. Albumin in the interstitial space can contribute to edema and inflammation.  This sounds *plausible*.

* **B. 정맥류 부위의 세균 감염 (Bacterial infection in varicose vein area):** While secondary bacterial infections can occur in stasis dermatitis (especially if ulcers develop), infection is *not* the primary mechanism of *developing* stasis dermatitis.  It's a complication *of* stasis dermatitis or ulcers, not the cause of the initial skin changes. This is *less likely* to be the primary mechanism.

* **C. 혈관 외로 유출된 적혈구의 용해 (Lysis of extravasated red blood cells):** This is a *key* point in stasis dermatitis.  Extravasated RBCs release hemoglobin.  Hemoglobin breaks down into hemosiderin, an iron-containing pigment. Hemosiderin deposition in the skin is responsible for the characteristic *brown* discoloration (hyperpigmentation) of stasis dermatitis. This sounds *very likely*.

* **D. 혈관 외로 유출된 대식세포의 식작용 (Phagocytosis by extravasated macrophages):** Macrophages are involved in inflammation and tissue repair. They *will* be present in the area and *will* phagocytose debris, including RBCs and hemosiderin. However, their phagocytosis is a *response* to the underlying issue (RBC extravasation and lysis), not the primary *mechanism causing* the dermatitis. This is *less likely* to be the *primary* mechanism, although macrophages are involved in the overall process.

* **E. 혈관 외로 유출된 림프구의 면역반응 (Immune response by extravasated lymphocytes):** Lymphocytes are also involved in inflammation and immune responses. In chronic inflammation like stasis dermatitis, lymphocytes are present.  However, the *primary driver* of the skin changes isn't primarily a lymphocyte-mediated immune reaction like in allergic contact dermatitis.  While lymphocytes contribute to the inflammatory milieu, they aren't the *initiating mechanism* responsible for the characteristic skin changes. This is *less likely* to be the primary mechanism.

**4.  Comparing and Contrasting, Focusing on "Mechanism":**

We need to identify the *most direct and primary* mechanism for the *characteristic features* of stasis dermatitis, especially the brown discoloration.

* **Choice C (RBC lysis and hemosiderin deposition)** directly explains the brown discoloration, a hallmark of stasis dermatitis.  It's a direct consequence of venous hypertension and RBC extravasation.
* **Choice A (Albumin leakage)** contributes to edema but doesn't directly explain the *brown* discoloration.
* **Choices B, D, and E** are either secondary events (infection) or components of the inflammatory response but don't directly explain the *brown* pigmentation characteristic of stasis dermatitis.

**5.  Conclusion and Explanation:**

Choice C (혈관 외로 유출된 적혈구의 용해 - Lysis of extravasated red blood cells) is the most accurate and direct answer.

* **Explanation in Korean (similar to the provided example):** 정맥류가 지속되면 정맥압 상승으로 인해 혈관에서 적혈구가 혈관 밖으로 유출됩니다. 유출된 적혈구는 용해되어 헤모글로빈을 방출하고, 헤모글로빈은 헤모시데린으로 전환됩니다. 헤모시데린은 갈색 색소이므로, 피부에 침착되어 갈색의 색소 침착을 유발합니다. 또한, 적혈구 용해 과정에서 방출되는 물질들은 염증 반응을 유발하여 피부염을 악화시킵니다. 따라서 갈색경화성 정체피부염의 발생 기전은 혈관 외로 유출된 적혈구의 용해입니다.

* **Explanation in English (for further clarity):**  Persistent varicose veins lead to venous hypertension, causing red blood cells to leak out of blood vessels into the surrounding tissues. These extravasated red blood cells are then lysed (broken down), releasing hemoglobin. Hemoglobin is further degraded into hemosiderin, an iron-containing pigment that is brown in color.  Hemosiderin deposition in the skin causes the characteristic brown pigmentation of stasis dermatitis.  Furthermore, the breakdown products of red blood cells contribute to inflammation, exacerbating the dermatitis. Therefore, the mechanism of stasis dermatitis is primarily the lysis of extravasated red blood cells.

This detailed thought process systematically eliminates incorrect options and reinforces why choice C is the correct answer, linking it directly to the key pathological feature of stasis dermatitis – the brown discoloration and the underlying venous insufficiency mechanism.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **C. 혈관 외로 유출된 적혈구의 용해** 입니다.

**해설:**

갈색경화성 정체피부염(stasis dermatitis)은 만성 정맥 기능 부전으로 인해 발생하는 피부 질환입니다.  정맥류가 지속되면 다음과 같은 기전으로 갈색경화성 정체피부염이 발생합니다.

1. **정맥압 상승:** 정맥류는 정맥의 판막 기능 부전으로 인해 발생하며, 이는 다리 정맥의 혈액 순환 장애를 일으키고 정맥압을 상승시킵니다.
2. **혈관 투과성 증가:** 지속적인 정맥압 상승은 모세혈관과 소정맥의 투과성을 증가시킵니다.
3. **적혈구 및 혈장 성분 유출:** 증가된 혈관 투과성으로 인해 적혈구, 알부민, 섬유소원 등 혈장 성분들이 혈관 밖 조직으로 유출됩니다.
4. **적혈구 용해 및 헤모시데린 침착:** 혈관 밖으로 유출된 적혈구는 파괴(용해)되고, 적혈구 내의 헤모글로빈은 헤모시데린이라는 갈색 색소로 변환됩니다. 이 헤모시데린이 피부에 침착되어 갈색의 색소 침착을 유발합니다. 이것이 갈색경화성 정체피부염의 특징적인 갈색 변색의 원인입니다.
5. **염증 반응 및 섬유화:** 유출된 혈장 성분과 적혈구 용해 산물은 피부에 염증 반응을 유발하고, 만성적인 염증은 피부의 섬유화를 촉진하여 피부를 두껍고 단단하게 만들며 (경화), 가려움증, 통증, 궤양 등을 유발할 수 있습니다.

**오답 선택지 해설:**

* **A. 알부민의 혈관 외 침착:** 알부민은 혈관 밖으로 유출될 수 있지만, 갈색경화성 정체피부염의 주된 발생 기전이라기보다는 부종과 관련이 깊습니다. 알부민 자체는 갈색 색소 침착을 유발하지 않습니다.
* **B. 정맥류 부위의 세균 감염:** 세균 감염은 갈색경화성 정체피부염의 합병증으로 발생할 수 있지만, 일차적인 발생 기전은 아닙니다. 감염은 피부염을 악화시킬 수 있지만, 피부염 자체의 시작 원인은 아닙니다.
* **D. 혈관 외로 유출된 대식세포의 식작용:** 대식세포는 혈관 밖으로 유출되어 식작용을 할 수 있지만, 갈색경화성 정체피부염의 갈색 색소 침착의 직접적인 원인은 아닙니다. 대식세포는 염증 반응에 관여하지만, 주된 기전은 적혈구 용해와 헤모시데린 침착입니다.
* **E. 혈관 외로 유출된 림프구의 면역반응:** 림프구는 면역 반응에 관여하며, 갈색경화성 정체피부염에도 염증 반응의 일부로 림프구가 관여할 수 있습니다. 하지만 주된 발생 기전은 림프구의 면역 반응보다는 적혈구 용해와 헤모시데린 침착입니다.

**결론적으로, 갈색경화성 정체피부염의 핵심 발생 기전은 정맥압 상승으로 인한 적혈구의 혈관 외 유출 및 용해, 그리고 그 결과로 발생하는 헤모시데린 침착입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">3,145</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="6"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">nurse</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,019</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">45</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">지역사회간호사가 영아를 둔 다문화 여성을 대상으로 고형식에 대해 교육하려고 할 때 문화적 차이점을 확인하기 위해 사정해야 할 사항은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">유치의 개수</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">아기의 월령</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">고형식 수행 여부</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">아기의 키와 몸무게</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">출신국과 한국의 음식 문화</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">
The question is asking about what a community health nurse should assess to understand cultural differences when educating a multicultural woman with an infant about solid foods.  Let's break down each option and think about its relevance to cultural differences and solid food education.

* **A. 유치의 개수 (Number of baby teeth):**  While the number of teeth *can* be an indicator of readiness for certain textures of food (and sometimes related to developmental stage), it's not directly tied to cultural differences in solid food introduction.  Different cultures might introduce solids at different stages regardless of teeth, and the types of solids offered could vary culturally.  Teeth are more of a biological factor than a cultural one in this context.

* **B. 아기의 월령 (Infant's age in months):**  Age is a crucial factor in determining when to start solids in general.  However, cultural practices can significantly influence *when* and *how* solids are introduced.  For example, some cultures might start earlier or later than the generally recommended age, and the types of first foods might differ based on cultural norms.  Age provides a baseline, but cultural context is essential for tailoring education.

* **C. 고형식 수행 여부 (Whether solid foods are being given):**  Knowing if the mother is *already* introducing solids is important.  If she is, the nurse needs to understand *what* she's giving and *why*.  This can reveal cultural practices and potential misunderstandings or needs for guidance.  If she isn't, the nurse needs to understand her knowledge and beliefs about when to start, which can also be culturally influenced.  This option seems quite relevant to understanding current practices and potential cultural influences.

* **D. 아기의 키와 몸무게 (Infant's height and weight):**  Growth parameters are important for assessing the infant's overall health and nutritional status.  While nutrition is related to solid food introduction, height and weight themselves don't directly reveal cultural differences in *approaches* to solid foods.  They are more about the *outcome* of feeding practices, not the cultural practices themselves.  Growth monitoring is important in general, but not the primary factor for assessing cultural differences in solid food education.

* **E. 출신국과 한국의 음식 문화 (Country of origin and Korean food culture):**  This option directly addresses cultural differences.  Understanding the mother's country of origin and its food culture is crucial to understand her background beliefs and practices regarding infant feeding.  Comparing her culture's food practices with Korean food culture (the context of the nurse's practice and potentially the dominant culture the mother is navigating) is essential for culturally sensitive education.  This option appears highly relevant to assessing cultural differences.

**Comparing C and E:** Both C and E are strong contenders.

* **C (고형식 수행 여부):**  Focuses on current practice.  It's important to know what's happening *now*.  However, it doesn't directly address the *cultural background* driving those practices.

* **E (출신국과 한국의 음식 문화):** Directly addresses the cultural background.  Knowing her origin and comparing it to the local culture provides the context for understanding *why* certain practices might be in place or preferred.

**The question is specifically about identifying cultural differences.**  While knowing if solids are being given (C) is useful information, understanding the cultural *context* (E) is more directly relevant to identifying and addressing cultural differences in solid food education.  Knowing the cultural background helps the nurse understand the *reasons* behind current practices and tailor education accordingly.

**Consider a scenario:** A nurse is educating a woman from a Southeast Asian country about solid foods.

* Knowing the number of teeth (A) or height/weight (D) is generally useful but not culturally specific.
* Knowing the infant's age (B) is important for general guidance but doesn't capture cultural nuances.
* Knowing if she's giving solids (C) is helpful to know current practice, but not *why* she's doing it that way.
* Knowing her country of origin and understanding its food culture (E) is *crucial*.  For example, in some cultures, rice porridge might be a very early and culturally preferred first food, while in others, pureed fruits or vegetables might be more common.  Understanding these cultural norms is essential for respectful and effective education.  Comparing it to Korean food culture can also highlight potential differences or areas where she might need support navigating the new cultural context.


**Conclusion:** Option E, "출신국과 한국의 음식 문화 (Country of origin and Korean food culture)," is the most direct and relevant factor to assess to understand cultural differences when educating a multicultural woman about solid foods.  It provides the cultural context needed to tailor education effectively.  While C is also relevant, E is more fundamental for understanding cultural differences.


Therefore, the answer is likely **E**.

Let's re-examine the options in Korean to double-check the nuances:

* A. 유치의 개수: Number of deciduous teeth (baby teeth)
* B. 아기의 월령: Baby's age in months
* C. 고형식 수행 여부: Whether solid food is being implemented/given
* D. 아기의 키와 몸무게: Baby's height and weight
* E. 출신국과 한국의 음식 문화: Country of origin and Korean food culture

The question specifically asks about assessing "문화적 차이점 (cultural differences)."  Option E directly addresses this.  The other options are less directly related to cultural differences in solid food education specifically.

**Final Answer: E.**

Let's confirm the logic again.  To provide culturally competent education on solid foods, a community health nurse needs to understand the mother's cultural background and how it might differ from the dominant culture (Korean in this case).  This understanding is best achieved by assessing her country of origin and the food culture of both her origin and the host country. This allows for tailoring the education to respect her cultural practices while ensuring the infant's nutritional needs are met within a safe and healthy framework.
</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">**정답은 E. 출신국과 한국의 음식 문화**입니다.

**해설:**

지역사회간호사가 다문화 여성에게 영아 고형식 교육을 할 때 문화적 차이를 확인하기 위해 가장 먼저 사정해야 할 것은 **출신국과 한국의 음식 문화**입니다. 그 이유는 다음과 같습니다.

* **문화적 배경의 중요성:**  고형식 시작 시기, 종류, 방법 등은 문화적 배경에 따라 크게 다를 수 있습니다.  각 문화권마다 전통적으로 영아에게 먹이는 음식, 선호하는 질감, 식재료 등이 다르며, 이러한 문화적 차이를 이해하는 것이 중요합니다.
* **효과적인 교육:**  다문화 여성의 출신국 음식 문화를 이해하면, 한국 문화와의 차이점을 파악하고, 그녀의 문화적 배경을 존중하면서 한국 문화에 적응할 수 있도록 맞춤형 교육을 제공할 수 있습니다. 예를 들어, 특정 문화권에서는 쌀미음을 먼저 시작하는 반면, 다른 문화권에서는 과일이나 채소를 먼저 시작할 수 있습니다. 이러한 차이를 알고 교육해야 교육의 효과를 높일 수 있습니다.
* **신뢰 관계 형성:**  간호사가 대상자의 문화적 배경에 관심을 가지고 이해하려는 노력을 보이면, 대상자와의 신뢰 관계를 형성하는 데 도움이 됩니다. 신뢰 관계는 효과적인 간호 중재의 기본입니다.

**다른 선택지 오답 이유:**

* **A. 유치의 개수:** 유치의 개수는 고형식 시작 시기를 결정하는 일반적인 지표가 될 수 있지만, 문화적 차이를 파악하는 데 직접적인 정보는 아닙니다. 유치 발달은 개인차가 크고 문화적 배경과 직접적인 관련은 적습니다.
* **B. 아기의 월령:** 아기의 월령은 고형식 시작 시기를 결정하는 중요한 요소이지만, 문화적 차이를 설명해주지는 않습니다. 월령은 일반적인 가이드라인일 뿐, 문화에 따라 고형식 시작 시기에 대한 관점이 다를 수 있습니다.
* **C. 고형식 수행 여부:** 고형식 수행 여부를 확인하는 것은 현재 상황을 파악하는 데 도움이 되지만, 문화적 차이의 근본적인 원인을 알 수는 없습니다. 이미 고형식을 하고 있다면 어떤 종류의 음식을 주고 있는지, 그 이유는 무엇인지 문화적 배경과 함께 파악해야 합니다.
* **D. 아기의 키와 몸무게:** 아기의 키와 몸무게는 성장 발달 상태를 평가하는 중요한 지표이지만, 문화적 차이를 직접적으로 반영하지 않습니다. 영양 상태 평가에 필요하지만, 문화적 차이 사정의 우선순위는 아닙니다.

**결론적으로, 다문화 여성에게 효과적인 고형식 교육을 제공하기 위해서는 그녀의 문화적 배경을 이해하는 것이 가장 중요하며, 이를 위해 출신국과 한국의 음식 문화에 대한 사정이 필수적입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,411</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="7"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">dental_technician</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,019</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">안궁(face bow)에 관한 설명으로 옳은 것은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">교합관계를 재현하기 위한 기구이다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">전방운동의 가이드(guide) 역할을 하는 기구이다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">측방운동의 가이드(guide) 역할을 하는 기구이다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">두개골에서 상악의 위치 관계를 옮기는 기구이다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">보철물을 제작하는 데에 가이드(guide) 역할을 하는 기구 이다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">4</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to arrive at the correct answer (D) for the question about face bows.

**1. Understanding the Question:**

The question is asking for the *correct* description of a face bow.  This immediately tells me I need to know what a face bow is and what it does.  The Korean term "안궁" is given, and it's translated as "face bow" in English.  The answer choices are all in Korean and relate to different aspects of dental procedures.  I need to translate and understand each choice in the context of a face bow.

**2.  Initial Brainstorm and Recall about Face Bows:**

My immediate thoughts about face bows are:

* **Dentistry:** It's a dental instrument.
* **Relating jaws to skull:**  It's used to transfer the relationship of the upper jaw (maxilla) to the skull.  This is the key function I recall.
* **Articulator:** It's used in conjunction with an articulator (교합기 in Korean), a device that simulates jaw movements for dental lab work.
* **Mounting maxillary cast:** The face bow helps mount the maxillary cast (upper jaw model) onto the articulator in a way that mimics the patient's actual jaw position relative to their skull.
* **Not about guides for movements:** It's *not* primarily about guiding jaw movements like protrusion (forward) or lateral (sideways).  Those are related to condylar guidance and incisal guidance, which are *set on the articulator* *after* mounting the casts, often *using* face bow information, but the face bow itself isn't the guide.
* **Not directly for prosthesis fabrication guide:** While the face bow information *is* crucial for accurate prosthesis fabrication, it's not *directly* a "guide" in the sense of shaping the prosthesis itself. It sets up the *articulation* which *then* guides prosthesis fabrication.

**3. Analyzing Each Answer Choice (and Translating):**

Let's translate and analyze each option:

* **A. 교합관계를 재현하기 위한 기구이다. (It is an instrument to reproduce occlusal relationships.)**
    * *Analysis:*  While face bows contribute to reproducing occlusal relationships on the articulator, this is a *very* broad statement and could apply to many dental instruments.  It's not *specific* to the primary function of a face bow. It's *partially* true but not the best answer.

* **B. 전방운동의 가이드(guide) 역할을 하는 기구이다. (It is an instrument that acts as a guide for protrusive movement.)**
    * *Analysis:* Face bows do *not* directly guide protrusive movement.  Protrusive movement is guided by the condylar guidance on the articulator, set *after* face bow transfer.  This is *incorrect*.

* **C. 측방운동의 가이드(guide) 역할을 하는 기구이다. (It is an instrument that acts as a guide for lateral movement.)**
    * *Analysis:* Similar to B, face bows do *not* directly guide lateral movement. Lateral movement is also guided by condylar guidance on the articulator. This is *incorrect*.

* **D. 두개골에서 상악의 위치 관계를 옮기는 기구이다. (It is an instrument that transfers the positional relationship of the maxilla from the skull.)**
    * *Analysis:* This is the *most accurate and specific* description of a face bow's primary function.  "두개골" (skull), "상악" (maxilla), "위치 관계" (positional relationship), and "옮기는 기구" (instrument to transfer) perfectly describe what a face bow does. This looks like the correct answer.

* **E. 보철물을 제작하는 데에 가이드(guide) 역할을 하는 기구 이다. (It is an instrument that acts as a guide in fabricating prostheses.)**
    * *Analysis:* Again, while face bow information is *essential* for accurate prosthesis fabrication, the face bow itself isn't a *direct guide* in the *fabrication process*. It provides the *foundation* (accurate articulation) upon which a prosthesis can be fabricated correctly.  It's too broad and not the *primary* function.  It's *indirectly* related, but not the best answer.

**4.  Confirming the Best Answer:**

Comparing the analyses, option D stands out as the most precise and accurate description of the core function of a face bow. Options A and E are too general, while B and C are factually incorrect.

**5. Final Answer Selection:**

Therefore, the best and most correct answer is **D**.

**Self-Correction/Refinement during the Process:**

* Initially, I might have considered A as *partially* correct because face bows *do* contribute to occlusal relationships.  However, realizing it's too broad and doesn't capture the *specific* function helped me refine my thinking.
* I double-checked my understanding of "guide" in the context of B, C, and E. I clarified that "guide" in these options is meant in the sense of *directly controlling movement* or *shaping the prosthesis*, which is not what a face bow does directly. It's more about establishing the *correct starting point* for articulation.
* I focused on the keyword "두개골에서 상악의 위치 관계를 옮기는" (transferring the positional relationship of the maxilla from the skull) in option D and recognized this as the defining purpose of a face bow.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **D. 두개골에서 상악의 위치 관계를 옮기는 기구이다.** 입니다.

**해설:**

* **안궁 (Face Bow) 의 주요 기능:** 안궁은 환자의 **두개골**을 기준으로 **상악** 치아궁의 **3차원적인 위치 관계**를 채득하여 교합기라는 기계로 옮기는 기구입니다.  쉽게 말해, 환자의 얼굴에서 윗턱의 위치를 정확하게 본떠서 교합기에 재현하는 역할을 합니다.

* **각 선택지별 오답 이유:**

    * **A. 교합관계를 재현하기 위한 기구이다.**  (X) : 교합관계 재현에 *일정 부분* 기여하지만, 안궁의 *주요 기능*은 교합관계 자체를 재현하는 것이 아니라 **상악의 위치 관계**를 옮기는 것입니다. 교합관계는 교합기 상에서 하악 모형과 함께 재현됩니다.  따라서 너무 포괄적인 설명입니다.

    * **B. 전방운동의 가이드(guide) 역할을 하는 기구이다.** (X) : 전방운동의 가이드 (protrusive guide) 는 주로 교합기 상에서 **과로 (condylar path)** 설정을 통해 재현됩니다. 안궁은 전방운동 가이드와 직접적인 관련이 없습니다.

    * **C. 측방운동의 가이드(guide) 역할을 하는 기구이다.** (X) : 측방운동의 가이드 (lateral guide) 역시 주로 교합기 상에서 **과로 (condylar path)** 및 **Bennet angle** 설정을 통해 재현됩니다. 안궁은 측방운동 가이드와 직접적인 관련이 없습니다.

    * **E. 보철물을 제작하는 데에 가이드(guide) 역할을 하는 기구 이다.** (X) : 안궁은 보철물 제작 과정에서 **정확한 교합**을 구현하는 데 *필수적인 정보*를 제공하지만, 직접적으로 보철물 제작을 *가이드* 하는 기구는 아닙니다. 보철물 제작 가이드는 주로 인상재, 왁스업, 레진 등 다른 재료와 기구를 통해 이루어집니다.  안궁은 그 **기초적인 위치 정보**를 제공하는 역할입니다.

**결론적으로, 안궁의 가장 핵심적인 기능은 두개골을 기준으로 한 상악의 위치 관계를 정확하게 옮겨 교합기에서 재현하여, 환자의 실제 구강 내 상황과 유사한 환경에서 보철물을 제작할 수 있도록 돕는 것입니다. 따라서 D가 가장 정확한 설명입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">4,750</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="8"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">pharm</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,020</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">3</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">64</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">현재 유방암 치료 중인 52세 환자에게 폐경기 혈관운동증상(vasomotor symptom) 과 우울증상이 나타나 치료를 시작하려고 한다. 적절한 약물은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">라록시펜(raloxifene)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">벤라팍신(venlafaxine)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">메드록시프로게스테론(medroxyprogesterone)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">바제독시펜/에스트로겐(bazedoxifene/conjugated equine estrogen)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">에스트라디올/메드록시프로게스테론(estradiol/medroxyprogesterone)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to arrive at the correct answer for this clinical scenario.

**1. Deconstructing the Question:**

* **Patient Profile:** 52-year-old woman, currently undergoing breast cancer treatment.  This is *critical*. Breast cancer treatment immediately raises red flags regarding hormone-sensitive therapies.
* **Symptoms:** Vasomotor symptoms (hot flashes, night sweats) and depressive symptoms. These are common menopausal symptoms, but also could be side effects of breast cancer treatment itself (like chemotherapy or endocrine therapy).
* **Goal:**  Treat vasomotor and depressive symptoms *in the context of ongoing breast cancer treatment*. This means we need to prioritize safety and avoid exacerbating the cancer or interfering with its treatment.
* **Question Type:**  "Appropriate medication." This is a medication selection question, requiring knowledge of drug classes and their contraindications/indications, particularly in the context of breast cancer.

**2. Analyzing Each Answer Option:**

* **A. Raloxifene (라록시펜):**
    * Class: Selective Estrogen Receptor Modulator (SERM).
    * Mechanism: Estrogen agonist in bone, antagonist in breast and uterus.
    * Breast Cancer: Used for breast cancer risk reduction and treatment of osteoporosis in postmenopausal women.  However, it's *not* for vasomotor symptoms and *could* potentially have complex interactions in a patient currently *undergoing* breast cancer treatment.  While it's not directly contraindicated, it's not a primary choice for vasomotor symptoms, and we need to be cautious in a patient actively being treated.  *Initial thought: Maybe, but unlikely best option for symptoms.*

* **B. Venlafaxine (벤라팍신):**
    * Class: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI).
    * Mechanism: Antidepressant, also effective for vasomotor symptoms in menopausal women, especially those who cannot or should not take hormone therapy.
    * Breast Cancer: Generally considered safe in breast cancer patients.  Non-hormonal approach.  Addresses both depression and vasomotor symptoms. *Initial thought: Strong candidate.*

* **C. Medroxyprogesterone (메드록시프로게스테론):**
    * Class: Progestin (synthetic progesterone).
    * Mechanism: Can sometimes help with vasomotor symptoms, but less effective than estrogen. Historically used, but not preferred.
    * Breast Cancer:  Progestins *can* stimulate breast cancer growth in some cases.  Generally contraindicated or used with extreme caution in breast cancer patients.  Definitely not a first-line choice. *Initial thought:  Likely contraindicated, very risky.*

* **D. Bazedoxifene/Conjugated Equine Estrogen (바제독시펜/에스트로겐):**
    * Class:  Estrogen with a SERM (bazedoxifene).  "Tissue-selective estrogen complex (TSEC)".
    * Mechanism:  Estrogen component for vasomotor symptoms; bazedoxifene to protect the uterus from estrogen's proliferative effects.
    * Breast Cancer: *Estrogen is generally contraindicated in breast cancer patients*, especially those currently being treated.  Adding bazedoxifene doesn't negate the estrogen risk in breast tissue.  This combination is for menopausal symptoms, but absolutely contraindicated due to the estrogen component. *Initial thought:  Strong contraindication, definitely wrong.*

* **E. Estradiol/Medroxyprogesterone (에스트라디올/메드록시프로게스테론):**
    * Class:  Estrogen and Progestin (Hormone Therapy - HT).
    * Mechanism: Estrogen for vasomotor symptoms; progestin to protect the uterus from estrogen.
    * Breast Cancer: *Absolutely contraindicated* in breast cancer patients, especially during active treatment.  Estrogen and progestin can fuel breast cancer growth.  This is the classic hormone therapy regimen and is the *opposite* of what's safe in this context. *Initial thought:  Strongest contraindication, definitively wrong.*

**3. Prioritization and Selection:**

* **Rule out contraindicated options:** D and E are estrogen-containing therapies, absolutely contraindicated in breast cancer. C (medroxyprogesterone alone) is also risky and less effective, not a good choice.
* **Compare remaining options:** A (raloxifene) and B (venlafaxine).
    * Raloxifene is a SERM, and while not directly contraindicated, it's not the best choice for vasomotor symptoms, and its complex estrogen agonist/antagonist profile raises concerns during active breast cancer treatment. It's more for osteoporosis prevention and breast cancer risk reduction in *high-risk* women, not symptom management in *active* breast cancer.
    * Venlafaxine is a non-hormonal SNRI, effective for both vasomotor symptoms and depression. It's considered safe and often used in breast cancer patients experiencing menopausal symptoms.

**4. Final Answer and Justification:**

Venlafaxine (벤라팍신) is the most appropriate choice because:

* It effectively treats both vasomotor symptoms and depressive symptoms.
* It is a non-hormonal option, avoiding the risks associated with estrogen or progestin in a breast cancer patient.
* It is generally considered safe and well-tolerated in breast cancer patients.

Therefore, the answer is **B**.

**Self-Correction/Refinement during the process:**

Initially, I might have briefly considered raloxifene because it has some "breast-related" actions. However, upon closer examination, realizing it's not primarily for symptom relief and the context of *active* breast cancer treatment, venlafaxine emerges as the clearly superior and safer choice.  The key is always to prioritize patient safety and contraindications, especially in complex cases like this.  Thinking about *why* each option is right or wrong, and explicitly considering the patient's specific situation, leads to the correct answer.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **B. 벤라팍신(venlafaxine)** 입니다.

**해설:**

**환자 상태:**

* 52세 여성
* 현재 유방암 치료 중
* 폐경기 혈관운동증상 (vasomotor symptom, 안면홍조, 야간 발한 등)
* 우울 증상

**각 선택지 분석:**

* **A. 라록시펜(raloxifene):**  선택적 에스트로겐 수용체 조절제(SERM)로, 폐경 후 여성의 골다공증 치료 및 유방암 예방에 사용됩니다.  하지만 혈관운동증상 완화 효과는 제한적이며, 유방암 환자에게는 주된 치료 옵션이 아닙니다. 오히려 유방암 치료 중인 환자에게는 신중하게 사용해야 합니다.

* **B. 벤라팍신(venlafaxine):**  세로토닌-노르에피네프린 재흡수 억제제(SNRI) 계열의 항우울제로, 혈관운동증상 완화 효과가 입증되었습니다.  특히 유방암 환자나 호르몬 치료가 금기인 여성에게 혈관운동증상 치료의 1차 선택 약물로 권장됩니다. 우울 증상 개선에도 효과적이므로 이 환자에게 적절한 선택입니다.

* **C. 메드록시프로게스테론(medroxyprogesterone):**  프로게스틴 제제로, 과거 혈관운동증상 치료에 사용되기도 했지만, 에스트로겐에 비해 효과가 떨어지고 부작용 위험이 있습니다. 특히 유방암 환자에게는 프로게스테론이 유방암 세포 성장을 촉진할 수 있다는 우려 때문에 일반적으로 권장되지 않습니다.

* **D. 바제독시펜/에스트로겐(bazedoxifene/conjugated equine estrogen):**  에스트로겐과 선택적 에스트로겐 수용체 조절제(SERM) 복합제입니다. 에스트로겐은 혈관운동증상 완화에 효과적이지만, 유방암 병력이 있거나 현재 치료 중인 환자에게는 금기입니다. 에스트로겐은 유방암 재발 위험을 높일 수 있습니다.

* **E. 에스트라디올/메드록시프로게스테론(estradiol/medroxyprogesterone):**  에스트로겐과 프로게스테론 복합 호르몬 치료제입니다.  D와 마찬가지로 에스트로겐 성분 때문에 유방암 환자에게는 금기입니다.

**결론:**

유방암 치료 중인 환자에게 혈관운동증상과 우울 증상 치료를 위해 가장 적절한 약물은 **B. 벤라팍신(venlafaxine)** 입니다. 벤라팍신은 비호르몬 제제로 유방암에 대한 위험 없이 혈관운동증상과 우울 증상을 동시에 효과적으로 관리할 수 있습니다.

**참고:**

* 유방암 환자의 폐경기 증상 관리는 호르몬 치료보다는 비호르몬 치료를 우선적으로 고려합니다.
* 벤라팍신 외에도 선택적 세로토닌 재흡수 억제제(SSRI) 계열의 항우울제 (예: 파록세틴, 시탈로프람, 에스시탈로프람) 또한 혈관운동증상 완화에 효과적이며 유방암 환자에게 사용 가능합니다.
* 환자의 상태와 선호도, 약물 부작용 등을 고려하여 개별적으로 치료 계획을 수립해야 합니다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">3,579</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="9"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">dentist</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,020</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">28</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">총의치 악간관계 기록과정에서 다음 술식으로 채득하는 것은?
· 술자의 왼손으로 환자의 구강내 상하악 기록상을 치조제에 정확하게 위치시킨다. · 술자의 오른손 엄지를 환자의 이부에 위치시키고 턱을 가볍게 잡는다. · 환자의 하악을 후상방으로 가볍게 밀면서 접번운동을 확인 후 폐구시킨다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">중심위</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">전방활주로</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">최대개구위</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">최전방접촉위</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">후방한계개구로</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to arrive at the correct answer for the given question about interocclusal record taking in complete dentures.

**1. Deconstructing the Question:**

The question is asking about a specific technique for obtaining an interocclusal record in complete denture prosthodontics.  It provides a step-by-step procedure and asks what position this procedure is intended to record.  The key is to carefully analyze the described steps.

**2. Analyzing the Provided Steps:**

Let's go through each step and interpret its significance:

* **"술자의 왼손으로 환자의 구강내 상하악 기록상을 치조제에 정확하게 위치시킨다."** (The operator's left hand accurately positions the maxillary and mandibular record bases onto the alveolar ridges within the patient's mouth.)
    * *Interpretation:* This step sets the stage for recording a jaw relationship. Record bases are used in complete denture fabrication to simulate denture bases and provide a stable platform for recording jaw positions.  "치조제" (alveolar ridge) is crucial – it indicates we're dealing with edentulous patients.

* **"술자의 오른손 엄지를 환자의 이부에 위치시키고 턱을 가볍게 잡는다."** (The operator's right thumb is positioned on the patient's chin and gently holds the jaw.)
    * *Interpretation:* This step describes how the operator is manipulating the patient's mandible.  Placing the thumb on the chin and gently holding the jaw implies controlled mandibular manipulation.

* **"환자의 하악을 후상방으로 가볍게 밀면서 접번운동을 확인 후 폐구시킨다."** (Gently push the patient's mandible posteriorly and superiorly, check for hinge movement, and then close the mouth.)
    * *Interpretation:* This is the *most* critical step. "후상방으로 가볍게 밀면서" (gently push posteriorly and superiorly) is the key maneuver. "접번운동" (hinge movement) is also extremely important. This procedure is designed to guide the mandible into a specific, repeatable position.  Pushing posteriorly and superiorly, along with checking for hinge movement, strongly suggests an attempt to locate the **centric relation**.

**3. Connecting Steps to Dental Concepts:**

Now, let's link these interpreted steps to known dental concepts, especially related to interocclusal records:

* **Centric Relation (CR):**  CR is a maxillomandibular relationship where the condyles are in their most superior-anterior position in the glenoid fossae, resting against the posterior slopes of the articular eminences, with the discs interposed.  It's a hinge position, and it's considered a reproducible and physiologically acceptable starting point for denture construction.  The described technique of pushing posteriorly and superiorly *strongly* aligns with attempts to achieve CR.

* **Protrusive Record (전방활주로):** This record captures the mandible in a protruded position, used for setting condylar guidance on articulators. The described technique doesn't involve protrusion; it's about posterior and superior movement.

* **Maximum Intercuspation (MI) or Maximum Opening (최대개구위):** MI is the position of maximum tooth contact. Maximum opening is the widest mouth opening.  The described technique isn't about either of these.  It's about a specific jaw *relationship*, not maximum opening or tooth intercuspation (which isn't relevant in edentulous patients with record bases).

* **Retruded Contact Position (RCP) or Centric Occlusion (CO) (최전방접촉위):** RCP/CO refers to the first tooth contact in centric relation.  While related to CR, the description emphasizes achieving the condylar position (hinge movement) rather than just the first contact.  The focus is on the *position* of the condyles, which is the definition of CR.  "최전방접촉위" (most anterior contact position) could be misinterpreted as CO, but in the context of the procedure described (posterior-superior guidance), it's not the best fit.  Also, "최전방접촉위" is a less common term, and while it might sometimes be used synonymously with CO, it doesn't capture the essence of the CR-seeking maneuver.

* **Maximum Retrusion (후방한계개구로):** This refers to the most retruded position the mandible can achieve.  While the technique involves posterior movement, the description doesn't aim for the *extreme* retrusion.  It's about a controlled, reproducible hinge position, not just pushing the mandible as far back as possible.  Also, "후방한계개구로" is a less direct translation and might be confusing in this context. "후방한계개구로" might refer to the posterior limit of opening movement, which is not what the procedure is describing.

**4. Selecting the Best Answer:**

Based on the analysis, the procedure described is clearly aimed at recording **Centric Relation (중심위)**. The key phrases "후상방으로 가볍게 밀면서" (gently push posteriorly and superiorly) and "접번운동" (hinge movement) are strong indicators of a centric relation recording technique.

**5. Confirming and Refining (Self-Correction):**

Let's re-read the question and the steps to ensure no misinterpretations. The steps are consistent with a common technique for guiding the mandible into centric relation in edentulous patients. The options are:

* A. 중심위 (Centric Relation) - **Strong candidate**
* B. 전방활주로 (Protrusive Record) - Incorrect, procedure is posterior, not anterior.
* C. 최대개구위 (Maximum Opening Position) - Incorrect, procedure is about jaw relation, not opening.
* D. 최전방접촉위 (Most Anterior Contact Position) - Less precise, and the technique is focused on condylar position, not first contact.  Also, "최전방접촉위" is a slightly unusual term; "중심교합위" (Centric Occlusion) would be more common and still not the best fit.
* E. 후방한계개구로 (Maximum Retrusion Opening) -  Incorrect, procedure is not about maximum retrusion or opening limit.

**Conclusion:**  The most accurate answer is **A. 중심위 (Centric Relation)**. The described technique is a classic method for guiding the mandible into centric relation for recording in complete denture prosthodontics.  The other options are not supported by the described steps.  The Korean terms also reinforce this conclusion, with "중심위" being the standard term for Centric Relation in Korean dentistry.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **A. 중심위**입니다.

**해설:**

제시된 술식은 하악을 후상방으로 유도하여 접번운동을 확인하는 과정으로, 이는 **중심위(Centric Relation)**를 채득하기 위한 대표적인 방법입니다.

각 선택지별 설명은 다음과 같습니다.

* **A. 중심위 (Centric Relation):**  하악 과두가 관절와의 가장 상방-후방 위치에 놓이는 악위 관계입니다. 총의치 제작 시 기준 악위로 사용되며, 재현성이 높은 위치입니다. 제시된 술식은 하악을 후상방으로 유도하여 중심위를 채득하는 전형적인 방법과 일치합니다.

* **B. 전방활주로 (Protrusive Record):** 하악을 전방으로 내밀었을 때의 악위 관계를 기록하는 것입니다.  주로 교합기 상에서 전방유도각을 설정하기 위해 사용됩니다. 제시된 술식은 하악을 전방으로 내미는 것이 아니라 후상방으로 유도하므로 전방활주로와는 거리가 멉니다.

* **C. 최대개구위 (Maximum Opening Position):** 입을 최대한 크게 벌렸을 때의 위치입니다. 악관절 질환 평가 등에 사용될 수 있지만, 악간관계 기록과는 관련이 적습니다. 제시된 술식은 입을 벌리는 동작과는 관련이 없고, 하악의 특정 위치를 유도하는 것에 초점을 맞추고 있습니다.

* **D. 최전방접촉위 (Most Anterior Contact Position):** 하악을 최대한 전방으로 내밀어 치아가 처음 닿는 위치를 의미할 수 있습니다. 하지만 일반적으로 "최전방접촉위"라는 용어는 중심위나 중심교합위와 같은 특정 악위 관계를 지칭하는 표준적인 용어는 아닙니다.  제시된 술식은 하악을 후상방으로 유도하므로 최전방접촉위와는 반대 방향입니다.

* **E. 후방한계개구로 (Maximum Retrusion Opening):** 하악을 최대한 후방으로 밀면서 입을 벌릴 때의 경로를 의미합니다.  악관절 평가 등에 사용될 수 있지만, 악간관계 기록과는 직접적인 관련이 적습니다.  제시된 술식은 하악을 후방으로 유도하지만, 개구 운동보다는 폐구 상태에서 중심위를 기록하는 것을 목표로 합니다.

**결론적으로, 제시된 술식은 하악을 후상방으로 유도하여 접번운동을 확인하는 중심위 채득 방법과 정확히 일치하므로, 정답은 A. 중심위입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">16</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="10"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">doctor</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,013</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">26</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">6개월 남아가 출생 후부터 하지의 움직임이 없어 병원에 왔다. 개구리 다리 모양을 하고 누워 있었다.혀에 근섬유다발수축(fasciculation) 이 보였다. 다리에 자극을 주어도 움직임이 없었고, 깊은힘줄반사는없었다. 혈액검사 결과는 다음과 같았다. 진단은?아스파르테이트아미노전달효소 30 U/L, 알라닌아미노전달효소 20 U/L,크레아틴키나아제 100 U/L (참고치, 5～130), 젖산탈수소효소 170 U/L (참고치, 170～580) </span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">뇌성마비</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">중증근무력증</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">길랭- 바레증후군</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">진행근디스트로피</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">척수근위축증</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down this medical case step-by-step to arrive at the most likely diagnosis.

**1. Understanding the Patient Presentation:**

* **Age:** 6 months old infant. This is crucial, as certain conditions are more common or present differently at this age.
* **Chief Complaint:** Lack of leg movement since birth. This is a significant neurological symptom.
* **Posture:** "Frog-leg position."  This posture in infants often suggests hypotonia (low muscle tone) and weakness, particularly in the hips and legs.
* **Physical Exam Findings:**
    * **Tongue fasciculations:** Involuntary muscle twitches of the tongue. This is a key finding indicating *lower motor neuron* involvement.
    * **No leg movement to stimulation:**  Strongly suggests paralysis or severe weakness in the legs.
    * **Absent deep tendon reflexes:**  This is another crucial finding pointing towards *lower motor neuron* pathology.

**2. Interpreting the Lab Results:**

* **Aspartate aminotransferase (AST) 30 U/L, Alanine aminotransferase (ALT) 20 U/L:** These are liver enzymes.  The values are within normal limits.  This is not particularly helpful for differentiating the given diagnoses.  It rules out significant liver damage, which is not directly relevant to the neurological symptoms.
* **Creatine kinase (CK) 100 U/L (Reference: 5-130 U/L):** CK is an enzyme released from muscle tissue when it's damaged. The value is *within the normal range*.  While some muscle diseases elevate CK, a normal CK level doesn't exclude all muscle disorders.  It makes rapidly progressing muscle degeneration *less likely*, but doesn't rule out slower or congenital myopathies entirely.  However, in the context of other findings, it weakens the possibility of something like Duchenne muscular dystrophy (which usually has *very* high CK levels).
* **Lactate dehydrogenase (LDH) 170 U/L (Reference: 170-580 U/L):** LDH is another enzyme found in many tissues, including muscle.  The value is at the *lower end of the normal range*. This is also not particularly helpful in differentiating the diagnoses and does not point strongly to muscle damage.

**3.  Analyzing the Differential Diagnoses and Matching with Findings:**

Let's evaluate each option based on the clinical picture:

* **A. Cerebral Palsy (뇌성마비):**
    * **Pros:** Can present with limb weakness and abnormal posture.
    * **Cons:**  *Usually* presents with *upper motor neuron* signs (increased reflexes, spasticity).  Tongue fasciculations and absent deep tendon reflexes are *not* typical of cerebral palsy.  Cerebral palsy is caused by brain damage, not primarily lower motor neuron issues.  While hypotonia can occur in some forms of CP, the combination of hypotonia, absent reflexes, and fasciculations makes CP less likely as the *primary* diagnosis.

* **B. Myasthenia Gravis (중증근무력증):**
    * **Pros:** Can cause muscle weakness, and in infants, it can present with generalized weakness ("floppy baby").
    * **Cons:**  *No fasciculations*.  Myasthenia gravis is a *neuromuscular junction* disorder, not a motor neuron disease. Deep tendon reflexes are typically *normal* or only mildly reduced.  Tongue fasciculations are not a feature.

* **C. Guillain-Barré Syndrome (길랭-바레증후군):**
    * **Pros:** Can cause rapidly progressive weakness, areflexia (absent reflexes), and hypotonia.
    * **Cons:**  *Rare* in infants, especially at birth.  GBS is usually an *acquired* condition, often post-infectious.  Presenting *at birth* is extremely atypical.  While GBS affects peripheral nerves, tongue fasciculations are less commonly described.  However, in severe cases with bulbar involvement, cranial nerve issues could manifest. Still, less typical than the other findings.

* **D. Progressive Muscular Dystrophy (진행근디스트로피):**
    * **Pros:** Can cause muscle weakness and hypotonia. Some types can present early in infancy.
    * **Cons:**  CK is usually *significantly elevated* in muscular dystrophies, especially Duchenne and Becker.  The *normal CK* makes this less likely.  Fasciculations are *not* a typical feature of muscular dystrophies. Deep tendon reflexes might be reduced later in the disease, but are not the primary early finding.

* **E. Spinal Muscular Atrophy (SMA) (척수근위축증):**
    * **Pros:** Fits *perfectly* with the clinical picture.
        * **Onset at birth/early infancy:**  SMA Type 1 (Werdnig-Hoffmann disease) is a severe form presenting at birth or within the first few months of life.
        * **Generalized weakness, especially legs:**  "Frog-leg position" is classic for SMA Type 1.
        * **Tongue fasciculations:**  A *hallmark* of SMA due to lower motor neuron involvement.
        * **Absent deep tendon reflexes:**  Another *hallmark* of lower motor neuron disease like SMA.
        * **Normal CK (or only slightly elevated):**  Consistent with SMA.  CK might be slightly elevated due to chronic muscle atrophy, but not dramatically so in early stages.
        * **Normal liver enzymes and LDH:** Consistent with SMA.

**4. Conclusion:**

Considering all the clinical and lab findings, **Spinal Muscular Atrophy (SMA)** is the most consistent diagnosis.  The key findings of *tongue fasciculations*, *absent deep tendon reflexes*, *generalized weakness (especially legs)*, and the *infantile onset* strongly point towards SMA.  The normal CK level does not rule out SMA and is indeed typical in early SMA.

Therefore, the answer is **E. 척수근위축증 (Spinal Muscular Atrophy)**.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **E. 척수근위축증**입니다.

**해설:**

제시된 증상과 검사 결과는 척수근위축증 (Spinal Muscular Atrophy, SMA)의 전형적인 특징을 보입니다. 각 선택지를 하나씩 살펴보겠습니다.

* **A. 뇌성마비 (Cerebral Palsy):** 뇌성마비는 출생 전후의 뇌 손상으로 인해 발생하며, 운동 및 자세 장애를 일으킵니다. 하지만 뇌성마비는 일반적으로 *상위 운동 신경원* 질환으로, 심부건반사항진, 경직과 같은 증상을 보입니다. 혀의 근섬유다발수축은 흔하지 않으며, 심부건반사 소실은 뇌성마비의 주요 특징이 아닙니다.

* **B. 중증근무력증 (Myasthenia Gravis):** 중증근무력증은 신경-근 접합부의 이상으로 인해 발생하는 질환으로, 근육의 피로와 쇠약이 특징입니다. 하지만 중증근무력증은 *변동성* 근력 약화를 보이며, 혀의 근섬유다발수축은 흔하지 않습니다. 심부건반사는 일반적으로 정상입니다.

* **C. 길랭-바레 증후군 (Guillain-Barré Syndrome):** 길랭-바레 증후군은 급성 염증성 탈수초성 다발신경병증으로, 급성으로 진행하는 근력 약화와 심부건반사 소실을 특징으로 합니다. 하지만 길랭-바레 증후군은 일반적으로 *감각 이상*을 동반하며, 혀의 근섬유다발수축은 흔하지 않습니다. 또한, 길랭-바레 증후군은 출생 시부터 증상이 나타나는 경우는 드물고, 주로 감염 후 수일에서 수주 후에 발생합니다.

* **D. 진행근디스트로피 (Progressive Muscular Dystrophy):** 진행근디스트로피는 유전적인 근육 질환으로, 근육 섬유의 퇴행과 쇠약을 일으킵니다. 진행근디스트로피 중 일부는 영아기에 발병할 수 있지만, 일반적으로 *크레아틴키나아제 (CK) 수치가 매우 높게 상승*합니다. 제시된 검사 결과에서 CK 수치는 정상 범위 내에 있으므로 진행근디스트로피의 가능성은 낮습니다. 또한, 혀의 근섬유다발수축은 진행근디스트로피의 특징적인 증상은 아닙니다.

* **E. 척수근위축증 (Spinal Muscular Atrophy, SMA):** 척수근위축증은 운동 신경 세포의 퇴행으로 인해 발생하는 유전 질환으로, 근육의 쇠약과 위축을 특징으로 합니다. 특히 *제1형 척수근위축증 (Werdnig-Hoffmann disease)*은 영아기에 발병하며, 출생 시부터 또는 생후 6개월 이내에 심각한 근력 약화가 나타납니다.

**제시된 증상과 척수근위축증의 특징:**

* **6개월 남아, 출생 후부터 하지 움직임 없음:** 척수근위축증은 특히 하지 근력 약화를 두드러지게 나타냅니다.
* **개구리 다리 모양:** 척수근위축증 환아는 특징적으로 개구리 다리 자세를 취합니다. 이는 고관절 외전 및 무릎 굴곡으로 인한 자세입니다.
* **혀의 근섬유다발수축 (fasciculation):** 혀의 근섬유다발수축은 척수근위축증의 매우 특징적인 소견입니다. 이는 운동 신경 세포의 퇴행으로 인해 발생하는 현상입니다.
* **다리에 자극을 주어도 움직임 없음, 심부건반사 소실:** 척수근위축증은 하위 운동 신경원 질환으로, 근력 약화 및 심부건반사 소실을 유발합니다.
* **정상 범위의 혈액 검사 결과 (CK, LDH):** 척수근위축증은 근육 자체의 질환이 아니므로, CK 수치는 일반적으로 정상이거나 경미하게 상승할 수 있습니다. 제시된 CK 수치는 정상 범위 내에 있습니다. LDH 또한 정상 범위 내에 있습니다.

**결론적으로, 제시된 임상 양상과 검사 결과는 척수근위축증 (특히 제1형)에 가장 부합합니다.** 따라서 정답은 **E. 척수근위축증** 입니다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">910</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="11"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">doctor</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,014</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">6</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">인간의 하루주기리듬(circadian rhythm) 을 주관하는 생물학적 시계인 하루주기조정자(circadian pacemaker) 가 위치하고 있는 부위는?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">솔기핵(raphe nucleus)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">청색반점(locus ceruleus)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">꼬리핵(caudate nucleus)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">렌즈핵(lentiform nucleus)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">시신경교차상핵(suprachiasmatic nucleus)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">The question is asking about the location of the circadian pacemaker in the human brain.
- I need to identify the brain region that is responsible for regulating the circadian rhythm.
- I know that the circadian rhythm is the body's internal clock that regulates sleep-wake cycles and other physiological processes over a 24-hour period.
- I need to recall the specific brain structure known to be the master circadian pacemaker.

Let's consider each option:
A. 솔기핵 (raphe nucleus):  The raphe nucleus is primarily associated with serotonin production and regulation of mood, sleep, and pain. While it plays a role in sleep, it is not the primary circadian pacemaker.

B. 청색반점 (locus ceruleus): The locus ceruleus is the main site for norepinephrine production in the brain. It is involved in arousal, attention, and stress response.  While it is related to wakefulness, it's not the master circadian pacemaker.

C. 꼬리핵 (caudate nucleus): The caudate nucleus is part of the basal ganglia and is involved in motor control, procedural learning, and habit formation. It is not directly related to circadian rhythm regulation.

D. 렌즈핵 (lentiform nucleus): The lentiform nucleus is also part of the basal ganglia and includes the putamen and globus pallidus. It is involved in motor control and is not the primary circadian pacemaker.

E. 시신경교차상핵 (suprachiasmatic nucleus - SCN): The suprachiasmatic nucleus is a small nucleus in the hypothalamus, located just above the optic chiasm. It is well-established as the primary circadian pacemaker in mammals, including humans.  It receives direct input from the retina about light levels, which helps synchronize the body's internal clock with the external environment (day-night cycle).

Based on my knowledge, the suprachiasmatic nucleus (SCN) is the correct answer.  It is the master clock that regulates circadian rhythms.

Therefore, the answer is E. 시신경교차상핵 (suprachiasmatic nucleus).</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **E. 시신경교차상핵(suprachiasmatic nucleus)** 입니다.

**해설:**

* **하루주기리듬(circadian rhythm)** 은 약 24시간 주기로 반복되는 생체 리듬으로, 수면-각성 주기, 호르몬 분비, 체온 변화 등 다양한 생리적 과정에 영향을 미칩니다.
* **하루주기조정자(circadian pacemaker)** 는 이러한 하루주기리듬을 주관하는 생물학적 시계 역할을 하는 뇌 부위입니다.

각 선택지를 살펴보면 다음과 같습니다:

* **A. 솔기핵(raphe nucleus):** 솔기핵은 주로 세로토닌을 생성하며, 기분, 수면, 통증 조절에 관여합니다. 수면에 영향을 미치지만, 하루주기리듬의 주관자는 아닙니다.
* **B. 청색반점(locus ceruleus):** 청색반점은 노르에피네프린을 생성하며, 각성, 주의 집중, 스트레스 반응에 관여합니다. 각성에 영향을 미치지만, 하루주기리듬의 주관자는 아닙니다.
* **C. 꼬리핵(caudate nucleus):** 꼬리핵은 기저핵의 일부로, 운동 조절, 절차 기억, 습관 형성에 관여합니다. 하루주기리듬과는 직접적인 관련이 적습니다.
* **D. 렌즈핵(lentiform nucleus):** 렌즈핵 역시 기저핵의 일부로, 운동 조절에 관여합니다. 하루주기리듬과는 직접적인 관련이 적습니다.
* **E. 시신경교차상핵(suprachiasmatic nucleus - SCN):** 시신경교차상핵은 시상하부에 위치한 작은 핵으로, **포유류의 주요 하루주기조정자** 로 알려져 있습니다. 시신경으로부터 빛 정보를 직접 받아들여 외부 환경(낮과 밤)에 생체 시계를 동기화시키는 역할을 합니다.

따라서, 인간의 하루주기리듬을 주관하는 생물학적 시계, 즉 하루주기조정자는 **시신경교차상핵(suprachiasmatic nucleus)** 입니다.

**정답:** **E**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">982</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="12"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">doctor</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,014</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">3</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">64</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">42세 산과력 2-0-1-2인 여자가 2주 전 시작된 질출혈로 병원에 왔다. 평소 월경은 30일 간격으로 규칙적이었으며, 최종월경시작일은 4주 전이었다. 혈압 110/70 mmHg, 맥박 72회/분, 체온 36.7℃였다. 초음파검사에서 자궁 및 자궁부속기는 정상이었다. 혈액 및 소변검사와 자궁내막생검 결과는 다음과 같았다. 진단은? 혈액: 혈색소 11.6 g/dL, 백혈구 8,000/mm^3, 혈소판 250,000/mm^3 소변임신반응: 음성 자궁내막: 부조화 증식기 자궁내막(disordered proliferative endometrium) </span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">자궁내막암</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">자궁내막염</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">자궁내막유착증</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">자궁내막증식증</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">기능장애자궁출혈</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to arrive at the diagnosis of dysfunctional uterine bleeding (DUB) in this case.

**1.  Understanding the Patient's Presentation:**

* **Age:** 42 years old -  This is important.  Women in their 40s are in perimenopause, where hormonal fluctuations are common and can lead to irregular bleeding.
* **Parity (2-0-1-2):**  Two full-term pregnancies, one abortion, two living children.  This obstetrical history doesn't directly point to a diagnosis, but it's relevant patient history.
* **Chief Complaint:** Vaginal bleeding for 2 weeks.  This is the primary symptom and needs to be explained.
* **Menstrual History:** Regular 30-day cycles, LMP 4 weeks ago.  Initially seems normal, but the current bleeding is *outside* of her expected menstrual cycle.
* **Vitals:** Normal blood pressure, pulse, and temperature.  This rules out acute infection or significant hypovolemia for now.
* **Pelvic Ultrasound:** Normal uterus and adnexa. This is crucial. It rules out structural abnormalities like fibroids, polyps, ovarian cysts, or ectopic pregnancy as the *primary* cause of bleeding.
* **Lab Results:**
    * **Hemoglobin 11.6 g/dL:** Slightly low, indicating some blood loss, but not severely anemic.
    * **WBC 8,000/mm^3:** Normal, rules out significant infection.
    * **Platelets 250,000/mm^3:** Normal, rules out bleeding disorders related to platelets.
    * **Urine Pregnancy Test: Negative:**  Rules out pregnancy as the cause of bleeding.
    * **Endometrial Biopsy: Disordered Proliferative Endometrium:** This is the key finding.  "Proliferative" means the endometrium is growing (estrogen-driven). "Disordered" or "Dyssynchronous" implies that the growth is not happening in a coordinated, cyclical way, which is typical in a normal menstrual cycle.

**2.  Systematic Differential Diagnosis (Thinking through the options and ruling them out):**

* **A. Endometrial Cancer (자궁내막암):**
    * **Why consider it?**  Abnormal bleeding is a key symptom of endometrial cancer, especially in perimenopausal and postmenopausal women.
    * **Why rule it out (or at least make it less likely)?**
        * **Age:** While possible at 42, endometrial cancer is more common in older women.
        * **Endometrial Biopsy Result:** "Disordered proliferative endometrium" is *not* typical of endometrial cancer. Cancerous endometrium would show atypical cells, hyperplasia with atypia, or adenocarcinoma.  "Disordered proliferative" is a *benign* finding, albeit abnormal in its dyssynchrony.
        * **Normal Ultrasound:** While not definitive, a normal ultrasound makes structural cancer less likely (though not impossible).
    * **Conclusion:**  Less likely given the biopsy and ultrasound, but endometrial cancer *cannot* be completely ruled out without further investigation if the bleeding persists or worsens.

* **B. Endometritis (자궁내막염):**
    * **Why consider it?**  Infection can cause abnormal bleeding.
    * **Why rule it out?**
        * **Normal Vitals:** No fever (36.7℃) or tachycardia (pulse 72 bpm) which are often seen in acute infection.
        * **Normal WBC:**  WBC count is within the normal range, not elevated, which would be expected in infection.
        * **"Proliferative" Endometrium:** Endometritis would typically cause inflammation and potentially a more mixed or necrotic picture on biopsy, not primarily "proliferative."
    * **Conclusion:**  Unlikely given the normal vitals, WBC, and biopsy result.

* **C. Asherman's Syndrome (자궁내막유착증):**
    * **Why consider it?** Asherman's can cause abnormal bleeding (often *reduced* or absent menstruation, but sometimes irregular bleeding).  It's associated with prior uterine procedures (D&amp;C, etc.).
    * **Why rule it out?**
        * **Patient History:** No mention of prior D&amp;C or uterine surgery.
        * **Bleeding:**  Patient has *excessive* bleeding, not reduced. Asherman's more typically presents with amenorrhea or hypomenorrhea.
        * **"Proliferative" Endometrium:**  Asherman's is characterized by *scarring* and *thinning* of the endometrium, not disordered proliferation.
    * **Conclusion:**  Unlikely given the history, bleeding pattern, and biopsy result.

* **D. Endometrial Hyperplasia (자궁내막증식증):**
    * **Why consider it?**  Endometrial hyperplasia is a precursor to endometrial cancer, and it *can* present with abnormal bleeding.
    * **Why rule it out (partially)?**
        * **Biopsy Result:**  The biopsy says "disordered proliferative endometrium," *not* "endometrial hyperplasia."  While disordered proliferation can be *a form* of simple hyperplasia *without atypia*, the term "disordered proliferative" is more often used to describe the benign hormonal imbalance of DUB, rather than a pre-cancerous lesion.  If the biopsy had mentioned "hyperplasia," especially with atypia, this would be much higher on the differential.  The absence of "hyperplasia" in the biopsy report is important.
    * **Conclusion:** Less likely given the specific biopsy term.  If the report had said "simple hyperplasia without atypia," it would be closer to DUB, but the term "disordered proliferative" is more directly associated with hormonal imbalance.

* **E. Dysfunctional Uterine Bleeding (기능장애자궁출혈):**
    * **Why consider it?**
        * **Age:** Perimenopausal age is the classic demographic.
        * **Irregular Bleeding:**  Presents with bleeding outside normal menstruation.
        * **Normal Ultrasound:** Rules out structural causes.
        * **Negative Pregnancy Test:** Rules out pregnancy.
        * **"Disordered Proliferative Endometrium":** This is the *hallmark* biopsy finding for DUB.  It reflects anovulation or inconsistent ovulation, leading to unopposed estrogen stimulation and irregular endometrial shedding.
    * **Conclusion:**  Highly likely.  All pieces of the puzzle fit.

**3.  Final Diagnosis and Justification:**

Dysfunctional Uterine Bleeding (DUB) (기능장애자궁출혈) is the most likely diagnosis.

* **Reasoning:**
    * The patient is perimenopausal, a typical age group for DUB.
    * She presents with abnormal vaginal bleeding.
    * Ultrasound is normal, ruling out structural lesions.
    * Pregnancy is ruled out.
    * Endometrial biopsy shows "disordered proliferative endometrium," which is the characteristic histological finding in DUB due to hormonal imbalances (often anovulation or oligo-ovulation).

**4.  Further Management (Although not asked in the question, it's good to consider):**

* **Confirm Diagnosis:**  Rule out other less likely possibilities if bleeding persists or worsens.  Repeat biopsy if needed.
* **Treatment:** Depends on severity of bleeding and patient's desire for future fertility.  Options include:
    * **Observation:** If bleeding is mild and patient is not anemic.
    * **Hormonal therapy:** Progestins (oral or IUD) to regulate cycles and reduce bleeding.  Combined oral contraceptives if contraception is also desired.
    * **NSAIDs:** To reduce bleeding during periods.
    * **Iron supplementation:** If anemic.
    * **Endometrial ablation or hysterectomy:**  For severe, refractory cases, especially if fertility is no longer desired.


By systematically going through the patient's presentation, considering the differential diagnoses, and carefully evaluating the lab results, especially the biopsy, we arrive at the most appropriate diagnosis: Dysfunctional Uterine Bleeding.  The key is to recognize that "disordered proliferative endometrium" in the context of abnormal bleeding and normal pelvic exam is highly suggestive of DUB.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **E. 기능장애자궁출혈** 입니다.

**해설:**

**환자의 증상 및 검사 결과 분석:**

* **42세 여성, 2주 전부터 시작된 질출혈:**  가장 중요한 증상입니다.
* **규칙적인 월경력, 최종월경시작일 4주 전:** 평소 월경 주기는 규칙적이었으나, 현재 출혈은 월경 주기에 맞지 않는 비정상 출혈입니다.
* **정상 활력 징후 (혈압, 맥박, 체온):** 급성 감염이나 심각한 전신 질환 가능성은 낮습니다.
* **정상 자궁 및 자궁부속기 초음파:**  자궁근종, 자궁내막 폴립, 난소 낭종 등 구조적인 이상으로 인한 출혈 가능성은 낮습니다.
* **혈액 검사:** 경미한 빈혈 (혈색소 11.6 g/dL) 외에는 정상입니다. 염증 소견 (백혈구 정상) 도 없습니다.
* **소변임신반응 음성:** 임신 관련 출혈은 아닙니다.
* **자궁내막생검: 부조화 증식기 자궁내막 (disordered proliferative endometrium):**  **핵심적인 진단 단서입니다.**

**각 선택지별 가능성 평가:**

* **A. 자궁내막암:**
    * 자궁내막암은 비정상 질출혈의 중요한 원인이지만, **자궁내막생검 결과가 "부조화 증식기 자궁내막"으로 암세포나 비정형 세포가 발견되지 않았으므로 가능성은 낮습니다.**  자궁내막암은 보통 증식증, 비정형 증식증, 또는 암세포 자체로 진단됩니다.
* **B. 자궁내막염:**
    * 자궁내막염은 염증으로 인한 출혈을 유발할 수 있지만, **정상 백혈구 수치와 정상 체온**으로 감염 가능성은 낮습니다. 또한, 자궁내막생검 결과가 염증성 변화보다는 "증식기" 변화를 보이고 있습니다.
* **C. 자궁내막유착증 (Asherman's syndrome):**
    * 자궁내막유착증은 자궁내막 손상 후 유착이 발생하여 월경량 감소나 무월경을 유발하는 질환입니다. **질출혈이 주 증상인 이 환자에게는 적합하지 않습니다.**
* **D. 자궁내막증식증:**
    * 자궁내막증식증은 자궁내막이 과도하게 증식하는 질환으로, 비정상 출혈을 유발할 수 있습니다. 하지만, 자궁내막생검 결과가 "부조화 증식기 자궁내막"으로, **증식증으로 명확하게 진단하기에는 부족합니다.** "부조화 증식기 자궁내막"은 자궁내막증식증의 초기 단계 혹은 기능장애자궁출혈에서 나타날 수 있는 비특이적인 소견입니다.
* **E. 기능장애자궁출혈 (Dysfunctional Uterine Bleeding, DUB):**
    * **가장 가능성이 높은 진단입니다.** 기능장애자궁출혈은 기질적인 질환 없이 호르몬 불균형으로 인해 발생하는 비정상 자궁 출혈을 의미합니다.
    * **환자의 나이 (42세, 가임기 후반), 규칙적인 월경력 변화, 정상 초음파, "부조화 증식기 자궁내막" 소견은 기능장애자궁출혈에 합당합니다.**  특히 "부조화 증식기 자궁내막"은 배란 장애 등으로 인해 프로게스테론의 작용 없이 에스트로겐에만 지속적으로 노출된 자궁내막에서 나타날 수 있으며, 이는 기능장애자궁출혈의 흔한 원인입니다.

**결론적으로,** 환자의 증상, 검사 결과, 특히 자궁내막생검 결과를 종합적으로 고려했을 때, **기능장애자궁출혈 (E)** 이 가장 가능성 높은 진단입니다.  다른 심각한 질환의 가능성은 낮지만, 지속적인 출혈 시 자궁내막암 등의 가능성을 배제하기 위해 추적 관찰이 필요할 수 있습니다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1,083</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="13"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">doctor</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,016</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">13</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">64세 남자가 의식이 흐려진 채로 발견되어 응급실에 실려왔다. 집안일로 속이 상해 식사를 하지 않고 3일 동안 매일 소주 4병을 마셨다고 하였다. 당뇨병이나 고혈압을 앓은 적은 없었고 평소 복용하는 약도 없다고 하였다. 의식은 혼미하였고 혈압 110/70 mmHg, 맥박 86회/분, 호흡 20회/분, 체온 36.3℃였다. 혈액검사 결과는 다음과 같았다. 원인은?포도당 46 mg/dL,  인슐린 1.5 μU/mL (참고치, 2 ~ 20) </span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">글루카곤 분비 억제</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">간 글리코겐분해 억제</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">간 포도당신합성 억제</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">말초 포도당 이용 증가</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">인슐린유사성장인자 분비 증가</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">3</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down this medical case step-by-step, mimicking a thought process for solving this clinical reasoning question.

**1. Initial Information Gathering and Problem Identification:**

* **Patient Profile:** 64-year-old male, altered consciousness, Korean (contextual for drinking habits).
* **Key History:** 3 days of heavy alcohol intake (4 bottles of Soju/day), no food intake, emotional distress related to housework. No prior diabetes, hypertension, or medications.
* **Vitals:**  Stable blood pressure (110/70 mmHg), normal heart rate (86 bpm), normal respiratory rate (20 bpm), normal temperature (36.3°C).  Vitals are not immediately alarming, suggesting no acute shock or infection.  However, altered consciousness *is* alarming.
* **Blood Glucose:**  **Extremely low glucose (46 mg/dL).** This is the most critical finding.
* **Insulin:** Low insulin (1.5 μU/mL, normal 2-20).  This is also significant and needs to be interpreted in the context of the low glucose.

**Problem Identification:** Hypoglycemia.  The altered consciousness is highly likely due to the low blood sugar.

**2.  Considering the History and Pathophysiology of Hypoglycemia:**

* **Alcohol and Hypoglycemia:** Alcohol is a known cause of hypoglycemia, especially in the context of fasting.  Alcohol metabolism in the liver has a significant impact on glucose homeostasis.
* **Fasting:**  No food intake for 3 days depletes liver glycogen stores.  The body relies more heavily on gluconeogenesis (making glucose from non-carbohydrate sources).
* **Soju:** Soju is an alcoholic beverage.  Ethanol is the key ingredient.

**3.  Mechanism of Alcohol-Induced Hypoglycemia:**

* **Ethanol Metabolism:** Ethanol is metabolized in the liver primarily by alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
* **NAD+/NADH Ratio Shift:**  This metabolic pathway consumes NAD+ and produces NADH. This increases the NADH/NAD+ ratio in the liver.
* **Impact on Gluconeogenesis:**  Several key steps in gluconeogenesis are NAD+-dependent (e.g., lactate to pyruvate, malate to oxaloacetate).  The increased NADH/NAD+ ratio *inhibits* these steps.
* **Impact on Glycolysis:**  Conversely, some steps in glycolysis are NADH-producing.  The increased NADH/NAD+ ratio *favors* glycolysis, but this is less relevant in a fasted state where the goal is to *produce* glucose, not consume it.
* **Impact on Glycogenolysis:**  While alcohol can initially stimulate glycogenolysis, prolonged alcohol intake and depleted glycogen stores will make glycogenolysis less effective.

**4.  Analyzing the Answer Choices in light of the Pathophysiology:**

* **A. Glucagon 분비 억제 (Glucagon secretion inhibition):** Glucagon is a counter-regulatory hormone that *raises* blood glucose. It stimulates glycogenolysis and gluconeogenesis.  If glucagon secretion is inhibited, this would worsen hypoglycemia.  Alcohol *can* suppress glucagon secretion to some extent, contributing to hypoglycemia.  This is a *possible* mechanism.

* **B. 간 글리코겐분해 억제 (Liver glycogenolysis inhibition):** Glycogenolysis is the breakdown of glycogen into glucose.  While alcohol doesn't directly *inhibit* glycogenolysis, in a state of depleted glycogen stores (due to fasting and alcohol metabolism), glycogenolysis would be less effective anyway.  And as mentioned before, alcohol *can* initially stimulate glycogenolysis, but not for long periods especially with fasting. Indirectly, the liver's energy being focused on alcohol metabolism might reduce its capacity for glycogenolysis.  Less direct than other options, but possibly contributing.

* **C. 간 포도당신합성 억제 (Liver gluconeogenesis inhibition):** Gluconeogenesis is the process of making new glucose from non-carbohydrate sources.  As discussed earlier, alcohol metabolism *directly inhibits* gluconeogenesis due to the NADH/NAD+ ratio shift. This is a *strong* mechanism.

* **D. 말초 포도당 이용 증가 (Increased peripheral glucose utilization):**  While insulin stimulates peripheral glucose uptake, insulin is *low* in this case (1.5 μU/mL).  Alcohol itself *doesn't* directly increase peripheral glucose uptake in a way that would explain this profound hypoglycemia.  This is less likely.  Furthermore, low insulin suggests decreased, not increased, peripheral glucose utilization.

* **E. 인슐린유사성장인자 분비 증가 (Increased insulin-like growth factor secretion):** Insulin-like growth factors (IGFs) have some insulin-like effects, but they are not the primary regulator of acute glucose homeostasis.  IGF-1, for example, is more involved in long-term growth and development.  And IGFs are unlikely to be acutely increased by alcohol in a way that causes significant hypoglycemia.  This is very unlikely.

**5.  Selecting the Best Answer:**

* **Option C (간 포도당신합성 억제 - Liver gluconeogenesis inhibition)** is the most direct and well-established mechanism for alcohol-induced hypoglycemia, especially in the context of fasting.  The NADH/NAD+ shift from alcohol metabolism directly impairs gluconeogenesis.

* **Option A (글루카곤 분비 억제 - Glucagon secretion inhibition)** is also a contributing factor, but perhaps less direct and less dominant than gluconeogenesis inhibition.

* **Option B (간 글리코겐분해 억제 - Liver glycogenolysis inhibition)** is less direct and less likely to be the primary mechanism.

* **Options D and E** are very unlikely.

**6. Final Answer and Justification:**

The most likely primary cause of hypoglycemia in this patient is **C. 간 포도당신합성 억제 (Liver gluconeogenesis inhibition)**.  The combination of heavy alcohol consumption and fasting leads to a metabolic state where the liver's ability to produce glucose through gluconeogenesis is impaired due to the altered NADH/NAD+ ratio caused by ethanol metabolism.  This, coupled with depleted glycogen stores from fasting, leads to a rapid drop in blood glucose and altered consciousness.

Therefore, the answer is **C**.

**(Self-Correction/Refinement):**  Initially, I might have considered A and C both strongly. However, focusing on the *primary* mechanism in the context of the question wording ("원인은?") and the pathophysiology, gluconeogenesis inhibition is the more direct and dominant effect of alcohol in this scenario. Glucagon suppression is more of a secondary/contributory factor.  Therefore, C is the most accurate and best answer.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">## 정답: C. 간 포도당신합성 억제

**해설:**

**환자의 상태:**

* **64세 남성, 의식 혼미:**  중추신경계 기능 저하를 시사합니다.
* **3일간 식사 안 하고 소주 4병/일:** 심한 알코올 섭취와 금식 상태입니다.
* **당뇨, 고혈압 병력 없음, 약물 복용력 없음:** 기존 질환이나 약물로 인한 가능성은 낮습니다.
* **정상 혈압, 맥박, 호흡, 체온:**  급성 쇼크나 심각한 감염의 가능성은 낮습니다.
* **혈액 검사:**
    * **포도당 46 mg/dL (저혈당):**  의식 혼미의 가장 유력한 원인입니다.
    * **인슐린 1.5 μU/mL (낮은 인슐린):**  저혈당 상황에서 인슐린 분비가 억제된 것은 정상적인 반응입니다.

**각 선택지 분석:**

* **A. 글루카곤 분비 억제:** 글루카곤은 혈당을 상승시키는 호르몬입니다. 저혈당 상황에서는 글루카곤 분비가 **촉진**되어야 혈당을 올리려고 합니다. 글루카곤 분비 억제는 저혈당을 악화시키므로, 원인이 될 수 없습니다.

* **B. 간 글리코겐분해 억제:** 글리코겐분해는 간에 저장된 글리코겐을 포도당으로 분해하여 혈당을 올리는 과정입니다.  알코올은 간에서 대사되면서 NADH/NAD+ 비율을 증가시켜 글리코겐분해를 **일시적으로 촉진**할 수 있습니다. 하지만 장기간 금식 상태에서는 간 글리코겐 저장량이 이미 고갈되었을 가능성이 높고, 알코올 대사로 인해 간 기능이 저하되어 글리코겐분해가 제대로 이루어지지 않을 수 있습니다.  하지만 **주된 원인**이라고 보기 어렵습니다.

* **C. 간 포도당신합성 억제:** 포도당신합성은 간에서 아미노산, 젖산, 글리세롤 등 비탄수화물 물질로부터 포도당을 새로 합성하는 과정입니다.  **알코올은 간에서 대사되면서 NADH/NAD+ 비율을 증가시키고, 이는 포도당신합성 과정의 중요한 효소 반응을 억제합니다.** 특히 금식 상태에서는 혈당 유지를 포도당신합성에 크게 의존하게 되는데, 알코올 섭취로 인해 포도당신합성이 억제되면 심각한 저혈당이 발생할 수 있습니다. **이것이 가장 유력한 원인입니다.**

* **D. 말초 포도당 이용 증가:** 인슐린은 말초 조직에서 포도당 이용을 촉진합니다. 하지만 환자의 인슐린 수치는 낮으므로, 말초 포도당 이용이 증가했을 가능성은 낮습니다. 오히려 저혈당 상황에서는 인슐린 분비가 억제되어 말초 포도당 이용이 감소하는 것이 정상적인 반응입니다.

* **E. 인슐린유사성장인자 분비 증가:** 인슐린유사성장인자 (IGF)는 인슐린과 유사한 작용을 하지만, 급성 저혈당의 원인으로 보기 어렵습니다. IGF는 주로 성장과 발달에 관여하며, 혈당 조절에 미치는 영향은 인슐린에 비해 미미합니다.

**결론:**

환자의 경우, 3일간의 금식과 과도한 알코올 섭취로 인해 간의 포도당신합성이 억제되어 심각한 저혈당이 발생한 것으로 판단됩니다. 따라서 가장 적절한 원인은 **C. 간 포도당신합성 억제** 입니다.

**추가 설명:**

* 알코올은 간에서 알코올 탈수소효소 (ADH)와 알데히드 탈수소효소 (ALDH)에 의해 대사됩니다. 이 과정에서 NAD+가 NADH로 환원되어 간세포 내 NADH/NAD+ 비율이 증가합니다.
* 높은 NADH/NAD+ 비율은 간세포 내 대사 경로에 영향을 미쳐, 특히 포도당신합성 경로를 억제합니다.
* 금식 상태에서는 간 글리코겐 저장량이 감소하고, 포도당신합성이 혈당 유지에 더욱 중요해집니다.
* 알코올 섭취로 인해 포도당신합성이 억제되면, 혈당이 급격히 떨어져 저혈당성 혼수가 발생할 수 있습니다.

**따라서 정답은 C 입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1,401</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="14"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">nurse_assistant</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,022</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">94</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">요추천자 직후 9세 남아가 소변을 보고 싶다고 할 때 간호 보조활동으로 옳은 것은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">이동식 변기에 앉힌다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">화장실을 다녀오게 한다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">유치도뇨세트를 준비한다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">침대 위에 서서 소변을 보게 한다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">누워서 소변기에 소변을 보게 한다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">
The question is asking about the appropriate nursing assistant activity when a 9-year-old boy wants to urinate immediately after a lumbar puncture. We need to consider the potential complications and restrictions after a lumbar puncture, especially in children.

Let's analyze each option:

* **A. 이동식 변기에 앉힌다. (Sit him on a portable commode.)**: This is a possibility. A portable commode is convenient for patients who have difficulty moving to the bathroom, but it still requires the patient to sit upright.

* **B. 화장실을 다녀오게 한다. (Let him go to the bathroom.)**:  Lumbar puncture is a procedure that involves inserting a needle into the spinal canal. One of the major concerns after a lumbar puncture is post-lumbar puncture headache (PLPH), which is often aggravated by standing or sitting upright.  Encouraging the child to walk to the bathroom might worsen potential headache and is generally not recommended immediately after the procedure.

* **C. 유치도뇨세트를 준비한다. (Prepare a Foley catheter set.)**:  A Foley catheter is an invasive procedure, and it is not a routine intervention just because a patient needs to urinate after a lumbar puncture. Catheterization is only considered if the patient is unable to void naturally and urinary retention is suspected. This is too invasive and not a first-line approach.

* **D. 침대 위에 서서 소변을 보게 한다. (Let him stand on the bed to urinate.)**:  Standing upright after a lumbar puncture can increase the risk and severity of a post-lumbar puncture headache. Also, having a child stand on the bed to urinate is unsafe and impractical. This option is highly inappropriate.

* **E. 누워서 소변기에 소변을 보게 한다. (Let him urinate into a bedpan while lying down.)**:  After a lumbar puncture, patients are often advised to lie flat for a period of time to minimize the risk of post-lumbar puncture headache. Urinating in a bedpan while lying down is a common and safe practice for patients who need to void but should remain lying down. This seems like the most appropriate option given the circumstances.

Considering the need to minimize movement and maintain a lying position to prevent or reduce post-lumbar puncture headache, options B and D are clearly not suitable. Option C is too invasive and not necessary as a first step. Option A is better than B and D, but still requires sitting up, which might be less desirable than remaining lying down. Option E allows the child to urinate while remaining in a lying position, which is the recommended position after a lumbar puncture.

Therefore, option E seems to be the most appropriate nursing assistant activity.

Let's double-check the typical post-lumbar puncture care.  Post-procedure care often includes:
    * Monitoring vital signs and neurological status.
    * Encouraging fluid intake to help with CSF production and hydration.
    * Pain management, if needed.
    * **Maintaining a flat or prone position for a period of time (often 1-2 hours or more) to minimize CSF leakage and prevent headache.**

Based on this typical care, minimizing upright posture immediately after lumbar puncture is important.  Option E, using a bedpan while lying down, aligns best with this principle.


**Final Answer Selection:** E. 누워서 소변기에 소변을 보게 한다. (Let him urinate into a bedpan while lying down.)

**Reasoning:**
After a lumbar puncture, especially in children, minimizing movement and maintaining a lying position is crucial to prevent or reduce post-lumbar puncture headache.  Among the options, using a bedpan while lying down (option E) is the only option that allows the child to urinate without getting up or sitting upright.  The other options either involve sitting up (A), walking to the bathroom (B), standing (D), or are unnecessarily invasive (C).  Using a bedpan while lying down is a standard nursing intervention to facilitate urination for patients who need to remain in a recumbent position.

</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **E. 누워서 소변기에 소변을 보게 한다.**입니다.

**해설:**

요추천자(Lumbar puncture, spinal tap)는 뇌척수액 검사를 위해 척추뼈 사이로 바늘을 삽입하는 시술입니다. 시술 후 가장 흔한 부작용 중 하나는 두통인데, 이는 뇌척수액이 누출되어 발생할 수 있습니다.  두통을 예방하거나 완화하기 위해 요추천자 후에는 일정 시간 동안 **머리를 낮추고 누워있는 자세**를 유지하는 것이 중요합니다.

각 선택지를 분석해 보겠습니다.

* **A. 이동식 변기에 앉힌다.** : 이동식 변기는 침상 옆에서 사용할 수 있어 편리하지만, 앉는 자세는 머리를 높이게 되어 뇌척수액 누출로 인한 두통을 악화시킬 수 있습니다. 따라서 요추천자 직후에는 적절하지 않습니다.

* **B. 화장실을 다녀오게 한다.** : 화장실까지 걸어가고 앉았다 일어나는 동작은 머리를 높이는 것은 물론이고 움직임 자체도 두통을 유발하거나 악화시킬 수 있습니다. 요추천자 직후에는 움직임을 최소화해야 합니다.

* **C. 유치도뇨세트를 준비한다.** : 유치도뇨는 소변을 스스로 볼 수 없는 경우나 수술 후 장시간 침상 안정이 필요한 경우 등에 고려됩니다. 단순 배뇨를 위해 요추천자 직후에 유치도뇨를 시행하는 것은 과도한 처치이며, 감염 등의 위험도 있습니다.

* **D. 침대 위에 서서 소변을 보게 한다.** : 침대 위에 서는 것은 매우 위험하며, 머리를 높이는 자세는 두통을 악화시킬 수 있습니다. 안전 문제와 의학적 측면 모두에서 부적절한 방법입니다.

* **E. 누워서 소변기에 소변을 보게 한다.** : 누운 자세는 머리를 낮게 유지하여 뇌척수액 누출을 최소화하고 두통을 예방하는 데 도움이 됩니다. 소변기는 침상에 누운 상태로 배뇨할 수 있도록 돕는 도구이므로, 요추천자 직후 소변을 보고 싶어하는 환자에게 가장 적절한 간호 보조 활동입니다.

**결론적으로, 요추천자 직후 9세 남아의 배뇨 요구 시 가장 안전하고 적절한 간호 보조는 누워서 소변기에 소변을 보도록 돕는 것입니다.**

**따라서 정답은 E입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">6,580</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="15"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">dental_technician</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,020</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">78</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">「의료법」상 진단서를 교부할 수 있는 의료인은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">약사</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">간호사</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">조산사</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">치과의사</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">방사선사</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">4</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">
The question is asking about who is authorized to issue a medical certificate according to the Medical Service Act in Korea.  I need to determine which of the listed professions is legally authorized to issue a diagnosis certificate (진단서).

Let's analyze each option based on my knowledge of healthcare professions and general understanding of who can make diagnoses and issue medical certificates:

* **A. 약사 (Pharmacist):** Pharmacists are experts in medications. They dispense drugs, counsel patients on drug use, and manage medication therapy.  However, they do not diagnose illnesses or issue medical certificates (진단서).  Their role is primarily related to medication management, not diagnosis.

* **B. 간호사 (Nurse):** Nurses provide direct patient care, administer medications, monitor vital signs, and assist doctors.  While nurses play a crucial role in patient care and assessment,  they are generally not authorized to independently diagnose illnesses or issue medical certificates.  Their role is to assist and implement the care plans prescribed by physicians.  There might be advanced practice nurses with expanded roles in some specific contexts, but generally, in a standard medical setting, nurses don't issue 진단서.

* **C. 조산사 (Midwife):** Midwives specialize in pregnancy, childbirth, and postpartum care. In Korea (and many other countries), midwives are legally recognized healthcare professionals. They can manage normal deliveries, provide prenatal and postnatal care.  Crucially, midwives, within their scope of practice (pregnancy and childbirth), are authorized to make diagnoses related to their specialty and issue certain types of medical certificates related to childbirth.  This is a potential candidate.

* **D. 치과의사 (Dentist):** Dentists are medical professionals specialized in oral health. They diagnose and treat diseases of the teeth, gums, and related structures.  Dentists are definitely authorized to make diagnoses and issue medical certificates (진단서) related to dental conditions.  This is another strong candidate.

* **E. 방사선사 (Radiologic Technologist/Radiographer):** Radiologic technologists operate medical imaging equipment like X-ray, CT, and MRI machines. They are skilled in capturing medical images, but they do not interpret these images or make diagnoses.  Diagnosis based on images is the responsibility of radiologists or other physicians. Radiographers are not authorized to issue medical certificates.


Based on this analysis:

* **Pharmacists (약사)** are not authorized.
* **Nurses (간호사)** are generally not authorized.
* **Midwives (조산사)** might be authorized within their specialty (pregnancy and childbirth).
* **Dentists (치과의사)** are definitely authorized, specifically for dental conditions.
* **Radiologic Technologists (방사선사)** are not authorized.


The question is about who can issue a "진단서" in general under the "의료법" (Medical Service Act).  "진단서" usually implies a medical certificate issued by a physician for a medical condition.  Considering the options and the general understanding of medical practice, both dentists and potentially midwives could issue certain types of 진단서 within their respective scopes.

However, "진단서" (diagnosis certificate) is most commonly associated with physicians (의사).  Looking at the options, "치과의사" (Dentist) is a type of physician, specifically a doctor of dental medicine.  "조산사" (Midwife), while a recognized healthcare professional who can make diagnoses and issue certificates related to childbirth, their scope is more limited compared to a general physician or dentist.

In the context of the Medical Service Act and the general understanding of "진단서,"  the most straightforward and broadly applicable answer would be a medical doctor or a dentist.  Between Dentists and Midwives,  Dentists are more generally and commonly associated with issuing "진단서" in various medical contexts beyond just childbirth.  While midwives can issue certificates related to childbirth,  dentists' authority to issue certificates is within their domain of dental health, and "진단서" in common parlance and legal context often refers to a certificate from a doctor.

Let's consider the term "의료인" (medical personnel/healthcare provider) in the context of the Medical Service Act.  Generally, "의료인" under Korean law includes doctors (의사), dentists (치과의사), oriental medicine doctors (한의사), midwives (조산사), and nurses (간호사).  However, the authority to issue a "진단서" is usually more restricted to doctors, dentists, and oriental medicine doctors, and potentially midwives within their specific domain.

Considering the options provided and the most common understanding of who issues "진단서" under the Medical Service Act,  **Dentists (치과의사)** are definitely authorized to issue diagnosis certificates within their scope of practice (dental and oral health).  Midwives are likely authorized to issue certificates related to childbirth.  Between these two, dentists have a broader scope of issuing "진단서" beyond just pregnancy/childbirth.

If I have to choose the *most* appropriate and generally correct answer from the given options, considering "진단서" in a broader medical context,  **Dentist (치과의사)** seems like the most fitting choice.  While midwives can issue certificates within their specialty, dentists' authority is more broadly recognized for issuing "진단서" related to health conditions within their domain.

Therefore, based on common medical practice, legal context, and the nature of "진단서,"  the most appropriate answer is likely **D. 치과의사 (Dentist)**.

Let's double-check if there's any specific nuance in Korean law that might lean towards midwives more strongly than dentists for issuing "진단서."  However, generally, dentists are unequivocally authorized to issue diagnosis certificates related to dental health.  And "진단서" in a general medical context is often associated with doctors and dentists.

Given the options and the most reasonable interpretation of "의료법" and "진단서,"  **D. 치과의사 (Dentist)** is the most likely and correct answer.  While midwives have a role in issuing certificates related to childbirth, dentists have a more general and broader scope of issuing "진단서" within their field of expertise.  Pharmacists, nurses, and radiographers are clearly not authorized to issue "진단서."

Final Answer Selection:  **D. 치과의사 (Dentist)** appears to be the most appropriate and correct answer.
</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">**정답은 D. 치과의사입니다.**

**해설:**

「의료법」상 진단서를 교부할 수 있는 의료인은 의사, 치과의사, 한의사입니다.  조산사는 제한적으로 출생, 사산, 사망 진단서를 발급할 수 있지만, 일반적인 질병에 대한 진단서는 발급할 수 없습니다. 약사, 간호사, 방사선사는 진단서를 발급할 수 있는 의료인이 아닙니다.

**각 선택지별 설명:**

* **A. 약사 (藥師):** 약사는 의약품 조제 및 복약 지도 등을 담당하는 의료인이지만, 진단 및 진단서 발급 권한은 없습니다.
* **B. 간호사 (看護師):** 간호사는 환자 간호 및 진료 보조 업무를 수행하지만, 독립적으로 진단을 내리고 진단서를 발급할 권한은 없습니다.
* **C. 조산사 (助産師):** 조산사는 임산부, 해산부 및 신생아에 대한 보건과 양호지도를 하며, 분만 시 진찰, 분만 보조 및 분만 후 처치 등을 담당합니다. 「의료법」 제28조에 따라 조산사는 자신이 분만한 출생, 사산, 또는 사망의 증명서를 발급할 수 있습니다. 그러나 일반적인 질병에 대한 진단서는 발급할 수 없습니다.
* **D. 치과의사 (齒科醫師):** 치과의사는 치과 의료를 담당하는 의료인으로, 「의료법」상 진단서를 발급할 수 있는 의료인에 해당됩니다. 치과 질환에 대한 진단서를 발급할 수 있습니다.
* **E. 방사선사 (放射線師):** 방사선사는 방사선 촬영 및 관련 기술 업무를 수행하는 의료기사이며, 진단 및 진단서 발급 권한은 없습니다.


**결론적으로, 「의료법」상 일반적인 진단서를 교부할 수 있는 의료인은 의사, 치과의사, 한의사이며, 제시된 선택지 중에서는 치과의사만이 이에 해당됩니다.**

**따라서 정답은 D입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">4,887</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="16"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">paramedic_1</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,021</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">98</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">소아 환자평가 시 학대를 의심할 수 있는 경우는?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">부모가 전과자인 경우</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">학업 성적이 낮은 경우</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">피부감염이 발생한 경우</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">손상경위와 임상증상이 일치하지 않은 경우</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">엉덩이나 팔, 다리에 몽고반점이 있는 경우</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">4</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to arrive at the correct answer and explanation for the Korean question about child abuse suspicion.

**1. Understanding the Question:**

The question is asking about situations where child abuse should be *suspected* during a pediatric patient evaluation.  The key word here is "suspected." It doesn't mean definitive proof, but rather indicators that should raise a red flag and warrant further investigation.

**2. Analyzing Each Option (and initial thoughts):**

* **A. 부모가 전과자인 경우 (Parents with a criminal record):**
    * **Initial thought:**  This feels discriminatory and not directly indicative of child abuse.  Having a criminal record doesn't automatically make someone an abuser.  It's a *risk factor*, but not a direct sign.
    * **Refinement:** While statistically, individuals with certain criminal histories *might* have a higher risk, it's not a reliable indicator *in itself* to suspect abuse in a clinical setting.  We need more direct signs related to the child.  This option seems weak and possibly biased.

* **B. 학업 성적이 낮은 경우 (Low academic performance):**
    * **Initial thought:**  Many factors can cause low academic performance – learning disabilities, socioeconomic issues, lack of parental support, etc. Child abuse *could* be a contributing factor, but it's very non-specific.
    * **Refinement:**  Low academic performance alone is not a strong indicator of abuse.  It's a symptom of *potential* problems, but too broad.  Abuse is a *possible* cause, but many other more likely causes exist.  This is also weak.

* **C. 피부감염이 발생한 경우 (Skin infection):**
    * **Initial thought:**  Skin infections are common in children.  Poor hygiene *could* be linked to neglect, which is a form of abuse. However, many skin infections are just infections, especially in young children in daycare, etc.
    * **Refinement:**  While neglect *can* lead to skin infections, it's not a direct or reliable indicator of abuse *in general*.  Good hygiene practices vary across families and cultures.  This is also a weak indicator and too broad.

* **D. 손상경위와 임상증상이 일치하지 않은 경우 (Discrepancy between the injury explanation and clinical findings):**
    * **Initial thought:**  This immediately stands out.  If a parent says "the child fell off the bed," but the injuries are inconsistent with a fall from bed height (e.g., spiral fractures, multiple bruises in various stages of healing, injuries in protected areas), that's a huge red flag.  This points to a potential attempt to conceal the true cause of injury.
    * **Refinement:**  This is a *strong* indicator.  Inconsistent stories are a classic sign of potential abuse.  It suggests someone is trying to hide what happened.  This option is very relevant to suspecting abuse.

* **E. 엉덩이나 팔, 다리에 몽고반점이 있는 경우 (Mongolian spots on buttocks, arms, or legs):**
    * **Initial thought:**  Mongolian spots are common birthmarks, especially in Asian populations. They are *not* bruises and are benign.  Confusing them with bruises is a common misconception.  This option is a *distraction* and tests knowledge of normal infant skin markings vs. abuse.
    * **Refinement:**  Mongolian spots are *normal* and *not* a sign of abuse. In fact, *mistaking* them for bruises can lead to *false* accusations of abuse.  This option is definitively *wrong* as an indicator of *suspecting* abuse. It's about *differentiating* normal findings from suspicious ones.

**3. Comparing the Options and Selecting the Best Answer:**

* Options A, B, and C are weak and non-specific. They are not reliable indicators for *suspecting* child abuse in a clinical setting. They might be *correlating factors* in some studies, but not direct clinical signs.
* Option E is the opposite of an indicator of abuse; it's a normal finding that should *not* be mistaken for abuse.
* Option D is the *strongest* and most *direct* clinical indicator of *suspecting* child abuse.  Discrepancies in the story and the physical findings are a major red flag for clinicians.

**4. Formulating the Explanation:**

The explanation needs to:

* Clearly state that **D is the correct answer**.
* Explain *why* D is correct (inconsistency = suspicious).
* Briefly explain *why* the other options are incorrect, focusing on why they are not *direct* or *reliable* indicators of *suspecting* abuse.  For E, it's important to explain what Mongolian spots are and why they are *not* bruises.
* Use clear and concise language, suitable for someone learning about child abuse indicators.

**5.  Korean Language Considerations (for the target audience):**

* Ensure the explanation is in clear and grammatically correct Korean.
* Use appropriate medical terminology in Korean (손상경위, 임상증상, 몽고반점, 피부감염, 학업 성적, 전과자).
* Maintain a respectful and informative tone.


By following these steps of analyzing each option, comparing their relevance to the question, and then constructing a clear explanation in Korean, we arrive at the correct answer (D) and the detailed explanation provided in the initial example.  The key is to focus on the *directness* and *reliability* of each option as a clinical indicator for *suspecting* child abuse.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **D. 손상경위와 임상증상이 일치하지 않은 경우**입니다.

**해설:**

소아 환자 평가 시 학대를 의심해야 하는 가장 중요한 경우는 **손상 경위와 임상 증상이 일치하지 않을 때** 입니다. 이는 보호자가 설명하는 사고나 손상의 원인과 실제 환자의 상태, 손상 부위, 손상 정도 등이 맞지 않는 경우를 의미합니다.  예를 들어, "침대에서 떨어졌다"고 설명하지만, 아이에게는 높은 곳에서 추락해야 생길 수 있는 심각한 골절이나 두부 손상이 있거나, 여러 부위에 다양한 시기의 멍이 발견되는 경우 학대를 의심해야 합니다.

**다른 선택지 설명:**

* **A. 부모가 전과자인 경우:** 부모의 전과 기록은 아동 학대의 위험 요인이 될 수 있지만, **전과 기록만으로 학대를 단정 지을 수는 없습니다.**  모든 전과자가 아동 학대자인 것은 아니며, 전과 기록이 없는 부모도 학대를 저지를 수 있습니다.  전과 기록은 학대 의심의 **추가적인 고려 사항**이 될 수 있지만, 핵심적인 의심 사유는 아닙니다.

* **B. 학업 성적이 낮은 경우:** 학업 성적 저하는 아동 학대의 간접적인 영향일 수 있지만, **학업 성적만으로 학대를 의심하기는 어렵습니다.**  학업 부진의 원인은 다양하며 (학습 장애, 가정 환경 문제, 발달 문제 등), 학대가 아닌 다른 요인일 가능성이 더 높습니다.

* **C. 피부감염이 발생한 경우:** 피부 감염은 위생 상태 불량이나 다른 질환으로 인해 발생할 수 있으며, **피부 감염만으로 학대를 의심하기는 어렵습니다.**  물론 심각한 방임은 피부 감염을 유발할 수 있지만, 피부 감염 자체는 흔한 소아 질환입니다. 방임으로 인한 학대를 의심하려면 다른 증상들과 함께 고려해야 합니다.

* **E. 엉덩이나 팔, 다리에 몽고반점이 있는 경우:** 몽고반점은 동양인에게 흔하게 나타나는 **정상적인 피부 변화**이며, **학대와 전혀 관련이 없습니다.**  오히려 몽고반점을 멍으로 오인하여 학대로 잘못 신고되는 경우가 있습니다. 몽고반점은 출생 시부터 나타나며, 시간이 지나면서 자연적으로 사라집니다.

**결론적으로,** 아동 학대를 의심하는 가장 중요한 단서는 **손상 경위와 임상 증상의 불일치**입니다.  다른 선택지들은 학대와 관련될 수 있지만, 직접적인 의심 사유는 아니며, 오히려 오해를 불러일으킬 수 있습니다.  의료진은 손상 경위와 임상 증상을 면밀히 비교하고, 아동의 안전을 최우선으로 고려하여 신중하게 판단해야 합니다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">7,159</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="17"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">nurse</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,021</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">51</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">흉부외상으로 흉막강 내 혈액이 축적되었을 때 우선적인 사정결과는?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">말초부종</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">말초감각 저하</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">강하고 느린 맥박</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">청진 시 호흡음 감소</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">환측 부위 타진 시 과공명음</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">4</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">
The question is asking about the priority assessment finding when blood accumulates in the pleural space due to chest trauma. This condition is called hemothorax.  Let's analyze each option and see which one is the most relevant and indicative of hemothorax.

* **Hemothorax:** Blood in the pleural space. Pleural space is the space between the visceral and parietal pleura, normally containing a small amount of lubricating fluid. Blood accumulation in this space is usually due to trauma, surgery, or sometimes spontaneously.

* **Consequences of Hemothorax:**
    * **Reduced Lung Expansion:** Blood in the pleural space takes up space, compressing the lung and preventing full expansion. This leads to impaired gas exchange and respiratory distress.
    * **Hypovolemia (if significant blood loss):** Depending on the amount of blood lost, it can lead to hypovolemia and shock.

Let's evaluate each option:

* **A. 말초부종 (Peripheral edema):** Peripheral edema is usually caused by fluid overload, heart failure, kidney problems, or venous insufficiency.  It's not a primary or direct consequence of hemothorax.  While severe hypovolemic shock *could* eventually lead to kidney issues and potentially edema, it's not a *priority* finding or the most direct result.  This is unlikely to be the *primary* or *priority* finding.

* **B. 말초감각 저하 (Decreased peripheral sensation):**  Decreased peripheral sensation can be caused by various conditions, including nerve damage, circulatory problems, or certain neurological conditions.  While severe hypovolemic shock *could* lead to decreased peripheral perfusion and potentially sensory changes, it's not the *most direct* and *priority* finding related to hemothorax itself.  It's a less direct consequence compared to respiratory findings.

* **C. 강하고 느린 맥박 (Strong and slow pulse):**  A strong and slow pulse (bradycardia) is not typically associated with hemothorax.  In fact, in response to blood loss and hypovolemia (if significant), the body usually tries to compensate with an *increased* heart rate (tachycardia) to maintain cardiac output.  Bradycardia might be seen in certain situations like increased intracranial pressure, but not typically in hemothorax. This option is unlikely.

* **D. 청진 시 호흡음 감소 (Decreased breath sounds on auscultation):**  Hemothorax directly affects the lungs. Blood in the pleural space compresses the lung, preventing it from expanding properly.  When auscultating the lungs, the breath sounds over the affected area will be diminished or absent due to the reduced air movement into that part of the lung. This is a *direct* and *primary* physical finding expected in hemothorax.

* **E. 환측 부위 타진 시 과공명음 (Hyperresonance on percussion of the affected side):**  Hyperresonance on percussion indicates increased air in the pleural space, such as in pneumothorax (air in the pleural space).  In hemothorax, the pleural space is filled with blood, which is a fluid. Fluid in the pleural space would generally lead to *dullness* or *flatness* on percussion, not hyperresonance. Hyperresonance is the opposite of what you'd expect in hemothorax.

**Comparing D and others:**

Option D (decreased breath sounds) is the most direct and immediate physical finding expected in hemothorax.  The other options are either less directly related, less likely, or even contradictory to the pathophysiology of hemothorax.

Therefore, the most appropriate answer is D.

**Final Answer Selection Process:**

1. **Understand the condition:** Hemothorax = blood in the pleural space.
2. **Consider the direct effects:** Blood occupies space, compressing the lung.
3. **Evaluate each option based on direct effects and typical findings:**
    * A. Peripheral edema - Indirect, less likely, not priority.
    * B. Decreased peripheral sensation - Indirect, less likely, not priority.
    * C. Strong and slow pulse - Contradictory to typical response to blood loss.
    * D. Decreased breath sounds - Direct result of lung compression, primary finding.
    * E. Hyperresonance on percussion - Opposite of what's expected in fluid accumulation.

4. **Select the best fit:** Option D (decreased breath sounds) is the most direct, relevant, and priority assessment finding in hemothorax.

Therefore, the answer is D.

Let's translate the options and the question to English for clarity:

**Question:** What is the priority assessment finding when blood accumulates in the pleural space due to chest trauma (hemothorax)?

A. Peripheral edema
B. Decreased peripheral sensation
C. Strong and slow pulse
D. Decreased breath sounds on auscultation
E. Hyperresonance on percussion of the affected side

**Conclusion:** The most appropriate answer is D.
</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **D. 청진 시 호흡음 감소**입니다.

**해설:**

흉부외상으로 인해 흉막강 내에 혈액이 축적되는 혈흉(hemothorax)은 폐를 압박하여 폐활량을 감소시키고 가스 교환을 방해합니다.  따라서 가장 우선적으로 나타나는 사정 결과는 호흡기계 변화와 관련된 증상입니다.

각 선택지를 분석해 보겠습니다.

* **A. 말초부종:** 말초부종은 주로 심부전, 신장 질환, 정맥 부전 등 순환기계 문제와 관련이 있으며, 혈흉의 직접적인 우선 사정 결과는 아닙니다. 혈액량 감소로 인해 발생할 수 있지만, 우선적인 증상은 아닙니다.

* **B. 말초감각 저하:** 말초감각 저하는 신경 손상, 말초혈관 질환 등 신경계 또는 혈관 문제와 관련이 깊습니다. 혈흉으로 인한 혈액량 감소로 말초 순환이 감소하여 감각 저하가 나타날 수 있지만, 호흡기계 증상보다 우선적인 사정 결과는 아닙니다.

* **C. 강하고 느린 맥박:** 강하고 느린 맥박 (서맥)은 일반적으로 혈흉과 관련이 없습니다. 오히려 혈액량 감소 시 심박수가 증가하는 빈맥이 나타날 가능성이 높습니다. 서맥은 두개내압 상승, 미주신경 자극 등 다른 상황에서 나타날 수 있습니다.

* **D. 청진 시 호흡음 감소:** 혈흉으로 인해 흉막강 내 혈액이 차면 폐가 압박되어 폐포로의 공기 이동이 감소합니다.  따라서 청진 시 환측 흉부에서 호흡음이 감소하거나 소실되는 것은 혈흉의 가장 직접적이고 우선적인 사정 결과입니다.

* **E. 환측 부위 타진 시 과공명음:** 과공명음은 흉강 내 공기가 증가했을 때 나타나는 타진음으로, 기흉(pneumothorax)의 특징적인 소견입니다. 혈흉은 흉강 내 혈액이 차는 것이므로, 타진 시 둔탁음(dullness)이나 편평음(flatness)이 나타나는 것이 일반적입니다. 과공명음은 혈흉과는 반대되는 소견입니다.


**결론적으로, 흉부외상으로 인한 혈흉 시 가장 우선적으로 사정해야 할 결과는 폐의 압박으로 인한 호흡음 감소입니다.**

**따라서 정답은 D입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,845</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="18"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">dental_technician</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,020</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">73</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">수직 부연결장치가 지나가는 부위의 언더컷(undercut)을 메워주는 과정은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">릴리프(relief)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">등고점(tripoding)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">형성 블록아웃(shaped block out)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">임의 블록아웃(arbitrary block out)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">평행 블록아웃(paralleled block out)</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down this Korean question and arrive at the correct answer.

**1. Deconstructing the Question:**

* **수직 부연결장치 (sujik bu-yeon-gyeol-jang-chi):**  This translates to "vertical minor connector."  In dentistry, this refers to a part of a removable partial denture that connects the major connector (like a palatal bar or lingual bar) to other components like clasps or rests.  Think of it as a supporting arm extending vertically.

* **지나가는 부위 (jinaganeun buwi):**  "Area it passes through" or "area it crosses."  This implies the minor connector is traversing a certain area in the mouth.

* **언더컷 (undercut):**  This is a crucial dental term. An undercut is a recessed area of a tooth or alveolar ridge that is *below* the height of contour. In simpler terms, it's a "cave" or "indentation" that can prevent the insertion and removal of a denture if not properly addressed.  Imagine a tooth with a bulge near the gumline; the area *below* that bulge toward the root is an undercut.

* **메워주는 과정 (mewo-juneun gwajeong):**  "Process of filling in" or "process of blocking out." This indicates we need to eliminate or reduce the undercut.

* **Question summary:** The question is asking for the process of filling in or eliminating undercuts in the area where a vertical minor connector of a removable partial denture will pass.  This is necessary to ensure the denture can be inserted and removed without interference or damage to the tissues.

**2. Analyzing the Answer Choices:**

* **A. 릴리프 (relief):** Relief in dentistry refers to creating space *under* a denture base or connector to prevent pressure on soft tissues.  It's about *reducing* pressure, not necessarily filling undercuts.  While relief is important in denture fabrication, it's not directly related to *filling* undercuts specifically for minor connector placement. It’s more about preventing tissue impingement and ensuring proper seating.

* **B. 등고점 (tripoding):** Tripoding is a technique used in surveying and dentistry to establish a stable and repeatable reference plane.  In dentistry, it's used on casts to orient them consistently on an articulator.  It has nothing to do with filling undercuts for minor connectors.

* **C. 형성 블록아웃 (hyeongseong beulloka-ut):**  "Shaped block out." Block out, in general, means to eliminate undercuts on a cast to facilitate the fabrication of a removable partial denture. "Shaped" implies a specific, contoured block out.  This sounds highly relevant to the question.  We are dealing with a specific structure (minor connector) and need a specific block out shape to accommodate it.

* **D. 임의 블록아웃 (imui beulloka-ut):** "Arbitrary block out." "Arbitrary" means random or not specifically defined. While block out in general is about removing undercuts, "arbitrary" suggests a less precise or uncontrolled method.  For a vertical minor connector, which needs to be accurately positioned and have proper tissue contact, an arbitrary block out is unlikely to be the correct approach.  It might be used in simpler situations or initial blocking out before more refined steps.

* **E. 평행 블록아웃 (pyeonghaeng beulloka-ut):** "Paralleled block out."  Paralleled block out is done using a dental surveyor with the cast oriented on a specific path of insertion.  It aims to create parallel surfaces to guide the denture insertion and removal.  This is a more precise and controlled form of block out.  It sounds very relevant to the placement of a vertical minor connector, which needs to be properly aligned with the path of insertion and avoid interference.

**3. Comparing and Contrasting C and E:**

Both "Shaped block out" and "Paralleled block out" seem related to blocking out undercuts for a minor connector. Let's refine the distinction.

* **Shaped block out (C):**  Focuses on the *shape* of the block out needed to accommodate the minor connector.  This could involve creating a specific contour or form to ensure the minor connector fits smoothly and functions correctly.

* **Paralleled block out (E):**  Emphasizes the *parallelism* of the block out to the path of insertion. This ensures the minor connector is aligned with the overall denture insertion path and avoids creating new undercuts or interferences during insertion/removal.

**4.  Connecting to Minor Connector Function:**

Vertical minor connectors need to be accurately placed and have appropriate tissue contact for support, stability, and retention of the denture.  They also need to be non-interfering during insertion and removal.  Therefore, a precise and controlled block out is necessary.

**5.  Choosing the Best Answer:**

While "shaped block out" (C) is generally relevant, "paralleled block out" (E) is more specific and accurate in the context of vertical minor connectors.  Paralleled block out is performed using a surveyor and takes into account the path of insertion, which is crucial for the function and comfort of a removable partial denture.  It's a more refined and standard procedure for creating space for components like minor connectors.

**6. Conclusion:**

The most appropriate answer is **E. 평행 블록아웃 (paralleled block out)** because it's the most precise and relevant technique for eliminating undercuts in the path of insertion for a vertical minor connector, ensuring proper denture fit and function.  While shaped block out is a broader term, paralleled block out is the more specific and technically correct method in this scenario.

**Final Answer: E**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **E. 평행 블록아웃(paralleled block out)** 입니다.

**해설:**

* **수직 부연결장치:** 가철성 국소 의치(틀니)의 주요 연결 장치(예: 구개부 연결장치, 설측 연결장치)와 다른 구성 요소(예: 유지 장치, 지지 장치)를 연결하는 수직으로 뻗은 작은 연결 장치입니다.

* **언더컷(Undercut):** 치아나 치조골의 특정 부위가 가장 볼록한 부분(height of contour) 아래로 움푹 들어간 부분입니다. 언더컷은 가철성 의치의 삽입 및 제거 경로를 방해하여 의치가 제대로 장착되지 못하게 하거나, 무리하게 삽입/제거 시 구강 조직에 손상을 줄 수 있습니다.

* **블록아웃(Block out):**  작업 모형 상에서 언더컷을 제거하거나 메워주는 과정입니다. 이는 의치의 삽입 및 제거 경로를 용이하게 하고, 의치 제작 과정에서 불필요한 변형이나 손상을 방지하기 위해 필수적입니다.

이제 각 선택지를 살펴보겠습니다.

* **A. 릴리프(Relief):** 릴리프는 의치상 또는 연결 장치 아래에 공간을 두어 특정 부위에 압력이 집중되는 것을 방지하는 과정입니다. 언더컷을 메우는 것과는 직접적인 관련이 적습니다.

* **B. 등고점(Tripoding):** 등고점은 작업 모형을 특정한 위치에 안정적으로 고정하고, 모형의 위치를 재현하기 위한 과정입니다. 언더컷 제거와는 관련이 없습니다.

* **C. 형성 블록아웃(Shaped block out):** 형성 블록아웃은 특정 형태를 부여하여 언더컷을 메우는 블록아웃 방법입니다.  수직 부연결장치가 지나가는 부위에 적합할 수 있지만, 좀 더 포괄적인 개념입니다.

* **D. 임의 블록아웃(Arbitrary block out):** 임의 블록아웃은 특별한 기준 없이 임의로 언더컷을 메우는 방법입니다. 정밀한 의치 제작에는 적합하지 않습니다.

* **E. 평행 블록아웃(Paralleled block out):** 평행 블록아웃은 의치의 삽입 및 제거 경로와 평행하게 언더컷을 메우는 방법입니다.  수직 부연결장치는 의치의 삽입 경로와 평행하게 설계되는 경우가 많으므로, **평행 블록아웃이 수직 부연결장치가 지나가는 부위의 언더컷을 메워주는 가장 적절한 과정**입니다.  평행 블록아웃을 통해 수직 부연결장치가 언더컷에 걸리지 않고 원활하게 삽입 및 제거될 수 있도록 공간을 확보할 수 있습니다.

**결론적으로, 수직 부연결장치가 지나가는 부위의 언더컷을 메워주는 과정은 의치의 삽입 경로를 고려하여 평행하게 언더컷을 제거하는 "평행 블록아웃"이 가장 적합합니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">4,949</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="19"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">nurse_assistant</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,022</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">47</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">인체에서 비타민D가 형성되도록 작용하고, 도르노선(건강선)이 있는 광선은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">α선</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">X선</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">적외선</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">자외선</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">가시광선</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">4</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to answer the question about vitamin D synthesis and the Dorno ray (health ray).

**1. Understanding the Question (Korean to English and Key Terms):**

The question is in Korean and asks: "인체에서 비타민D가 형성되도록 작용하고, 도르노선(건강선)이 있는 광선은?"

Let's translate and break down the key terms:

* **인체에서 (inche-eseo):** in the human body
* **비타민D (bitamin-D):** Vitamin D
* **형성되도록 작용하고 (hyeongseongdoerok jagyonghago):** works to form/synthesize/enable formation
* **도르노선 (doreuno-seon):** Dorno ray (also known as *건강선* - geon-gang-seon)
* **(건강선) ((geon-gang-seon)):** (health ray) - clarification of Dorno ray
* **있는 광선은? (inneun gwangseon-eun?):** which light ray is it?  (The "-eun" is a topic marker, and "-eun?" is a question marker)

So, the question is essentially asking:  "Which light ray acts in the human body to form Vitamin D and is also known as the Dorno ray (health ray)?"

**2. Recalling Knowledge about Vitamin D and Sunlight:**

My knowledge base immediately connects vitamin D synthesis with sunlight.  I recall learning that exposure to sunlight is crucial for the body to produce vitamin D.  More specifically, I know it's a certain *type* of sunlight.

**3. Considering the Options and Eliminating Incorrect Choices:**

Now let's go through each option and analyze if it fits the criteria (Vitamin D synthesis and Dorno ray):

* **A. α선 (alpha-seon): α-rays:**  Alpha rays are a type of particle radiation, not electromagnetic radiation (light). They are associated with radioactive decay.  They are *not* involved in vitamin D synthesis and are not the Dorno ray.  **Eliminate A.**

* **B. X선 (X-seon): X-rays:** X-rays are high-energy electromagnetic radiation. They are used for medical imaging because they can penetrate soft tissues. While they are part of the electromagnetic spectrum, they are *not* the primary type of sunlight responsible for vitamin D synthesis.  X-rays are also generally considered harmful in excessive amounts and not associated with "health rays."  **Eliminate B.**

* **C. 적외선 (jeok-oe-seon): Infrared rays:** Infrared rays are associated with heat.  While sunlight contains infrared, it's primarily responsible for warming us.  Infrared is not directly involved in vitamin D synthesis. It is also not known as the Dorno ray. **Eliminate C.**

* **D. 자외선 (ja-oe-seon): Ultraviolet rays:** Ultraviolet (UV) rays *are* the part of sunlight strongly linked to vitamin D synthesis. I recall learning that UVB rays, specifically, are crucial for the photochemical reaction in the skin that produces vitamin D.  The term "Dorno ray" or "health ray" is less common in modern scientific language but historically, and sometimes still, refers to UV rays, specifically the beneficial aspects. **This is a strong candidate.**

* **E. 가시광선 (gasi-gwangseon): Visible light:** Visible light is what we can see – the colors of the rainbow.  While sunlight *contains* visible light, it's not the primary driver of vitamin D synthesis. Visible light is essential for vision and photosynthesis in plants, but not directly for vitamin D in humans in the same way UV is.  It's not the Dorno ray in the context of vitamin D and health. **Eliminate E.**

**4. Confirming the Dorno Ray (건강선) Connection:**

To be absolutely certain, I can mentally (or actually if needed) search for "Dorno ray" or "건강선" and "vitamin D."  A quick search confirms that the Dorno ray, or *건강선* (health ray), is indeed an older term referring to the beneficial UV rays, specifically those responsible for vitamin D production.  It's sometimes used in more holistic or alternative health contexts.  While not a strictly scientific term in mainstream modern science, it's historically and colloquially linked to the beneficial effects of UV.

**5. Selecting the Best Answer:**

Based on the above reasoning, **D. 자외선 (Ultraviolet rays)** is the correct answer. It is the light ray responsible for vitamin D synthesis in the human body, and it is also historically associated with the term "Dorno ray" or "health ray."

**Final Answer Selection and Confidence:**

I am confident that **D. 자외선** is the correct answer.  The question is clearly designed to test knowledge of vitamin D synthesis and the historical/alternative health term "Dorno ray," both of which point directly to ultraviolet radiation.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **D. 자외선**입니다.

**해설:**

* **비타민 D 형성:** 자외선, 특히 UVB는 피부에서 비타민 D를 합성하는 데 필수적인 역할을 합니다. 자외선이 피부에 닿으면 피부 속 7-디하이드로콜레스테롤이라는 물질이 비타민 D3로 변환됩니다.
* **도르노선 (건강선):** 도르노선은 자외선을 가리키는 다른 이름입니다. 과거에는 자외선의 건강 증진 효과 (비타민 D 합성, 살균 작용 등)를 강조하며 도르노선 또는 건강선이라고 불렀습니다.

**각 선택지별 설명:**

* **A. α선 (알파선):** 방사선의 일종으로, 인체 투과력이 매우 약하며 비타민 D 합성과 관련이 없습니다.
* **B. X선 (엑스선):** 높은 에너지를 가진 전자기파로, 의료 영상 촬영 등에 사용되지만 비타민 D 합성과 관련이 없으며, 과다 노출 시 인체에 해롭습니다.
* **C. 적외선 (저외선):** 열 작용을 하는 전자기파로, 온열 치료 등에 사용되지만 비타민 D 합성과 관련이 없습니다.
* **D. 자외선 (자외선):** 비타민 D 합성에 필수적이며, 도르노선 (건강선)으로 불리기도 합니다. 과다 노출 시 피부암, 화상 등의 위험이 있지만 적절한 양의 노출은 건강에 유익합니다.
* **E. 가시광선 (가시광선):** 우리가 눈으로 볼 수 있는 빛으로, 비타민 D 합성에 직접적인 역할을 하지는 않습니다.

**따라서, 인체에서 비타민D가 형성되도록 작용하고, 도르노선(건강선)이 있는 광선은 자외선입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">6,543</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="20"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">dental_technician</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,019</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">7</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">납형(wax pattern)을 제작할 때 치아의 최대 풍융부가 과풍융 (over contouring)될 경우에 나타나는 현상은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">자정작용이 잘된다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">치주조직을 강화한다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">유리치은에 염증이 발생한다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">생리적 마사지의 효과가 있다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">치경부에 음식물 잔사가 저류되는 것을 막는다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">3</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to arrive at the correct answer and explanation for the question about over-contoured wax patterns in dentistry.

**1. Understanding the Question:**

The question is asking about the *consequences* of *over-contouring* the maximum convexity (greatest bulge or widest point) of a tooth when creating a wax pattern.  This is in the context of dental restorations (like crowns, bridges, etc.) where wax patterns are used to create the final prosthetic.

**2. Defining Key Terms:**

* **Wax Pattern (납형):**  A wax replica of the tooth or teeth being restored. It's used as a mold to create the final restoration in metal, ceramic, or other materials.
* **Maximum Convexity (최대 풍융부):** The widest part of the tooth's crown, both buccolingually (cheek-to-tongue) and mesiodistally (front-to-back). This is crucial for proper function, esthetics, and periodontal health.
* **Over-Contouring (과풍융):** Making the maximum convexity *too* prominent or bulging.  This means the restoration (if based on this wax pattern) will be wider than the natural tooth should be at that point.
* **Self-Cleansing Action (자정작용):** The natural cleaning of the teeth by saliva, tongue, cheeks, and chewing forces.  Proper contours are essential for this.
* **Periodontal Tissue (치주조직):** The tissues surrounding and supporting the teeth: gums (gingiva), periodontal ligament, cementum, and alveolar bone.
* **Free Gingiva (유리치은):** The unattached portion of the gingiva, forming a collar around the tooth. It's the most susceptible part of the gingiva to inflammation.
* **Physiological Massage (생리적 마사지):** The gentle stimulation of the gingiva during chewing, which promotes healthy blood circulation and keratinization of the gingiva.  Proper contours contribute to this.
* **Food Impaction (음식물 잔사 저류):** Food getting trapped between teeth and the gingiva, often due to improper contours.
* **Cervical Area (치경부):** The neck of the tooth, where the crown meets the root, and where the gingiva attaches.

**3. Analyzing Each Answer Choice in Relation to Over-Contouring:**

* **A. 자정작용이 잘된다. (Self-cleansing is good.):**  *Incorrect.* Over-contouring creates areas where saliva and the tongue can't easily reach to clean.  Food debris and plaque will accumulate more easily.  Therefore, self-cleansing will be *impaired*, not improved.

* **B. 치주조직을 강화한다. (Strengthens periodontal tissue.):** *Incorrect.* Over-contouring is detrimental to periodontal tissue.  It can lead to food impaction, plaque accumulation, and gingival inflammation.  It *weakens*, not strengthens, periodontal tissues.

* **C. 유리치은에 염증이 발생한다. (Inflammation occurs in the free gingiva.):** *Correct.* This is the most direct and common consequence of over-contouring. The excess contour presses on the free gingiva, creating a sheltered area for plaque and bacteria to accumulate. This leads to gingivitis (inflammation of the gingiva).

* **D. 생리적 마사지의 효과가 있다. (Has the effect of physiological massage.):** *Incorrect.*  Proper contours, not over-contours, contribute to physiological massage. Over-contouring can actually hinder this natural massaging action as the tongue and cheeks may not properly stimulate the gingiva during function. Instead, it can lead to trauma from food impaction and improper forces.

* **E. 치경부에 음식물 잔사가 저류되는 것을 막는다. (Prevents food debris from accumulating at the cervical area.):** *Incorrect.*  Over-contouring, especially at the cervical area, actually *promotes* food impaction.  It creates ledges and areas where food can get trapped and compressed against the gingiva.  Proper contours, on the other hand, are designed to direct food away from the gingival margin.

**4.  Connecting Over-Contouring to Periodontal Health (The Core Concept):**

The central theme here is the relationship between tooth contours and periodontal health.  Proper tooth contours are crucial for:

* **Gingival Health:**  Allowing for proper gingival adaptation and preventing irritation.
* **Self-Cleansing:** Facilitating natural cleaning by saliva, tongue, and cheeks.
* **Food Deflection:** Directing food away from the gingival sulcus (the space between the tooth and gingiva).
* **Occlusal Harmony:**  Ensuring proper bite forces and distribution.

Over-contouring disrupts all of these. It leads to:

* **Gingival Irritation/Inflammation:**  Direct pressure and plaque accumulation.
* **Impaired Self-Cleansing:**  Areas difficult to clean.
* **Food Impaction:**  Trapping food against the gingiva.
* **Potential Occlusal Problems:**  Interference with proper bite.

**5.  Formulating the Explanation:**

Based on the above analysis, the correct answer is C.  The explanation should clearly articulate *why* over-contouring leads to gingival inflammation.  This involves:

* **Direct Pressure:** The over-contoured area pushes against the free gingiva.
* **Plaque Accumulation:**  The over-contour creates a protected area where plaque and bacteria thrive because self-cleansing is reduced.
* **Gingivitis:** This plaque accumulation and irritation cause inflammation of the gingiva (gingivitis).

**6.  Review and Refine:**

Reread the question, answer choices, and explanation to ensure everything is clear, concise, and accurate.  Confirm that the explanation directly addresses why C is correct and why the other options are incorrect.  Make sure the terminology is appropriate for a dental context.

This systematic approach, starting from understanding the question and key terms, analyzing each option, and focusing on the core concept of periodontal health and tooth contours, leads to the correct answer and a comprehensive explanation.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **C. 유리치은에 염증이 발생한다.** 입니다.

**해설:**

납형 제작 시 치아의 최대 풍융부를 과풍융(over contouring)하게 되면 다음과 같은 현상이 나타납니다.

* **유리치은 염증 발생:** 과도하게 볼록하게 형성된 최대 풍융부는 잇몸(유리치은)에 압박을 가하게 됩니다. 이는 치태와 음식물 잔사가 쉽게 축적되는 환경을 조성하고, 잇몸을 자극하여 염증을 유발합니다. 특히 유리치은은 치아와 직접 맞닿아 있어 더욱 민감하게 반응합니다.

**오답 해설:**

* **A. 자정작용이 잘된다:** 과풍융은 오히려 자정작용을 방해합니다.  정상적인 치아 형태는 혀와 볼, 입술의 움직임, 그리고 타액의 흐름을 통해 자연스럽게 치아가 세척되는 자정작용을 돕습니다. 하지만 과풍융은 이러한 자연적인 세척 작용을 어렵게 만들어 치태와 음식물 잔사가 쉽게 축적됩니다.

* **B. 치주조직을 강화한다:** 과풍융은 치주조직에 오히려 해로운 영향을 미칩니다. 지속적인 압박과 염증은 치주조직을 약화시키고, 치주 질환을 유발할 수 있습니다.

* **D. 생리적 마사지의 효과가 있다:**  정상적인 치아 형태는 저작 운동 시 잇몸에 적절한 생리적 마사지 효과를 제공하여 혈액 순환을 촉진하고 잇몸 건강을 유지하는 데 도움을 줍니다. 하지만 과풍융은 오히려 잇몸에 과도한 압박을 가하거나, 정상적인 자극을 방해하여 생리적 마사지 효과를 저해합니다.

* **E. 치경부에 음식물 잔사가 저류되는 것을 막는다:** 과풍융은 오히려 치경부(치아와 잇몸 경계 부위)에 음식물 잔사가 더 쉽게 저류되도록 만듭니다. 과도하게 돌출된 부위는 음식물이 걸리기 쉽고, 칫솔질로도 깨끗하게 제거하기 어려워 충치나 치주 질환의 위험을 높입니다.

**결론적으로, 납형 제작 시 최대 풍융부의 과풍융은 치주 건강에 부정적인 영향을 미치며, 특히 유리치은에 염증을 유발하는 주요 원인이 됩니다.** 따라서 납형 제작 시에는 적절한 치아 형태와 풍융도를 재현하는 것이 매우 중요합니다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">4,752</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="21"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">dental_technician</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,021</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">45</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">치과용 석고제품 중 압축강도가 가장 낮은 것은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">경석고</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">보통석고</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">인상용석고</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">저팽창용 초경석고</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">고팽창용 초경석고</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">3</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to arrive at the correct answer to the question "치과용 석고제품 중 압축강도가 가장 낮은 것은?" (Among dental gypsum products, which has the lowest compressive strength?).

1. **Understanding the Question:** The question is asking about the compressive strength of different types of dental gypsum.  "가장 낮은" (lowest) is the key phrase.  We need to identify the gypsum product with the *weakest* compressive strength.

2. **Translating and Identifying Key Terms:**  Let's translate and understand the options:
    * 치과용 석고제품 (chigwa-yong seokgo-jepum): Dental gypsum products
    * 압축강도 (apchuk-gangdo): Compressive strength
    * 가장 낮은 (gajang najeun): Lowest, weakest
    * A. 경석고 (gyeong-seokgo):  Dental Stone (Type III) - often translated as "hard stone" or "dental stone, hard" in English.
    * B. 보통석고 (botong-seokgo): Plaster (Type II) - often translated as "model plaster" or "dental plaster".
    * C. 인상용석고 (insang-yong seokgo): Impression Plaster (Type I) - specifically for dental impressions.
    * D. 저팽창용 초경석고 (jeo-paengchang-yong cho-gyeong-seokgo): Low-expansion die stone (Type IV).  "초경석고" (cho-gyeong-seokgo) means "super hard stone" or "die stone." "저팽창용" (jeo-paengchang-yong) means "low expansion."
    * E. 고팽창용 초경석고 (go-paengchang-yong cho-gyeong-seokgo): High-expansion die stone (Type V). "고팽창용" (go-paengchang-yong) means "high expansion."

3. **Recalling Knowledge about Dental Gypsum Types:**  My knowledge base about dental materials immediately brings to mind the classification of dental gypsum products based on ADA (American Dental Association) specifications (or similar international standards).  These are categorized by type, roughly related to their strength and application:

    * **Type I: Impression Plaster:**  Weakest.  Designed for taking impressions, where detail reproduction is more important than high strength.  Easy to separate from the impression.
    * **Type II: Model Plaster:**  Slightly stronger than impression plaster. Used for study models, mounting casts on articulators, etc. Still relatively weak.
    * **Type III: Dental Stone (or Hard Stone):** Stronger than plaster. Used for working casts, diagnostic casts, and denture bases.  More durable and resistant to abrasion than plaster.
    * **Type IV: Die Stone (Low Expansion):**  Significantly stronger than dental stone.  High compressive strength and abrasion resistance. Low setting expansion for accurate dies used in crown and bridge fabrication.
    * **Type V: Die Stone (High Expansion):**  Similar to Type IV in strength but with controlled, higher setting expansion to compensate for the shrinkage of certain casting alloys.

4. **Relating Knowledge to the Options:** Now, let's match the options to the types and their relative strengths:

    * A. 경석고 (Dental Stone) - Type III -  Moderate strength.
    * B. 보통석고 (Plaster) - Type II -  Weaker strength than stone.
    * C. 인상용석고 (Impression Plaster) - Type I -  Weakest strength.
    * D. 저팽창용 초경석고 (Low-expansion die stone) - Type IV -  Highest strength (among these options).
    * E. 고팽창용 초경석고 (High-expansion die stone) - Type V -  Highest strength (similar to Type IV, among these options).

5. **Determining the Weakest:**  Based on the classification and understanding of the properties, Impression Plaster (Type I) is clearly the weakest among the given options.

6. **Selecting the Answer:**  Therefore, the answer is **C. 인상용석고 (Impression Plaster)**.

7. **Verification (Self-Correction/Confirmation):**  To double-check, I quickly review the characteristics of each gypsum type again.  Impression plaster is indeed formulated to be weak and easily broken, facilitating removal from the mouth and model separation.  Plaster is stronger, stone stronger still, and die stones are the strongest.  The question specifically asks for the *lowest* compressive strength, so Impression Plaster fits perfectly.  The other options are all stronger gypsum products.

This systematic process of translation, recall, comparison, and verification leads confidently to the correct answer, C.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **C. 인상용 석고**입니다.

**해설:**

치과용 석고 제품은 용도에 따라 다양한 종류가 있으며, 압축강도는 각 제품의 주요 특성 중 하나입니다. 압축강도는 석고가 압력에 얼마나 잘 견디는지를 나타내는 지표로, 높을수록 단단하고 강한 석고를 의미합니다.

각 석고 제품별 압축강도를 비교하면 다음과 같습니다.

* **인상용 석고 (Impression Plaster):**  **가장 낮은 압축강도**를 가집니다.  인상 채득 시 구강 내에서 쉽게 제거될 수 있도록 약하게 만들어졌으며, 정밀한 재현성보다는 용이한 제거에 초점을 맞춥니다.

* **보통 석고 (Model Plaster):** 인상용 석고보다는 강하지만, 경석고나 초경석고보다는 **압축강도가 낮습니다**. 주로 진단 모형 제작이나 교정 모형 제작 등 비교적 강도가 덜 요구되는 용도에 사용됩니다.

* **경석고 (Dental Stone):** 보통 석고보다 **압축강도가 높습니다**. 작업 모형, 왁스업, 의치상 제작 등 어느 정도 강도가 필요한 용도에 사용됩니다.

* **초경석고 (Die Stone):**  **압축강도가 가장 높습니다**.  정밀한 보철물 제작을 위한 다이 모형 제작에 사용되며, 높은 강도와 내마모성이 요구됩니다. 저팽창용 초경석고와 고팽창용 초경석고 모두 경석고보다 훨씬 높은 압축강도를 가집니다.

**따라서, 치과용 석고 제품 중 압축강도가 가장 낮은 것은 인상용 석고입니다.**

**추가 설명:**

* **압축강도 순서 (낮은 순 -> 높은 순):**  인상용 석고 &lt; 보통 석고 &lt; 경석고 &lt; 초경석고 (저팽창용, 고팽창용)

이러한 압축강도의 차이는 석고 제조 과정에서 사용되는 석고 입자의 형태, 크기, 물-석고 비율 등에 의해 결정됩니다.

**결론적으로 정답은 C 입니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5,013</div></div>
							</td>
					</tr><tr class="group cursor-pointer space-x-4 divide-x border-b outline-offset-[-2px] odd:bg-gray-50 hover:bg-gray-100 dark:odd:bg-gray-925 dark:hover:bg-gray-850  last:border-none" tabindex="0" data-row-idx="22"><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">dental_technician</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2,022</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">1</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">절치공을 통과하여 경구개의 전방 부위를 지배하는 신경은?</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">대구개신경</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">비구개신경</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">소구개신경</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">전상치조신경</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">중상치조신경</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">2</div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">Let's break down the thought process to arrive at the correct answer for the Korean question about nerves innervating the anterior hard palate via the incisive canal.

**1. Deconstructing the Question (Korean to English Translation and Key Terms)**

* **절치공 (jeolchi-gong):**  This translates to "incisive foramen" or "incisive canal."  This is a crucial anatomical landmark.
* **통과하여 (tong-gwaha-yeo):**  "Passing through" or "going through." This indicates the nerve passes through the incisive canal.
* **경구개 (gyeong-gu-gae):** "Hard palate."  This is the area of innervation.
* **전방 부위 (jeon-bang bu-wi):** "Anterior portion" or "front part." This specifies the region of the hard palate.
* **지배하는 신경 (ji-bae-ha-neun sin-gyeong):** "Nerve that innervates" or "nerve controlling." This is asking for the nerve's name.
* **신경 (sin-gyeong):** "Nerve."

**Putting it together in English:**  "Which nerve passes through the incisive canal to innervate the anterior portion of the hard palate?"

**Key Anatomical Concepts:**

* **Incisive Canal/Foramen:**  A passageway in the anterior midline of the hard palate, located just behind the central incisors.  It connects the nasal cavity and the oral cavity.
* **Hard Palate Innervation:** The hard palate is primarily innervated by branches of the maxillary nerve (V2), a branch of the trigeminal nerve (V).

**2. Analyzing the Answer Choices and Eliminating Incorrect Options**

Let's go through each option and consider its anatomical relevance:

* **A. 대구개신경 (dae-gu-gae sin-gyeong): Greater palatine nerve**
    * "대" (dae) means "large" or "greater."
    * "구개" (gu-gae) means "palate."
    * The greater palatine nerve emerges from the greater palatine foramen, located in the posterior hard palate (near the molars).  It innervates the *posterior* hard palate and gingiva.  Therefore, this is *unlikely* to be the answer as the question specifies the *anterior* hard palate.

* **B. 비구개신경 (bi-gu-gae sin-gyeong): Nasopalatine nerve**
    * "비" (bi) relates to "nose" or "nasal."
    * "구개" (gu-gae) means "palate."
    * The nasopalatine nerve is known to pass through the incisive canal/foramen. It originates from the sphenopalatine ganglion and travels along the nasal septum before entering the incisive canal to reach the anterior hard palate. This is a *strong candidate*.

* **C. 소구개신경 (so-gu-gae sin-gyeong): Lesser palatine nerve**
    * "소" (so) means "small" or "lesser."
    * "구개" (gu-gae) means "palate."
    * The lesser palatine nerve emerges from the lesser palatine foramen, located *posterior* to the greater palatine foramen. It primarily innervates the *soft palate* and tonsillar area.  It does *not* innervate the anterior hard palate and does not pass through the incisive canal.  This is *unlikely*.

* **D. 전상치조신경 (jeon-sang-chi-jo sin-gyeong): Anterior superior alveolar nerve (ASA)**
    * "전상" (jeon-sang) means "anterior superior."
    * "치조" (chi-jo) refers to the "alveolar process" (the bone supporting the teeth).
    * The ASA nerve innervates the anterior maxillary teeth (incisors, canines) and the *buccal* gingiva (cheek side) in the anterior maxilla. It runs within the maxillary bone and emerges onto the face. It does *not* pass through the incisive canal and primarily innervates teeth and buccal gingiva, not the palatal mucosa directly.  This is *unlikely*.

* **E. 중상치조신경 (jung-sang-chi-jo sin-gyeong): Middle superior alveolar nerve (MSA)**
    * "중상" (jung-sang) means "middle superior."
    * "치조" (chi-jo) refers to the "alveolar process."
    * The MSA nerve innervates the premolars, and sometimes the mesiobuccal root of the maxillary first molar, along with the buccal gingiva in the premolar region.  Like the ASA, it runs within the maxillary bone and doesn't pass through the incisive canal to innervate the hard palate.  This is *unlikely*.

**3. Confirmation and Conclusion**

Based on the anatomical knowledge and elimination process:

* **Nasopalatine nerve (비구개신경)** is the only nerve that correctly matches the description of passing through the incisive canal and innervating the anterior hard palate.

Therefore, the answer is **B. 비구개신경**.

**Final Answer Justification (in Korean, as requested):**

절치공은 경구개의 전방 중앙부에 위치하며, 비구개신경이 이 구멍을 통과하여 경구개의 전방 부위, 특히 앞니 부위의 점막과 골막을 지배합니다.  대구개신경은 후방 경구개를, 소구개신경은 연구개를 지배하며, 상치조신경들은 치아와 치조골, 그리고 뺨쪽 잇몸을 지배합니다. 따라서 절치공을 통과하여 경구개의 전방 부위를 지배하는 신경은 비구개신경이 가장 적절합니다.</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="" dir="auto"><span class="">정답은 **B. 비구개신경**입니다.

**해설:**

* **절치공 (Incisive foramen):**  경구개의 정중선, 앞니 바로 뒤에 위치한 구멍입니다.
* **비구개신경 (Nasopalatine nerve):**  접형구개신경절에서 기원하여 비강을 통해 내려와 절치공을 통과하여 경구개의 전방 부위, 특히 앞니 부위의 점막과 골막을 지배하는 감각 신경입니다.

**다른 선택지 설명:**

* **A. 대구개신경 (Greater palatine nerve):**  대구개공을 통해 경구개로 나와 구치 부위의 경구개 점막과 잇몸을 지배합니다. 절치공을 통과하지 않으며 경구개의 전방 부위를 지배하지 않습니다.
* **C. 소구개신경 (Lesser palatine nerve):**  소구개공을 통해 나와 연구개와 편도 부위를 지배합니다. 경구개를 지배하지 않습니다.
* **D. 전상치조신경 (Anterior superior alveolar nerve):**  상악동 전벽 내에서 주행하며 상악 전치와 견치, 그리고 해당 부위의 뺨쪽 잇몸과 상악동 전방 부위를 지배합니다. 경구개를 직접 지배하지 않으며 절치공을 통과하지 않습니다.
* **E. 중상치조신경 (Middle superior alveolar nerve):**  상악동 외벽 내에서 주행하며 상악 소구치와 제1대구치의 근심협측치근, 그리고 해당 부위의 뺨쪽 잇몸과 상악동 측벽 부위를 지배합니다. 경구개를 직접 지배하지 않으며 절치공을 통과하지 않습니다.

**따라서 절치공을 통과하여 경구개의 전방 부위를 지배하는 신경은 비구개신경이 가장 정확합니다.**</span></div></div>
							</td><td class="min-w-fit max-w-sm break-words p-2 "><div class="line-clamp-2 "><div class="text-right" dir="auto">5,135</div></div>
							</td>
					</tr></tbody></table>
		<div class="bg-linear-to-b sticky left-0 border-t border-dashed border-gray-300 from-gray-100 to-white py-3 text-center font-mono text-xs dark:border-gray-700 dark:from-gray-950 dark:to-gray-900">End of preview. <a href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/viewer/default/train" class="group"><span class="underline decoration-gray-300 group-hover:decoration-gray-400 dark:decoration-gray-500 dark:group-hover:decoration-gray-300">Expand</span>
						in <svg class="text-lg mr-0.5 inline -translate-y-px text-red-500" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 12 12"><path fill="currentColor" d="M2.5 2h7a1 1 0 0 1 1 1v6a1 1 0 0 1-1 1h-7a1 1 0 0 1-1-1V3a1 1 0 0 1 1-1Zm0 2v2h3V4h-3Zm4 0v2h3V4h-3Zm-4 3v2h3V7h-3Zm4 0v2h3V7h-3Z"></path></svg>Data Studio
					</a></div></div>




			<div class="bg-linear-to-b from-gray-100 to-white dark:from-gray-950 dark:to-gray-900 "><hr class="flex-none -translate-y-px border-t border-dashed border-gray-300 bg-white dark:border-gray-700 dark:bg-gray-950">
					<nav><ul class="flex select-none items-center justify-between space-x-2 text-gray-700 sm:justify-center py-1 text-center font-mono text-xs rounded-b-lg"><li><a class="flex items-center rounded-lg px-2.5 py-1 hover:bg-gray-50 dark:hover:bg-gray-800 pointer-events-none cursor-default text-gray-400 hover:text-gray-700" href=""><svg class="mr-1.5" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M10 16L20 6l1.4 1.4l-8.6 8.6l8.6 8.6L20 26z" fill="currentColor"></path></svg>
		Previous</a></li>
			<li class="hidden sm:block"><a class="rounded-lg px-2.5 py-1 bg-gray-50 font-semibold ring-1 ring-inset ring-gray-200 dark:bg-gray-900 dark:text-yellow-500 dark:ring-gray-900 hover:bg-gray-50 dark:hover:bg-gray-800" href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/viewer/default/train?p=0">1</a>
				</li><li class="hidden sm:block"><a class="rounded-lg px-2.5 py-1  hover:bg-gray-50 dark:hover:bg-gray-800" href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/viewer/default/train?p=1">2</a>
				</li><li class="hidden sm:block"><a class="rounded-lg px-2.5 py-1  hover:bg-gray-50 dark:hover:bg-gray-800" href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/viewer/default/train?p=2">3</a>
				</li><li class="hidden sm:block"><a class="rounded-lg px-2.5 py-1  pointer-events-none cursor-default" href="#">...</a>
				</li><li class="hidden sm:block"><a class="rounded-lg px-2.5 py-1  hover:bg-gray-50 dark:hover:bg-gray-800" href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/viewer/default/train?p=87">88</a>
				</li>
			<li><a class="flex items-center rounded-lg px-2.5 py-1 hover:bg-gray-50 dark:hover:bg-gray-800 " href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/viewer/default/train?p=1">Next
		<svg class="ml-1.5 transform rotate-180" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M10 16L20 6l1.4 1.4l-8.6 8.6l8.6 8.6L20 26z" fill="currentColor"></path></svg></a></li></ul></nav></div></div>






</div></div></div></div></div></div></div>

				
					<div class="SVELTE_HYDRATER contents" data-target="RepoCodeCopy" data-props="{}"><div></div></div>
					

					<div class="SVELTE_HYDRATER contents" data-target="SideNavigation" data-props="{&quot;titleTree&quot;:[],&quot;classNames&quot;:&quot;top-6&quot;}">

</div>
					<div class="2xl:pr-6"><div class="prose pl-6 -ml-6 hf-sanitized hf-sanitized-pfYj6XeKgrbqYSaNVaOOz">
	<!-- HTML_TAG_START --><h1 class="relative group flex items-center">
	<a rel="nofollow" href="#information" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="information">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Information
	</span>
</h1>
<p>This data includes the training data from KorMedMCQA, as well as a portion of the trainind data from the <strong>additional KorMedMCQA support set (private)</strong>.
This dataset is based on the responses generated by <em>gemini-flash-thinking-exp-01-21</em> model and has undergone <strong>MANUAL rejection sampling</strong>.</p>
<!-- HTML_TAG_END --></div>
</div></section>
			
			<section class="pt-6 border-gray-100 md:pb-24 md:pl-6 md:w-64 lg:w-80 xl:w-96 flex-none order-first md:order-none md:border-l pt-3! md:pt-6!"><dl class="flex items-baseline justify-between"><dt class="text-sm text-gray-500">Downloads last month</dt><div class="mx-4 flex-1 border-b border-dotted"></div><dd class="font-semibold">22</dd></dl>
				
				<div class="divider-column-vertical"></div>
				<div class="grid grid-cols-2 gap-x-2 md:flex md:flex-row md:flex-wrap"><div class="SVELTE_HYDRATER contents" data-target="DatasetAndModelActionsDropdown" data-props="{&quot;classNames&quot;:&quot;order-last&quot;,&quot;discussionsDisabled&quot;:false,&quot;repo&quot;:{&quot;type&quot;:&quot;dataset&quot;,&quot;name&quot;:&quot;ChuGyouk/medical-o1-train-kormedmcqa&quot;},&quot;canWrite&quot;:false,&quot;canDisable&quot;:false,&quot;repoIsPrivate&quot;:false,&quot;repoIsGated&quot;:false,&quot;repoIsDisabled&quot;:false,&quot;repoIsAdminFlaggedNFAA&quot;:false,&quot;repoHasBlockedOids&quot;:false}"><div class="order-last"><div class="relative ">
	<button class="btn px-1.5 py-1.5 " type="button">
		
			<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" class="p-0.5" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><circle cx="16" cy="7" r="3" fill="currentColor"></circle><circle cx="16" cy="16" r="3" fill="currentColor"></circle><circle cx="16" cy="25" r="3" fill="currentColor"></circle></svg>
		
		</button>
	
	
	</div></div>













</div>
					<div class="SVELTE_HYDRATER contents" data-target="DatasetLibrary" data-props="{&quot;classNames&quot;:&quot;md:w-full xl:w-auto xl:flex-none&quot;,&quot;libraries&quot;:[{&quot;language&quot;:&quot;python&quot;,&quot;library&quot;:&quot;datasets&quot;,&quot;function&quot;:&quot;load_dataset&quot;,&quot;loading_codes&quot;:[{&quot;config_name&quot;:&quot;default&quot;,&quot;arguments&quot;:{},&quot;code&quot;:&quot;from datasets import load_dataset\n\n# Login using e.g. `huggingface-cli login` to access this dataset\nds = load_dataset(\&quot;ChuGyouk/medical-o1-train-kormedmcqa\&quot;)&quot;}]},{&quot;language&quot;:&quot;python&quot;,&quot;library&quot;:&quot;pandas&quot;,&quot;function&quot;:&quot;pd.read_parquet&quot;,&quot;loading_codes&quot;:[{&quot;config_name&quot;:&quot;default&quot;,&quot;arguments&quot;:{&quot;splits&quot;:{&quot;train&quot;:&quot;data/train-00000-of-00001.parquet&quot;}},&quot;code&quot;:&quot;import pandas as pd\n\n# Login using e.g. `huggingface-cli login` to access this dataset\ndf = pd.read_parquet(\&quot;hf://datasets/ChuGyouk/medical-o1-train-kormedmcqa/data/train-00000-of-00001.parquet\&quot;)&quot;}]},{&quot;language&quot;:&quot;python&quot;,&quot;library&quot;:&quot;mlcroissant&quot;,&quot;function&quot;:&quot;Dataset&quot;,&quot;loading_codes&quot;:[{&quot;config_name&quot;:&quot;default&quot;,&quot;arguments&quot;:{&quot;record_set&quot;:&quot;default&quot;,&quot;partial&quot;:false},&quot;code&quot;:&quot;import requests\nfrom huggingface_hub.file_download import build_hf_headers\nfrom mlcroissant import Dataset\n\n# Login using e.g. `huggingface-cli login` to access this dataset\nheaders = build_hf_headers()  # handles authentication\njsonld = requests.get(\&quot;https://huggingface.co/api/datasets/ChuGyouk/medical-o1-train-kormedmcqa/croissant\&quot;, headers=headers).json()\nds = Dataset(jsonld=jsonld)\nrecords = ds.records(\&quot;default\&quot;)&quot;}]},{&quot;language&quot;:&quot;python&quot;,&quot;library&quot;:&quot;polars&quot;,&quot;function&quot;:&quot;pl.read_parquet&quot;,&quot;loading_codes&quot;:[{&quot;config_name&quot;:&quot;default&quot;,&quot;arguments&quot;:{&quot;splits&quot;:{&quot;train&quot;:&quot;data/train-00000-of-00001.parquet&quot;}},&quot;code&quot;:&quot;import polars as pl\n\n# Login using e.g. `huggingface-cli login` to access this dataset\ndf = pl.read_parquet('hf://datasets/ChuGyouk/medical-o1-train-kormedmcqa/data/train-00000-of-00001.parquet')\n&quot;}]}]}"><div class="relative md:w-full xl:w-auto xl:flex-none">
	<button class="from-gray-800! to-black! max-xl:mb-2 text-white! gap-1! border-gray-800! dark:border-gray-900!  btn w-full cursor-pointer text-sm" type="button">
		<svg class="mr-1.5 mr-0.5! " xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32" style="transform: rotate(360deg);"><path d="M31 16l-7 7l-1.41-1.41L28.17 16l-5.58-5.59L24 9l7 7z" fill="currentColor"></path><path d="M1 16l7-7l1.41 1.41L3.83 16l5.58 5.59L8 23l-7-7z" fill="currentColor"></path><path d="M12.419 25.484L17.639 6l1.932.518L14.35 26z" fill="currentColor"></path></svg>
			Use this dataset
		<svg class="-mr-1 text-gray-500" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 24 24"><path d="M16.293 9.293L12 13.586L7.707 9.293l-1.414 1.414L12 16.414l5.707-5.707z" fill="currentColor"></path></svg></button>
	
	
	</div>

</div>
					
					</div>
				<div class="divider-column-vertical"></div>
					<div class="flex flex-col flex-wrap xl:flex-row"><a class="bg-linear-to-r dark:via-none group mb-1.5 flex max-w-full flex-col overflow-hidden rounded-lg border border-gray-100 from-white via-white to-white px-2 py-1 hover:from-gray-50 dark:from-gray-900 dark:to-gray-925 dark:hover:to-gray-900 md:mr-1.5 pointer-events-none" rel="nofollow" target="_blank"><div class="truncate text-xs text-gray-400">Size of downloaded dataset files:</div>
		<div class="truncate text-sm ">
			<!-- HTML_TAG_START -->38.6 MB<!-- HTML_TAG_END --></div></a><a class="bg-linear-to-r dark:via-none group mb-1.5 flex max-w-full flex-col overflow-hidden rounded-lg border border-gray-100 from-white via-white to-white px-2 py-1 hover:from-gray-50 dark:from-gray-900 dark:to-gray-925 dark:hover:to-gray-900 md:mr-1.5 " href="/datasets/ChuGyouk/medical-o1-train-kormedmcqa/tree/refs%2Fconvert%2Fparquet/" rel="nofollow" target="_blank"><div class="truncate text-xs text-gray-400">Size of the auto-converted Parquet files:</div>
		<div class="truncate text-sm group-hover:underline">
			<!-- HTML_TAG_START -->38.6 MB<!-- HTML_TAG_END --></div></a><a class="bg-linear-to-r dark:via-none group mb-1.5 flex max-w-full flex-col overflow-hidden rounded-lg border border-gray-100 from-white via-white to-white px-2 py-1 hover:from-gray-50 dark:from-gray-900 dark:to-gray-925 dark:hover:to-gray-900 md:mr-1.5 pointer-events-none" rel="nofollow" target="_blank"><div class="truncate text-xs text-gray-400">Number of rows:</div>
		<div class="truncate text-sm ">
			<!-- HTML_TAG_START -->8,751<!-- HTML_TAG_END --></div></a></div>
				
				
				
				

				<div class="divider-column-vertical"></div>
					<h2 class="text-smd mb-5 flex items-baseline overflow-hidden whitespace-nowrap font-semibold text-gray-800"><svg class="mr-1 inline self-center flex-none" width="1em" height="1em" aria-hidden="true" focusable="false" role="img" viewBox="0 0 12 13" fill="none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><rect x="2" y="2.49902" width="8" height="3.76425" rx="1.16774" fill="currentColor" fill-opacity="0.4"></rect><rect x="6.21875" y="6.7334" width="3.78055" height="3.76425" rx="1.16774" fill="currentColor" fill-opacity="0.7"></rect><rect x="2" y="6.73438" width="3.78055" height="3.76425" rx="1.16774" fill="currentColor" fill-opacity="0.5"></rect></svg>
						Collection including
						<span class="ml-1 truncate font-mono text-[0.86rem] font-medium">ChuGyouk/medical-o1-train-kormedmcqa</span></h2>
					<div class="flex flex-col gap-3">

<div class="flex flex-col"><article class="overview-card-wrapper group/collection rounded-md! from-white! to-white! dark:from-gray-900! dark:to-gray-900! relative  peer"><a href="/collections/ChuGyouk/korean-medical-dataset-66bc742e78a0239bbfd56216" class="block p-2"><header class="mb-0.5 flex items-center" title="Korean Medical Dataset"><h4 class="text-md text-smd truncate font-semibold group-hover/collection:underline">Korean Medical Dataset</h4>
				<div class="ml-2 flex items-center rounded-sm sm:ml-2.5 bg-green-500/10 py-0.5 pl-1 pr-1.5 text-xs leading-none text-gray-700"><svg class="mr-0.5 flex-none text-green-700" width="1em" height="1em" aria-hidden="true" focusable="false" role="img" viewBox="0 0 12 13" fill="none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><rect x="2" y="2.49902" width="8" height="3.76425" rx="1.16774" fill="currentColor" fill-opacity="0.4"></rect><rect x="6.21875" y="6.7334" width="3.78055" height="3.76425" rx="1.16774" fill="currentColor" fill-opacity="0.7"></rect><rect x="2" y="6.73438" width="3.78055" height="3.76425" rx="1.16774" fill="currentColor" fill-opacity="0.5"></rect></svg>
					Collection
				</div></header>

			<div class="mr-1 flex items-center overflow-hidden whitespace-nowrap text-sm leading-tight text-gray-400"><span class="max-w-64 truncate">한국어 의료 관련 데이터</span>
					<span class="px-1.5 text-gray-300">• </span>
				<span>23 items</span>
				<span class="px-1.5 text-gray-300">• </span>
				<span class="truncate">Updated
					<time datetime="2025-03-21T06:08:28" title="2025-03-21T06:08:28.143Z">4 days ago</time></span>
				<span class="px-1.5 text-gray-300">•</span>

					<svg class="flex-none w-3 mr-1 text-gray-400" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 12 12" fill="transparent"><path d="M9.30013 9.29152H9.3H2.7H2.69987C2.62308 9.29154 2.54762 9.27146 2.481 9.23328C2.41437 9.1951 2.3589 9.14015 2.32009 9.07389C2.28128 9.00763 2.26048 8.93237 2.25977 8.85558C2.25907 8.7798 2.27796 8.70513 2.31458 8.63882L5.62238 2.9426L5.67518 2.85168C5.7059 2.81806 5.74178 2.78928 5.78164 2.76649C5.84813 2.72848 5.9234 2.70848 6 2.70848C6.0766 2.70848 6.15187 2.72848 6.21836 2.76649C6.28441 2.80425 6.33953 2.85848 6.37836 2.92389L9.68527 8.63855C9.72199 8.70493 9.74093 8.7797 9.74023 8.85558C9.73952 8.93237 9.71872 9.00763 9.67991 9.07389C9.6411 9.14015 9.58563 9.1951 9.519 9.23328C9.45238 9.27146 9.37692 9.29154 9.30013 9.29152Z" stroke="currentColor"></path></svg>

					5</div></a></article>
	<div class="overview-card-wrapper rounded-md! bg-linear-to-t! -z-1  from-gray-50! to-gray-50! shadow-none! dark:from-gray-925! dark:to-gray-925! -mt-[1.60rem] h-8 scale-x-[98%] transition-transform peer-hover:-translate-y-[2px] peer-hover:from-gray-100/80 dark:peer-hover:from-black"></div></div></div>
				<div class="divider-column-vertical md:hidden"></div></section></div></main>

	<footer class="b-12 mb-2 flex border-t border-gray-100 md:h-14"><nav class="container relative flex flex-col justify-between space-y-2 py-6 text-gray-500 max-md:*:self-start md:flex-row md:items-center md:space-y-0 md:py-0 md:text-sm"><div class="SVELTE_HYDRATER contents" data-target="ThemeSwitcher" data-props="{&quot;theme&quot;:&quot;system&quot;,&quot;isLoggedIn&quot;:false,&quot;menuClassNames&quot;:&quot;md:-top-24&quot;,&quot;classNames&quot;:&quot;max-md:mb-5 max-md:*:self-start&quot;}">
<div class="relative inline-block max-md:mb-5 max-md:*:self-start">
	<button class="rounded-full border border-gray-100 pl-2 py-1 pr-2.5  flex items-center text-sm text-gray-500 bg-white hover:bg-purple-50 hover:border-purple-200 dark:hover:bg-gray-800 dark:hover:border-gray-950 dark:border-gray-800 " type="button">
		<svg class="mr-1.5 text-gray-500" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" fill="currentColor" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M29 25H3a1 1 0 1 0 0 2h26a1 1 0 1 0 0-2Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M6 22.5h20a2 2 0 0 0 2-2V7a2 2 0 0 0-2-2H6a2 2 0 0 0-2 2v13.5a2 2 0 0 0 2 2ZM7 7a1 1 0 0 0-1 1v11a1 1 0 0 0 1 1h18a1 1 0 0 0 1-1V8a1 1 0 0 0-1-1H7Z" fill="currentColor"></path><path d="M6 8a1 1 0 0 1 1-1h18a1 1 0 0 1 1 1v11a1 1 0 0 1-1 1H7a1 1 0 0 1-1-1V8Z" fill="currentColor" fill-opacity=".4"></path><path d="M29 25H3a1 1 0 1 0 0 2h26a1 1 0 1 0 0-2Z" fill="currentColor"></path></svg>
			System theme
		</button>
	
	
	</div></div>
		<div class="font-semibold text-black md:hidden">Company</div>
		<a class="hover:underline" href="/terms-of-service">TOS</a>
		<a class="hover:underline" href="/privacy">Privacy</a>
		<a class="hover:underline" href="/huggingface">About</a>
		<a class="hover:underline" href="https://apply.workable.com/huggingface/">Jobs</a>
		<a href="/" class="max-md:mb-4! max-md:mt-8! group flex-none max-md:order-last"><svg class="h-7 w-7 transition-transform group-hover:-translate-y-px" viewBox="0 0 95 88" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M47.2119 76.5C66.4037 76.5 81.9619 60.9419 81.9619 41.75C81.9619 22.5581 66.4037 7 47.2119 7C28.02 7 12.4619 22.5581 12.4619 41.75C12.4619 60.9419 28.02 76.5 47.2119 76.5Z" fill="#FFD21E"></path><path d="M81.9619 41.75C81.9619 22.5581 66.4037 7 47.2119 7C28.02 7 12.4619 22.5581 12.4619 41.75C12.4619 60.9419 28.02 76.5 47.2119 76.5C66.4037 76.5 81.9619 60.9419 81.9619 41.75ZM8.46185 41.75C8.46185 20.349 25.8108 3 47.2119 3C68.6129 3 85.9619 20.349 85.9619 41.75C85.9619 63.151 68.6129 80.5 47.2119 80.5C25.8108 80.5 8.46185 63.151 8.46185 41.75Z" fill="#FF9D0B"></path><path d="M58.5024 32.2915C59.7768 32.7415 60.2839 35.3615 61.5713 34.6769C64.0095 33.3805 64.9351 30.353 63.6387 27.9148C62.3423 25.4767 59.3148 24.5511 56.8766 25.8475C54.4384 27.1439 53.5128 30.1714 54.8092 32.6096C55.4211 33.7604 57.3632 31.8892 58.5024 32.2915Z" fill="#3A3B45"></path><path d="M34.9454 32.2915C33.671 32.7415 33.164 35.3615 31.8766 34.6769C29.4384 33.3805 28.5128 30.353 29.8092 27.9148C31.1056 25.4767 34.1331 24.5511 36.5713 25.8475C39.0095 27.1439 39.9351 30.1714 38.6387 32.6096C38.0268 33.7604 36.0846 31.8892 34.9454 32.2915Z" fill="#3A3B45"></path><path d="M46.9619 56.289C56.7903 56.289 59.9619 47.5261 59.9619 43.0262C59.9619 40.6875 58.3898 41.4236 55.8718 42.6702C53.5449 43.8222 50.4102 45.4101 46.9619 45.4101C39.7822 45.4101 33.9619 38.5263 33.9619 43.0262C33.9619 47.5261 37.1334 56.289 46.9619 56.289Z" fill="#3A3B45"></path><mask id="mask0" style="mask-type:alpha" maskUnits="userSpaceOnUse" x="33" y="41" width="27" height="16"><path d="M46.9619 56.289C56.7903 56.289 59.9619 47.5261 59.9619 43.0262C59.9619 40.6875 58.3898 41.4236 55.8718 42.6702C53.5449 43.8222 50.4102 45.4101 46.9619 45.4101C39.7822 45.4101 33.9619 38.5263 33.9619 43.0262C33.9619 47.5261 37.1334 56.289 46.9619 56.289Z" fill="white"></path></mask><g mask="url(#mask0)"><path d="M47.2119 66.5C52.0018 66.5 55.8848 62.617 55.8848 57.8271C55.8848 54.0962 53.5291 50.9156 50.224 49.6915C50.1023 49.6464 49.9794 49.604 49.8553 49.5643C49.0219 49.2979 48.1337 52.1623 47.2119 52.1623C46.3506 52.1623 45.5186 49.2797 44.7332 49.5135C41.151 50.5799 38.5389 53.8984 38.5389 57.8271C38.5389 62.617 42.4219 66.5 47.2119 66.5Z" fill="#F94040"></path></g><path d="M70.7119 37C72.5068 37 73.9619 35.5449 73.9619 33.75C73.9619 31.9551 72.5068 30.5 70.7119 30.5C68.9169 30.5 67.4619 31.9551 67.4619 33.75C67.4619 35.5449 68.9169 37 70.7119 37Z" fill="#FF9D0B"></path><path d="M24.2119 37C26.0068 37 27.4619 35.5449 27.4619 33.75C27.4619 31.9551 26.0068 30.5 24.2119 30.5C22.4169 30.5 20.9619 31.9551 20.9619 33.75C20.9619 35.5449 22.4169 37 24.2119 37Z" fill="#FF9D0B"></path><path class="origin-bottom-right transition-transform group-hover:-rotate-6" d="M17.5238 48C15.9048 48 14.4578 48.665 13.4488 49.871C12.8248 50.618 12.1728 51.822 12.1198 53.625C11.4408 53.43 10.7878 53.321 10.1778 53.321C8.6278 53.321 7.2278 53.915 6.2378 54.994C4.9658 56.379 4.4008 58.081 4.6468 59.784C4.7638 60.595 5.0348 61.322 5.4398 61.995C4.5858 62.686 3.9568 63.648 3.6528 64.805C3.4148 65.712 3.1708 67.601 4.4448 69.547C4.3638 69.674 4.2878 69.806 4.2168 69.941C3.4508 71.395 3.4018 73.038 4.0778 74.568C5.1028 76.887 7.6498 78.714 12.5958 80.675C15.6728 81.895 18.4878 82.675 18.5128 82.682C22.5808 83.737 26.2598 84.273 29.4448 84.273C35.2988 84.273 39.4898 82.48 41.9018 78.944C45.7838 73.25 45.2288 68.042 40.2058 63.022C37.4258 60.244 35.5778 56.148 35.1928 55.249C34.4168 52.587 32.3648 49.628 28.9538 49.628H28.9528C28.6658 49.628 28.3758 49.651 28.0898 49.696C26.5958 49.931 25.2898 50.791 24.3568 52.085C23.3498 50.833 22.3718 49.837 21.4868 49.275C20.1528 48.429 18.8198 48 17.5238 48ZM17.5238 52C18.0338 52 18.6568 52.217 19.3438 52.653C21.4768 54.006 25.5928 61.081 27.0998 63.833C27.6048 64.755 28.4678 65.145 29.2448 65.145C30.7868 65.145 31.9908 63.612 29.3858 61.664C25.4688 58.733 26.8428 53.942 28.7128 53.647C28.7948 53.634 28.8758 53.628 28.9538 53.628C30.6538 53.628 31.4038 56.558 31.4038 56.558C31.4038 56.558 33.6018 62.078 37.3778 65.851C41.1538 69.625 41.3488 72.654 38.5968 76.69C36.7198 79.442 33.1268 80.273 29.4448 80.273C25.6258 80.273 21.7108 79.379 19.5168 78.81C19.4088 78.782 6.0658 75.013 7.7558 71.805C8.0398 71.266 8.5078 71.05 9.0968 71.05C11.4768 71.05 15.8058 74.592 17.6668 74.592C18.0828 74.592 18.3758 74.415 18.4958 73.983C19.2888 71.138 6.4388 69.942 7.5218 65.821C7.7128 65.092 8.2308 64.796 8.9588 64.797C12.1038 64.797 19.1598 70.328 20.6388 70.328C20.7518 70.328 20.8328 70.295 20.8768 70.225C21.6178 69.029 21.2118 68.194 15.9888 65.033C10.7658 61.871 7.0998 59.969 9.1848 57.699C9.4248 57.437 9.7648 57.321 10.1778 57.321C13.3488 57.322 20.8408 64.14 20.8408 64.14C20.8408 64.14 22.8628 66.243 24.0858 66.243C24.3668 66.243 24.6058 66.132 24.7678 65.858C25.6348 64.396 16.7148 57.636 16.2118 54.847C15.8708 52.957 16.4508 52 17.5238 52Z" fill="#FF9D0B"></path><path class="origin-bottom-right transition-transform group-hover:-rotate-6" d="M38.5967 76.6898C41.3487 72.6538 41.1537 69.6248 37.3777 65.8508C33.6017 62.0778 31.4037 56.5578 31.4037 56.5578C31.4037 56.5578 30.5827 53.3518 28.7127 53.6468C26.8427 53.9418 25.4697 58.7328 29.3867 61.6638C33.3037 64.5938 28.6067 66.5848 27.0997 63.8328C25.5927 61.0808 21.4777 54.0058 19.3437 52.6528C17.2107 51.2998 15.7087 52.0578 16.2117 54.8468C16.7147 57.6358 25.6357 64.3958 24.7677 65.8588C23.8997 67.3208 20.8407 64.1398 20.8407 64.1398C20.8407 64.1398 11.2687 55.4288 9.18465 57.6988C7.10065 59.9688 10.7657 61.8708 15.9887 65.0328C21.2127 68.1938 21.6177 69.0288 20.8767 70.2248C20.1347 71.4208 8.60465 61.6998 7.52165 65.8208C6.43965 69.9418 19.2887 71.1378 18.4957 73.9828C17.7027 76.8288 9.44465 68.5978 7.75565 71.8048C6.06565 75.0128 19.4087 78.7818 19.5167 78.8098C23.8267 79.9278 34.7727 82.2968 38.5967 76.6898Z" fill="#FFD21E"></path><path class="origin-bottom-left transition-transform group-hover:rotate-6" d="M77.3999 48C79.0189 48 80.4659 48.665 81.4749 49.871C82.0989 50.618 82.7509 51.822 82.8039 53.625C83.4829 53.43 84.1359 53.321 84.7459 53.321C86.2959 53.321 87.6959 53.915 88.6859 54.994C89.9579 56.379 90.5229 58.081 90.2769 59.784C90.1599 60.595 89.8889 61.322 89.4839 61.995C90.3379 62.686 90.9669 63.648 91.2709 64.805C91.5089 65.712 91.7529 67.601 90.4789 69.547C90.5599 69.674 90.6359 69.806 90.7069 69.941C91.4729 71.395 91.5219 73.038 90.8459 74.568C89.8209 76.887 87.2739 78.714 82.3279 80.675C79.2509 81.895 76.4359 82.675 76.4109 82.682C72.3429 83.737 68.6639 84.273 65.4789 84.273C59.6249 84.273 55.4339 82.48 53.0219 78.944C49.1399 73.25 49.6949 68.042 54.7179 63.022C57.4979 60.244 59.3459 56.148 59.7309 55.249C60.5069 52.587 62.5589 49.628 65.9699 49.628H65.9709C66.2579 49.628 66.5479 49.651 66.8339 49.696C68.3279 49.931 69.6339 50.791 70.5669 52.085C71.5739 50.833 72.5519 49.837 73.4369 49.275C74.7709 48.429 76.1039 48 77.3999 48ZM77.3999 52C76.8899 52 76.2669 52.217 75.5799 52.653C73.4469 54.006 69.3309 61.081 67.8239 63.833C67.3189 64.755 66.4559 65.145 65.6789 65.145C64.1369 65.145 62.9329 63.612 65.5379 61.664C69.4549 58.733 68.0809 53.942 66.2109 53.647C66.1289 53.634 66.0479 53.628 65.9699 53.628C64.2699 53.628 63.5199 56.558 63.5199 56.558C63.5199 56.558 61.3219 62.078 57.5459 65.851C53.7699 69.625 53.5749 72.654 56.3269 76.69C58.2039 79.442 61.7969 80.273 65.4789 80.273C69.2979 80.273 73.2129 79.379 75.4069 78.81C75.5149 78.782 88.8579 75.013 87.1679 71.805C86.8839 71.266 86.4159 71.05 85.8269 71.05C83.4469 71.05 79.1179 74.592 77.2569 74.592C76.8409 74.592 76.5479 74.415 76.4279 73.983C75.6349 71.138 88.4849 69.942 87.4019 65.821C87.2109 65.092 86.6929 64.796 85.9649 64.797C82.8199 64.797 75.7639 70.328 74.2849 70.328C74.1719 70.328 74.0909 70.295 74.0469 70.225C73.3059 69.029 73.7119 68.194 78.9349 65.033C84.1579 61.871 87.8239 59.969 85.7389 57.699C85.4989 57.437 85.1589 57.321 84.7459 57.321C81.5749 57.322 74.0829 64.14 74.0829 64.14C74.0829 64.14 72.0609 66.243 70.8379 66.243C70.5569 66.243 70.3179 66.132 70.1559 65.858C69.2889 64.396 78.2089 57.636 78.7119 54.847C79.0529 52.957 78.4729 52 77.3999 52Z" fill="#FF9D0B"></path><path class="origin-bottom-left transition-transform group-hover:rotate-6" d="M56.3271 76.6898C53.5751 72.6538 53.7701 69.6248 57.5461 65.8508C61.3221 62.0778 63.5201 56.5578 63.5201 56.5578C63.5201 56.5578 64.3411 53.3518 66.2111 53.6468C68.0811 53.9418 69.4541 58.7328 65.5371 61.6638C61.6201 64.5938 66.3171 66.5848 67.8241 63.8328C69.3311 61.0808 73.4461 54.0058 75.5801 52.6528C77.7131 51.2998 79.2151 52.0578 78.7121 54.8468C78.2091 57.6358 69.2881 64.3958 70.1561 65.8588C71.0241 67.3208 74.0831 64.1398 74.0831 64.1398C74.0831 64.1398 83.6551 55.4288 85.7391 57.6988C87.8231 59.9688 84.1581 61.8708 78.9351 65.0328C73.7111 68.1938 73.3061 69.0288 74.0471 70.2248C74.7891 71.4208 86.3191 61.6998 87.4021 65.8208C88.4841 69.9418 75.6351 71.1378 76.4281 73.9828C77.2211 76.8288 85.4791 68.5978 87.1681 71.8048C88.8581 75.0128 75.5151 78.7818 75.4071 78.8098C71.0971 79.9278 60.1511 82.2968 56.3271 76.6898Z" fill="#FFD21E"></path></svg></a>
		<div class="max-md:mt-8! font-semibold text-black md:hidden">Website</div>

		<a class="hover:underline" href="/models">Models</a>
		<a class="hover:underline" href="/datasets">Datasets</a>
		<a class="hover:underline" href="/spaces">Spaces</a>
		<a class="hover:underline" href="/pricing">Pricing</a>
		<a class="hover:underline" href="/docs">Docs</a></nav></footer></div>

		<script>
			import("\/front\/build\/kube-68d7aa0\/index.js");
			window.moonSha = "kube-68d7aa0\/";
			window.__hf_deferred = {};
		</script>

		<!-- Stripe -->
		<script>
			if (["hf.co", "huggingface.co"].includes(window.location.hostname)) {
				const script = document.createElement("script");
				script.src = "https://js.stripe.com/v3/";
				script.async = true;
				document.head.appendChild(script);
			}
		</script>
	</body>
</html>
